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ABSTRACT
The DNA damage response is a conserved process found in all domains of life that serves 
to protect the genetic material of living organisms. When an organism encounters DNA 
modifications or ‘DNA damage,’ a response is elicited resulting in increased levels of DNA 
repair proteins and activation of a cell cycle checkpoint. In bacteria the DNA damage response 
has been studied extensively in Escherichia coli. Although the activation of the DNA damage 
response is conserved in many bacteria, the downstream steps of DNA repair and cell cycle 
regulation diverge significantly. Therefore, exactly how bacteria respond to DNA damage is still 
not clear. I used forward genetics in the model organism Bacillus subtilis to screen for non-
essential genes that are required for mitigating the toxicity of three distinct classes of DNA 
damage inducing drugs. I identified two proteases that function in the DNA damage checkpoint. 
Through studies employing genetics, cell biology, and biochemical approaches, I present that 
these two proteases degrade the cell division inhibitor that is expressed as part of the DNA 
damage response. Thus, these two proteases aid in establishing the level of cell division inhibitor 
required for checkpoint activation, while also serving to clear excess inhibitor preventing further 
checkpoint activation. Additionally, a detailed investigation using genetics and cell biology 
uncovered a DNA damage checkpoint antagonist that functions by preventing the cell division 
inhibitor from activating the checkpoint. Therefore, the checkpoint antagonist aids in 
establishing the threshold for checkpoint activation along with the checkpoint proteases. The 
genetic screens also revealed a putative DNA repair pathway. Two genes in a putative operon 
encoding a helicase and an exonuclease were important for DNA damage caused by a single 
DNA damaging agent. Genetic analyses indicate that these genes operate as part of a novel 
nucleotide excision repair pathway that appears to be specific to a natural antibiotic. Finally, I 
studied a protein that is annotated as a potential mismatch repair protein, yet had no detectable 
mismatch repair phenotype. My investigation demonstrated that this protein functions by 
promoting homologous recombination, likely by acting as a secondary Holliday junction 
endonuclease. Together, my studies have uncovered new pathways of DNA repair and cell cycle 
xi 
 
regulation in the DNA damage response in bacteria. Further, in each of my investigations I 
identified at least two ways of performing a single function in the DNA damage response, 
uncovering a more general strategy of favoring a robust DNA damage response in B. subtilis. 
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CHAPTER I
The bacterial DNA damage response 
 
Introduction 
Living organisms are defined by features that distinguish them from non-living matter, 
and one of the most fundamental aspects of living organisms is the ability to reproduce. The 
storage and passage of information allows this process to occur. Information in biological 
systems is stored in deoxyribonucleic acids (DNA). The identification of DNA as the genetic 
material (1, 2) and determination of DNA structure (3) provided the key background knowledge 
required to understand how cells replicate and protect their genetic material. Intriguingly, 
scientists had already started to recognize that DNA could be modified and repaired prior to fully 
understanding that DNA serves as the genetic material (4). Still, after understanding the structure 
and major function of DNA, scientists could begin to fully appreciate the complex assortment of 
cellular functions critical for DNA replication. DNA can be modified by light, ionizing radiation, 
and a plethora of chemicals, and such modifications impair the process of DNA replication. In 
response, cells have evolved numerous DNA repair mechanisms to cope with these 
environmental stresses. In addition, the cell must coordinate DNA replication with the process of 
cell growth and division and vice versa. Through coordinating DNA replication with cell 
division, cells ensure that each daughter cell will receive a complete set of genetic material. 
Given the importance of the genetic material, it is no surprise that cells have numerous 
mechanisms to repair and protect their DNA. 
 
DNA damage prevents accurate DNA replication 
Although DNA is considered a stable medium for storing information, there are many 
ways that DNA can be modified (5, 6). The result of many DNA modifications is referred to as 
DNA damage. Sources of DNA damage include endogenous metabolic intermediates such as 
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reactive oxygen species as well as exogenous sources of radiation and chemicals that react 
directly with DNA (6-8). In addition, there are many antibiotics produced by plants and bacteria 
that cause DNA damage (9). Thus, DNA damage is a prevalent obstacle encountered by all 
organisms in nature. 
DNA damage prevents accurate DNA replication, though the exact mechanism differs 
depending on the type of DNA damage encountered during DNA replication. For example, 
treatment with UV results in a very rapid decrease in DNA replication due to the production of 
thymine-thymine dimers (10, 11). Replicative DNA polymerases cannot utilize thymine dimers 
as a template because the active site only allows for a single templating base during catalysis 
(12-15). Similarly, alkylating agents, such as methyl methanesulfonate, can methylate DNA 
bases, preventing accurate base pairing during DNA synthesis (16). A distinct type of alkylating 
agents, bi-functional alkylating agents such as mitomycin C, can react with complementary DNA 
strands resulting in an interstrand cross-link (17). Interstrand DNA cross-links are particularly 
toxic because the two strands cannot be separated, thus preventing replication and transcription 
of DNA (18, 19). Yet another type of DNA damage is a break in the phosphodiester backbone of 
DNA caused by agents such as ionizing radiation and the naturally produced peptides bleomycin 
and phleomycin (6). A break is toxic to cells because the replication machinery depends on the 
integrity of the template for synthesis of the nascent DNA strand (20, 21). Therefore, although 
there are diverse types of DNA damage, the major impediment is the inability to access and 
replicate the information stored within DNA. 
 
DNA damage activates the SOS response in bacteria 
The SOS response is a highly conserved stress response pathway that is activated when 
bacteria encounter DNA damage (22-25). Activation of the SOS response results in increased 
transcription of genes important for DNA repair, DNA damage tolerance, and cell cycle 
regulation (26-28). The collection of genes controlled by the SOS regulatory cascade is referred 
to as the SOS regulon. Proximal to the promoters of genes in the SOS regulon are DNA binding 
sites for the transcriptional repressor LexA (29-32). When bound to LexA binding sites, LexA 
prevents transcription of the SOS regulon (33-36). Thus, activation of the SOS response requires 
inactivation of LexA, resulting in activated gene transcription (Fig 1.1). 
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 How is the signal of DNA damage transduced to inactivate LexA? Early genetic studies 
demonstrated that RecA is required for SOS activation (37). RecA catalyzes the pairing of 
ssDNA to the complementary sequence in dsDNA resulting in synapsis (38, 39). RecA was also 
shown to be required for LexA inactivation in vitro, which led to the suggestion that RecA was a 
protease that was responsible for cleaving LexA (40). Further study demonstrated that RecA 
acted as a co-factor when bound to ssDNA that stimulated the auto-proteolytic activity of LexA 
(41). Thus, LexA is a transcriptional repressor that undergoes auto-digestion stimulated by the 
RecA/ssDNA nucleoprotein filament (Fig 1.1). A unique feature of the SOS regulatory cascade 
is that many different DNA damaging treatments result in activation of the pathway. A diverse 
set of DNA lesions can cause activation of the SOS response because the signal that relays DNA 
damage to the SOS response is generation of a RecA/ssDNA nucleoprotein filament that can be 
formed through DNA repair or replication of damaged template DNA. 
How does DNA damage lead to the accumulation of ssDNA in vivo? Treatment with 
double strand break inducing agents such as bleomycins or ionizing radiation leads to induction 
of the SOS response (42-44). Repair of double stranded breaks occurs through homologous 
recombination (38, 45, 46), during which ssDNA is generated by the helicase/nuclease complex 
RecBCD in E. coli (20), or AddAB in B. subtilis (47). RecBCD and AddAB bind to double 
strand DNA breaks (47, 48) and generate a free 3′ end onto which RecA is loaded (49-53). Thus, 
double strand breaks result in the generation of a RecA/ssDNA nucleoprotein filament that can 
activate the SOS response. In B. subtilis, replication is required for formation of a RecA-GFP 
focus and DNA damage is not sufficient, though it is still not clear whether replication is 
required for SOS activation (54). In E. coli, replication is not required to stimulate LexA 
cleavage following treatment with bleomycin (43). The generation of ssDNA following 
treatments that cause other types of DNA lesions such as pyrimidine dimers from UV light is less 
clear, though the process depends on DNA replication (43). One idea is that the stalling of DNA 
polymerase results in uncoupling of the replicative helicase from the replisome generating excess 
ssDNA (55). A second model is that the replication machinery stalls at lesions such as 
pyrimidine dimers and will skip ahead, leaving a gap of ssDNA that was not replicated (55). A 
primer generated from an RNA transcript (56) or by primase (57) can allow DNA polymerase to 
advance beyond a DNA lesion on the leading strand. The resulting ssDNA gap generated by 
DNA polymerase skipping ahead on the leading strand can be used as a substrate for loading 
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RecA by the RecFOR complex (58). Indeed, activation of the SOS response following UV 
exposure is also dependent on the RecFOR proteins (59). Thus, when cells encounter DNA 
damage, the general distress signal is a RecA/ssDNA nucleoprotein filament, which is the initial 
step in the DNA repair pathway homologous recombination. Therefore, bacteria make use of a 
DNA repair intermediate generated early in the repair process to activate expression of the genes 
important for mitigating the stress induced by DNA damage (Fig 1.1). 
 
Homologous recombination in bacteria 
DNA damage is a ubiquitous stressor encountered by all organisms. Thus, to ensure the 
integrity of the genetic material, cells possess repair pathways as diverse as the DNA lesions 
encountered in the environment (6). Homologous recombination is a highly conserved pathway 
that functions in several DNA exchange reactions in bacteria (60). Homologous recombination 
participates in the repair of several types of DNA damage including lesions caused by DNA 
methylation, alkylation, cross-links, and double strand DNA breaks (18, 19, 61). In all cases, the 
purpose of homologous recombination as a DNA repair pathway is to restore lost sequence 
information using a second copy of the chromosome. For simplicity, the model for homologous 
recombination will be explained using the process of double strand break repair (Fig 1.2). 
 Repair of double strand DNA breaks begins when a helicase nuclease complex 
recognizes the broken end of the chromosome (20). In E. coli, the RecBCD complex can bind to 
a dsDNA end, whereas the AddAB complex performs this function in B. subtilis (62). The end 
processing enzymes RecBCD or AddAB then generate a free 3′ overhang (20, 62). RecA is 
loaded onto the ssDNA by RecBCD or the RecFOR complex (50, 51, 58). RecA performs a 
homology search to find and pair the broken chromosome with the intact sister chromosome (38, 
46). The process continues with the branch migration enzymes RuvAB, which function as a 
helicase to separate the strands of the sister chromosome providing the template for DNA 
polymerase to synthesize the sequence information lost at the site of the DNA break (63). The 
resulting Holliday junction is resolved by the Holliday junction endonuclease RuvC in E. coli or 
RecU in B. subtilis resulting in two intact chromosomes (63-65). Although homologous 
recombination is a well-studied process in bacteria, there remain several genes present in 
bacterial genomes with phenotypes similar to genes involved in homologous recombination, yet 
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no clear role in the pathway (45). I present a reverse genetic analysis of the gene mutS2 in 
Chapter V, which suggests that MutS2 functions as a back-up to RecU in B. subtilis. 
 
Nucleotide excision repair in bacteria 
Nucleotide excision repair (NER) is a major DNA repair pathway present in both 
prokaryotes and eukaryotes (66). The NER machinery is capable of removing many types of 
DNA lesions that result in bulky adducts or other helix distorting lesions (67). In bacteria, the 
mechanism of NER was elucidated through studies in the model organism E. coli (68-70). The 
genes uvrA, uvrB, and uvrC were identified by mapping several mutants that were sensitive to 
UV light to three distinct loci in the E. coli genome (71). These three genes encode the 
nucleotide excision repair machinery UvrABC, which recognizes and initiates the removal of 
damaged DNA (Fig 1.3). 
 The process of nucleotide excision repair begins by recognition of a DNA lesion. Purified 
UvrA binds to UV irradiated DNA with greater affinity than untreated DNA, and ATP is 
required for preferential binding (72). The ATPase domains of UvrA are also required for 
recognizing damaged DNA preferentially (73). Based on studies in vitro with purified 
components, it was long thought that a UvrA dimer complexed with one or two UvrB molecules 
performed genome surveillance and DNA damage recognition (68, 69, 74). Recent work using 
single molecule microscopy in live cells demonstrated that UvrA can bind to damaged DNA in 
vivo in the absence of UvrB (75). Further, recruitment of UvrB stimulates the release of UvrA 
from DNA, and UvrA ATPase activity is required for UvrA release (75). UvrB is hypothesized 
to verify the presence of a DNA lesion by using its helicase activity to unwind the DNA (76, 77). 
Following lesion verification, UvrB recruits UvrC (78, 79). Successful recruitment of UvrC 
ultimately leads to incisions occurring on either side of the DNA lesion at approximate 7-8 
nucleotides 5′ to the lesion and 3-4 nucleotide 3′ to the lesion (80-82). The subsequent steps of 
repair are carried out by the helicase UvrD, the DNA polymerase Pol I, and DNA ligase in E. 
coli (69, 70). Repair synthesis by Pol I required the action of UvrD to stimulate the 
disassociation of UvrC and removal of the excised DNA (83, 84). The resulting product 
generated by Pol I is a substrate for DNA ligase (83, 84), thus completing the repair process. 
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 Although nucleotide excision repair is well studied in E. coli, the process in B. subtilis 
has not been studied in detail. Although uvrABC and polA (gene coding for Pol I) are conserved, 
cho and uvrD are not. There is evidence to suggest that the helicase PcrA in B. subtilis can 
function in place of UvrD (85), though how the excision repair process occurs in vivo remains 
unclear. Further, there is evidence in E. coli that multiple NER pathways exist (86, 87), and it is 
unclear whether other pathways exist in other bacteria. In Chapter IV, I describe the discovery of 
a novel nucleotide excision repair pathway specific to DNA damage caused by the antibiotic 
mitomycin C. 
 
DNA damage-dependent cell cycle regulation in bacteria 
DNA replication and cell division are essential processes that must be coordinated to 
ensure that subsequent generations receive an accurate and complete set of genetic material. 
Under normal conditions DNA replication and cell division occur at rates that allow DNA 
replication and segregation of a complete chromosome to each daughter cell. When a cell 
encounters DNA damage, however, DNA replication is blocked, which requires cell division to 
be delayed to provide enough time for DNA repair and completion of DNA replication. Bacteria 
make use of multiple mechanisms to ensure that cell division occurs after DNA replication and 
segregation of the chromosomes including nucleoid occlusion, SOS-independent regulation of 
the divisome, and an SOS-dependent DNA damage checkpoint. Below, I discuss each of these 
mechanisms that regulate cytokinesis in bacteria.  
Nucleoid Occlusion 
 A straightforward mechanism of preventing cell division prior to completion of DNA 
replication is nucleoid occlusion. Nucleoid occlusion prevents the cell division machinery from 
operating in the same location as the nucleoid. Thus, the nucleoid occludes the cell division 
machinery. In E. coli nucleoid occlusion is carried out by a protein called SlmA (88, 89). SlmA 
was identified using a genetic screen searching for genes that were important for cell division in 
the absence of the Min system (90). The Min system, composed of MinCDE, prevents cell 
division from occurring at the cell poles (91). Therefore, the logic was that mutants defective in 
both pathways responsible for selection of the site of cell division would not survive. Indeed, 
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mutants in slmA were isolated (90). Intriguingly, deletion of slmA alone did not change the 
frequency of cell division septum formation over the nucleoid, however, deletion of both slmA 
and minCDE resulted in a drastic increase in septa forming over the nucleoid region (90). 
Importantly, when the researchers blocked DNA replication, deletion of slmA caused a marked 
increase in septum formation over nucleoids (90). Therefore, SlmA is required to prevent cell 
division from occurring at the same location as the nucleoid, thereby providing feedback 
inhibition to the cell division machinery based on DNA replication.  
 How does SlmA prevent cell division from occurring over the nucleoid? GFP-SlmA 
localizes to the nucleoid, and if the helix-turn-helix domain is removed GFP-SlmA becomes 
diffusely cytosolic (90). The helix-turn-helix domain of SlmA is similar to the sequence specific 
DNA binding domains of the TetR family of bacterial transcriptional repressors (90). Indeed, 
SlmA was found to be a sequence specific DNA binding protein that interacts with several 
distinct sites on the E. coli chromosome (92, 93). In addition to DNA binding activity, SlmA can 
also inhibit FtsZ filament formation (93). FtsZ is a tubulin-like protein that forms a ring structure 
composed of several filaments at the site of cell division (94). Although SlmA can inhibit FtsZ 
filament formation, SlmA bound to its DNA binding site inhibits FtsZ far more efficiently (93). 
Therefore, SlmA localizes to the nucleoid by binding at distinct chromosomal loci and prevents 
cell division by inhibiting FtsZ ring formation, thereby providing a mechanism to delay cell 
division if replication and segregation of the chromosome has not completed. 
 The model bacterium B. subtilis also uses nucleoid occlusion to inhibit cell division, 
though the mechanism differs from the system discovered in E. coli. The nucleoid occlusion 
gene noc was identified as a gene that was required in the absence of the Min system (95). When 
both Noc and the Min system were absent, FtsZ failed to form a distinct band at mid-cell (95). 
Further, when DNA replication was blocked in cells without Noc, division septa formed over the 
nucleoids, providing evidence that Noc prevents cell division over the nucleoid (95). Noc is a 
sequence specific DNA binding protein that binds to several distinct chromosomal loci (96). The 
N-terminus of Noc is an amphipathic helix that interacts with the cell membrane (97). Thus, Noc 
is thought to bind to the B. subtilis chromosome and localize to the inner leaflet of the cell 
membrane, which in turn prevents assembly of a complex of proteins necessary for cell division 
called the divisome (97), providing a mechanism by which the nucleoid can delay cell division to 
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allow for DNA replication to complete. In addition, a Noc-independent form of nucleoid 
occlusion following arrest of DNA replication has been observed in B. subtilis, though the 
mechanism and cellular factors responsible for this phenomenon are not clear (98). 
SOS-independent regulation of the divisome 
 In addition to the nucleoid regulating cell division directly, the status of DNA replication 
provides feedback inhibition to the cell division machinery. Transcriptomic studies of the SOS 
response in B. subtilis revealed that many genes were regulated by DNA damage independently 
of the SOS activating protein RecA (99). Further analysis showed that several operons were 
regulated by the essential replication initiator protein DnaA and had binding sites for DnaA in 
their promoters (99). One of the genes that is repressed following inhibition of DNA replication 
is ftsL (99). FtsL is one of the essential protein components of the cell division machinery, and 
previous studies had shown that FtsL is a highly unstable protein (100-102). Inhibition of DNA 
replication caused an increase in cell length independent of the SOS-dependent cell division 
inhibitor (see below); however, overexpression of FtsL resulted in shorter cells on average, 
indicating that a decrease in FtsL is responsible for delaying cell division in response to a block 
in DNA replication (99). Thus, it appears that DnaA relays a block in DNA replication to the cell 
division machinery by repressing expression of the unstable divisome protein FtsL. 
SOS-dependent DNA damage checkpoint 
 Although the above mechanisms contribute to the regulation of cell division in response 
to DNA replication status, the most well understood mechanism of control in bacteria is the 
SOS-dependent cell cycle checkpoint. The bacterial DNA damage checkpoint was originally 
discovered in E. coli. Long before the effects of treatment with UV light on DNA synthesis were 
understood (11, 103), E. coli cells were found to elongate and grow into long filaments following 
exposure to UV light (104). More than three decades later, the existence of a specific cell 
division inhibitor was hypothesized (105). The hypothesis was that the gene encoding the cell 
division inhibitor was regularly repressed, and inhibition of DNA replication would result in de-
repression and therefore accumulation of a protein that could prevent cell division (105). 
Remarkably, this hypothesis was upheld over the course of several years of subsequent 
investigation of the DNA damage checkpoint in bacteria. 
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Mutants lacking the ability to elongate or filament in response to DNA damage were 
isolated and originally called sfiA because the mutations suppressed filamentation (106). A 
subsequent study determined that sfiA mutations were in the same gene as sulA mutations, which 
were so named because they suppressed DNA damage sensitivity of lon mutants (107, 108). To 
test whether sulA was controlled by exogenous DNA damage treatments, a LacZ reporter at the 
sulA locus was monitored following several types of DNA damage treatment, which verified that 
sulA expression was inducible by DNA damage (109). The promoter of sulA contains a binding 
site for the repressor LexA (110), and binding of LexA at the promoter of sulA repressed 
transcription (111). Thus, activation of the SOS-response, and therefore inactivation of LexA, 
results in high levels of sulA expression.  
Other methods of increasing SulA protein levels, including over-expression in the 
absence of DNA damage or deletion of lon leads to filamentation (112-114). One of the first 
steps in cell division is the assembly of the FtsZ ring at the future division site (94). Over-
expression of SulA prevents formation of the FtsZ ring in vivo (115). One of the original 
mutations that suppressed DNA damage-induced filamentation, sfiB, mapped to the ftsZ locus. 
Further studies demonstrated that mutations in ftsZ could suppress filamentation resulting from 
SulA accumulation, suggesting that FtsZ could be the direct target of SulA (116, 117). In 
addition, over-expression of FtsZ rescued inhibition of cell division following UV treatment in 
lon mutants, further establishing a link between SulA function and FtsZ (118).  An interaction 
between SulA and FtsZ was detected using a yeast two-hybrid assay. Moreover, several 
mutations in SulA that abolished its ability to inhibit cell division also abolished the interaction 
with FtsZ, and mutations in FtsZ that are not susceptible to SulA over-expression also abolished 
the interaction (119). Experiments using an FtsZ polymerization assay in vitro demonstrated that 
SulA could directly inhibit FtsZ polymerization (117, 120). Mutations in SulA that cannot block 
cell division failed to inhibit FtsZ polymerization, whereas mutations in FtsZ that are refractory 
to SulA accumulation were insensitive to SulA (117, 120). A detailed kinetic analysis of SulA 
inhibition of FtsZ polymerization revealed that SulA increased the concentration of FtsZ required 
for polymerization, and that SulA interaction with FtsZ functions by sequestering FtsZ 
monomers (121). Therefore, increased SulA production that results from SOS activation results 
in temporary inhibition of FtsZ ring assembly, thereby delaying cell division until the SOS 
response is turned off and SulA is degraded (Fig 1.4). 
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The accumulation of SulA is reversed by Lon protease activity. As mentioned above, 
sulA was originally identified by isolation of a mutation that suppressed DNA damage sensitivity 
in a lon mutant (107, 108). The Lon protein was later determined to be an ATP-dependent 
protease (122), leading to the hypothesis that SulA could be a substrate of Lon. Indeed, SulA was 
found to be highly unstable in Lon+ cells; however, in a lon mutant SulA was stabilized, 
indicating that SulA stability is regulated by Lon protease (113). Intriguingly, despite a 
significant increase in SulA stability in lon mutants, pulse-chase labeling experiments 
demonstrated that SulA was still susceptible to proteolysis in vivo (113). Subsequent studies 
identified a second ATP-dependent protease, ClpYQ, that affects the stability of SulA in vivo and 
degrades SulA in vitro (123-125). Although the evidence that Lon protease activity regulated 
SulA stability in vivo was convincing, it was not clear that SulA was a direct substrate of Lon 
protease. Studies using purified Lon protease demonstrated that SulA was indeed a direct 
substrate (126). Thus, Lon protease provides recovery from the DNA damage cell cycle 
checkpoint imposed by SulA, thereby allowing for cell division to proceed (Fig 1.4). 
 The identification of a DNA damage checkpoint in bacteria was an important conceptual 
advance; however, extrapolation of the mechanism beyond E. coli has proven challenging. The 
cell division inhibitor SulA is not well conserved in bacteria. Nonetheless, treatment with DNA 
damaging agents does lead to cell filamentation in B. subtilis (127). The SOS response is 
conserved in B. subtilis, however sulA is not conserved (128). Thus, it was not clear what gene 
product acted as the inhibitor in B. subtilis. To identify the gene coding for the cell division 
inhibitor, a micro-array experiment was performed using wild-type and lexA mutant cells, 
reasoning that if there is an SOS-dependent cell division inhibitor it will be highly transcribed in 
cells lacking the LexA repressor (129). One of the highly transcribed genes in the lexA mutant 
was yneA, and a Northern blot analysis confirmed that the yneA operon was induced in the 
absence of functional LexA (129). The yneA operon is located adjacent to lexA in the B. subtilis 
genome, and inspection of the promoter region of yneA revealed two binding sites for LexA, 
providing evidence that LexA regulates yneA expression directly (129). Indeed, purified LexA 
can bind to the promoter region of yneA (31). 
Examination of lexA mutant cells showed that they were significantly longer relative to 
the wild-type strain, indicating that cell division is inhibited in the lexA mutant (129). Deletion of 
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the yneA operon returned cell length to normal in the lexA mutant strain, suggesting that yneA is 
necessary for inhibiting cell division (129). To test if expression of yneA is sufficient for 
increased cell length, yneA was placed under the control of an IPTG inducible promoter, and 
cells were found to increase in length following addition of IPTG (129). Cell elongation 
following treatment with DNA damage was also mostly dependent on yneA, strongly suggesting 
that YneA is the SOS induced cell division inhibitor (129). Thus, yneA expression is induced by 
DNA damage, and inhibition of cell division is dependent on yneA (Fig 1.5). 
The mechanism of YneA-dependent inhibition of cell division is still not understood. 
Given that SulA prevents FtsZ ring assembly (115), it was hypothesized that YneA could also 
inhibit FtsZ (129). Visualization of FtsZ following YneA expression showed that FtsZ rings still 
form at mid-cell, suggesting that YneA inhibits a different cellular target (130). YneA is a small 
protein containing an N-terminal transmembrane domain and a C-terminal LysM domain (129, 
130). LysM domains in proteins often interact with the peptidoglycan cell wall (131). Expression 
of YneA causes increased cell length; however, following a shift to medium that does not induce 
YneA expression, the cells begin to divide and YneA is rapidly degraded (130). These 
experiments suggest that YneA reversibly inhibits cell division. An alanine scanning 
mutagenesis analysis of the transmembrane domain demonstrated that several residues that 
clustered to a single face of the alpha helix were critical for YneA function in vivo, suggesting 
that YneA may interact with one of the proteins with a transmembrane domain that functions as 
part of the divisome (130). The transmembrane domain is necessary, though not sufficient for 
YneA to inhibit cell division (130). Interestingly, Mo and Burkholder found that YneA is 
cleaved, releasing the YneA C-terminus from the transmembrane domain and into the medium 
(130). Mutation of the putative signal peptide cleavage site did not appreciably decrease YneA 
processing, though mutation to a canonical signal peptide cleavage site resulted in increased 
YneA processing (130). Further, a mutation at the C-terminus of YneA was found to increase 
YneA stability (130). An analysis of cell elongation using these YneA variants demonstrated that 
YneA was processed more quickly resulting in shorter cells, whereas the stabilizing mutation 
resulted in increased cell length, suggesting that full-length YneA is the active form of the 
protein (130). Together, these studies lead to a model wherein YneA is the SOS-dependent cell 
division inhibitor that establishes the DNA damage checkpoint, and degradation of YneA by an 
unknown protease results in cell cycle progression (Fig 1.5). 
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 As several studies continued the search for DNA damage cell cycle checkpoints in other 
bacteria, it became clear that the mechanism discovered in E. coli was not representative of other 
species (132-136). In fact, the use of a small membrane bound protein similar to YneA in B. 
subtilis appears to be the more wide-spread mechanism. Identification of additional cell division 
inhibitors has proved challenging as homology searches have failed to identify homologs in 
distantly related bacterial species, requiring empirical identification. The differences in DNA 
damage checkpoint mechanisms likely reflect the diversity of bacterial life styles, given that the 
need to delay cell division in response to DNA damage will depend on growth rate, the 
frequency and severity of DNA damage encountered in the environment, and DNA repair 
capability of each organism. 
Following the discovery of YneA in B. subtilis, the next cell division inhibitor was 
identified in Mycobacterium tuberculosis. The cell division inhibitor Rv2719c was identified by 
a micro-array experiment as an SOS induced gene (137, 138); and it is located adjacent to LexA 
similar to YneA (139). Intriguingly, many of the DNA damage inducible genes in M. 
tuberculosis are induced independent of RecA (137). Rv2719c is DNA damage inducible, and its 
regulation is not dependent on RecA (138). A mutational analysis of the promoter of Rv2719c 
demonstrated that mutation of LexA binding sites resulted in high levels of reporter expression 
regardless of DNA damage treatment, suggesting that Rv2719c is regulated by LexA but not 
RecA (139). Further analysis of Rv2719c expression and cell length demonstrated that increased 
expression is correlated with increased cell length, and specific over-expression of Rv2719c is 
sufficient to cause an increase in cell length (132). Increased expression of Rv2719c does not 
appear to affect FtsZ as is the case for SulA (132). Rv2719c is a protein containing a 
transmembrane domain and a LysM domain similar to YneA. Purified Rv2719c was found to 
possess cell wall hydrolase activity in vitro, and expression of a GFP-Rv2719c fusion had a 
localization pattern similar to nascent peptidoglycan synthesis, suggesting that inhibitor activity 
may be exerted on the cell wall by Rv2719c (132). Overall, Rv2719c is an SOS-inducible cell 
division inhibitor regulated by LexA independent of RecA, that may act on the cell wall or cell 
wall synthesis machinery to establish a DNA damage-dependent cell cycle checkpoint. 
The observation that yneA and rv2719c are adjacent to lexA in the genomes of their 
respective organisms and that they are transcribed divergently led to the discovery of the DNA 
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damage inducible cell division inhibitor in Corynebacterium glutamicum and S. aureus (133, 
136). The divS gene in C. glutamicum is located adjacent to lexA and its expression is dependent 
on RecA (133). Cell elongation following treatment with DNA damaging agents is dependent on 
recA and divS (133). An analysis of the promoter uncovered LexA binding sites, and LexA binds 
to the promoter region in vitro (140). Over-expression of DivS resulted in increased cell length, 
indicating that increased DivS expression is sufficient to inhibit cell division (133). The DivS 
protein has three domains: an N-terminal domain, a transmembrane domain, and a C-terminal 
domain. The N-terminus was found to be dispensable for cell division inhibition, whereas nine 
amino acids at the C-terminus were required (133). The sites of nascent peptidoglycan synthesis 
and formation of FtsZ rings were found to be decreased following treatment with DNA damage, 
which required DivS (133). Over-expression of DivS also resulted in decreased sites of nascent 
peptidoglycan synthesis (133). The authors hypothesized that disruption of septal peptidoglycan 
synthesis by DivS was a result of blocking FtsZ ring formation (133), though the exact 
mechanism by which DivS activates the DNA damage checkpoint and prevents cell division is 
not clear. The cell division inhibitor SosA in S. aureus is also located adjacent to lexA in the 
genome (136). Investigation of SosA function revealed a direct interaction with PBP1 (136), 
which is crucial for peptidoglycan synthesis at the division septum (141, 142). Although SosA 
appears to interact with PBP1, exactly how SosA inhibits cell division remains unclear. 
 The discovery of the SOS inducible cell division inhibitor in Caulobacter crescentus 
required the use of micro-arrays because the inhibitor is not located near lexA in the genome. 
Expression of the gene encoding the cell division inhibitor sidA increased rapidly following 
treatment with MMC or UV light, and inspection of the promoter revealed putative LexA 
binding sites (134). Deletion of lexA resulted in severe cell elongation that could be rescued by 
deletion of sidA, and over-expression of sidA resulted in significant cell elongation (134), 
demonstrating that SidA over-expression is sufficient to inhibit cell division (134). SidA is a 
small protein that contains a transmembrane domain. A genetic suppressor screen identified 
mutations in ftsW and ftsI, genes encoding two essential components of the divisome involved in 
peptidoglycan synthesis at the division septum, that could suppress cell division inhibition from 
over-expressing SidA (134). SidA was found to interact with FtsW in a bacterial two-hybrid 
assay, and when an untagged FtsW was produced with tagged SidA and FtsI a slight interaction 
was observed (134). SidA did not alter the localization or recruitment of these divisome proteins 
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to the site of division, and experiments using fluorescently labeled vancomycin did not find a 
defect in septal peptidoglycan synthesis following SidA over-expression (134). Together, these 
data support a model wherein SidA is an SOS-induced cell division inhibitor that inhibits the 
activity of the divisome through an undetermined mechanism to establish the DNA damage 
checkpoint.  
SOS-independent DNA damage checkpoint 
A subsequent study in C. crescentus identified a second, SOS-independent cell division 
inhibitor, DidA, whose expression is still DNA damage inducible and that acts by inhibiting the 
divisome (135). DidA is also a small protein containing a transmembrane domain. The authors 
identified a new transcription factor, DriD, that positively regulates didA expression. 
Interestingly, DriD is activated via a DNA damage-dependent mechanism, though it is still 
unclear how DNA damage activates DriD (135). Therefore, in C. crescentus there are two cell 
division inhibitors that interact with the divisome to prevent cell division following DNA 
damage, thus establishing the cell cycle checkpoint. The mechanism of relieving the checkpoint 
remains unknown. 
 
Conclusion 
The bacterial DNA damage response has been studied for decades. Although significant 
progress has been made using the model organism E. coli, it is becoming clear that the 
mechanisms of DNA damage-dependent cell division regulation in other bacteria differ 
significantly. Instead of the small cytoplasmic inhibitor of FtsZ, SulA, the cell division inhibitors 
in other bacteria are small membrane bound proteins that in some cases have been found to 
interact with other components of the cell division machinery (134-136). Still, the mechanism of 
establishing the DNA damage cell cycle checkpoint by membrane bound cell division inhibitors 
has remained unclear, and the mechanism of recovery has not been determined in any organism. 
In the highly tractable model organism B. subtilis, the cell division inhibitor has been identified; 
however, the mechanism of action remains to be elucidated. Although YneA is rapidly degraded 
(130), it was not clear what proteases were responsible for degrading YneA and how they are 
regulated. In Chapter II, I demonstrate that YneA is degraded by two previously uncharacterized 
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proteases. Further, in Chapter III I identify another previously uncharacterized gene that 
negatively regulates YneA, thereby helping to set the threshold for checkpoint activation. Thus, a 
major thrust of this dissertation is illuminating how the DNA damage checkpoint is established 
and relieved in B. subtilis.  
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Figures 
 
Figure 1.1 A model for activation of the bacterial SOS response. Activation of the SOS 
response begins with accumulation of ssDNA that occurs when high levels of DNA damage are 
present (green polygons). The ssDNA is subsequently coated with the protein RecA. The 
resulting RecA/ssDNA nucleoprotein filament stimulates the protease activity of the 
transcriptional repressor LexA (yellow protein). LexA undergoes auto-cleavage, which results in 
de-repression of the LexA regulon. Many of the genes in the LexA regulon are involved in DNA 
repair, DNA damage tolerance, and regulation of cell division a process known as a cell cycle 
checkpoint. Yellow boxes represent LexA binding sites, and purple boxes represent -35 and -10 
promoter sequences. 
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Figure 1.2 Double strand break repair via homologous recombination in bacteria. A double 
strand break is recognized by the end processing machinery, which generates a free 3′ end. RecA 
is loaded onto ssDNA and performs a homology search. After synthesis of the sequence 
information lost at the site of the break, the resulting Holliday junction is resolved, yielding two 
intact chromosomes. 
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Figure 1.3 Nucleotide excision repair in bacteria. A bulky adduct or thymine dimer is 
recognized by UvrA. After lesion recognition, UvrB is recruited and lesion verification is 
performed. Subsequent recruitment of the nuclease UvrC results in two incisions, one on either 
side of the lesion. 
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Figure 1.4 DNA damage-dependent cell cycle checkpoint in E coli. When E. coli cells 
encounter DNA damage (green polygons), the SOS response is activated and the cell division 
inhibitor SulA is over-expressed. SulA prevents cell division by inhibiting assembly of the FtsZ 
ring. Following DNA repair and SOS termination, SulA is degraded by Lon protease, allowing 
cell division to proceed. 
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Figure 1.5 DNA damage-dependent cell cycle checkpoint in B. subtilis. When B. subtilis cells 
encounter DNA damage (green polygons), the SOS response is activated and the cell division 
inhibitor YneA is over-expressed. YneA inhibits cell division through an unknown mechanism 
and subsequent to DNA repair is degraded by unknown proteases, which allows cell division to 
proceed. 
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CHAPTER II 
Discovery of a dual protease mechanism that promotes DNA damage 
checkpoint recovery 
 
 
Abstract 
The DNA damage response is a signaling pathway found throughout biology. In many 
bacteria the DNA damage checkpoint is enforced by inducing expression of a small, membrane 
bound inhibitor that delays cell division providing time to repair damaged chromosomes. How 
cells promote checkpoint recovery after sensing successful repair is unknown. By using a high-
throughput, forward genetic screen, we identified two unrelated proteases, YlbL and CtpA, that 
promote DNA damage checkpoint recovery in Bacillus subtilis. Deletion of both proteases leads 
to accumulation of the checkpoint protein YneA. We show that DNA damage sensitivity and 
increased cell elongation in protease mutants depends on yneA. Further, expression of YneA in 
protease mutants was sufficient to inhibit cell proliferation. Finally, we show that both proteases 
interact with YneA and that one of the two proteases, CtpA, directly cleaves YneA in vitro. With 
these results, we report the mechanism for DNA damage checkpoint recovery in bacteria that use 
membrane bound cell division inhibitors. 
Author summary 
Prokaryotes and eukaryotes coordinate cell division to genome integrity using DNA 
damage checkpoints. Many bacteria express a small, membrane binding protein to slow cell 
division when obstacles to DNA replication are encountered. Cell division inhibitors of this class 
have been identified in several bacterial species, yet the mechanism used to alleviate inhibition 
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30 
 
has remained unknown. Using forward genetics, we identified two unstudied genes, coding for 
the proteases YlbL and CtpA, that when deleted result in sensitivity to drugs that directly damage 
DNA. We show that sensitivity to DNA damage in protease mutants is a result of accumulation 
of the cell division inhibitor. Further, we show that YlbL and CtpA are responsible for degrading 
the cell division inhibitor allowing for cell division to resume. Importantly, these two proteases 
are not homologs, demonstrating a striking example of a bacterium using non-homologous 
enzymes to degrade a single substrate. Our investigation uncovers the previously unknown 
mechanism used to remove a cell division inhibitor, while also illuminating a potential strategy 
that bacteria can use to regulate signaling pathways. The use of multiple, unrelated proteins to 
perform a single function may represent a strategy employed throughout biological systems. 
 
Introduction 
The DNA damage response (DDR, SOS response in bacteria) is an important pathway for 
maintaining genome integrity in all domains of life. Misregulation of the DDR in humans can 
result in various disease conditions (1, 2), and in bacteria the SOS response has been found to be 
important for survival under many stressors (3-5). The DNA damage response in all organisms 
results in three principle outcomes: a transcriptional response, which can vary depending on the 
type of DNA damage incurred, DNA repair, and activation of a DNA damage checkpoint (6-9). 
In eukaryotes, the G1/S and G2/M checkpoints are established by checkpoint kinases, which 
transduce the signal of DNA damage through inactivation of the phosphatase Cdc25 (7). 
Checkpoint kinase dependent inhibition of Cdc25 leads to accumulation of phosphorylated 
cyclin dependent kinases, which prevents cell cycle progression (7). In bacteria, the SOS-
dependent DNA damage checkpoint relies on expression of a cell division inhibitor, though the 
type of inhibitor varies between bacterial species. 
In Escherichia coli, the SOS-dependent DNA damage checkpoint is the best understood bacterial 
checkpoint (6). Upon activation of the SOS response, the cytoplasmic cell division inhibitor 
SulA is expressed (10). SulA accumulation leads to a block in septum formation by preventing 
the assembly of the cytokinetic ring by FtsZ, a homolog of eukaryotic tubulin (11, 12). SulA 
binds directly to FtsZ (13) and inhibits FtsZ polymerization (14, 15). Recovery from the SulA-
induced checkpoint occurs through proteolysis of SulA. Lon is the primary protease responsible 
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for clearing SulA (16-18), although ClpYQ (HslUV) were found to contribute to SulA 
degradation in the absence of Lon (19-21). Thus, the mechanisms of DNA damage checkpoint 
activation by the cytoplasmic protein SulA and subsequent recovery are well understood in E. 
coli. The SulA-dependent checkpoint, however, is restricted to E. coli and a subset of closely 
related bacteria. It is becoming increasingly clear that most other bacteria use a DNA damage 
checkpoint with an entirely different mechanism of enforcement and recovery. 
An evolutionarily broad group of bacterial organisms have been shown to use a notably 
different DNA damage checkpoint mechanism (22-25). In these Gram-positive and Gram-
negative organisms, a small protein with a transmembrane domain is expressed that inhibits cell 
division without targeting FtsZ. One example is in the Gram-negative bacterium Caulobacter 
crescentus, where the SidA and DidA proteins bind to the essential membrane bound divisome 
components, FtsW/N, that contribute to peptidoglycan remodeling (22, 26). Another example is 
the Gram-positive bacterium Bacillus subtilis in which the SOS-dependent cell division inhibitor 
is YneA (23). YneA contains an N-terminal transmembrane domain with the majority of the 
protein found in the extracellular space (27). Upon SOS activation, LexA-dependent repression 
of yneA is relieved and yneA is expressed (23). Increased expression of yneA results in cell 
elongation, though FtsZ ring formation still occurs (27), suggesting YneA inhibits cell division 
through a mechanism distinct from that of SulA. Further investigation found that overexpressed 
YneA is released into the medium, and that full length YneA is likely the active form of the 
protein (27). The mechanism(s) responsible for YneA inactivation is unknown. Therefore, 
although the use of a small, membrane bound cell division inhibitor is wide-spread among 
bacteria, in all cases studied the mechanism of checkpoint recovery remains unknown (22-26). 
We report a set of forward genetic screens to three different classes of DNA damaging 
agents using transposon mutagenesis followed by deep sequencing (Tn-seq). Our screen 
identified two proteases, YlbL and CtpA, that are important for growth in the presence of DNA 
damage. Mechanistic investigation demonstrates that YlbL and CtpA have overlapping 
functions, and in the absence of these two proteases, DNA damage-dependent cell elongation is 
increased and checkpoint recovery is slowed. A proteomic analysis identified accumulation of 
YneA in the double protease mutant. We also found that DNA damage sensitivity of protease 
mutants depends solely on yneA. Further, we show that both proteases interact with full length 
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YneA in a bacterial two-hybrid assay, and that CtpA is able to digest YneA in a purified system. 
With these results, we present a model of DNA damage checkpoint recovery for bacteria that use 
the more wide-spread mechanism employing a small, membrane bound cell division inhibitor. 
 
Results 
Forward genetic screen rationale and analysis 
In order to better understand the DNA damage response in bacteria, we performed three 
forward genetic screens using B. subtilis. We generated a transposon insertion library consisting 
of more than 120,000 distinct insertions (Table 2.1). The coverage of each transposon mutant in 
the library was plotted against the genome coordinates, which showed that the distribution of 
insertions was approximately uniform across the chromosome in the population of mutants (Fig 
2.1A). Two small exceptions were detected where coverage decreased. Decreased coverage 
corresponds to regions where many essential genes are clustered (Fig 2.1A, arrow heads). With 
the goal of  identifying mutants important for the DNA damage response, we grew parallel 
cultures of either control or DNA damage treatment over three growth periods, modelling our 
experimental design after a previous report (Fig 2.1B) (28). Mitomycin C (MMC), methyl 
methane sulfonate (MMS), and phleomycin (Phleo) were chosen for screening because these 
agents represent three different classes of antibiotics that damage DNA directly. MMC causes 
inter- and intra-strand crosslinks and larger adducts (29, 30), MMS causes smaller adducts 
consisting of DNA methylation (31), and Phleo results in single and double stranded breaks (32, 
33). As a result, we reasoned that the combined data would provide a collection of genes that are 
generally important for the DNA damage response. 
After sequencing, we performed quality control analysis. First, given that sequencing data 
are count data, the distribution of the coverage should be log-normal (34). Indeed, the 
distribution of each replicate for the initial library and starter culture samples is approximately 
log-normal (Fig 2.2A). We also found that the distributions for the remaining time points of the 
pooled replicates followed an approximate log-normal distribution (Fig 2.2B). The sequencing 
data and viable cell count data (Table 2.1) were used to calculate the fitness of each insertion 
mutant in each condition (Fig 2.1C) (35, 36). The relative fitness of each insertion was 
calculated by taking the ratio of treatment to control (Fig 2.1C), thereby isolating fitness effects 
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of the treatments. The relative fitness of each gene was determined by averaging the relative 
fitness calculated for each insertion within a gene (Fig 2.1C). To verify that a t-test would be 
appropriate for determining relative fitness deviating significantly from one, we plotted the 
distribution of insertion relative fitness. All the distributions were normal with a mean close to 
one (Fig 2.2C). We determined the relative fitness for every gene with sufficient data (see 
supplemental methods), and report the relative fitness values and the adjusted p-values for genes 
with the lowest 200 relative fitness values in each growth period (37) (Table 2.3).  
Tn-seq identified genes involved in DNA repair and genes of unknown function 
Initial inspection found that transposon insertion in several genes known to be involved 
in DNA repair (recA, ruvAB, recN, and recOR (38)) resulted in decreased relative fitness in 
growth period one of all experiments (Table 2.2). A closer analysis of recN, addA, and polA, 
three genes that are found toward the top of the lists in all treatments, showed that relative fitness 
is less than one in most cases, though in the Phleo experiment, it appears that the cultures were 
adapting to the treatment by growth period three (Fig 2.1D). For comparison, we also plotted the 
relative fitness of thrC, a gene involved in threonine biosynthesis, and found the relative fitness 
to be about one in all conditions examined (Fig 2.1D). Importantly, insertion in uvrA, a 
component of the nucleotide excision repair machinery (38, 39) which helps repair MMC 
adducts but not MMS or Phleo related damage (40, 41), decreased relative fitness in growth 
periods 2 and 3 with MMC, but did not significantly decrease relative fitness in MMS or Phleo 
(Fig 2.1D and Table 2.2). Taken together, these results validate the approach by demonstrating 
that we were able to identify genes known to be involved in DNA repair.  
We also wondered whether our results contained false positives. To test this, we decided 
to experimentally validate the genes with the forty lowest relative fitness values from growth 
period two in the MMC experiment. We found that eight of the forty gene deletions were not 
sensitive to MMC in a spot titer assay (Table 2.3). Several genes that were false positives are 
located in the genome near genes with validated phenotypes, suggesting that polar effects explain 
some of the false positives (Table 2.3; see supplemental results for detailed analysis). To 
identify genes required generally as part of the DNA damage response, we examined the 200 
genes from growth period two with the lowest relative fitness and an adjusted p-value less than 
0.01 from all three experiments (Table 2.4). We found that 21 genes overlapped for all three 
34 
 
experiments (Fig 2.1E), some of which are known to be involved in DNA repair (recN, addB, 
polA, radA), while several genes have no known function (e.g., ylbL and ctpA) (Table 2.4). 
YlbL and CtpA require putative catalytic residues for function 
Among the genes important for growth in the presence of DNA damage, we focused on 
two putative proteases YlbL and CtpA. YlbL is predicted to have three domains: a 
transmembrane domain, a Lon protease domain, and a PDZ domain (Fig 2.3A). CtpA is 
predicted to have four domains: a transmembrane domain, a S41 peptidase domain, a PDZ 
domain, and a C-terminal peptidoglycan (PG) binding domain (Fig 2.3A). In all three Tn-seq 
experiments, the relative fitness of insertions in either ylbL or ctpA was significantly less than 
one in the second and third growth periods (Fig 2.3B), suggesting that absence of either protease 
results in sensitivity to DNA damage. In contrast, a control gene amyE, which is involved in 
starch utilization, had a relative fitness of approximately one in all conditions examined (Fig 
2.3B). To verify the Tn-seq results, we constructed clean deletions of ylbL and ctpA and found 
both mutants to be sensitive to DNA damage in a spot titer assay (Fig 2.3C). Each phenotype 
was also complemented by ectopic expression of each protease in its respective mutant 
background (Fig 2.3C). To identify putative catalytic residues, we aligned the protease domain 
of YlbL to LonA and LonB from B. subtilis and Lon from E. coli. The sequence alignment 
revealed that YlbL contains a putative catalytic dyad consisting of a serine (S234) and a lysine 
(K279) (Fig 2.4A). Similarly, we aligned CtpA to its homologs CtpB from B. subtilis and Prc 
from E. coli, which identified a putative catalytic triad consisting of a serine (S297), a lysine 
(K322), and a glutamine (Q326) (Fig 2.4B). To test whether these putative catalytic residues 
were required for function, we attempted to complement the DNA damage sensitivity phenotype 
via ectopic expression of serine and lysine mutants. Both the serine and lysine mutants of YlbL 
and CtpA failed to complement the deletion phenotypes (Fig 2.3C). The variants and the wild-
type proteases were ectopically expressed to the same level in vivo (Fig 2.3D), suggesting that 
the lack of complementation is not due to instability caused by the amino acid changes. With 
these results, we conclude that protease activity is required for YlbL and CtpA to function in 
response to DNA damage. 
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YlbL and CtpA have overlapping functions 
The similarity in phenotypes led us to hypothesize that YlbL and CtpA have overlapping 
functions. To test this, we performed a cross-complementation experiment using spot titer assays 
for MMC sensitivity. Over-expression of YlbL, but not YlbL-S234A, complemented a ctpA 
deletion (Fig 2.5A & B). Similarly, over-expression of CtpA, but not CtpA-S297A, 
complemented a ylbL deletion (Fig 2.5A & B). In addition, deletion of both proteases rendered 
B. subtilis hypersensitive to MMC, even more so than loss of uvrA, which codes for the protein 
responsible for recognizing MMC adducts as part of nucleotide excision repair (Fig 2.5C) (38, 
39). To further test the hypothesis that YlbL and CtpA have overlapping functions, we over-
expressed each of the proteases separately in the double protease mutant background and 
observed a complete rescue of MMC sensitivity upon expression of the wild type (WT), but not 
the serine variants (Fig 2.5D & E). 
DNA damage-dependent cell division delay is increased in protease deletions 
The experiments performed thus far cannot distinguish between sensitivity to MMC 
resulting from cell death, growth inhibition or both. To determine whether sensitivity arises from 
cell death, we performed a survival assay using an acute treatment of MMC. We detected a slight 
decrease in percent survival as MMC concentration increased in the ΔylbL and the double mutant 
strain (Fig 2.6A). We compared the decrease in percent survival in single and double protease 
mutants to a ΔuvrA strain, which has been shown previously to be acutely sensitive to MMC 
(40). The strain lacking uvrA was very sensitive to an acute treatment of MMC (Fig 2.6A), 
whereas, the double protease deletion strain was significantly less sensitive to acute exposure 
compared with ΔuvrA (compare Fig 2.5C & 2.6A). Taken together, we conclude that MMC 
sensitivity of the protease mutants observed in spot titer assays is primarily caused by growth 
inhibition. 
We hypothesized that sensitivity to DNA damage resulting from growth inhibition could 
also be explained by inhibiting cell proliferation, or by inhibiting cell division rather than cell 
growth. To distinguish between these two possibilities, we measured cell length, because 
inhibition of proliferation should be observed as an increase in cell length, consistent with a 
failure in checkpoint recovery. Thus, we designed a MMC recovery assay, reasoning that 
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following treatment with MMC, cells lacking YlbL, CtpA, or both, would remain elongated 
showing slower checkpoint recovery relative to the WT strain. We grew cultures either in a 
vehicle control or in the presence of MMC. After a two-hour treatment, the MMC containing 
media was removed and cells were washed. Cells were then transferred to fresh media without 
MMC and allowed to continue growth to assay for checkpoint recovery. Although cells appeared 
to be elongated in the ΔylbL and double mutant strains, there was heterogeneity in the population 
(Fig 2.7A). As a result, we measured the cell length of at least 900 cells for each genotype and 
each condition and plotted the cell length distributions as histograms (Fig 2.7B). There was no 
difference in the vehicle control cell length distributions (Fig 2.7B). The MMC treatment of all 
strains resulted in a rightward shift in the distribution for all strains (Fig 2.7B, compare upper 
panels). When comparing the protease deletions to the WT, the difference in distribution could 
be visualized by considering the percentage of cells greater than 6.75 μm in length, which is 
about three cell lengths of 2.25 μm each. We found that deletion of ylbL resulted in an increase 
in the percentage of cells longer than 6.75 μm in MMC treated cultures and after both two hours 
and four hours of recovery (Fig 2.7C). Deletion of ctpA, however, resulted in a very slight, 
though significant (p-value = 0.0142 for one-tailed Z-test), increased percentage of cells longer 
than 6.75 μm after 4 hours of recovery (Fig 2.7C). The double mutant resulted in a percentage of 
cells slightly greater than ΔylbL alone after both two hours (p-value = 0.0001 for one-tailed Z-
test) and four hours (p-value = 0.0088 for one-tailed Z-test) of recovery (Fig 2.7C).  
Taken together, we conclude that YlbL is the primary protease under these conditions, 
with CtpA also contributing. We also conclude that cells lacking YlbL or both YlbL and CtpA 
take longer to divide following exposure to MMC, which is consistent with DNA damage 
sensitivity resulting from inhibition of cell proliferation. Further, the observation of inhibition of 
cell proliferation suggests that YlbL and CtpA proteases could be important for DNA damage 
checkpoint recovery (see below).   
YlbL and CtpA levels are not regulated by DNA damage 
A potential model to regulate YlbL and CtpA in response to DNA damage is to increase 
protein levels following exposure to DNA damage. Increased protease levels in response to DNA 
damage could promote the DNA damage checkpoint recovery when needed. To test this model, 
we monitored YlbL and CtpA protein levels via Western blotting over the course of the MMC 
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recovery assay. YlbL and CtpA protein levels did not change relative to the loading control 
DnaN throughout the course of the experiment (Fig 2.6B & C). As a positive control, we 
performed the same experiment and monitored RecA protein levels and found that, indeed, RecA 
protein levels increased (Fig 2.6B & C), as expected because recA is induced as part of the SOS 
response (42, 43). We conclude that YlbL and CtpA protein levels are not regulated by DNA 
damage. 
The cell division inhibitor YneA accumulates in protease mutants 
The data presented thus far led us to hypothesize that in the absence of YlbL and CtpA, a 
protein accumulates which results in inhibition of cell division (Fig 2.8A). To identify the 
accumulating protein, we performed an analysis of the entire proteome of WT and double 
protease mutant cell extracts. We chose to analyze the proteomes of cells after two hours of 
recovery, because the cell length distributions differed most between WT and the double 
protease mutant (Fig 2.7B). We found that the normalized spectral count data had similar 
distributions for both WT and the double mutant, which were approximately log normal (Fig 
2.9A). We verified that the distribution of the test statistic (the difference in double mutant 
average and WT average) was normally distributed (Fig 2.9B), thus allowing a t-test to be used. 
We also performed a principle component analysis and found that WT replicates and double 
mutant replicates each clustered together (Fig 2.9C). 
In total, 2329 proteins were detected, and 183 proteins were found to be differentially 
represented (p-value < 0.05) in the double mutant relative to WT (Table 2.5). Of the proteins 
differentially represented in the double mutant, 104 had a fold change greater than one (Fig 2.8B, 
red points). There are three major mechanisms that have been reported in B. subtilis to inhibit 
cell division: 1) Noc dependent nucleoid occlusion (44), 2) FtsL depletion (45, 46), and 3) 
expression of YneA (23). One possibility was that Noc protein levels were higher in the double 
mutant, but we observed no difference in Noc levels (Fig 2.9D). Another possibility was that 
FtsL or the protease RasP, which degrades FtsL, was affected in the protease mutant background 
(46). We found no difference in relative protein abundance of FtsL or RasP (Fig 2.9D), ruling 
out the FtsL/RasP pathway. Among the top 10 proteins that were more abundant in the double 
mutant was YneA, the SOS-dependent cell division inhibitor (Table 2.5). We asked if the 
enrichment of YneA was simply because it is SOS induced. We analyzed the relative abundance 
38 
 
of several other proteins that are known to be SOS induced, including RecA, UvrA, UvrB, DinB, 
and YneB (42), which is encoded in an operon with YneA (23). We found that none of these 
other proteins were enriched in the double mutant (Fig 2.9E). These results suggest that YneA 
accumulation is not a result of increased SOS activation, and regulation of YneA accumulation is 
likely to be post translational, because the protein levels of another member of the operon, YneB 
were unchanged. Taken together, our proteomics data suggest that YlbL and CtpA promote DNA 
damage checkpoint recovery through regulating YneA protein abundance. 
We directly tested for YneA accumulation in protease mutants throughout the MMC 
recovery assay using Western blotting. YneA accumulated in all protease deletion strains after 2 
hours and 4 hours of recovery, though YneA accumulation in ΔctpA was slight (Fig 2.8C). In the 
double mutant, YneA accumulated in the MMC treatment condition in addition to both recovery 
time points (Fig 2.8C). In the double mutant we observed multiple YneA species, which we 
hypothesize to be the result of unnaturally high YneA protein levels resulting in non-specific 
cleavage by other proteases. With these results, we suggest that YneA is a substrate of YlbL and 
CtpA, both of which degrade YneA allowing for checkpoint recovery. 
yneA is required for DNA damage sensitivity and cell elongation phenotypes 
Although accumulation of YneA fit our data well, we considered that the other proteins 
enriched greater than five-fold in the double mutant may have contributed to the DNA damage 
sensitivity phenotype. To test this, we constructed deletions of each gene in WT and the double 
mutant and tested for MMC sensitivity. We found that no single deletion of each of the 10 genes 
resulted in sensitivity to MMC (Fig 2.10A). In the double mutant, only deletion of yneA was able 
to rescue the sensitivity to MMC (Fig 2.10A). We verified that deletion of yneA could rescue 
MMC sensitivity in all protease mutant backgrounds (Fig 2.11A). We examined cell length in 
the DNA damage recovery assay. As expected, deletion of yneA resulted in less severe cell 
elongation relative to WT (compare WT in Fig 2.7B and ΔyneA∷loxP in Fig 2.11B). In 
addition, deletion of ylbL, ctpA, or both no longer changed the cell length distribution in the 
absence of yneA at the two-hour recovery time point (Fig 2.11B, 2.11C, and 2.10B). In the 
MMC treatment, we did observe a slight increase (p-value = 0.0004 for one-tailed Z-test) in the 
percentage of cells greater than 6.75 μm in the double protease deletion strain compared to WT 
(Fig 2.11C). Given that MMC sensitivity and most cell elongation in protease mutants depends 
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on yneA, we hypothesized that expression of YneA alone would be sufficient to inhibit growth to 
a greater extent in the protease mutants. Indeed, strains lacking YlbL, CtpA or both were more 
sensitive to over-expression of yneA from an IPTG inducible promoter than WT (Fig 2.11D). 
Further, we show that YneA accumulated in the protease mutant strains following yneA ectopic 
expression (Fig 2.11E). We conclude that YneA accumulation results in severe growth inhibition 
in cells lacking YlbL and CtpA. 
CtpA specifically digests YneA in vitro 
To test the hypothesis that YneA is a direct substrate of the proteases we purified YneA 
(a.a. 28-103), CtpA (a.a 38-466), and YlbL (a.a 36-341) lacking their N-terminal transmembrane 
domains to allow for isolation. We were unable to detect protease activity from YlbL using 
YneA, lysozyme, or casein as substrates (Figure 2.12; see discussion). When purified CtpA was 
incubated with YneA, we observed digestion of YneA over time, but no digestion was observed 
using CtpA-S297A (Fig 2.13A). To test if CtpA activity against YneA was specific we 
completed the same reaction using lysozyme as a substrate and detected no activity (Fig 2.13B). 
We conclude that YneA is a direct and specific substrate of CtpA. 
YlbL-S234A and CtpA-S297A interact with YneA 
Although we could not detect YlbL protease activity in vitro we asked if YlbL could 
interact with YneA. To test this, we used a bacterial two-hybrid assay (47, 48). We used this 
assay because it is effective at detecting interactions between membrane proteins (22, 26, 49). 
We tested YlbL-S234A and CtpA-S297A to prevent digestion of YneA, and assayed for 
interaction with full length YneA or YneA without its transmembrane domain (YneAΔN) as a 
control. We found that YlbL and CtpA both interacted with full length YneA (Fig 2.13C), but no 
interaction was detected with YneAΔN (Fig 2.13C), likely due to YneA failing to localize to the 
membrane. Given that YlbL did not have activity in vitro and we detected an interaction with 
YneA in the bacterial two-hybrid assay, we suggest that YneA is a direct substrate of YlbL and 
that YlbL requires full length YneA for interaction. 
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Discussion 
How do YlbL and CtpA recognize YneA as a substrate? An intriguing facet of this 
checkpoint recovery mechanism is the use of unrelated proteases. YlbL and CtpA both have 
transmembrane domains and PDZ domains, but the peptidase domains are very different. CtpA 
has a S41 peptidase domain and is homologous to Tail-specific protease or Tsp (also Prc), which 
recognizes the C-terminus of its substrate through its PDZ domain (50, 51). We suggest that 
CtpA also recognizes YneA through the PDZ domain and that this mechanism explains how 
CtpA recognizes its other cognate substrates. In fact, the study by Mo and Burkholder identified 
a residue at the C-terminus of YneA (D97) which when mutated to alanine stabilizes YneA (27). 
It is tempting to speculate that D97 in YneA is important for CtpA to recognize YneA. The 
mechanism by which YlbL recognizes YneA is less clear. YlbL has a unique domain 
organization not found in other studied proteases. YlbL does not have the AAA+ ATPase 
domain common in other Lon proteases, which is logical given that YlbL likely resides 
extracellularly in order to degrade YneA. Instead of an ATPase domain, YlbL has a PDZ 
domain, which could act as a substrate recognition domain or as an inhibitory domain similar to 
the PDZ domain of DegS (52-54). The bacterial two hybrid assay suggests that YlbL does 
recognize YneA directly (Fig 2.13C), though we cannot rule out the possibility that there is an 
adaptor protein that recognizes YneA when these proteins are tethered to the membrane. We also 
did not identify a potential adaptor in the Tn-seq data further suggesting a direct interaction does 
occur between YlbL and YneA. A final possibility is that YlbL recognizes YneA through the 
transmembrane domain, which then activates the Lon peptidase domain to degrade or cleave 
YneA. This would also explain the reason we were unable to detect activity using YlbL lacking 
its transmembrane domain. In any case, further experiments are necessary to elucidate the 
mechanism by which YlbL recognizes YneA.  
All organisms control cellular processes through regulated signaling. To regulate a 
cellular process a signaling pathway must have mechanisms of activation and inactivation. Many 
bacteria use a small membrane protein as an SOS-induced DNA damage checkpoint protein (22-
25). The mechanism of checkpoint recovery, however, for organisms using membrane protein 
checkpoints has remained unclear. Our comprehensive study identified a dual protease 
mechanism of DNA damage checkpoint recovery (Fig 2.13D). Proteases YlbL and CtpA are 
constitutively present in the plasma membrane of cells even in the absence of DNA damage. 
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After encountering DNA damage, YneA expression is induced. We hypothesize that YlbL and 
CtpA activities become saturated by increased YneA expression, which results in a delay of cell 
division. Following DNA repair, expression of YneA decreases and YlbL and CtpA clear any 
remaining YneA allowing cell division to resume.  
DNA damage checkpoints are of fundamental importance to biology, and we have 
discovered the pathway responsible for checkpoint inactivation and cell cycle re-entry in B. 
subtilis. These findings represent an important advance in identifying how checkpoint recovery 
occurs in bacteria. The membrane bound cell division inhibitors identified to date (22-25) are not 
homologs of YneA, and in fact the only unifying feature is that they are small membrane bound 
proteins (22-25). This poses a great challenge because the components of checkpoint 
enforcement and recovery need to be experimentally identified. Our study serves as a model to 
identify the checkpoint recovery proteases through forward genetics, which in turn could be used 
to identify the enforcement protein through proteomics. The critical feature of our approach was 
the use of several growth periods in Tn-seq, which allowed us to identify both proteases. Thus, 
we propose a strategy using the combined approaches of forward genetics and targeted 
proteomics to identify the DNA damage checkpoint pathways in genetically tractable bacterial 
pathogens.  
Recovery from a DNA damage checkpoint is a critical process for all organisms. One 
theme found throughout biology is the use of multiple proteins with overlapping functions. In 
eukaryotes, the phosphorylation events that establish the checkpoint are removed by multiple 
phosphatases (55, 56). In E. coli, there are two cytoplasmic proteases, Lon and ClpYQ, that have 
been found to degrade the cell division inhibitor SulA  (16, 18-20). Our study further extends the 
use of multiple factors in regulating checkpoint recovery to B. subtilis by describing a 
mechanism using two proteases. In eukaryotes, multiple proteins with overlapping functions 
often exist due to spatial or temporal restrictions, which appears to at least partially explain the 
use of multiple factors in checkpoint recovery (55, 56). In E. coli, ClpYQ was found to be 
important at higher temperatures in the absence of Lon (19), again suggesting that each protease 
functions under specific conditions. In the case of YlbL and CtpA, however, there appears to be 
a shared responsibility in rich media. Deletion of each protease results in DNA damage 
sensitivity and the double mutant has a more severe sensitivity. In contrast, during growth in 
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minimal media, YlbL appears to be the primary protease, as the cell elongation phenotype is 
more pronounced in cells lacking ylbL. Still it is unclear how or when each protease functions. 
Why isn’t one protease sufficient to degrade YneA? Do the proteases occupy distinct loci in the 
cell, requiring that each protease degrades a specific YneA pool? Another possibility is that 
protease levels are constrained by another evolutionary pressure, such as substrates unique to 
each protease. Thus, the cell cannot maintain the individual proteases at levels required to titrate 
YneA as part of the DDR, because the levels of another substrate would be too low. Another 
explanation is that using multiple factors is an evolutionary strategy that increases the fitness of 
an organism. It is clear that checkpoint recovery is crucial, because the fitness of cells lacking 
ylbL or ctpA is significantly decreased in the presence of DNA damage (Table 2.2).  
Although the dual protease mechanism described here resolves an important step in the 
DDR, our data also reveal the complexity of the system. After we exposed cells to MMC the 
cells elongated. We noticed, however, that not all elongation depended on yneA (Fig 2.11B), 
suggesting another mechanism for cell cycle control. In B. subtilis, there have been reports of 
yneA-independent control of cell division following replication stress (45, 57, 58). The essential 
cell division component FtsL has been reported to be unstable, and depletion leads to inhibition 
of cell division (58). Further, ftsL transcript levels were reported to decrease following 
replication stress independent of the SOS response (45), thus linking depletion of the unstable 
FtsL protein to cell division control following replication stress. A study using a replication 
block, consisting of the Tet-repressor bound to a Tet-operator array, observed cell division 
inhibition independent of yneA, noc, and FtsL (57). Interestingly, recent studies of Caulobacter 
crescentus uncovered two cell division inhibitors that are expressed in response to DNA damage, 
with one inhibitor SOS-dependent and the other SOS-independent (22, 26). In B. megaterium, a 
recent study found that the transcript of yneA is unstable following exposure to DNA damage 
(59), suggesting yet another layer of regulation. No factor was identified to regulate yneA 
transcripts in the previous study, though it is possible that one of the genes of unknown function 
identified in our screens could regulate yneA mRNA. Together, these studies highlight the 
complexity of regulating the DNA damage checkpoint in bacteria. 
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Materials and Methods 
Bacteriological methods and chemicals 
Bacterial strains, plasmids, and oligonucleotides used in this study are listed in Tables 
2.6, 2.7, and 2.8 and the construction of strains and plasmids is detailed in the supplemental 
methods. All Bacillus subtilis strains are isogenic derivatives of PY79 (60). Bacillus subtilis 
strains were grown in LB (10 g/L NaCl, 10 g/L tryptone, and 5 g/L yeast extract) or S750 
minimal media with 2% glucose (1x S750 salts (diluted from 10x S750 salts: 104.7g/L MOPS, 
13.2 g/L, ammonium sulfate, 6.8 g/L monobasic potassium phosphate, pH 7.0 adjusted with 
potassium hydroxide), 1x metals (diluted from 100x metals: 0.2 M MgCl2, 70 mM CaCl2, 5 mM 
MnCl2, 0.1 mM ZnCl2, 100 μg/mL thiamine-HCl, 2 mM HCl, 0.5 mM FeCl3), 0.1% potassium 
glutamate, 2% glucose, 40 μg/mL phenylalanine, 40 μg/mL tryptophan) at 30°C with shaking 
(200 rpm). Mitomycin C (MMC), methyl methane sulfonate (MMS), and phleomycin were used 
at the concentrations indicated in the figures. The following antibiotics were used for selection in 
B. subtilis as indicated in the method details: spectinomycin (100 μg/mL), chloramphenicol (5 
μg/mL), and erythromycin (0.5 μg/mL). Selection of Escherichia coli (MC1061 or TOP10 cells 
for cloning or BL21 for protein expression) transformants was performed using the following 
antibiotics: spectinomycin (100 μg/mL) or kanamycin (50 μg/mL). 
Tn-seq 
A transposon insertion library was constructed similar to (61) with modifications 
described in the supplemental methods. Tn-seq experiments were designed with multiple growth 
periods similar to a prior description (28), with a detailed description in the supplemental 
methods. Sequencing library construction and data analysis were performed as described 
previously (35, 61) with modifications described in the supplemental methods. Sequencing data 
were deposited into the GEO database with accession number GSE109366. 
Spot titer assays 
B. subtilis strains were struck out on LB agar and incubated at 30°C overnight. The next 
day, a single colony was used to inoculate a 2 mL LB culture in a 14 mL round bottom culture 
tube, which was incubated at 37°C on a rolling rack until OD600 was 0.5-1. Cultures were 
normalized to OD600 = 0.5 and serial diluted. The serial dilutions were spotted (4 μL) on the agar 
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media indicated in the figures and the plates were incubated at 30°C overnight (16-20 hours). All 
spot titer assays were performed at least twice. 
Survival assays 
Survival assays using an acute treatment of mitomycin C were performed as previously 
described (62). Cultures were grown to an OD600 of about 1, and triplicate samples of 0.6 mL of 
an OD600 = 1 equivalent were taken and cells were pelleted via centrifugation: 10,000 g for 5 
minutes at room temperature (all subsequent centrifugation steps were identical). Cells were 
washed with 0.6 mL 0.85% NaCl (saline) and pelleted via centrifugation. Cell pellets were re-
suspended in 0.6 mL saline, and 100 μL aliquots were distributed for each MMC concentration. 
MMC was added to each tube to yield the final concentration stated in the figure in a total 
volume of 200 μL, and cells were incubated at 37°C for 30 minutes. Cells were pelleted via 
centrifugation to remove MMC, re-suspended in saline, and a serial dilution yielding a scorable 
number of cells (about 30-300) was plated on LB agar to determine the surviving fraction of 
cells. Each experiment was performed three times in triplicate for each strain. 
Antiserum production 
Purified proteins (see supplemental methods for purification protocols) were submitted to 
Covance for antibody production using rabbits. Two rabbits were used in the 77 day protocol, 
and the serum with the least background was used for Western blots. 
Western blotting 
For YlbL, CtpA, RecA, and DnaN Western blots, a cell pellet equivalent of 1 mL OD600 
= 1 was re-suspended in 100 μL 1x SMM buffer (0.5 M sucrose, 0.02 M maleic acid, 0.02 M 
MgCl2, adjusted to pH 6.5) containing 1 mg/mL lysozyme and 2x Roche protease inhibitors at 
room temperature for 1 or 2 hours. Samples were then lysed by addition of 6x SDS loading dye 
(0.35 M Tris, pH 6.8, 30% glycerol, 10% SDS, 0.6 M DTT, and 0.012% bromophenol blue) to 
1x. Samples (12 μL) were separated via 10% SDS-PAGE, and transferred to nitrocellulose using 
a Trans-Blot Turbo (BioRad) according to the manufacturer’s directions. Membranes were 
blocked in 5% milk in TBST (25 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) at room 
temperature for 1 hour or at 4°C overnight. Blocking buffer was removed, and primary 
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antibodies were added in 2% milk in TBST (αYlbL, 1:5000 or 1:8000; αCtpA, 1:5000; αRecA, 
1:4000; αDnaN, 1:4000). Primary antibody incubation was performed at room temperature for 1 
hour or overnight at 4°C. Primary antibodies were removed and membranes were washed three 
times with TBST for 5 minutes at room temperature. Secondary antibodies (Licor; 1:15000) were 
added in 2% milk in TBST and incubated at room temperature for 1 hour. Membranes were 
washed three times as above and imaged using the Li-COR Odyssey imaging system. All 
Western blot experiments were performed at least twice with independent samples. Molecular 
weight markers were used in the YlbL and CtpA blots. YlbL migrates to a location between the 
30 and 40 kDa markers, consistent with its predicted molecular weight of 37.6 kDa. CtpA 
migrated to a location between the 40 and 80 kDa markers consistent with its molecular weight 
of 51.1 kDa. 
For YneA Western blots, cell pellets, 10 mL OD600  = 1 for MMC recovery assay and 25 
mL OD600 = 1 for over-expression, were re-suspended in 400 or 500 μL, respectively, of 
sonication buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 20% glycerol, 2x Roche protease 
inhibitors, and 5 mM PMSF), and lysed via sonication. SDS loading dye was added to 2x and 
samples were incubated at 100°C for 7 minutes. Samples (10 μL) were separated using 16.5% 
Tris-Tricine-SDS-PAGE (BioRad) and transferred to a nitrocellulose membrane using a Trans-
blot Turbo (BioRad) according to the manufacturer’s directions. All subsequent steps were 
performed as above with a 1:3000 primary antibody dilution. 
Mitomycin C recovery assay 
An LB agar plate grown at 30°C overnight was washed with pre-warmed S750 minimal 
media and used to inoculate a culture of S750 minimal media at an OD600 = 0.1. The cultures 
were incubated at 30°C until an OD600 of about 0.2 (2- 2.5 hours). MMC was added to 100 
ng/mL and cultures were incubated at 30°C for 2 hours. Cells were pelleted via centrifugation 
(4,696 g for 7 minutes) and the media was removed. Cell pellets were washed in an equal 
volume of 1x PBS, pH 7.4, and pelleted again via centrifugation as above. Cell pellets were re-
suspended in an equal volume of pre-warmed S750 minimal media and incubated at 30°C for four 
hours. Samples for microscopy and Western blot analysis were taken after the two hour MMC 
treatment and at two and four hours following recovery, as indicated in the figures. The vehicle 
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control samples were treated for 2 hours with an equivalent volume of the vehicle in which 
MMC was suspended (25% (v/v) DMSO). 
Microscopy 
A 500 μL sample from the MMC recovery assay above was taken and FM4-64 was added 
to 2 μg/mL and incubated at room temperature for 5 minutes. Samples were then transferred to 
1% agarose pads made of 1x Spizizen’s salts. Images were captured using an Olympus BX61 
microscope. 
Cell length analysis 
Cells were scored for cell length using the measuring tool in ImageJ software. For each 
image scored, all cells that were in focus were measured. The number of cells scored for each 
strain/condition is stated in the figures (n=cells measured). The histograms were generated using 
ggplot2 in R. All scoring was done using unadjusted images. Representative images shown in the 
figures were modified in ImageJ by subtracting the background (rolling ball radius method) and 
adjusting the brightness and contrast. Any adjustments made were applied to the entire image. 
Proteomics experimental details 
Samples (5 mL OD600 = 1) were harvested from cultures grown as described in the MMC 
recovery assay section at 2 hours recovery via centrifugation: 4,696 g at room temperature for 10 
minutes. Samples were washed twice with 500 μL 1x PBS, pH 7.4 and pelleted via 
centrifugation: 10,000 g at room temperature for 5 minutes. Samples were frozen in liquid 
nitrogen and stored at -80°C. Samples were submitted for mass-spectrometry analysis to MS 
Bioworks. Further sample processing and data analysis was performed by MS Bioworks as 
described in the supplemental methods. The raw data files are available upon request and the 
processed data table is provided (Table 2.5). 
YneA and lysozyme digestion assays 
YneA digestion reactions were prepared as a 20 μL reaction in 20 mM Tris pH 7.5, 20 
mM NaCl, and 20% glycerol containing 150 μM YneA, and 2 μM CtpA. Reactions were 
incubated at 30°C for the time indicated in the figure. Reactions were stopped by addition of 6x 
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SDS-dye to 1x and incubating at 100°C for 5 minutes. Reaction products were separated via 
16.5% Tris-Tricine SDS-PAGE. Proteins were detected by staining with coomassie blue. 
Lysozyme digestion assays were performed as for YneA using 2 mg/mL lysozyme and reactions 
were incubated at 30°C for 3 hours. 
Bacterial two-hybrid assays 
Bacterial two hybrid assays were performed as previously described (47, 48, 63). Briefly, 
T18 and T25 fusion plasmids were co-transformed into BTH101 cells and co-transformants were 
selected on LB agar + 100 μg/mL ampicillin + 50 μg/mL kanamycin at 37°C overnight. Cultures 
of LB + 100 μg/mL ampicillin + 50 μg/mL kanamycin were inoculated using several colonies 
and incubated at 37°C for 90 minutes. Cultures were diluted 250-fold and 4 μL were spotted on 
LB agar + 100 μg/mL ampicillin + 50 μg/mL kanamycin + 0.5 mM IPTG + 40 μg/mL X-gal and 
incubated at 30°C for 48 hours, then at room temperature for 24 hours. The brightness and 
contrast of the images were adjusted using Adobe Photoshop with changes applied to the entire 
image. All bacterial two-hybrid assays were performed at least twice. 
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Figures and Tables 
 
Figure 2.1 Forward genetic screen experimental design and data analysis. (A) A plot of the 
log10 of insertion coverage on the y-axis and genomic position in nucleotides on the x-axis. (B) 
Experimental design for Tn-seq experiments. The transposon library was used to inoculate starter 
cultures to allow cultures to reach exponential phase. Cultures were split into control and 
treatment and grown for three growth periods. (C) Equations used to calculate relative fitness 
(W, fitness; G, generations, N, number of cells at the start (N0) or end (Nf) of growth period; F, 
insertion frequency at the start (F0) or end (Ff) of growth period; n, number of insertions used to 
calculate average). (D) The mean gene relative fitness is plotted as a bar graph for the genes 
indicated for all three Tn-seq experiments, error bars represent the 95% confidence interval. (E) 
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A Venn diagram depicting overlaps of the 200 genes with the lowest fitness and an adjusted p-
value less than 0.01 for all three Tn-seq experiments in growth period two. 
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Figure 2.2 Tn-seq data analysis. (A) Sequencing read distributions for transposon (Tn) 
insertion locations containing greater than 0 reads for each replicate of the library samples (left) 
or the starter culture samples (right) from the MMC experiment. The y-axis is the frequency of 
Tn sites, and the x-axis is the log10 of sequencing reads. The dotted vertical line is drawn at 
log10(100). (B) Sequencing read distributions are plotted for the indicated samples as in panel A, 
except the replicates were summed prior to plotting. The library and starter cultures are the same 
in the Ctrl and MMC plots; the library and starter cultures are the same in the MMS and Phleo 
plots, which are shown twice in each case to allow direct comparison. The dotted vertical line is 
drawn at log10(350). (C) Relative fitness distributions are plotted for Tn insertions with more 
than 10 sequencing reads in the control samples. The y-axis is the frequency of Tn sites and the 
x-axis is the relative fitness. The dotted vertical line is drawn at 1.0. All three growth periods are 
plotted for the indicated experiments. 
 
Figure 2.3 YlbL and CtpA require putative catalytic residues for function. (A) Schematics 
of YlbL and CtpA proteins depicting the domain organization. (B) The mean gene relative 
fitness is plotted as a bar graph for amyE, ylbL, and ctpA for all three Tn-seq experiments, error 
bars represent the 95% confidence interval. (C) Spot titer assays using the genotypes indicated 
and plated on LB agar media containing the indicated drugs. (D) Western blot analysis of cell 
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lysates from the indicated genotypes grown with or without xylose using antiserum against YlbL 
(upper panel) and DnaN (lower panel). (E) Western blot analysis of cell lysates from the 
indicated genotypes grown with or without xylose using antiserum against CtpA (upper panel) 
and DnaN (lower panel). 
 
Figure 2.4 YlbL and CtpA catalytic residue identification. (A) The Lon protease domain of 
YlbL was aligned to LonA and LonB from B. subtilis and Lon from E. coli. The alignments 
show that YlbL contains the conserved catalytic dyad of Lon proteases consisting of serine 234 
and lysine 279. (B) The S41 protease domain of CtpA was aligned to CtpB from B. subtilis and 
Prc from E. coli. The alignments showed that CtpA contains a conserved catalytic triad 
consisting of serine 297, lysine 322, and glutamine 326. 
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Figure 2.5 YlbL and CtpA have overlapping functions. (A) Spot titer assay using the 
indicated genotypes and media. (B) Western blot analysis of cell lysates from the genotypes in 
panel A, using the indicated antiserum. (C & D) Spot titer assay using the indicated genotypes 
and media. (E) Western blot analysis of cell lysates from the genotypes indicated in panel D, 
using the indicated antiserum. 
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Figure 2.6 YlbL and CtpA levels are not regulated by DNA damage. (A) MMC survival 
assay using strains with the indicated genotypes to test if MMC sensitivity is caused by cell 
death. The concentration of MMC used during a 30 minute incubation is listed on the x-axis, and 
the y-axis is the percent of cells surviving the treatment relative to the no treatment (0 ng/mL) 
condition. Each point is the average of three technical replicates from three individual 
experiments (n=9), and the error bars represent the standard error of the mean. (B) 
Representative Western blot analysis of cell lysates throughout the MMC recovery assay using 
YlbL, CtpA, DnaN, or RecA antiserum. (C) Quantification of Western blot data plotted as a bar 
graph. The bars represent the average from three experiments (YlbL, CtpA, and DnaN) or two 
experiments (RecA), and the error bars are the standard deviation (YlbL and CtpA) or the range 
(RecA) of the measurements. The y-axis is the relative protein levels, which is the indicated 
protein level normalized to the loading control, DnaN, and the no treatment measurement. 
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Figure 2.7 DNA damage delays cytokinesis in cells with protease deletions. (A) 
Representative micrographs of cells with the indicated genotypes at the indicated time points. 
Membranes were stained with FM4-64. Scale bar is 5 μm. (B) Cell length distributions plotted as 
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histograms. The y-axis in all graphs is normalized by the sample size yielding the density, and 
the x-axis is the cell length in μm. The number of cells scored in each distribution is indicated as 
“n=” and the genotype of each strain is indicated. The dotted vertical line in the “Vehicle” 
distributions is plotted at 2.25 μm, the approximate mean for all strains. The dotted vertical line 
in the remaining distributions is at 6.75 μm, which is three times the average length of untreated 
cells. (C) The proportion of cells represented by the histograms in panel B with length greater 
than 6.75 μm is plotted as a bar graph. The error bars represent the standard deviation,	ට௣ሺଵି௣ሻ௡ , 
where p represents the proportion and n is the sample size. The asterisk indicates a p-value less 
than 0.05. 
 
 
Figure 2.8 YneA accumulates in protease mutants. (A) A model for the function of YlbL and 
CtpA in regulating cell division. (B) Proteomics data plotted as fold change (Double 
Mutant/WT) vs. the p-value. Points plotted in black have a fold change less than one or a p-value 
greater than or equal to 0.05, and points plotted in red have a fold change greater than one and a 
p-value less than 0.05. (C) Western blot analysis of cell lysates from strains with the indicated 
genotypes at the indicated time points from the MMC recovery assay (see methods), using YneA 
or DnaN antiserum. 
58 
 
 
Figure 2.9 YneA accumulates in protease mutants. (A) The averages of the normalized 
spectral counts are plotted as histograms for WT (blue) and ΔylbL, ΔctpA double mutant (DM; 
red). The y-axis is the count and the x-axis is the log10(normalized spectral counts for the average 
of three replicates). (B) The distribution of the test statistic (WT average – DM average) is 
plotted as a histogram. (C) A principle component analysis was performed using the normalized 
spectral counts from WT (blue) and DM (red) samples using the “prcomp” function in R. The 
first two coordinates are plotted as the x- and y-axes, respectively. (D & E) The average relative 
protein levels (WT/DM) from the proteomics dataset are plotted for the indicated proteins, and 
the error bars represent the standard deviation. The inset in panel E shows a closer look around 
one for clarity. 
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Figure 2.10 yneA is required for DNA damage sensitivity and cell elongation phenotypes. 
(A) Strains with the indicated genotypes (plates at left) were struck onto the indicated media 
(column labels) and incubated at 30°C overnight. Deletion of yneA suppresses the ΔylbL, ΔctpA 
double mutant (DM) MMC sensitivity phenotype. (B) Representative micrographs of cells 
stained with FM4-64 from the indicated genotypes at the indicated time points in the MMC 
recovery assay. The scale bar is 5 μm. 
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Figure 2.11 yneA is required for DNA damage sensitivity and cell elongation phenotypes. 
(A) Spot titer assay using the indicated genotypes and media.  (B) Cell length distributions 
plotted as histograms. The number of cells scored in each distribution is indicated as “n=” and 
the genotype of each strain is indicated above the distributions. The dotted vertical line in the 
“Vehicle” distributions is at the approximate mean of 2.25 μm. The dotted vertical line in the 
remaining distributions is at 6.75 μm. The y-axis in all graphs is normalized by the sample size 
yielding the density, and the x-axis is the cell length in μm. (C) The proportion of cells greater 
than 6.75 μm from the distributions in panel B is plotted as a bar graph. The error bars represent 
the standard deviation,	ට௣ሺଵି௣ሻ௡ , where p represents the proportion and n is the sample size. The 
asterisk indicates a p-value less than 0.05. (D) Spot titer assay testing the effect of over 
production of YneA using the indicated concentration of the inducer IPTG. (E) Western blot 
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analysis of cell lysates using 100 μM IPTG for YneA expression with the indicated genotypes, 
using the indicated antiserum. 
 
 
Figure 2.12 Purified YlbL lacking its N-terminal transmembrane shows no protease 
activity in vitro. (A) Protease assay using fluorescently labeled casein. YlbL, YlbL-S234A, 
CtpA, and CtpA-S297A, all lacking their N-terminal transmembrane domains were incubated 
with casein. The casein was fluorescently labeled such that the signal was quenched until 
digested by a protease. (B) YneA digestion assay. YlbL and CtpA were incubated with 
increasing concentrations of YneA. The first lane is a molecular weight marker (M). (C) 
Lysozyme digestion assay. YlbL was incubated with lysozyme. 
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Figure 2.13 DNA damage checkpoint recovery in Bacillus subtilis. (A) Protease assay 
incubating purified CtpA or CtpA-S297A with purified YneA for the indicated time followed by 
SDS-PAGE and staining with coomassie blue. (B) Protease assay incubating purified CtpA or 
CtpA-S297A with commercially available lysozyme for 3 hours followed by SDS-PAGE and 
staining with coomassie blue. (C) Bacterial two hybrid assay using T18 fusions (rows) and T25 
fusions (columns) co-transformed into E. coli. The T25 plasmids are: the empty vector (T25), 
T25-YlbL-S234A (T25-YlbL), and T25-CtpA-S297A (T25-CtpA). The T18 plasmids are: the 
empty vector (T18), T18-YneA, and T18-YneAΔN (which lacks the transmembrane domain). 
(D) A model for YlbL- and CtpA-dependent DNA damage checkpoint recovery. YlbL and CtpA 
are present as membrane proteases, and when high amounts of DNA damage are present, YneA 
production overwhelms both proteases resulting in delayed cell division. After DNA repair is 
complete and YneA expression decreases, YneA is cleared and cell division proceeds. 
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Figure 2.14 Disruption of ylbK results in a polar effect on ylbL. (A) Spot titer assay using the 
indicated genotypes and media. (B) Schematic of ylbK and ylbL loci, with the putative ribosome 
binding site, proposed to control ylbL translation, labeled in yellow. (C) Western blot analysis of 
cell lysates of the indicated genotypes using YlbL or DnaN antiserum. 
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       Viable cell counts per 0.1 mL  
Experiment Sample Aliquot Treatment OD600 after 
outgrowth 
Time (h) Volume for 
back dilution 
(mL) 
1 2 3 Average 
Mitomycin C 
1 A Library N/A initial library N/A 0.27 40 51 18 36.3 
2 B Library N/A initial library N/A 0.27 46 57 67 56.7 
3 C Library N/A initial library N/A 0.27 31 128 57 72.0 
4 A Starter Culture 0.801 4.5 1.561 54 37 37 42.7 
5 B Starter Culture 0.795 4.5 1.572 70 53 57 60.0 
6 C Starter Culture 0.923 4.5 1.354 31 60 83 58.0 
7 A 
Vehicle 
1.91 3 0.654 243 168 209 206.7 
8 B 1.84 3 0.679 183 185 231 199.7 
9 C 1.97 3 0.635 258 254 252 254.7 
10 A 
15 ng/mL MMC 
1.52 3 0.822 47 41 55 47.7 
11 B 1.57 3 0.796 41 57 47 48.3 
12 C 1.63 3 0.767 66 52 55 57.7 
13 A 
Vehicle 
1.5 3 0.833 163 171 189 174.3 
14 B 1.45 3 0.862 173 151 154 159.3 
15 C 1.32 3 0.947 133 154 174 153.7 
16 A 
15 ng/mL MMC 
1.45 4.75 0.862 36 42 41 39.7 
17 B 1.46 4.75 0.856 46 42 47 45.0 
18 C 1.37 4.75 0.912 63 52 30 48.3 
19 A 
Vehicle 
1.94 3 N/A 173 214 223 203.3 
20 B 1.55 3 N/A 219 185 202 202.0 
21 C 1.86 3 N/A 250 251 228 243.0 
22 A 
15 ng/mL MMC 
1.53 5.25 N/A 42 48 36 42.0 
23 B 1.53 5.25 N/A 66 39 67 57.3 
24 C 1.6 5.25 N/A 63 82 82 75.7 
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Std Dev Dilution 
factor 
cells/mL Number of 
cells in 
inoculum 
Number of 
cells after 
growth 
Reads mapped Tnsites with 
>= 10 reads 
16.8 1.0E-07 3.63E+09 N/A N/A 25,717,552  124,742 
10.5 1.0E-07 5.67E+09 N/A N/A 20,998,165  122,781 
50.2 1.0E-07 7.20E+09 N/A N/A 27,266,350  125,359 
9.8 1.0E-05 4.27E+07 9.81E+08 2.14E+09 18,068,418  112,657 
8.9 1.0E-05 6.00E+07 1.53E+09 3.02E+09 26,157,733  117,909 
26.1 1.0E-05 5.80E+07 1.94E+09 2.92E+09 20,234,204  113,777 
37.6 1.0E-05 2.07E+08 6.66E+07 5.49E+09 26,868,722  110,169 
27.2 1.0E-05 2.00E+08 9.43E+07 5.31E+09 20,347,670  106,578 
3.1 1.0E-05 2.55E+08 7.85E+07 6.71E+09 26,068,577  109,800 
7.0 1.0E-05 4.77E+07 6.66E+07 1.27E+09 18,355,525  104,348 
8.1 1.0E-05 4.83E+07 9.43E+07 1.28E+09 21,188,844  107,052 
7.4 1.0E-05 5.77E+07 7.85E+07 1.52E+09 34,690,534  112,553 
13.3 1.0E-05 1.74E+08 1.35E+08 4.47E+09 15,422,397  100,441 
11.9 1.0E-05 1.59E+08 1.36E+08 4.09E+09 23,506,462  107,195 
20.5 1.0E-05 1.54E+08 1.62E+08 3.94E+09 16,657,662  101,421 
3.2 1.0E-05 3.97E+07 3.92E+07 1.02E+09 18,050,792  102,356 
2.6 1.0E-05 4.50E+07 3.85E+07 1.16E+09 21,321,795  105,193 
16.8 1.0E-05 4.83E+07 4.42E+07 1.25E+09 16,814,156  101,041 
26.7 1.0E-05 2.03E+08 1.45E+08 5.25E+09 17,323,113  99,837 
17.0 1.0E-05 2.02E+08 1.37E+08 5.22E+09 18,945,785  103,569 
13.0 1.0E-05 2.43E+08 1.46E+08 6.31E+09 19,070,938  102,109 
6.0 1.0E-05 4.20E+07 3.42E+07 1.09E+09 22,090,553  102,536 
15.9 1.0E-05 5.73E+07 3.85E+07 1.48E+09 33,129,406  108,112 
11.0 1.0E-05 7.57E+07 4.41E+07 1.96E+09 43,808,521  110,543 
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Experiment Sample Aliquot Treatment OD600 after 
outgrowth 
Time (h) Volume for 
back dilution 
(mL) 
1 2 3 Average 
MMS & 
Pheomycin 
1 A N/A N/A initial library N/A 0.5 ND ND ND ND 
2 B N/A N/A initial library N/A 0.5 ND ND ND ND 
3 C N/A N/A initial library N/A 0.5 ND ND ND ND 
4 A N/A 0.82 9.5 1.52 97 72 75 81.3 
5 B N/A 0.879 9.5 1.42 71 81 82 78.0 
6 C N/A 0.781 9.5 1.6 56 46 63 55.0 
7 A 
Vehicle 
1.496 3 0.836 372 220 188 260.0 
8 B 1.512 3 0.827 264 192 198 218.0 
9 C 1.5 3 0.834 244 155 185 194.7 
10 A 
50 μg/mL MMS 
1.51 3.25 0.828 82 102 109 97.7 
11 B 1.508 3.25 0.829 139 146 167 150.7 
12 C 1.466 3.25 0.853 128 121 129 126.0 
13 A 
25 ng/mL 
Phleomycin 
1.482 3.25 0.844 140 143 151 144.7 
14 B 1.534 3.25 0.815 129 156 155 146.7 
15 C 1.494 3.25 0.837 140 141 123 134.7 
16 A 
Vehicle 
1.404 3 0.891 150 133 145 142.7 
17 B 1.432 3 0.873 125 129 187 147.0 
18 C 1.404 3 0.891 110 157 135 134.0 
19 A 
50 μg/mL MMS 
1.484 3.75 0.843 142 185 138 155.0 
20 B 1.45 3.75 0.862 119 120 113 117.3 
21 C 1.424 3.75 0.878 139 113 136 129.3 
22 A 
25 ng/mL 
Phleomycin 
1.478 4 0.846 173 131 176 160.0 
23 B 1.578 4 0.793 162 154 244 186.7 
24 C 1.404 4 0.891 158 149 209 172.0 
25 A 
Vehicle 
1.546 3 N/A 146 118 204 156.0 
26 B 1.38 3 N/A 194 141 114 149.7 
27 C 1.392 3 N/A 137 172 147 152.0 
28 A 50 μg/mL MMS 1.768 4 N/A 166 165 213 181.3 
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29 B 1.784 4 N/A 173 170 236 193.0 
30 C 1.892 4 N/A 178 166 181 175.0 
31 A 
25 ng/mL 
Phleomycin 
1.882 4 N/A 288 400 320 336.0 
32 B 1.718 4 N/A 220 211 213 214.7 
33 C 1.716 4 N/A 362 213 322 299.0 
 
 
Std Dev Dilution 
factor 
cells/mL Number of 
cells in 
inoculum 
Number of 
cells after 
growth 
Reads mapped Tnsites with 
>= 10 reads 
ND ND ND N/A N/A 35,843,091 126,497 
ND ND ND N/A N/A 16,541,861 118,456 
ND ND ND N/A N/A 15,754,152 117,697 
13.7 1.0E-05 8.13E+07 ND 4.11E+09 27,956,965 115,134 
6.1 1.0E-05 7.80E+07 ND 3.94E+09 25,538,172 114,266 
8.5 1.0E-05 5.50E+07 ND 2.78E+09 23,836,182 113,304 
98.3 1.0E-05 2.60E+08 1.24E+08 6.90E+09 22,106,601 96,669 
39.9 1.0E-05 2.18E+08 1.11E+08 5.76E+09 20,265,859 95,577 
45.3 1.0E-05 1.95E+08 8.80E+07 5.18E+09 44,365,650 103,508 
14.0 1.0E-05 9.77E+07 1.24E+08 2.59E+09 60,006,387 106,978 
14.6 1.0E-05 1.51E+08 1.11E+08 3.98E+09 11,507,552 85,925 
4.4 1.0E-05 1.26E+08 8.80E+07 3.35E+09 41,343,336 103,165 
5.7 1.0E-05 1.45E+08 1.24E+08 3.84E+09 48,823,094 105,073 
15.3 1.0E-05 1.47E+08 1.11E+08 3.87E+09 13,240,328 88,983 
10.1 1.0E-05 1.35E+08 8.80E+07 3.58E+09 14,655,221 89,930 
8.7 1.0E-05 1.43E+08 2.17E+08 3.69E+09 15,374,897 90,181 
34.7 1.0E-05 1.47E+08 1.80E+08 3.80E+09 19,755,901 94,282 
23.5 1.0E-05 1.34E+08 1.62E+08 3.46E+09 14,092,828 88,014 
26.1 1.0E-05 1.55E+08 8.09E+07 4.00E+09 20,493,595 94,277 
3.8 1.0E-05 1.17E+08 1.25E+08 3.03E+09 19,078,748 93,789 
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14.2 1.0E-05 1.29E+08 1.07E+08 3.34E+09 17,204,870 92,051 
25.2 1.0E-05 1.60E+08 1.22E+08 4.14E+09 15,834,903 90,135 
49.8 1.0E-05 1.87E+08 1.20E+08 4.82E+09 11,148,113 84,358 
32.4 1.0E-05 1.72E+08 1.13E+08 4.44E+09 37,289,108 100,198 
43.9 1.0E-05 1.56E+08 1.27E+08 4.04E+09 15,933,177 90,922 
40.7 1.0E-05 1.50E+08 1.28E+08 3.87E+09 15,080,780 89,795 
18.0 1.0E-05 1.52E+08 1.19E+08 3.94E+09 22,500,677 95,409 
27.4 1.0E-05 1.81E+08 1.31E+08 4.69E+09 20,224,601 94,064 
37.3 1.0E-05 1.93E+08 1.01E+08 4.99E+09 19,106,876 92,938 
7.9 1.0E-05 1.75E+08 1.14E+08 4.53E+09 19,327,030 93,310 
57.7 1.0E-05 3.36E+08 1.35E+08 8.68E+09 15,917,971 89,971 
4.7 1.0E-05 2.15E+08 1.48E+08 5.54E+09 18,353,865 92,047 
77.1 1.0E-05 2.99E+08 1.53E+08 7.74E+09 18,317,223 91,222 
 
Table 2.1 Tn-seq data collected. OD600 measurements, incubation times, viable cell counts, growth rates estimated based on viable 
cell counts, number of generations estimated based on viable cell counts and incubation times, sequencing sample IDs, sequencing 
reads, reads mapped, and the number of Tn insertions with more than 10 reads for each sample are presented. 
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Mitomycin C Growth period 1 Mitomycin C Growth period 2 Mitomycin C Growth period 3 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
ktrC 0.580 7.3E-04 recN 0.200 1.2E-16 uvrB 0.423 1.7E-40 
recN 0.613 1.3E-54 sepF 0.400 8.0E-06 uvrA 0.466 1.2E-67 
mntB 0.634 4.2E-10 uvrB 0.409 7.2E-68 uvrC 0.478 4.0E-33 
mntC 0.638 1.8E-19 uvrC 0.484 1.6E-56 recN 0.536 2.0E-07 
mntA 0.641 2.6E-13 uvrA 0.489 1.7E-135 U712_09520 0.553 5.1E-07 
ponA 0.660 2.6E-85 addA 0.537 2.0E-10 ylbL 0.561 5.8E-36 
recA 0.666 8.1E-03 rnhC 0.544 3.6E-07 rnhC 0.564 2.9E-04 
mntD 0.671 4.9E-20 crh 0.565 3.0E-03 yprA 0.587 1.3E-106 
recG 0.679 1.4E-17 ruvB 0.568 1.5E-03 yprB 0.589 3.6E-35 
addA 0.684 3.3E-33 ylbL 0.581 1.6E-45 polA 0.607 2.5E-54 
addB 0.689 6.4E-26 ponA 0.587 3.5E-14 lgt 0.608 5.8E-06 
recU 0.708 8.2E-06 bcrC 0.595 4.6E-10 ctpA 0.610 6.5E-38 
gtaB 0.711 4.4E-03 ecsA 0.603 1.7E-04 cymR 0.621 2.2E-11 
codV 0.720 5.6E-06 recR 0.606 2.2E-03 ysoA 0.630 5.4E-20 
clpY 0.723 8.8E-08 queA 0.612 5.3E-06 ylbK 0.635 5.2E-16 
pgcA 0.728 2.7E-06 addB 0.622 4.0E-09 ig1981 0.651 5.2E-03 
codY 0.739 1.1E-06 ig3151 0.627 5.2E-09 ig1437 0.660 8.7E-07 
ig1685 0.739 5.5E-06 ecsB 0.627 4.5E-16 dnaH 0.664 2.5E-07 
ruvB 0.744 6.4E-15 polA 0.649 1.6E-68 ig2 0.665 3.7E-08 
ahrC 0.746 7.2E-03 ylmG 0.656 5.4E-12 ylmG 0.667 3.3E-09 
odhA 0.755 5.9E-04 lgt 0.661 1.2E-13 recD2 0.672 3.2E-57 
ftsH 0.761 5.4E-03 ctpA 0.673 1.9E-52 bcrC 0.673 5.3E-05 
yaaO 0.774 5.8E-04 ripX 0.674 3.4E-04 ecsB 0.673 2.6E-08 
recO 0.783 5.4E-02 ytmP 0.690 2.5E-23 ig2807 0.683 1.0E-11 
ig3172 0.785 1.8E-03 recG 0.695 3.4E-03 ig3151 0.684 1.2E-04 
ruvA 0.785 8.1E-12 ig3116 0.700 9.3E-07 radA 0.690 3.3E-34 
ig2955 0.792 1.6E-04 dnaN 0.702 2.5E-03 ig100 0.705 3.1E-11 
ymdB 0.794 1.3E-12 ig1437 0.705 3.5E-04 ig2610 0.706 4.1E-06 
metN 0.805 1.3E-08 ig1200 0.714 4.5E-04 ig2551 0.712 2.1E-09 
whiA 0.807 1.9E-03 ydzU 0.714 3.1E-06 yneB 0.712 1.4E-14 
yjbH 0.808 1.1E-06 walH 0.715 3.2E-17 spoIIIE 0.713 1.7E-59 
glpD 0.810 5.2E-09 tagO 0.717 3.5E-03 ylmE 0.714 8.9E-09 
pnpA 0.811 6.4E-04 ylmE 0.718 1.6E-08 ig1935 0.714 5.3E-05 
ig37 0.813 3.2E-03 sdaAB 0.724 5.5E-12 yycI 0.715 1.1E-07 
metQ 0.816 5.8E-07 ysoA 0.725 1.2E-22 ig1717 0.715 2.9E-10 
ccpA 0.824 6.9E-11 ig2551 0.726 1.0E-11 yrrB 0.719 1.7E-15 
ripX 0.824 1.4E-09 recX 0.729 5.2E-02 sdaAB 0.730 8.5E-08 
sdhB 0.824 3.2E-03 walJ 0.729 4.1E-18 ig1921 0.732 3.2E-06 
ig1503 0.828 6.3E-02 recD2 0.731 6.4E-68 ig2801 0.744 5.7E-09 
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bcd 0.829 1.1E-06 ig812 0.741 1.2E-03 nrdR 0.748 6.6E-06 
ig1525 0.829 5.0E-02 ig2801 0.742 3.8E-14 recJ 0.751 1.0E-35 
minJ 0.829 2.9E-05 radA 0.742 5.4E-30 ctsR 0.758 2.3E-04 
yneA 0.831 1.7E-07 ylbK 0.746 2.2E-11 recG 0.759 6.7E-05 
walH 0.835 1.1E-10 U712_09520 0.752 2.7E-05 ig2774 0.759 3.8E-11 
braB 0.836 5.7E-15 ig3234 0.755 4.7E-07 addA 0.759 5.1E-04 
ig1977 0.838 6.6E-03 sodA 0.763 5.1E-04 yjzG 0.761 3.4E-05 
sodA 0.839 1.7E-06 cymR 0.770 1.5E-11 ig3623 0.761 2.0E-05 
ctaB 0.843 6.2E-12 yprA 0.773 3.6E-92 ig3404 0.762 1.3E-13 
ytxG 0.844 5.7E-03 yprB 0.777 7.7E-32 ig2409 0.764 5.8E-09 
rnc 0.846 7.1E-03 ig199 0.777 9.2E-08 ig3234 0.765 2.9E-05 
buk 0.848 7.8E-14 ywrC 0.785 4.1E-03 ig199 0.766 5.2E-07 
yvrJ 0.849 1.2E-02 ig2940 0.788 2.5E-03 atpI 0.769 5.5E-11 
queA 0.850 9.0E-11 yycI 0.790 3.9E-15 ig3558 0.775 9.7E-22 
rnhC 0.851 3.0E-09 ig2409 0.790 1.5E-09 ig1983 0.778 5.1E-07 
metP 0.851 7.0E-09 ig2807 0.792 7.8E-09 U712_00035 0.783 2.2E-02 
czrA 0.852 1.9E-03 ig3518 0.792 6.5E-04 walH 0.784 1.3E-07 
ig1623 0.853 2.3E-04 yhcF 0.795 3.0E-10 ig1925 0.784 5.0E-11 
ssrSA 0.853 2.2E-02 ylmH 0.796 4.2E-13 rnjB 0.788 4.7E-44 
menH 0.854 1.0E-07 ig589 0.800 2.7E-24 ctaB 0.788 1.0E-05 
asnS 0.856 1.8E-08 yufK 0.804 3.1E-17 ponA 0.792 7.4E-06 
minC 0.856 3.4E-03 yfhH 0.804 1.3E-04 atpD 0.792 1.3E-04 
ig2118 0.857 1.1E-04 yrrB 0.805 5.0E-11 ig3116 0.792 5.4E-03 
yvcJ 0.857 1.0E-02 atpI 0.805 2.0E-10 pcrA 0.793 8.6E-06 
yneB 0.857 1.7E-09 spxA 0.805 2.9E-05 ylmD 0.795 2.9E-10 
aroB 0.859 1.2E-05 ylmD 0.809 4.8E-07 abh 0.796 3.6E-08 
yozB 0.862 2.6E-04 recJ 0.809 3.7E-34 ig1505 0.797 3.7E-11 
ptsI 0.862 2.4E-09 pcrA 0.810 2.1E-04 ig110 0.798 3.1E-06 
mswH 0.862 1.2E-04 pbpD 0.812 4.1E-42 abrB 0.798 2.1E-04 
ugtP 0.863 2.2E-06 ig2610 0.813 7.2E-09 lytA 0.799 2.6E-09 
yozO 0.864 1.3E-03 ig2683 0.815 2.9E-14 ig1456 0.806 1.5E-02 
ig1843 0.866 9.8E-03 abrB 0.818 2.6E-08 bsuMB 0.813 1.4E-03 
ig1836 0.866 2.3E-05 BSU30466 0.818 2.7E-04 ig1602 0.814 2.9E-06 
fliQ 0.867 3.0E-03 U712_17635 0.819 8.2E-04 tig 0.814 3.0E-11 
ig1596 0.867 1.8E-05 ig100 0.819 1.0E-09 ig1515 0.816 4.5E-05 
nagBB 0.867 1.2E-05 ig1983 0.821 1.1E-10 yvrJ 0.817 1.7E-03 
ig50 0.867 2.8E-02 ig2628 0.823 1.1E-02 ig3123 0.818 3.4E-06 
ig1907 0.868 3.2E-06 rpmGB 0.823 7.1E-04 ig1708 0.819 5.5E-04 
cshB 0.868 3.1E-07 ig3131 0.825 8.0E-06 ig1601 0.821 1.5E-11 
spoVE 0.868 5.0E-04 yaaT 0.835 2.4E-05 yaaT 0.821 3.3E-04 
yppC 0.868 4.4E-04 yvsG 0.837 1.9E-17 yyaN 0.822 1.1E-09 
ig1515 0.870 3.4E-03 ltaSB 0.838 5.7E-02 ccpA 0.822 1.1E-07 
aroF 0.870 1.4E-01 U712_17630 0.839 5.0E-03 ig99 0.824 6.8E-04 
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ig1859 0.871 5.4E-04 yitW 0.842 5.6E-05 bcd 0.824 1.5E-02 
ezrA 0.871 1.0E-03 ig1717 0.843 3.0E-05 bkdAB 0.824 9.5E-08 
sigH 0.872 2.8E-06 tagF 0.843 9.5E-04 ig1266 0.825 2.3E-06 
rttM 0.872 1.2E-01 ytzH 0.844 3.3E-04 ig1418 0.826 9.9E-05 
ig1928 0.872 6.5E-05 ig3404 0.844 5.7E-11 ig248 0.827 5.5E-09 
ig3659 0.872 3.5E-04 ig2365 0.845 3.9E-06 ig286 0.827 4.2E-12 
ndoA 0.872 8.5E-03 ydjO 0.846 2.6E-05 menA 0.831 9.6E-03 
polC 0.873 3.9E-02 ig1161 0.848 3.9E-03 spoVE 0.832 4.0E-07 
ig1633 0.874 1.0E-05 yhaJ 0.848 1.0E-20 rsiV 0.832 1.0E-12 
ig2418 0.874 2.3E-02 ig2961 0.850 4.6E-05 spxA 0.832 6.6E-04 
qoxC 0.875 2.2E-03 sftA 0.850 4.6E-38 cdnD 0.833 1.2E-60 
ypuC 0.875 1.9E-02 ydeS 0.851 1.9E-14 ndoA 0.834 3.8E-03 
ptb 0.875 2.0E-06 gtaB 0.852 6.4E-02 tagA 0.834 1.8E-02 
recR 0.876 3.4E-04 ig1981 0.856 1.1E-01 pbpA 0.835 1.3E-28 
rex 0.876 4.8E-09 ig587 0.856 4.9E-13 ig1281 0.835 1.7E-03 
ymcA 0.877 2.2E-02 ig644 0.856 2.3E-05 rpmGB 0.835 5.3E-03 
ig1580 0.878 7.6E-03 ig2502 0.858 1.7E-09 qoxA 0.835 8.9E-03 
pgi 0.878 1.3E-05 ig2650 0.858 3.1E-03 ig2365 0.836 5.2E-09 
yxeJ 0.878 1.4E-01 ig590 0.858 4.8E-12 bsuMA 0.836 4.8E-03 
ig1602 0.879 4.7E-04 U712_00035 0.858 2.6E-03 yneT 0.837 1.2E-12 
mraW 0.879 5.5E-06 ig3206 0.859 2.2E-04 ig2420 0.838 5.1E-06 
U712_00035 0.880 5.8E-04 ywzH 0.859 1.1E-08 ylbF 0.838 1.5E-04 
qoxA 0.880 3.3E-09 rex 0.859 1.1E-04 yufK 0.838 7.1E-13 
yprA 0.881 2.3E-55 ig2756 0.860 1.5E-05 pgl 0.838 4.4E-06 
comGC 0.881 4.7E-02 mrpA 0.861 7.3E-03 ig3639 0.839 3.3E-19 
fliL 0.881 2.8E-06 sigV 0.861 1.2E-07 ig3614 0.839 8.7E-12 
miaA 0.882 3.7E-02 pheT 0.862 2.2E-01 ig374 0.840 3.9E-03 
ig2391 0.882 7.3E-03 ig588 0.863 1.4E-03 ig1689 0.841 5.7E-04 
ig35 0.882 3.5E-03 ig7 0.864 1.1E-01 yocH 0.843 1.1E-17 
fin 0.883 7.3E-03 hemL 0.864 4.4E-08 sigV 0.843 7.6E-11 
dnaK 0.884 9.8E-06 accA 0.865 2.1E-01 fapR 0.843 1.4E-04 
yfmN 0.884 1.1E-01 mutM 0.865 5.2E-06 ydeS 0.844 5.3E-13 
aroD 0.884 4.7E-02 ig3118 0.866 5.6E-07 ig1429 0.844 1.5E-04 
yoyC 0.884 5.3E-02 ig3011 0.867 5.5E-05 ig2114 0.844 4.0E-04 
ig2293 0.884 5.7E-04 ig3623 0.867 2.4E-03 gpsB 0.845 1.5E-02 
pyk 0.884 2.1E-03 sdpR 0.867 2.9E-14 ig2558 0.845 7.1E-06 
rnpZA 0.885 1.0E-04 ytnI 0.868 6.3E-04 bkdAA 0.845 1.5E-08 
spoIIAB 0.885 3.1E-04 ig3558 0.869 1.2E-14 ig3099 0.846 7.7E-05 
yqaH 0.886 3.4E-02 ytrB 0.869 1.1E-15 ig1582 0.846 5.0E-03 
ig112 0.886 2.1E-02 ig2513 0.869 6.7E-04 metQ 0.847 4.2E-03 
ylbF 0.886 1.2E-06 ig3279 0.870 7.7E-12 ypoC 0.847 1.0E-06 
ig1479 0.886 2.1E-02 ig3556 0.870 3.1E-07 ig55 0.847 2.2E-06 
ig2117 0.887 3.8E-05 U712_13350 0.871 4.7E-03 spoVAB 0.847 3.9E-07 
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yxlC 0.887 5.4E-02 yufS 0.872 2.4E-02 ig1369 0.848 2.0E-04 
yndH 0.887 7.4E-08 ig3123 0.872 4.8E-02 yobS 0.848 2.4E-08 
yuxK 0.888 5.1E-03 ig633 0.872 4.1E-03 ig3161 0.848 1.5E-05 
ig1381 0.888 2.2E-03 rsh 0.874 1.3E-03 yufS 0.848 1.5E-03 
ksgA 0.889 5.7E-04 ig2798 0.875 9.7E-03 ig1108 0.848 3.9E-08 
ig1981 0.889 1.1E-01 ig3155 0.877 1.9E-03 ig1479 0.848 4.4E-02 
ig2479 0.890 4.8E-02 cotT 0.877 2.4E-04 ig3423 0.848 4.7E-06 
ypoP 0.890 9.1E-03 ig2639 0.877 1.4E-03 U712_09140 0.848 1.1E-06 
cheB 0.891 2.1E-07 lmrB 0.877 5.2E-31 ylbJ 0.849 1.9E-10 
atpH 0.891 3.4E-03 ytrC 0.878 4.4E-35 ig2955 0.849 1.7E-03 
U712_10355 0.892 7.0E-02 ytrA 0.879 2.3E-05 ig1898 0.849 4.5E-03 
ig2492 0.893 6.4E-03 ygaB 0.879 1.8E-03 ig1381 0.850 9.5E-07 
aroC 0.893 1.2E-07 ig3113 0.879 2.9E-04 U712_02515 0.851 3.5E-08 
ig3099 0.893 1.1E-02 yneB 0.880 1.3E-05 yyaB 0.851 2.4E-13 
ytrA 0.894 1.5E-06 ktrC 0.880 6.5E-02 U712_06030 0.852 3.9E-05 
ig1906 0.894 4.6E-09 tagA 0.881 2.2E-03 ig480 0.852 1.4E-10 
yqkE 0.894 1.3E-02 ig3114 0.881 2.5E-03 addB 0.852 1.1E-04 
rnr 0.894 2.2E-11 ig499 0.882 7.0E-07 ig1692 0.852 1.7E-11 
yqzD 0.894 8.4E-05 ig987 0.883 9.9E-08 ig489 0.852 1.1E-04 
ylyA 0.894 4.9E-03 U712_14410 0.883 2.3E-02 ig1332 0.853 8.8E-06 
ig125 0.895 1.6E-02 ktrA 0.884 1.3E-09 ig987 0.853 1.9E-13 
bsrI 0.896 1.7E-01 yxaD 0.884 3.0E-05 ig2103 0.854 2.7E-04 
mgtE 0.896 2.2E-03 ig3120 0.885 2.7E-04 ig963 0.854 4.6E-04 
yobD 0.896 7.7E-05 gerAA 0.885 9.2E-19 ktrD 0.855 1.3E-24 
ig2397 0.896 2.1E-01 ytrD 0.885 5.4E-30 ig3279 0.855 7.6E-13 
yncF 0.897 8.5E-05 ydzF 0.885 2.4E-09 ltaSB 0.855 8.4E-03 
ig3244 0.897 1.1E-01 ig2774 0.885 6.3E-04 ynzD 0.855 2.9E-04 
ig2205 0.897 2.1E-03 yrhO 0.886 8.6E-16 ig2502 0.855 5.9E-09 
ftsE 0.897 3.1E-06 ig3219 0.887 9.5E-04 ig1478 0.855 1.3E-03 
U712_13765 0.897 2.2E-02 csbA 0.887 3.3E-08 ig2047 0.855 7.4E-05 
pupG 0.897 7.0E-06 U712_04285 0.887 2.5E-10 ig415 0.856 3.7E-07 
ig2013 0.898 1.1E-04 yuxG 0.888 1.0E-27 ig7 0.856 5.9E-02 
trmF 0.898 2.3E-03 xpaC 0.889 4.6E-02 ig3487 0.857 1.2E-08 
dnaJ 0.898 2.4E-05 yteS 0.890 7.0E-03 ig1089 0.857 3.7E-04 
ig2030 0.898 3.8E-02 ig2713 0.890 1.6E-06 ig1078 0.857 1.0E-03 
rhaU 0.898 8.3E-02 ig3161 0.891 1.5E-03 ig1941 0.858 3.4E-03 
ig3299 0.899 6.8E-02 ig3244 0.891 3.2E-02 hemL 0.858 1.3E-05 
hfq 0.899 2.3E-02 capB 0.891 3.1E-16 ig2065 0.858 1.0E-04 
ig1452 0.899 1.1E-02 yyaN 0.892 3.4E-04 ig2650 0.858 1.3E-03 
lpdV 0.899 1.0E-08 yqzI 0.893 2.6E-02 ig256 0.859 6.3E-08 
ig2020 0.899 1.4E-03 nrnA 0.893 6.2E-03 ig1857 0.860 9.8E-22 
ig1782 0.899 2.9E-04 spoIIIE 0.893 3.9E-19 U712_18390 0.860 8.7E-04 
ig1649 0.899 2.4E-04 rsiV 0.893 1.1E-06 dnaE 0.860 2.1E-04 
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cymR 0.899 2.8E-04 U712_15675 0.894 3.1E-04 ig1827 0.861 2.0E-10 
ig1804 0.900 1.4E-04 yyaB 0.894 5.0E-07 ig1845 0.861 8.1E-06 
ig1978 0.900 2.9E-02 apt 0.895 7.2E-05 ptsI 0.861 9.8E-03 
speE 0.901 5.5E-06 abh 0.895 9.1E-05 yxaD 0.861 1.6E-08 
ynzG 0.901 5.5E-03 ig2690 0.895 1.2E-10 ig3638 0.862 3.2E-16 
yozI 0.901 9.4E-05 copZ 0.896 1.1E-01 ig617 0.862 3.0E-03 
sdaAA 0.901 6.5E-06 yhaH 0.896 1.8E-04 ylmH 0.862 1.4E-05 
ig1451 0.901 1.8E-01 csoR 0.896 5.7E-07 ig1371 0.862 2.8E-09 
yodL 0.902 8.0E-03 manA 0.896 1.2E-08 ig1963 0.862 7.3E-07 
metA 0.902 4.6E-13 ig1283 0.897 1.1E-04 rplI 0.863 3.9E-13 
ig2079 0.902 4.5E-03 mutS2 0.897 2.6E-14 sbp 0.863 5.1E-06 
cwlC 0.903 2.0E-06 bsuMA 0.897 3.8E-02 ig3617 0.863 1.6E-07 
cheD 0.904 1.0E-03 ig925 0.897 3.3E-04 mutM 0.863 2.1E-05 
ig1773 0.904 5.6E-04 ygaF 0.897 7.4E-06 ig2963 0.863 1.5E-05 
ftsX 0.904 1.5E-04 ig3659 0.897 5.2E-02 nth 0.863 1.4E-03 
cdd 0.904 2.5E-02 sdhB 0.897 3.8E-02 metP 0.863 5.1E-03 
accA 0.904 3.8E-02 ig3181 0.898 1.2E-06 ig1938 0.864 1.6E-08 
yodC 0.904 8.3E-09 yfkF 0.898 4.1E-11 ig212 0.864 1.5E-05 
mnmA 0.905 5.2E-02 yhcG 0.898 9.4E-07 ig1228 0.864 2.0E-06 
rimP 0.905 7.9E-02 yvzB 0.898 9.3E-03 ig2513 0.864 1.7E-02 
ylqD 0.905 4.7E-05 ylbF 0.898 1.4E-03 ig2475 0.864 3.2E-14 
rsmB 0.905 9.9E-06 ig508 0.899 1.7E-03 ig988 0.865 6.6E-08 
cheY 0.905 4.8E-06 yfhO 0.900 1.4E-48 ig2476 0.865 2.2E-07 
ig2136 0.905 6.8E-02 ig502 0.900 1.7E-03 ig261 0.865 8.5E-05 
fur 0.905 1.2E-07 ig958 0.900 5.5E-05 yyaH 0.866 2.2E-06 
menA 0.906 6.3E-03 ig1162 0.900 4.9E-06 walJ 0.866 1.3E-05 
yocB 0.906 1.3E-04 ig3018 0.900 8.9E-07 ig2355 0.866 1.4E-03 
ig2308 0.906 1.3E-04 ywrB 0.901 4.8E-05 ig1503 0.867 1.7E-02 
bkdAA 0.906 1.5E-09 yusO 0.901 1.8E-05 ytnI 0.867 3.9E-03 
nrdR 0.906 1.5E-02 yhcD 0.901 2.0E-05 ig1920 0.867 8.7E-12 
sdaAB 0.906 4.1E-06 ktrD 0.901 1.2E-17 rsiX 0.867 5.6E-20 
ymaC 0.906 9.7E-03 ig1101 0.901 4.5E-03 ig1344 0.867 2.6E-09 
 
 
MMS Growth period 1 MMS Growth period 2 MMS Growth period 3 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
ruvA 0.586 2.5E-06 polA 0.589 1.0E-54 polA 0.601 1.3E-28 
ruvB 0.621 2.5E-07 hemL 0.650 9.7E-05 walJ 0.705 2.0E-03 
pgcA 0.631 6.4E-05 ezrA 0.673 1.1E-17 ezrA 0.712 3.0E-09 
atpD 0.684 2.7E-03 walJ 0.743 1.9E-05 recN 0.793 1.2E-24 
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recR 0.695 5.2E-06 mntD 0.769 4.5E-02 cymR 0.798 3.5E-05 
rho 0.718 2.0E-06 sdaAB 0.782 2.1E-09 sdaAB 0.805 5.8E-08 
ponA 0.721 3.9E-04 radA 0.782 1.3E-33 yycI 0.820 1.6E-01 
hemL 0.750 1.4E-10 resE 0.783 3.9E-04 recD2 0.837 5.4E-23 
ytpQ 0.761 5.7E-04 recN 0.791 8.3E-30 radA 0.840 2.1E-26 
addA 0.769 2.9E-15 ig2551 0.808 4.8E-03 addA 0.840 1.1E-02 
addB 0.769 3.2E-14 yycI 0.823 2.5E-02 ig100 0.854 7.6E-05 
recG 0.782 8.0E-03 ylmE 0.827 4.8E-03 ig3623 0.858 3.1E-03 
ccpA 0.803 1.7E-02 cymR 0.827 1.1E-05 ig1200 0.858 3.2E-02 
ugtP 0.806 5.3E-03 recD2 0.829 1.8E-34 sodA 0.868 9.1E-02 
ig3284 0.808 3.2E-05 ig2204 0.833 3.2E-02 ig1717 0.876 1.1E-04 
ybbR 0.817 1.4E-03 ig1200 0.834 5.6E-03 yozN 0.877 8.5E-04 
yitW 0.818 1.1E-01 ig3219 0.846 6.7E-02 ig2409 0.879 1.3E-02 
spoIIP 0.818 6.0E-04 addB 0.853 2.9E-04 ig3590 0.885 3.1E-02 
pabC 0.821 1.9E-03 ig1503 0.854 1.6E-03 ysoA 0.887 6.6E-10 
atpA 0.825 7.0E-03 yfhH 0.856 1.5E-02 ylmD 0.893 1.3E-01 
mcsA 0.827 6.4E-06 parB 0.861 1.0E-04 spoIIIE 0.893 2.3E-02 
pabA 0.829 7.8E-03 ig100 0.862 1.2E-06 ig1503 0.894 4.7E-02 
walJ 0.833 1.8E-03 ylmG 0.863 1.4E-02 yrrB 0.894 1.0E-07 
ig2118 0.835 1.7E-02 spxA 0.864 3.3E-06 ponA 0.895 1.5E-01 
aroC 0.836 4.0E-03 yrrB 0.865 2.0E-12 ylmE 0.896 2.2E-04 
spoIIIE 0.838 1.4E-05 ytxG 0.868 2.8E-02 spxA 0.896 5.2E-03 
pgi 0.839 2.4E-04 recJ 0.875 8.7E-22 ig3284 0.899 1.5E-02 
mntD 0.844 2.2E-07 ig2409 0.881 1.0E-03 recJ 0.900 2.3E-21 
clpC 0.848 4.6E-07 ponA 0.882 9.0E-03 gpsB 0.900 3.0E-02 
yhdK 0.848 2.3E-04 rsfS 0.883 4.4E-02 pyrB 0.900 1.4E-01 
kinC 0.848 9.4E-06 ylbK 0.887 5.2E-10 yppC 0.901 9.8E-03 
queA 0.850 8.1E-03 ysoA 0.888 2.2E-09 addB 0.903 4.4E-03 
yycI 0.850 5.3E-03 ytxM 0.892 1.5E-01 ig2688 0.906 5.0E-02 
sigG 0.850 1.2E-03 yqaG 0.894 2.7E-04 bsuMA 0.907 3.7E-01 
ig112 0.853 1.5E-02 ig812 0.894 1.3E-01 ctpA 0.907 2.0E-16 
znuB 0.854 1.9E-13 abrB 0.897 5.9E-02 yshA 0.908 2.9E-03 
znuC 0.856 2.1E-05 ig2205 0.900 6.5E-03 ig2639 0.908 1.9E-02 
rnhC 0.857 2.8E-04 efp 0.901 1.0E-02 ygaF 0.909 4.0E-03 
nagBB 0.857 5.9E-04 ylbL 0.902 3.1E-15 ig1835 0.911 4.0E-02 
sigE 0.857 5.7E-03 spoIIB 0.904 2.9E-02 rnpZA 0.912 8.5E-02 
ywlE 0.857 1.3E-07 phrE 0.904 4.1E-03 yqxD 0.912 6.1E-02 
cshB 0.859 8.0E-02 addA 0.905 8.7E-02 ppiB 0.915 5.3E-04 
dltC 0.860 1.2E-03 xseA 0.907 8.3E-04 U712_12375 0.915 5.7E-02 
ybbP 0.860 2.7E-03 ig159 0.908 1.0E-02 ig1611 0.916 2.4E-01 
rocG 0.861 5.0E-06 ig2269 0.909 4.4E-02 ig3118 0.918 5.7E-02 
mcsB 0.861 1.4E-06 ypuI 0.909 8.3E-04 pgl 0.919 4.4E-02 
mntA 0.862 6.0E-03 ylmH 0.909 3.4E-03 ig2551 0.919 2.7E-01 
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asnO 0.862 5.1E-07 ywzG 0.910 4.1E-03 ig588 0.919 1.2E-01 
spoVT 0.862 1.8E-05 ykuD 0.910 3.6E-03 ig1814 0.920 1.7E-01 
fabHA 0.862 2.2E-02 speE 0.910 1.2E-01 ig1773 0.920 4.8E-03 
speA 0.863 9.6E-03 disA 0.911 4.2E-19 alkA 0.920 2.6E-15 
yjbI 0.865 7.8E-02 ig2280 0.911 1.9E-04 ylbL 0.921 2.0E-13 
mntB 0.865 2.9E-03 abh 0.912 4.8E-03 U712_07230 0.921 8.9E-02 
menA 0.866 5.1E-02 leuD 0.912 1.1E-02 xseA 0.922 7.0E-03 
ig1388 0.866 8.1E-03 ig993 0.912 9.0E-02 ig3006 0.923 1.8E-02 
lgt 0.867 3.3E-04 sigV 0.912 1.5E-04 ig991 0.924 1.1E-02 
pdaA 0.867 1.7E-02 yrkL 0.913 9.6E-10 asnS 0.924 3.3E-01 
pbpA 0.868 2.5E-03 tgt 0.915 2.0E-02 ig112 0.924 3.5E-01 
ig375 0.869 3.0E-04 ctpA 0.915 1.3E-17 ig1745 0.924 1.2E-01 
ig3518 0.869 7.9E-02 ig2248 0.915 8.5E-04 ig624 0.925 1.5E-01 
znuA 0.869 3.8E-21 ig2195 0.916 2.3E-02 ig2722 0.925 9.8E-04 
ig3006 0.871 1.8E-03 apt 0.917 8.3E-04 ig1582 0.925 4.9E-02 
cysK 0.871 4.1E-07 yjlB 0.917 7.7E-02 mecA 0.926 8.5E-02 
ig1071 0.871 1.1E-03 yycD 0.918 1.5E-03 ig1283 0.926 9.5E-02 
cwlD 0.872 3.7E-02 spoIVA 0.918 6.1E-03 yyaB 0.926 1.4E-05 
ig2955 0.872 1.3E-01 htpX 0.918 3.4E-04 ig2183 0.926 2.5E-02 
metP 0.874 8.9E-03 pycA 0.918 7.6E-23 ig3106 0.928 3.9E-01 
U712_14655 0.875 7.1E-02 ecfA 0.919 1.8E-01 yebD 0.929 1.2E-01 
rsiW 0.876 2.5E-04 yqfT 0.919 5.4E-02 ig694 0.929 6.6E-03 
parB 0.876 5.1E-03 rpsT 0.920 9.8E-02 ig644 0.929 2.0E-01 
spoIIIAH 0.879 5.6E-02 nth 0.921 8.6E-02 znuC 0.929 2.0E-01 
ywrC 0.880 3.6E-02 ig2560 0.921 1.0E-03 pbpA 0.929 1.1E-01 
ig331 0.880 1.4E-02 ypoC 0.921 1.0E-02 aroH 0.930 5.6E-02 
walH 0.881 8.2E-02 prkC 0.921 1.7E-04 ig680 0.930 1.3E-01 
ig2204 0.881 7.8E-02 ytbD 0.921 1.6E-03 yqfC 0.930 2.4E-01 
spoIIR 0.882 6.0E-05 ytpP 0.922 7.4E-02 cspD 0.930 1.2E-01 
ig46 0.882 4.4E-06 yqfA 0.923 4.7E-04 yoyD 0.930 3.0E-01 
ig3423 0.882 1.9E-03 pabC 0.923 1.3E-01 walH 0.931 4.8E-01 
ywzH 0.883 1.1E-02 ig1429 0.923 2.6E-03 yycD 0.931 5.5E-03 
spoIVCA 0.883 1.8E-03 ig2235 0.924 4.1E-02 ig2774 0.931 1.3E-01 
ig3250 0.883 8.3E-03 ig1129 0.924 5.4E-04 ig2560 0.931 3.1E-03 
mntC 0.885 1.9E-04 U712_07190 0.924 4.9E-03 ig3607 0.931 6.3E-03 
ig166 0.885 6.9E-03 ig2348 0.924 3.0E-02 ig3151 0.931 2.4E-01 
relP 0.885 1.1E-03 comER 0.924 2.8E-06 ig444 0.931 1.8E-01 
yqfD 0.886 1.3E-02 yojB 0.924 4.2E-02 ig3502 0.932 7.9E-03 
rnpZA 0.886 3.8E-02 ylzJ 0.926 5.4E-02 ig3385 0.934 2.9E-01 
gpr 0.886 8.1E-02 ylqD 0.926 3.5E-03 ig2755 0.934 5.4E-02 
ig159 0.887 6.2E-02 yshE 0.926 3.6E-03 ig1682 0.934 2.6E-02 
ig1465 0.887 6.3E-03 yjcD 0.927 1.9E-14 ywzH 0.934 2.5E-01 
ig1482 0.888 5.2E-02 rsiV 0.927 3.0E-03 fin 0.934 2.8E-01 
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ig298 0.889 1.7E-06 sspB 0.927 2.2E-02 ig1963 0.934 1.7E-02 
purR 0.889 1.9E-06 splA 0.927 6.4E-03 disA 0.934 1.4E-14 
dacB 0.889 2.0E-06 walH 0.928 4.4E-01 yoyE 0.935 2.2E-01 
glpD 0.890 3.6E-06 ig3155 0.928 1.8E-02 U712_14285 0.935 7.7E-02 
ig3474 0.890 5.7E-04 spoVID 0.928 5.4E-04 ig1308 0.935 1.5E-01 
ig98 0.890 3.4E-04 mhqR 0.929 1.1E-01 ig2420 0.935 1.4E-02 
U712_02515 0.891 1.7E-02 gntZ 0.929 2.2E-04 ig2019 0.935 2.0E-01 
albA 0.891 3.1E-09 ig2264 0.929 8.0E-04 aroB 0.936 2.9E-01 
ig62 0.892 2.2E-03 mifM 0.929 4.1E-03 ypoC 0.936 1.6E-01 
gltT 0.893 2.9E-05 ig727 0.929 2.1E-01 yneB 0.936 1.9E-05 
truA 0.893 7.8E-07 mgtE 0.930 3.6E-02 ig1671 0.936 9.8E-04 
pgl 0.894 1.4E-05 yvzF 0.931 8.6E-03 ig1818 0.936 1.8E-03 
ig3184 0.895 2.5E-02 kinC 0.931 9.9E-03 ig1141 0.936 5.9E-05 
ig1226 0.895 1.1E-03 yqzI 0.931 1.3E-01 ig1906 0.936 1.1E-03 
dltB 0.896 9.2E-10 yqeM 0.931 8.1E-04 spoVD 0.936 1.2E-01 
efeM 0.896 1.4E-10 ig1307 0.931 1.9E-02 parB 0.937 7.2E-02 
ig3356 0.896 1.1E-09 dgkA 0.931 1.3E-05 U712_16090 0.937 3.0E-01 
spoIIIAA 0.897 4.1E-02 ykzD 0.931 3.0E-02 ykzM 0.937 3.9E-02 
yunB 0.897 7.7E-04 ylmD 0.931 2.9E-01 ig1071 0.937 1.6E-01 
ecfAB 0.897 5.1E-02 fabHA 0.932 1.3E-01 ig1885 0.937 9.8E-04 
oxaAA 0.897 3.8E-04 mcsA 0.932 2.2E-01 yoaF 0.938 1.0E-04 
ig3247 0.898 2.3E-03 drm 0.932 1.6E-04 gntZ 0.938 8.6E-03 
ig2120 0.898 7.7E-02 spoIIM 0.932 5.5E-02 ig3194 0.938 2.5E-01 
atpI 0.899 1.0E-04 ig2241 0.933 2.2E-04 ylbK 0.938 5.9E-04 
ig3276 0.899 7.2E-03 nfo 0.933 5.9E-05 ymaB 0.938 1.4E-01 
yaaL 0.900 1.6E-02 ig2365 0.933 8.5E-04 ig1341 0.938 3.5E-02 
ig34 0.900 6.2E-04 yrpD 0.933 1.5E-08 yobD 0.938 1.0E-02 
ywpF 0.900 2.2E-03 ecsB 0.934 2.2E-02 yyzH 0.938 3.4E-02 
resE 0.900 1.2E-01 htrC 0.934 1.1E-05 ugtP 0.939 2.6E-01 
ig3235 0.900 2.7E-03 mutS2 0.934 4.9E-06 ig1405 0.939 2.6E-02 
ig1633 0.900 5.5E-04 yqfQ 0.934 2.1E-04 ig3009 0.939 5.6E-02 
ig1154 0.900 2.4E-03 ig2349 0.934 6.4E-03 yczN 0.939 5.1E-02 
spoIID 0.900 2.3E-04 U712_13115 0.935 7.0E-02 ig653 0.939 3.7E-02 
ig1325 0.901 7.3E-02 ig3593 0.935 2.4E-02 ig2617 0.939 1.3E-01 
ig3303 0.901 1.4E-04 sufA 0.935 3.3E-01 ig1976 0.940 4.6E-01 
mscL 0.902 3.0E-03 pyrAB 0.935 8.6E-05 U712_03800 0.940 1.4E-03 
pit 0.902 1.6E-04 yvgO 0.935 5.5E-02 ig3105 0.940 2.5E-02 
yvrJ 0.902 2.0E-01 yqfD 0.935 8.3E-02 ig490 0.940 5.9E-02 
speE 0.902 4.5E-02 argI 0.936 1.3E-02 ig1752 0.940 1.9E-04 
albB 0.902 4.0E-03 ig2368 0.936 4.1E-03 ig688 0.940 1.3E-01 
fliL 0.902 1.8E-04 yrhD 0.936 2.9E-01 U712_18660 0.940 7.9E-03 
ig1281 0.903 1.6E-02 ytrH 0.936 2.8E-06 ig3334 0.940 1.1E-01 
ig3264 0.903 8.4E-03 ig2074 0.936 2.0E-03 yocN 0.941 3.7E-01 
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ig1921 0.903 2.6E-01 ig1434 0.936 2.6E-05 ig1101 0.941 6.2E-02 
spoVD 0.903 5.8E-03 yqbI 0.937 8.3E-03 ig2234 0.941 7.0E-02 
ig3428 0.904 1.7E-06 rsmE 0.937 1.3E-03 ig2756 0.941 2.1E-02 
qoxB 0.904 1.4E-04 ig1070 0.937 2.3E-01 ykuJ 0.942 1.7E-02 
ig2397 0.905 1.3E-01 sigG 0.937 1.4E-01 ctsR 0.942 6.5E-01 
ig3590 0.905 2.1E-03 ig807 0.937 2.7E-01 ig1708 0.942 1.5E-01 
ig321 0.905 2.0E-02 ig1142 0.937 7.4E-02 yfmL 0.942 2.7E-01 
ig2396 0.906 2.8E-02 ig2225 0.937 8.6E-02 ykuK 0.942 5.9E-05 
ig3411 0.906 1.4E-05 yrhO 0.937 1.2E-04 cotT 0.942 2.1E-02 
ig3279 0.906 2.9E-08 yizB 0.937 8.8E-02 ig1349 0.942 1.6E-01 
U712_17630 0.906 2.6E-02 pyrK 0.938 4.1E-04 ig3505 0.942 1.2E-01 
ig3391 0.906 4.2E-06 yppC 0.938 7.7E-02 ig1110 0.943 1.6E-01 
ig2805 0.907 5.5E-02 ig2338 0.938 1.8E-01 ig658 0.943 5.7E-02 
ecsC 0.907 5.9E-03 U712_11340 0.938 1.0E-01 ig78 0.943 7.8E-02 
ig1240 0.907 3.2E-03 thiG 0.938 3.0E-02 tapA 0.943 1.4E-02 
spoIVFB 0.907 1.7E-02 yqeC 0.938 2.4E-03 ig1915 0.943 4.4E-02 
dltA 0.908 1.3E-08 yphF 0.938 5.6E-04 ig1829 0.943 4.8E-04 
whiA 0.908 8.3E-02 yrzE 0.939 9.3E-03 apt 0.944 1.3E-01 
ycgE 0.909 9.8E-02 ybbP 0.939 3.3E-01 ig660 0.944 9.8E-02 
ig2723 0.909 5.5E-02 yrrO 0.939 3.5E-03 ywlE 0.944 1.2E-01 
recX 0.909 7.1E-02 ytoI 0.939 1.7E-05 ig2598 0.944 3.9E-02 
yczE 0.909 3.5E-04 ig1201 0.939 5.7E-02 ig3117 0.944 2.0E-02 
walK 0.909 1.2E-01 yqfZ 0.939 2.0E-01 treA 0.944 3.4E-03 
ig220 0.910 8.2E-03 yrdN 0.939 1.8E-02 yusD 0.944 3.1E-01 
U712_05070 0.910 6.7E-03 ypoP 0.940 4.4E-02 ig1806 0.945 3.5E-02 
ig644 0.910 4.2E-02 tsaD 0.940 3.9E-01 yozG 0.945 8.4E-03 
ig360 0.911 6.2E-03 yoyG 0.941 3.4E-02 ig1680 0.945 1.3E-02 
ygaF 0.911 1.3E-02 ig1430 0.941 7.7E-02 U712_09520 0.945 3.3E-01 
psd 0.911 1.1E-03 yrdC 0.941 2.3E-08 ig1233 0.945 2.9E-03 
ig2684 0.911 2.0E-01 yqjX 0.941 1.2E-02 ig2092 0.946 1.6E-01 
ig222 0.911 8.9E-06 ytxO 0.941 1.7E-02 yuzH 0.946 1.6E-01 
ig3564 0.911 3.0E-12 polYB 0.941 2.6E-06 ig2773 0.946 6.5E-03 
U712_02080 0.911 4.3E-02 ig1461 0.941 4.8E-02 ig1201 0.946 4.2E-02 
ig3219 0.911 1.9E-02 yqbO 0.941 1.5E-27 yyaN 0.946 1.0E-01 
ig455 0.911 4.1E-03 spoVB 0.941 5.0E-03 ig1589 0.946 3.5E-01 
ig3292 0.912 1.7E-01 sftA 0.941 2.0E-13 ig2845 0.946 1.0E-02 
opuAB 0.912 2.0E-08 ig1264 0.941 3.9E-04 ig917 0.946 1.6E-01 
ecfT 0.912 5.7E-02 yraJ 0.941 2.2E-04 ecsB 0.946 1.6E-01 
cdnD 0.912 6.6E-09 yqzE 0.942 2.4E-03 U712_09540 0.946 9.0E-02 
U712_01385 0.912 5.6E-03 comZ 0.942 1.8E-02 U712_17570 0.947 2.2E-01 
yqfC 0.913 4.0E-02 dck 0.942 6.0E-03 sigG 0.947 5.9E-01 
ig870 0.913 2.9E-01 ykzQ 0.942 7.6E-04 ig102 0.947 4.3E-02 
ig1611 0.913 5.3E-02 ig969 0.942 9.3E-02 yobR 0.947 1.9E-02 
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rttM 0.913 1.0E-02 yqxD 0.942 1.9E-01 yozK 0.947 1.7E-01 
dnaE 0.913 1.0E-01 proB 0.942 4.6E-03 ig1887 0.947 9.7E-03 
U712_16090 0.913 1.6E-01 slp 0.942 8.7E-03 gerT 0.947 4.8E-03 
ig125 0.913 8.6E-03 fruA 0.942 6.9E-07 ig3470 0.947 8.7E-04 
ig118 0.914 3.3E-04 ktrC 0.942 8.4E-03 ig1652 0.947 3.1E-01 
ig2610 0.914 2.4E-01 ig2420 0.942 3.7E-02 ig3610 0.947 4.4E-02 
ig199 0.914 2.2E-02 pstC 0.942 6.8E-04 ig203 0.947 5.3E-05 
dltE 0.914 2.2E-03 yqaS 0.942 1.0E-04 yobU 0.947 1.8E-02 
U712_14500 0.914 4.7E-03 sigZ 0.943 4.3E-03 ig2718 0.947 3.7E-02 
tatCy 0.914 1.1E-02 comGF 0.943 8.3E-02 ig1250 0.948 2.7E-01 
ig3306 0.915 5.7E-03 yqcB 0.943 1.4E-02 ig1879 0.948 1.4E-01 
ig88 0.915 1.7E-02 ig2515 0.943 4.7E-02 ig1742 0.948 5.9E-04 
yrzS 0.915 1.8E-02 adhA 0.943 1.8E-06 ig833 0.948 2.6E-02 
ig342 0.916 4.5E-05 moeA 0.943 1.3E-06 BSU30466 0.948 9.0E-02 
dtd 0.916 6.1E-02 ig2038 0.943 2.3E-02 ig633 0.948 2.6E-01 
U712_08775 0.916 1.9E-02 yqxK 0.943 9.3E-06 ig2611 0.948 1.9E-01 
ig612 0.916 3.2E-04 yqaM 0.943 3.1E-03 ig3656 0.948 1.9E-01 
bacA 0.916 8.0E-03 yqeF 0.944 5.1E-06 ig580 0.948 1.3E-02 
ig3502 0.916 9.5E-03 glpG 0.944 4.7E-07 yrzL 0.948 2.1E-01 
speB 0.916 2.4E-05 ohrB 0.944 2.4E-02 ig1184 0.948 1.7E-01 
spoIIIAE 0.916 8.6E-02 qcrB 0.944 2.1E-03 ig2492 0.949 2.0E-01 
ig78 0.916 3.5E-04 bacA 0.944 2.2E-01 U712_14500 0.949 1.6E-01 
ygzB 0.916 1.4E-01 relP 0.944 8.2E-02 spoIVB 0.949 8.2E-02 
U712_09520 0.917 3.1E-02 ypbG 0.945 6.4E-03 yfhF 0.949 6.4E-02 
 
 
Phleomycin Growth period 1 Phleomycin Growth period 2 Phleomycin Growth period 2 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
Feature/gene Mean 
Relative 
fitness 
Adjusted 
p-value 
atpA 0.566 7.8E-04 ezrA 0.617 1.2E-16 ezrA 0.696 1.1E-04 
ruvA 0.624 1.9E-06 ig1200 0.649 1.5E-05 U712_09520 0.751 1.6E-02 
oxaAA 0.652 7.6E-15 tig 0.652 2.3E-11 bkdAB 0.781 2.0E-02 
ig2955 0.672 1.0E-02 bkdAA 0.652 2.5E-16 tig 0.787 5.0E-06 
recA 0.680 1.4E-04 oxaAA 0.655 3.8E-13 yrbF 0.791 6.5E-02 
ruvB 0.702 6.3E-06 ig1556 0.671 1.2E-04 bkdB 0.795 4.1E-05 
ytpQ 0.708 2.5E-03 recN 0.681 4.9E-33 dltB 0.797 1.2E-15 
U712_06030 0.740 4.7E-02 dltD 0.696 5.3E-13 spxA 0.797 3.7E-05 
pgcA 0.764 8.6E-03 ig3276 0.697 8.0E-04 dltA 0.801 1.1E-07 
ywzH 0.764 4.7E-08 dltC 0.708 1.8E-03 dnaK 0.802 1.9E-35 
addB 0.776 5.6E-11 ig2807 0.720 3.5E-08 ig2807 0.806 1.2E-04 
rho 0.789 2.2E-05 bkdB 0.722 2.5E-13 ugtP 0.809 2.8E-03 
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ig2118 0.791 3.8E-03 dltA 0.722 2.9E-16 bkdAA 0.810 2.3E-03 
yqeY 0.794 1.7E-02 fabHA 0.728 9.1E-05 recN 0.814 5.4E-15 
recR 0.804 7.7E-04 ylmG 0.735 1.9E-03 ig248 0.821 1.1E-03 
yabP 0.809 4.2E-02 ig1503 0.742 7.7E-06 ytmP 0.824 1.6E-08 
dltC 0.810 3.5E-04 bkdAB 0.743 6.1E-09 ig100 0.824 6.8E-05 
yaaB 0.810 2.3E-03 dltB 0.748 3.7E-17 ykzP 0.825 5.0E-06 
walH 0.813 1.9E-04 U712_09520 0.748 1.1E-03 oxaAA 0.829 5.2E-03 
addA 0.814 5.4E-11 cymR 0.758 5.4E-06 sdaAB 0.834 2.6E-06 
recN 0.815 1.5E-33 yhgE 0.762 4.6E-37 ktrD 0.837 5.7E-24 
spoIIQ 0.816 2.9E-03 ig2551 0.763 8.4E-05 yugI 0.838 1.7E-06 
ig3219 0.817 4.6E-02 ykzP 0.779 1.9E-06 ig199 0.840 1.6E-03 
pbpA 0.818 8.1E-06 yrbF 0.780 1.8E-04 spoIIIE 0.844 3.9E-05 
recX 0.818 6.8E-03 ig2476 0.781 2.0E-15 ig1437 0.845 2.6E-04 
mntA 0.819 1.5E-04 ktrD 0.783 2.1E-34 flgD 0.845 7.7E-05 
walJ 0.822 1.8E-04 spxA 0.784 7.2E-06 kinC 0.847 5.7E-05 
sigG 0.828 2.2E-02 sdaAB 0.785 9.6E-09 yqxD 0.851 9.0E-04 
ponA 0.828 3.0E-03 pit 0.786 1.3E-08 ig3623 0.854 6.2E-03 
dltB 0.830 3.1E-27 buk 0.787 4.1E-04 ig1589 0.855 5.3E-02 
spoIID 0.832 5.6E-07 ig1437 0.793 1.0E-04 defB 0.857 1.8E-13 
dltD 0.834 5.4E-10 ktrC 0.800 2.7E-14 ponA 0.858 9.4E-03 
rnhC 0.835 4.3E-04 yrrB 0.801 1.8E-18 yhaJ 0.864 4.2E-21 
recG 0.837 1.2E-02 ecfAB 0.801 1.2E-03 pit 0.864 3.4E-05 
dltA 0.838 2.0E-13 ig2133 0.802 5.0E-05 U712_05070 0.867 1.6E-04 
queA 0.843 7.0E-03 ig890 0.802 1.7E-07 dnaJ 0.869 2.3E-13 
clpC 0.846 4.4E-07 ig2204 0.804 7.6E-04 ig1071 0.871 3.9E-02 
ecfA 0.846 1.0E-01 yjlB 0.804 1.4E-02 walJ 0.873 6.4E-03 
pabC 0.849 1.1E-02 ig1108 0.804 2.7E-08 yhgE 0.877 1.4E-15 
U712_17630 0.853 6.4E-03 yqxD 0.808 5.1E-04 ig588 0.878 5.4E-03 
ig110 0.853 2.1E-03 queA 0.808 2.2E-02 ywhA 0.879 1.9E-08 
ywrC 0.856 5.9E-02 ysoA 0.809 5.8E-18 ecsB 0.880 4.6E-03 
U712_17635 0.856 2.6E-03 lpdV 0.811 4.7E-09 minD 0.880 2.8E-05 
cymR 0.857 1.1E-03 ptsG 0.813 4.6E-26 ig3151 0.881 1.7E-01 
walK 0.858 5.2E-03 yhaJ 0.813 4.7E-25 cysK 0.881 2.6E-03 
cysK 0.861 5.0E-08 rppG 0.814 5.6E-06 yppC 0.881 3.2E-04 
dltE 0.861 1.1E-05 ig1589 0.815 3.5E-03 fliF 0.883 4.0E-15 
spoIIIAA 0.864 4.1E-04 kinC 0.816 1.7E-08 ktrC 0.884 1.7E-06 
mntC 0.865 6.4E-06 ig2127 0.816 2.0E-05 yjzD 0.884 1.6E-04 
pgi 0.865 9.9E-03 tgt 0.816 1.2E-11 ywzD 0.886 3.4E-03 
cwlD 0.867 1.3E-03 ylmH 0.817 1.9E-06 ig2140 0.886 3.8E-07 
ygzB 0.868 5.2E-02 yjzD 0.817 6.6E-09 mcsB 0.886 3.9E-05 
ig3006 0.869 9.0E-04 recD2 0.818 1.5E-29 yhcF 0.888 3.6E-02 
ig62 0.870 8.0E-04 ylmE 0.819 2.6E-03 dltD 0.889 1.2E-01 
ig367 0.871 7.6E-03 ylbK 0.823 7.2E-17 ig2042 0.889 3.0E-06 
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sigE 0.871 9.5E-02 addB 0.823 3.6E-03 ybbP 0.890 4.1E-03 
ig3276 0.871 8.0E-04 ypoP 0.823 1.5E-04 treA 0.891 7.3E-07 
ecfT 0.875 1.5E-01 ig2365 0.824 2.3E-06 yrrB 0.891 8.5E-07 
pabA 0.876 5.9E-02 ig1887 0.825 3.3E-10 yvyC 0.891 2.8E-04 
ig212 0.877 5.6E-05 ygaC 0.831 4.8E-10 fabHA 0.891 1.1E-01 
ydzH 0.877 2.2E-03 ig248 0.833 2.2E-03 ig1390 0.892 1.5E-05 
ywbE 0.877 5.1E-02 addA 0.834 1.8E-03 ig2756 0.893 9.3E-05 
spoIVCA 0.878 2.8E-05 veg 0.835 2.3E-03 yycI 0.894 1.7E-01 
ig199 0.879 5.5E-03 ig2116 0.836 2.9E-10 motB 0.894 2.4E-08 
mscL 0.880 7.9E-05 ktrA 0.840 3.9E-11 bsuMA 0.895 1.6E-01 
spoVFB 0.881 5.9E-02 ecsB 0.841 1.1E-06 fliG 0.896 2.3E-07 
ig474 0.883 2.9E-04 ybbP 0.842 6.2E-03 ig2133 0.896 3.1E-02 
ig3171 0.884 1.6E-02 rnpZA 0.846 8.6E-03 ypoP 0.896 2.0E-02 
speE 0.884 2.5E-02 flgD 0.846 2.8E-05 yozO 0.897 2.0E-02 
ugtP 0.885 2.7E-01 ig2269 0.852 5.6E-04 ig1299 0.897 3.9E-02 
ig2801 0.885 1.8E-03 defB 0.852 1.0E-15 yjbK 0.898 5.6E-08 
purR 0.886 7.4E-07 ig3234 0.854 9.6E-04 sigW 0.898 4.4E-06 
pit 0.886 9.2E-08 gpsB 0.855 5.5E-03 ytoI 0.898 2.7E-12 
ig3279 0.886 4.8E-07 ig1101 0.856 4.3E-05 glcT 0.898 1.2E-05 
gerR 0.887 1.1E-01 yfhH 0.856 2.6E-03 yozN 0.899 1.6E-02 
ig3427 0.887 2.6E-03 ytgP 0.857 2.0E-17 ig1556 0.900 1.2E-01 
ig3428 0.888 1.1E-06 ig969 0.857 4.8E-06 spoVAA 0.900 4.6E-09 
whiA 0.888 1.3E-01 xseA 0.858 7.1E-07 ig680 0.900 8.4E-02 
nagBB 0.889 3.5E-04 ig1283 0.858 1.3E-02 flgE 0.900 2.4E-09 
ywcI 0.890 2.6E-06 ig2140 0.860 4.4E-09 fliZ 0.903 3.8E-03 
ig248 0.890 4.8E-05 yozO 0.860 1.9E-04 ig2220 0.904 1.7E-03 
ig125 0.890 8.1E-04 ig514 0.862 6.0E-03 ig1380 0.905 1.9E-06 
yvrJ 0.890 4.7E-02 glcT 0.862 5.9E-14 ylbK 0.905 4.7E-07 
ig1685 0.891 4.1E-02 ig3131 0.862 2.1E-02 rpfA 0.905 1.5E-01 
ig295 0.891 9.8E-04 ig1461 0.863 3.9E-04 ig1108 0.905 2.0E-03 
clsA 0.891 7.5E-11 yhcH 0.863 4.4E-06 secDF 0.906 8.4E-62 
spoIIIAH 0.892 3.5E-02 ig1226 0.864 1.6E-03 pepF 0.906 5.7E-24 
ig3230 0.892 3.6E-06 mntD 0.864 4.9E-02 fliS 0.906 2.1E-09 
yunB 0.892 8.4E-05 ymfM 0.864 1.8E-05 ig2116 0.907 2.1E-06 
ig3518 0.893 2.5E-02 ig1095 0.865 1.0E-03 ig382 0.907 7.1E-02 
mcsB 0.894 2.2E-06 motA 0.866 4.4E-15 U712_12375 0.908 1.3E-02 
ig3086 0.895 6.5E-03 ig1717 0.866 2.1E-07 ig1110 0.908 5.8E-03 
albA 0.895 3.9E-07 ig2042 0.867 6.9E-07 spoIIIAH 0.909 4.1E-03 
mntD 0.895 1.4E-04 sftA 0.867 4.6E-37 ftsE 0.909 1.3E-14 
ig3292 0.897 6.0E-02 levD 0.868 1.5E-05 mhqR 0.909 6.8E-02 
U712_02515 0.898 6.0E-02 ig2087 0.869 3.9E-03 lspA 0.910 5.2E-04 
ywqB 0.898 3.1E-14 ig2338 0.869 2.6E-02 recD2 0.910 3.3E-14 
ig3206 0.898 1.4E-03 ig1071 0.869 7.9E-03 fliK 0.910 4.0E-06 
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ig3502 0.899 2.9E-02 yfkF 0.870 2.5E-06 lipM 0.911 2.0E-05 
ig3235 0.899 5.0E-03 yppC 0.870 5.8E-04 mtnD 0.911 3.5E-03 
asnO 0.899 5.9E-04 ig2220 0.871 1.1E-04 ygaB 0.911 1.5E-02 
yycI 0.899 5.2E-03 ytmP 0.871 9.4E-08 ig2424 0.912 3.9E-03 
abrB 0.900 1.9E-02 ecfA 0.871 5.3E-02 ydeS 0.913 1.4E-06 
ig581 0.900 6.4E-03 spoVAB 0.871 1.7E-04 ig1325 0.914 2.4E-02 
rocG 0.901 2.4E-06 yknV 0.872 6.9E-33 lpdV 0.915 3.2E-02 
ybaN 0.901 2.8E-05 ig2647 0.872 3.5E-13 ptsG 0.915 1.0E-03 
ig1388 0.901 6.3E-03 ig719 0.872 4.6E-07 sigD 0.915 1.1E-08 
lgt 0.901 1.1E-04 ctpA 0.873 1.1E-27 ylmE 0.915 4.1E-03 
ig159 0.901 6.0E-02 ylmD 0.873 7.5E-02 yneB 0.915 1.1E-07 
ycnL 0.901 2.0E-06 yhfA 0.874 9.2E-12 ig1717 0.915 4.2E-06 
ig439 0.902 5.8E-02 ywnF 0.874 1.4E-03 motA 0.916 1.1E-07 
ig3184 0.902 1.2E-02 ig2205 0.875 1.2E-02 ig907 0.916 3.9E-02 
ig46 0.902 7.0E-05 ylbL 0.876 1.2E-22 ymfK 0.916 2.2E-02 
ig375 0.903 5.7E-04 ig1178 0.876 1.9E-03 yqzD 0.917 1.4E-04 
glcR 0.903 4.2E-04 ponA 0.876 2.0E-02 gltC 0.917 3.4E-05 
mntB 0.903 7.1E-03 ig1390 0.876 1.6E-04 cymR 0.917 1.7E-02 
U712_17570 0.903 8.5E-02 sigV 0.877 7.4E-05 ykqA 0.917 1.7E-06 
ecfAB 0.904 8.1E-02 ig2019 0.877 6.2E-03 ppiB 0.917 6.3E-05 
csbA 0.904 2.0E-05 sigO 0.877 7.6E-06 ygaF 0.918 3.4E-04 
ig3423 0.904 1.2E-02 mhqR 0.878 1.3E-02 addB 0.918 9.4E-02 
ig3264 0.905 6.6E-04 spoVAA 0.878 1.1E-08 pbpA 0.918 4.7E-02 
ig3337 0.905 3.9E-04 ykqA 0.878 7.8E-11 yrzL 0.918 5.2E-02 
ig520 0.906 3.3E-03 fliG 0.878 2.7E-12 ig581 0.918 1.1E-02 
ywzD 0.906 3.2E-04 ygaB 0.878 1.9E-05 ig1503 0.918 3.4E-02 
ig387 0.906 3.7E-02 yhcF 0.878 1.5E-04 ylxF 0.918 7.5E-04 
atpI 0.906 3.9E-02 yhgD 0.879 4.5E-04 mecA 0.919 9.3E-02 
ig98 0.907 1.1E-04 ig2648 0.880 4.9E-04 ig3105 0.919 6.1E-03 
rpfA 0.907 1.1E-01 skfF 0.880 3.6E-51 yhdK 0.919 1.3E-01 
ccpA 0.908 3.1E-01 ig1384 0.880 3.5E-08 ykrP 0.920 1.2E-05 
yvcI 0.908 9.4E-02 ig2475 0.880 3.5E-12 spoIIQ 0.920 2.2E-01 
ig3310 0.908 1.3E-05 yknU 0.880 2.6E-46 moaC 0.921 5.2E-03 
ig3468 0.909 2.3E-04 cysK 0.880 2.7E-04 ig633 0.921 5.9E-02 
mcsA 0.909 5.4E-04 dnaK 0.881 1.3E-24 ig2476 0.921 4.5E-06 
yczE 0.909 1.6E-03 polA 0.881 1.8E-20 levD 0.921 1.4E-02 
ydiK 0.909 1.0E-04 ig3151 0.883 1.4E-02 ig1103 0.921 5.7E-08 
ig329 0.910 2.6E-03 yqjX 0.883 4.6E-04 yfiY 0.922 7.9E-03 
sdhB 0.910 3.7E-02 ymfK 0.883 6.5E-04 ysoA 0.922 7.8E-05 
ig7 0.910 7.5E-02 yjbI 0.884 3.5E-03 spoVG 0.922 4.0E-07 
ig70 0.910 4.3E-03 ig100 0.884 3.2E-04 ecfAB 0.922 2.5E-01 
ig3247 0.911 1.2E-02 cysH 0.884 4.6E-07 yplP 0.922 1.9E-05 
ig226 0.911 5.2E-04 spoIIIE 0.884 1.3E-02 fliT 0.922 3.1E-10 
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ig34 0.912 1.3E-03 ig1299 0.885 1.0E-02 yhgD 0.922 2.1E-02 
metP 0.912 2.0E-01 ig2035 0.885 7.7E-05 ig2533 0.923 2.4E-02 
ig78 0.912 9.6E-03 skfE 0.886 9.5E-23 ig993 0.923 3.7E-02 
yqfC 0.912 2.1E-01 yutC 0.886 2.7E-05 yloV 0.924 5.0E-05 
cspD 0.912 1.2E-01 ig3206 0.886 2.3E-01 fliD 0.924 1.9E-23 
speA 0.913 3.7E-02 ig1505 0.886 2.6E-02 ig1101 0.924 4.0E-02 
spoVT 0.913 2.5E-04 ig1201 0.887 1.4E-04 relP 0.924 1.5E-01 
opuAC 0.913 7.9E-06 ig2050 0.887 4.9E-04 flhF 0.925 4.7E-15 
ig463 0.913 8.5E-04 ig2317 0.887 3.0E-02 ig2639 0.925 1.4E-01 
spoVD 0.913 1.1E-02 ylzJ 0.887 8.0E-03 ig2317 0.925 4.0E-02 
ig3106 0.913 5.3E-02 fliI 0.888 8.3E-10 cggR 0.926 8.9E-03 
ybbR 0.914 1.0E-02 ig1107 0.888 1.9E-04 ftsX 0.926 2.7E-09 
rttO 0.914 3.3E-02 ig1328 0.888 7.0E-03 ytgP 0.926 7.1E-07 
jag 0.914 9.9E-05 ylxM 0.889 4.8E-04 ig1362 0.926 3.1E-09 
ig407 0.914 9.8E-04 cotV 0.889 4.3E-07 flgB 0.926 2.7E-05 
spoIIP 0.914 3.9E-02 ytoI 0.889 6.7E-16 hag 0.926 3.3E-06 
spoIIR 0.914 1.1E-03 yqeM 0.889 3.3E-08 ig3596 0.927 5.5E-04 
ydzU 0.914 3.1E-03 ig1287 0.889 1.8E-05 ig1349 0.927 1.0E-02 
ig324 0.915 3.8E-03 ig3301 0.891 1.7E-01 ylmH 0.927 4.2E-02 
ig3306 0.915 1.3E-04 slp 0.891 1.6E-04 yhcG 0.927 1.8E-04 
ig3151 0.915 1.0E-01 ig1123 0.892 1.9E-05 spoVAEA 0.927 8.2E-04 
ig100 0.915 1.5E-05 ig907 0.892 1.1E-02 ig2019 0.928 1.7E-01 
ig1556 0.915 2.3E-02 htpX 0.892 7.9E-08 flgC 0.928 3.1E-03 
spoVB 0.915 4.8E-03 parB 0.893 2.5E-03 yqhL 0.928 1.2E-02 
ywpF 0.915 3.7E-03 ig1418 0.894 4.6E-04 rsmD 0.928 2.8E-02 
ig512 0.916 1.7E-04 pbpA 0.894 2.8E-04 cheD 0.928 2.3E-07 
lutC 0.916 2.0E-04 yneB 0.894 5.8E-13 U712_19710 0.929 4.6E-02 
ig292 0.916 4.4E-06 mecA 0.894 1.3E-02 tgt 0.929 1.2E-02 
ftsX 0.916 8.3E-12 comER 0.895 3.4E-09 ytzH 0.929 2.9E-02 
ywlE 0.916 1.3E-04 yhaL 0.895 2.6E-04 yutC 0.929 7.4E-04 
U712_18660 0.917 8.4E-04 ykhA 0.895 1.9E-06 BSU27786 0.929 1.1E-01 
ig179 0.917 4.3E-07 cheY 0.895 1.7E-02 ig726 0.929 1.6E-03 
ig3161 0.917 4.0E-04 ypoC 0.895 1.1E-02 yqzC 0.930 5.2E-04 
cdnD 0.917 3.5E-09 yhgB 0.895 3.2E-03 ig2409 0.930 3.0E-02 
ig3391 0.917 5.9E-04 ig1302 0.896 3.0E-11 ig1769 0.930 1.2E-05 
ykaA 0.918 3.1E-01 ig1895 0.896 5.0E-06 cheA 0.931 8.5E-22 
ftsE 0.918 1.1E-11 radA 0.896 5.7E-23 fliI 0.931 1.5E-04 
ywmB 0.918 3.1E-10 spoIIIAF 0.896 1.4E-01 fliM 0.931 2.8E-05 
ig19 0.918 4.1E-02 minD 0.897 2.6E-04 ydfH 0.932 6.9E-03 
ywdI 0.918 3.3E-03 ig1241 0.897 3.6E-06 ig380 0.932 2.3E-07 
bacA 0.918 1.9E-02 ig2033 0.897 1.2E-03 yycP 0.932 1.7E-11 
U712_01385 0.918 3.1E-03 yplP 0.897 3.4E-09 ig2013 0.932 8.0E-02 
ctsR 0.918 4.1E-02 yhcG 0.898 1.0E-03 yyaN 0.932 6.5E-02 
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ig406 0.919 2.9E-06 U712_06080 0.898 2.4E-05 ig2961 0.932 5.5E-01 
ig478 0.919 1.2E-04 pstS 0.898 2.9E-05 U712_14285 0.933 1.0E-01 
yrbF 0.919 1.1E-02 ecfT 0.898 6.1E-02 ykuK 0.933 1.1E-07 
U712_00035 0.919 1.5E-02 ydeS 0.898 2.1E-08 pgl 0.933 6.8E-02 
yxeE 0.919 3.9E-07 ykzQ 0.898 1.6E-06 ywnH 0.933 3.8E-03 
bsdC 0.919 2.5E-08 fruR 0.898 1.6E-05 ig3136 0.933 2.3E-04 
ig2961 0.919 8.1E-02 yabP 0.898 5.4E-02 ig3423 0.933 9.4E-03 
veg 0.919 2.6E-02 ig1070 0.898 2.5E-04 fliY 0.933 5.7E-08 
yyaB 0.919 3.6E-05 ig2628 0.899 6.2E-02 dltE 0.933 6.0E-02 
U712_01115 0.919 1.1E-01 ygaE 0.899 3.8E-09 ig3117 0.933 2.8E-02 
ig3181 0.919 2.5E-06 sdaAA 0.900 1.6E-06 ig2628 0.934 5.1E-01 
yczH 0.919 1.0E-06 ampS 0.900 2.8E-14 ig807 0.934 3.7E-01 
ig488 0.919 2.8E-04 kduI 0.900 1.2E-08 flgL 0.934 5.2E-10 
tdk 0.919 3.9E-03 yhcK 0.900 2.6E-13 ig1845 0.934 8.9E-02 
yqfD 0.919 4.5E-02 ig1392 0.900 1.2E-11 pyrC 0.934 1.2E-01 
ig3558 0.920 1.7E-07 ig977 0.901 4.2E-04 rbsD 0.935 7.7E-02 
 
Table 2.2 Tn-seq relative fitness lists. The relative fitness values for genes with the lowest 200 
relative fitness for each growth period for all three Tn-seq experiments are presented along with 
the adjusted p-value (BH method; see materials and methods). The gene names or locus tags are 
listed, and intergenic regions are annotated as “ig” with a number. 
 
Gene Mean 
Fitness 
Annotated function Validation Proximal gene 
recN 0.200 Homologous Recombination (64); this study  
sepF 0.400 Cell Division This study  
uvrB 0.409 Nucleotide excision repair This study  
uvrC 0.484 Nucleotide excision repair This study  
uvrA 0.489 Nucleotide excision repair (40); this study  
addA 0.537 Homologous Recombination (65)  
rnhC 0.544 RNase HIII This study  
crh 0.565 regulation of carbon metabolism This study  
ruvB 0.568 Homologous Recombination (66); this study  
ylbL 0.581 putative lon-like protease This study  
ponA 0.587 Peptidoglycan glycosyl transferase This study  
bcrC 0.595 UPP phosphatase This study  
ecsA 0.603 ABC transporter This study  
recR 0.606 Homologous Recombination (67); this study  
queA 
0.612 S-adenosylmethionine tRNA 
ribosyltransferase-isomerase 
Not Sensitive downstream of ruvAB 
addB 0.622 Homologous Recombination (68)  
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ecsB 0.627 ABC transporter This study  
polA 0.649 DNA polymerase I (40)  
ylmG 0.656 hypothetical protein Not sensitive downstream of sepF 
lgt 0.661 lipomodification of lipoproteins  Not sensitive  
ctpA 0.673 c-terminal processing protease This study  
ripX 0.674 Homologous Recombination (69); this study  
ytmP 0.690 putative kinase/phosphotransferase  This study  
recG 0.695 Homologous Recombination (69); this study  
ydzU 0.714 unknown This study  
walH 0.715 Regulation of cell wall metabolism This study  
ylmE 0.718 hypothetical protein Not sensitive upstream of sepF 
sdaAB 0.724 L-serine dehydratase Not sensitive upstream of recG 
ysoA 0.725 putative hydrolase This study  
recX 0.729 Homologous Recombination (70)  
walJ 0.729 Regulation of cell wall metabolism This study  
recD2 0.731 Homologous Recombination (41)  
radA 0.742 Homologous Recombination This study  
ylbK 0.746 putative phospholipase Not sensitive upstream of ylbL 
sodA 0.763 super-oxide dismutase This study  
cymR 0.770 regulation of sulfur metabolism Not sensitive upstream of recD2 
yprA 0.773 putative helicase This study  
yprB 0.777 putative DnaQ-like exonuclease This study  
ywrC 0.785 regulation of chromate export Not sensitive  
yycI 0.790 Regulation of cell wall metabolism This study  
 
Table 2.3 Tn-seq yields many false positive results. The forty genes with the lowest relative 
fitness in the second growth period of MMC Tn-seq experiment are listed. Each gene was 
deleted and the deletion mutants were tested for sensitivity to MMC using a spot titer assay and a 
range of MMC concentrations. Genes labeled as not sensitive had no difference in growth 
relative to the WT strain on MMC containing media, with the exception of ylbK, which resulted 
in a polar effect on ylbL (see Figure 2.14). 
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MMC, MMS, & 
Phleomycin 
MMC & 
Phleomycin 
MMC & MMS MMS & Phleomycin 
recN addA uvrC ezrA 
ylbL ecsB ponA ig1503 
addB ylmG walJ parB 
polA ytmP ig2409 xseA 
ctpA ig1437 recJ htpX 
ig1200 U712_09520 hemL comER 
ylmE ig3234 yrhO ylqD 
sdaAB ig2807 rsiV kinC 
ysoA yhcF apt yqeM 
ig2551 yfhH abh ytoI 
recD2 ig1717 yhaH ykzQ 
radA yhaJ mutS2 slp 
ylbK ydeS  ktrC 
cymR ygaB  ptsG 
ylmH yneB  ykzP 
yrrB ktrA  yknV 
spxA yfkF  yhgE 
ig100 yhcG   
ig2365 ktrD   
sftA ig1101   
sigV ytgP   
 ig719   
 sigO   
 ig2476   
 
Table 2.4 Tn-seq list overlaps. The genes with the lowest relative fitness with an adjusted p-
value less than 0.01 are listed for each experiment. 
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Identified Proteins (183) 
Iron(3+)-hydroxamate import system permease protein FhuG OS=Bacillus subtilis (strain 168) GN=fhuG PE=3 SV=1 
Putative ribonuclease-like protein YfkH OS=Bacillus subtilis (strain 168) GN=yfkH PE=4 SV=1 
Lipoteichoic acid synthase 1 OS=Bacillus subtilis (strain 168) GN=ltaS1 PE=1 SV=1 (aka ltaSA) 
Uncharacterized protein YkgA OS=Bacillus subtilis (strain 168) GN=ykgA PE=3 SV=2 
Uncharacterized N-acetyltransferase CgeE OS=Bacillus subtilis (strain 168) GN=cgeE PE=4 SV=2 
Putative phosphotransferase YtmP OS=Bacillus subtilis (strain 168) GN=ytmP PE=3 SV=1 
Cell division suppressor protein YneA OS=Bacillus subtilis (strain 168) GN=yneA PE=1 SV=1 
Stress response protein YsnF OS=Bacillus subtilis (strain 168) GN=ysnF PE=2 SV=3 
Exo-glucosaminidase LytG OS=Bacillus subtilis (strain 168) GN=lytG PE=1 SV=1 
General stress protein 30 OS=Bacillus subtilis (strain 168) GN=yxaB PE=1 SV=5 
Putative S-adenosyl-L-methionine-dependent methyltransferase YktD OS=Bacillus subtilis (strain 168) GN=yktD 
PE=3 SV=1 
Uncharacterized oxidoreductase YhxD OS=Bacillus subtilis (strain 168) GN=yhxD PE=3 SV=2 
Uncharacterized protein YqgF OS=Bacillus subtilis (strain 168) GN=yqgF PE=3 SV=1 
1-phosphofructokinase OS=Bacillus subtilis (strain 168) GN=fruK PE=3 SV=1 
Uncharacterized protein YvyC OS=Bacillus subtilis (strain 168) GN=yvyC PE=1 SV=1 
Two-component system WalR/WalK regulatory protein YycI OS=Bacillus subtilis (strain 168) GN=yycI PE=1 SV=1 
Putative ATP-dependent DNA helicase YjcD OS=Bacillus subtilis (strain 168) GN=yjcD PE=1 SV=1 
General stress protein 39 OS=Bacillus subtilis (strain 168) GN=ydaD PE=1 SV=3 
Adapter protein MecA 2 OS=Bacillus subtilis (strain 168) GN=mecB PE=1 SV=1 
Anti-sigma-W factor RsiW OS=Bacillus subtilis (strain 168) GN=rsiW PE=1 SV=2 
Probable manganese catalase OS=Bacillus subtilis (strain 168) GN=ydbD PE=1 SV=1 
Uncharacterized protein YvyF OS=Bacillus subtilis (strain 168) GN=yvyF PE=4 SV=1 
Holliday junction ATP-dependent DNA helicase RuvB OS=Bacillus subtilis (strain 168) GN=ruvB PE=1 SV=2 
Flagellar motor switch protein FliM OS=Bacillus subtilis (strain 168) GN=fliM PE=1 SV=1 
General stress protein 69 OS=Bacillus subtilis (strain 168) GN=yhdN PE=1 SV=2 
Transcriptional regulatory protein YvrH OS=Bacillus subtilis (strain 168) GN=yvrH PE=3 SV=4 
Pyrophosphatase PpaX OS=Bacillus subtilis (strain 168) GN=ppaX PE=1 SV=1 
Phage-like element PBSX protein XkdA OS=Bacillus subtilis (strain 168) GN=xkdA PE=4 SV=4 
Prolipoprotein diacylglyceryl transferase OS=Bacillus subtilis (strain 168) GN=lgt PE=1 SV=1 
Probable polyketide biosynthesis zinc-dependent hydrolase PksB OS=Bacillus subtilis (strain 168) GN=pksB PE=1 
SV=1 
Probable flavodoxin 2 OS=Bacillus subtilis (strain 168) GN=ykuP PE=3 SV=2 
Chemotaxis protein CheV OS=Bacillus subtilis (strain 168) GN=cheV PE=1 SV=1 
Aliphatic sulfonates import ATP-binding protein SsuB OS=Bacillus subtilis (strain 168) GN=ssuB PE=1 SV=4 
Uncharacterized protein YlzI OS=Bacillus subtilis (strain 168) GN=ylzI PE=4 SV=1 
Heme-degrading monooxygenase HmoB OS=Bacillus subtilis (strain 168) GN=hmoB PE=1 SV=1 
UPF0374 protein YgaC OS=Bacillus subtilis (strain 168) GN=ygaC PE=3 SV=2 
Molybdenum cofactor biosynthesis protein B OS=Bacillus subtilis (strain 168) GN=moaB PE=3 SV=1 
Putative aldehyde dehydrogenase YfmT OS=Bacillus subtilis (strain 168) GN=yfmT PE=2 SV=1 
GTP cyclohydrolase 1 type 2 homolog OS=Bacillus subtilis (strain 168) GN=yqfO PE=3 SV=2 
Sensory transduction protein LytT OS=Bacillus subtilis (strain 168) GN=lytT PE=3 SV=1 
Uncharacterized protein ymdB OS=Bacillus subtilis (strain 168) GN=ymdB PE=1 SV=2 
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Peptidyl-tRNA hydrolase OS=Bacillus subtilis (strain 168) GN=spoVC PE=3 SV=1 
Ribosomal RNA large subunit methyltransferase H OS=Bacillus subtilis (strain 168) GN=rlmH PE=1 SV=1 
Catalase-2 OS=Bacillus subtilis (strain 168) GN=katE PE=3 SV=2 
DNA polymerase III PolC-type OS=Bacillus subtilis (strain 168) GN=polC PE=1 SV=2 
Uncharacterized N-acetyltransferase YesJ OS=Bacillus subtilis (strain 168) GN=yesJ PE=3 SV=1 
Methyl-accepting chemotaxis protein McpB OS=Bacillus subtilis (strain 168) GN=mcpB PE=1 SV=2 
Methyl-accepting chemotaxis protein McpA OS=Bacillus subtilis (strain 168) GN=mcpA PE=1 SV=2 
Uncharacterized protein YtwF OS=Bacillus subtilis (strain 168) GN=ytwF PE=4 SV=2 
FMN-dependent NADH-azoreductase 1 OS=Bacillus subtilis (strain 168) GN=azoR1 PE=2 SV=1 
L-aspartate oxidase OS=Bacillus subtilis (strain 168) GN=nadB PE=3 SV=1 
2-oxoisovalerate dehydrogenase subunit alpha OS=Bacillus subtilis (strain 168) GN=bfmBAA PE=1 SV=1 
Uncharacterized HTH-type transcriptional regulator YobS OS=Bacillus subtilis (strain 168) GN=yobS PE=4 SV=1 
Uncharacterized oxidoreductase YjdA OS=Bacillus subtilis (strain 168) GN=yjdA PE=3 SV=1 
Thioredoxin reductase OS=Bacillus subtilis (strain 168) GN=trxB PE=1 SV=3 
General stress protein 16O OS=Bacillus subtilis (strain 168) GN=yocK PE=1 SV=3 
UPF0111 protein YkaA OS=Bacillus subtilis (strain 168) GN=ykaA PE=3 SV=1 
Ribosome biogenesis GTPase A OS=Bacillus subtilis (strain 168) GN=rbgA PE=1 SV=1 
Putative glycosyltransferase CsbB OS=Bacillus subtilis (strain 168) GN=csbB PE=2 SV=1 
Uncharacterized protein YhjD OS=Bacillus subtilis (strain 168) GN=yhjD PE=4 SV=1 
Minor teichoic acid biosynthesis protein GgaB OS=Bacillus subtilis (strain 168) GN=ggaB PE=3 SV=1 
Putative ribonuclease YeeF OS=Bacillus subtilis (strain 168) GN=yeeF PE=1 SV=2 
Phosphate acetyltransferase OS=Bacillus subtilis (strain 168) GN=pta PE=1 SV=3 
Pantothenate synthetase OS=Bacillus subtilis (strain 168) GN=panC PE=3 SV=1 
Chemotaxis protein CheA OS=Bacillus subtilis (strain 168) GN=cheA PE=1 SV=2 
UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase OS=Bacillus subtilis (strain 168) 
GN=murE PE=3 SV=1 
3-methyl-2-oxobutanoate hydroxymethyltransferase OS=Bacillus subtilis (strain 168) GN=panB PE=3 SV=1 
Dephospho-CoA kinase OS=Bacillus subtilis (strain 168) GN=coaE PE=3 SV=1 
Uncharacterized protein YtxK OS=Bacillus subtilis (strain 168) GN=ytxK PE=4 SV=2 
HTH-type transcriptional regulator NsrR OS=Bacillus subtilis (strain 168) GN=nsrR PE=4 SV=1 
Response regulator aspartate phosphatase B OS=Bacillus subtilis (strain 168) GN=rapB PE=3 SV=1 
Methyl-accepting chemotaxis protein McpC OS=Bacillus subtilis (strain 168) GN=mcpC PE=1 SV=2 
Uncharacterized ATP-dependent helicase YprA OS=Bacillus subtilis (strain 168) GN=yprA PE=3 SV=1 
Transcriptional regulatory protein CssR OS=Bacillus subtilis (strain 168) GN=cssR PE=1 SV=1 
Branched-chain-amino-acid aminotransferase 2 OS=Bacillus subtilis (strain 168) GN=ilvK PE=1 SV=5 
Recombination protein RecR OS=Bacillus subtilis (strain 168) GN=recR PE=3 SV=2 
Uncharacterized protein YpjQ OS=Bacillus subtilis (strain 168) GN=ypjQ PE=1 SV=1 
Uncharacterized protein YwnB OS=Bacillus subtilis (strain 168) GN=ywnB PE=4 SV=1 
Dihydroxy-acid dehydratase OS=Bacillus subtilis (strain 168) GN=ilvD PE=1 SV=4 
Cystathionine beta-lyase MetC OS=Bacillus subtilis (strain 168) GN=metC PE=1 SV=1 
UPF0403 protein YphP OS=Bacillus subtilis (strain 168) GN=yphP PE=1 SV=1 
DNA polymerase III subunit alpha OS=Bacillus subtilis (strain 168) GN=dnaE PE=3 SV=1 
33 kDa chaperonin OS=Bacillus subtilis (strain 168) GN=hslO PE=1 SV=1 
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RNA polymerase sigma factor SigA OS=Bacillus subtilis (strain 168) GN=sigA PE=1 SV=2 
Carbamoyl-phosphate synthase pyrimidine-specific large chain OS=Bacillus subtilis (strain 168) GN=pyrAB PE=3 
SV=1 
ATP-dependent helicase/deoxyribonuclease subunit B OS=Bacillus subtilis (strain 168) GN=addB PE=1 SV=2 
Methionine--tRNA ligase OS=Bacillus subtilis (strain 168) GN=metG PE=3 SV=1 
Ferrochelatase OS=Bacillus subtilis (strain 168) GN=hemH PE=1 SV=1 
Glycine--tRNA ligase beta subunit OS=Bacillus subtilis (strain 168) GN=glyS PE=3 SV=2 
Holliday junction ATP-dependent DNA helicase RuvA OS=Bacillus subtilis (strain 168) GN=ruvA PE=3 SV=2 
Putative uncharacterized hydrolase YsaA OS=Bacillus subtilis (strain 168) GN=ysaA PE=3 SV=2 
Phosphoglycerate kinase OS=Bacillus subtilis (strain 168) GN=pgk PE=1 SV=3 
Dihydroorotase OS=Bacillus subtilis (strain 168) GN=pyrC PE=3 SV=2 
Pyruvate carboxylase OS=Bacillus subtilis (strain 168) GN=pyc PE=3 SV=1 
2,3-dihydroxybenzoate-AMP ligase OS=Bacillus subtilis (strain 168) GN=dhbE PE=1 SV=2 
Transaldolase OS=Bacillus subtilis (strain 168) GN=tal PE=1 SV=4 
Swarming motility protein SwrC OS=Bacillus subtilis (strain 168) GN=swrC PE=1 SV=2 
Uncharacterized membrane protein YhaH OS=Bacillus subtilis (strain 168) GN=yhaH PE=4 SV=1 
Nuclease SbcCD subunit C OS=Bacillus subtilis (strain 168) GN=sbcC PE=3 SV=3 
Glyceraldehyde-3-phosphate dehydrogenase 1 OS=Bacillus subtilis (strain 168) GN=gapA PE=1 SV=2 
Hypoxanthine-guanine phosphoribosyltransferase OS=Bacillus subtilis (strain 168) GN=hprT PE=3 SV=1 
Uncharacterized protein YxjG OS=Bacillus subtilis (strain 168) GN=yxjG PE=4 SV=3 
DNA gyrase subunit B OS=Bacillus subtilis (strain 168) GN=gyrB PE=3 SV=1 
Carbamoyl-phosphate synthase pyrimidine-specific small chain OS=Bacillus subtilis (strain 168) GN=pyrAA PE=3 
SV=1 
3-dehydroquinate dehydratase OS=Bacillus subtilis (strain 168) GN=yqhS PE=1 SV=1 
Uncharacterized protein YqhY OS=Bacillus subtilis (strain 168) GN=yqhY PE=3 SV=2 
50S ribosomal protein L23 OS=Bacillus subtilis (strain 168) GN=rplW PE=1 SV=2 
Transcriptional regulatory protein DegU OS=Bacillus subtilis (strain 168) GN=degU PE=1 SV=2 
Sporulation initiation inhibitor protein Soj OS=Bacillus subtilis (strain 168) GN=soj PE=1 SV=1 
Uncharacterized oxidoreductase YcsN OS=Bacillus subtilis (strain 168) GN=ycsN PE=3 SV=1 
Heme-degrading monooxygenase HmoA OS=Bacillus subtilis (strain 168) GN=hmoA PE=1 SV=2 
Putative aldehyde dehydrogenase DhaS OS=Bacillus subtilis (strain 168) GN=dhaS PE=3 SV=1 
Immunity protein WapI OS=Bacillus subtilis (strain 168) GN=wapI PE=1 SV=1 
Putative esterase YitV OS=Bacillus subtilis (strain 168) GN=yitV PE=4 SV=2 
Citrate synthase 2 OS=Bacillus subtilis (strain 168) GN=citZ PE=1 SV=2 
Guanylate kinase OS=Bacillus subtilis (strain 168) GN=gmk PE=3 SV=2 
3-oxoacyl-[acyl-carrier-protein] reductase FabG OS=Bacillus subtilis (strain 168) GN=fabG PE=3 SV=3 
Uncharacterized protein YkvS OS=Bacillus subtilis (strain 168) GN=ykvS PE=4 SV=2 
Uncharacterized protein YxaI OS=Bacillus subtilis (strain 168) GN=yxaI PE=4 SV=1 
10 kDa chaperonin OS=Bacillus subtilis (strain 168) GN=groS PE=1 SV=2 
Probable phosphate butyryltransferase OS=Bacillus subtilis (strain 168) GN=yqiS PE=3 SV=2 
Uncharacterized protein YvfG OS=Bacillus subtilis (strain 168) GN=yvfG PE=1 SV=1 
Glutamyl-tRNA(Gln) amidotransferase subunit C OS=Bacillus subtilis (strain 168) GN=gatC PE=3 SV=3 
Uncharacterized protein YwfO OS=Bacillus subtilis (strain 168) GN=ywfO PE=4 SV=2 
Uncharacterized protein YdjO OS=Bacillus subtilis (strain 168) GN=ydjO PE=4 SV=1 
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Carbon storage regulator homolog OS=Bacillus subtilis (strain 168) GN=csrA PE=1 SV=1 
Uncharacterized lipoprotein YjhA OS=Bacillus subtilis (strain 168) GN=yjhA PE=1 SV=1 
Putative amidohydrolase YhaA OS=Bacillus subtilis (strain 168) GN=yhaA PE=3 SV=3 
UPF0291 protein YnzC OS=Bacillus subtilis (strain 168) GN=ynzC PE=1 SV=1 
Cell wall-binding protein YqgA OS=Bacillus subtilis (strain 168) GN=yqgA PE=1 SV=2 
PTS system fructose-specific EIIB component OS=Bacillus subtilis (strain 168) GN=levE PE=1 SV=1 
Uncharacterized peptidase YuxL OS=Bacillus subtilis (strain 168) GN=yuxL PE=3 SV=3 
Uncharacterized protein YdhI OS=Bacillus subtilis (strain 168) GN=ydhI PE=4 SV=1 
Uncharacterized protein YkuJ OS=Bacillus subtilis (strain 168) GN=ykuJ PE=1 SV=1 
Uncharacterized protein YkzF OS=Bacillus subtilis (strain 168) GN=ykzF PE=1 SV=1 
Surfactin synthase subunit 2 OS=Bacillus subtilis (strain 168) GN=srfAB PE=1 SV=3 
Sec-independent protein translocase protein TatAc OS=Bacillus subtilis (strain 168) GN=tatAc PE=3 SV=1 
Uncharacterized protein YwqB OS=Bacillus subtilis (strain 168) GN=ywqB PE=4 SV=2 
DNA-entry nuclease OS=Bacillus subtilis (strain 168) GN=nucA PE=4 SV=2 
Spore coat-associated protein N OS=Bacillus subtilis (strain 168) GN=tasA PE=1 SV=1 
Sec-independent protein translocase protein TatAy OS=Bacillus subtilis (strain 168) GN=tatAy PE=1 SV=1 
Stage V sporulation protein S OS=Bacillus subtilis (strain 168) GN=spoVS PE=1 SV=1 
Transcriptional repressor SdpR OS=Bacillus subtilis (strain 168) GN=sdpR PE=2 SV=1 
Surfactin synthase subunit 3 OS=Bacillus subtilis (strain 168) GN=srfAC PE=1 SV=2 
Sporulation delaying protein C OS=Bacillus subtilis (strain 168) GN=sdpC PE=1 SV=1 
Signal peptidase I W OS=Bacillus subtilis (strain 168) GN=sipW PE=1 SV=1 
Uncharacterized protein YwqH OS=Bacillus subtilis (strain 168) GN=ywqH PE=4 SV=1 
Asparagine synthetase [glutamine-hydrolyzing] 2 OS=Bacillus subtilis (strain 168) GN=asnH PE=1 SV=2 
Uncharacterized lipoprotein YcdA OS=Bacillus subtilis (strain 168) GN=ycdA PE=1 SV=1 
Uncharacterized protein YwoF OS=Bacillus subtilis (strain 168) GN=ywoF PE=3 SV=1 
Surfactin synthase subunit 1 OS=Bacillus subtilis (strain 168) GN=srfAA PE=1 SV=4 
Response regulator aspartate phosphatase F OS=Bacillus subtilis (strain 168) GN=rapF PE=1 SV=2 
Uncharacterized protein YsxB OS=Bacillus subtilis (strain 168) GN=ysxB PE=4 SV=2 
Trifunctional nucleotide phosphoesterase protein YfkN OS=Bacillus subtilis (strain 168) GN=yfkN PE=1 SV=1 
Uncharacterized protein YfmG OS=Bacillus subtilis (strain 168) GN=yfmG PE=4 SV=1 
Uncharacterized protein YxbA OS=Bacillus subtilis (strain 168) GN=yxbA PE=4 SV=1 
D-gamma-glutamyl-meso-diaminopimelic acid endopeptidase CwlS OS=Bacillus subtilis (strain 168) GN=cwlS PE=1 
SV=1 
Flagellin OS=Bacillus subtilis (strain 168) GN=hag PE=1 SV=2 
Uncharacterized protein YxbC OS=Bacillus subtilis (strain 168) GN=yxbC PE=1 SV=1 
Protein LiaH OS=Bacillus subtilis (strain 168) GN=liaH PE=2 SV=1 
Single-stranded DNA-binding protein B OS=Bacillus subtilis (strain 168) GN=ssbB PE=1 SV=1 
Response regulator aspartate phosphatase A OS=Bacillus subtilis (strain 168) GN=rapA PE=2 SV=2 
Thioredoxin-like protein SkfH OS=Bacillus subtilis (strain 168) GN=skfH PE=1 SV=2 
NTD biosynthesis operon regulator NtdR OS=Bacillus subtilis (strain 168) GN=ntdR PE=4 SV=1 
Uncharacterized protein YpbG OS=Bacillus subtilis (strain 168) GN=ypbG PE=2 SV=1 
Response regulator aspartate phosphatase C OS=Bacillus subtilis (strain 168) GN=rapC PE=3 SV=1 
Putative phage-related protein YobO OS=Bacillus subtilis (strain 168) GN=yobO PE=4 SV=1 
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Uncharacterized protein YtfP OS=Bacillus subtilis (strain 168) GN=ytfP PE=4 SV=2 
Uncharacterized protein YxnB OS=Bacillus subtilis (strain 168) GN=yxnB PE=4 SV=1 
N-acetylmuramoyl-L-alanine amidase XlyA OS=Bacillus subtilis (strain 168) GN=xlyA PE=1 SV=1 
ComG operon protein 1 OS=Bacillus subtilis (strain 168) GN=comGA PE=1 SV=2 
Uncharacterized protein YebG OS=Bacillus subtilis (strain 168) GN=yebG PE=4 SV=1 
SkfA peptide export ATP-binding protein SkfE OS=Bacillus subtilis (strain 168) GN=skfE PE=1 SV=1 
Uncharacterized protein YlbL OS=Bacillus subtilis (strain 168) GN=ylbL PE=1 SV=2 
Uncharacterized protein YpmA OS=Bacillus subtilis (strain 168) GN=ypmA PE=4 SV=1 
Uncharacterized protein YxbB OS=Bacillus subtilis (strain 168) GN=yxbB PE=3 SV=1 
Carboxy-terminal processing protease CtpA OS=Bacillus subtilis (strain 168) GN=ctpA PE=2 SV=1 
Sporulation inhibitor sda OS=Bacillus subtilis (strain 168) GN=sda PE=1 SV=1 
Uncharacterized protein XkzA OS=Bacillus subtilis (strain 168) GN=xkzA PE=4 SV=1 
Putative peptide biosynthesis protein YydG OS=Bacillus subtilis (strain 168) GN=yydG PE=4 SV=1 
Endonuclease V OS=Bacillus subtilis (strain 168) GN=nfi PE=1 SV=2 
HTH-type transcriptional regulator GanR OS=Bacillus subtilis (strain 168) GN=ganR PE=4 SV=1 
Uncharacterized protein YjcM OS=Bacillus subtilis (strain 168) GN=yjcM PE=3 SV=1 
 
Accession Number Molecular 
weight kDa 
SpC 
27255 
SpC 
27256 
SpC 
27257 
SpC 
27258 
SpC 
27259 
SpC 
27260 
sp|P49937|FHUG_BACSU 36 0 0 0 2 2 2 
sp|O34437|YFKH_BACSU 30 0 0 0 3 2 2 
sp|Q797B3|LTAS1_BACSU 73 0 0 0 9 16 15 
sp|O34497|YKGA_BACSU 32 0 0 0 2 2 2 
sp|P42093|CGEE_BACSU 30 0 0 0 3 3 2 
sp|C0SPC1|YTMP_BACSU 24 0 0 0 2 2 3 
sp|Q45056|YNEA_BACSU 12 0 0 0 5 10 7 
sp|P94560|YSNF_BACSU 31 0 2 0 3 7 9 
sp|O32083|LYTG_BACSU 32 0 0 2 4 6 6 
sp|P42101|GS30_BACSU 40 0 2 0 4 4 4 
sp|Q45500|YKTD_BACSU 35 0 0 2 4 2 4 
sp|P40398|YHXD_BACSU 32 3 4 2 6 11 12 
sp|P54488|YQGFA_BACSU 80 5 6 0 10 9 13 
sp|O31714|K1PF_BACSU 33 4 0 4 7 6 7 
sp|P39737|YVYC_BACSU 13 6 3 4 10 9 13 
sp|Q45612|YYCI_BACSU 33 3 2 2 6 4 5 
sp|O31626|YJCD_BACSU 87 2 4 2 5 7 5 
sp|P80873|GS39_BACSU 31 4 3 3 8 5 8 
sp|P50734|MECA2_BACSU 22 3 2 2 4 4 6 
sp|Q45588|RSIW_BACSU 23 12 14 16 29 23 25 
sp|P80878|MCAT_BACSU 30 5 4 5 9 8 8 
sp|P39807|YVYF_BACSU 16 7 6 5 8 12 11 
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sp|O32055|RUVB_BACSU 37 3 5 7 9 8 9 
sp|P23453|FLIM_BACSU 38 7 7 9 12 12 15 
sp|P80874|GS69_BACSU 37 4 5 7 8 9 10 
sp|P94504|YVRH_BACSU 27 7 8 8 13 11 14 
sp|Q9JMQ2|PPAX_BACSU 24 8 9 8 16 10 15 
sp|P39780|XKDA_BACSU 24 7 11 10 14 15 16 
sp|O34752|LGT_BACSU 31 12 10 10 17 15 18 
sp|O34769|PKSB_BACSU 26 8 7 7 12 10 12 
sp|O34589|FLAW_BACSU 17 26 22 18 37 31 34 
sp|P37599|CHEV_BACSU 35 27 22 28 45 34 40 
sp|P97027|SSUB_BACSU 29 7 5 6 8 9 10 
sp|C0H412|YLZI_BACSU 8 4 3 5 6 6 6 
sp|P38049|HMOB_BACSU 19 7 7 6 11 8 11 
sp|Q796Z1|YGAC_BACSU 21 14 11 12 20 15 20 
sp|O34457|MOAB_BACSU 18 11 10 10 16 17 13 
sp|O06478|ALDH5_BACSU 53 42 52 55 80 78 62 
sp|P54472|GCH1L_BACSU 41 18 12 15 21 24 21 
sp|P94514|LYTT_BACSU 28 5 4 4 7 6 6 
sp|O31775|YMDB_BACSU 29 18 13 18 24 22 25 
sp|P37470|PTH_BACSU 21 21 16 16 27 24 25 
sp|Q45601|RLMH_BACSU 18 20 18 17 27 26 25 
sp|P42234|CATE_BACSU 77 33 34 39 48 53 49 
sp|P13267|DPO3_BACSU 163 104 99 91 147 134 135 
sp|O31513|YESJ_BACSU 20 13 9 12 17 16 15 
sp|P39215|MCPB_BACSU 72 79 73 70 102 92 118 
sp|P39214|MCPA_BACSU 72 37 50 43 61 57 64 
sp|O32072|YTWF_BACSU 12 15 15 17 22 20 23 
sp|O35022|AZOR1_BACSU 23 66 47 51 81 76 67 
sp|P38032|NADB_BACSU 58 54 68 54 79 75 86 
sp|P37940|ODBA_BACSU 36 15 19 16 21 23 24 
sp|O34892|YOBS_BACSU 21 10 8 10 13 11 14 
sp|O31642|YJDA_BACSU 27 12 12 11 17 17 13 
sp|P80880|TRXB_BACSU 35 26 28 26 37 33 37 
sp|P80872|G16O_BACSU 19 9 8 10 11 13 12 
sp|O34454|YKAA_BACSU 24 68 49 54 80 74 74 
sp|O31743|RBGA_BACSU 32 25 29 29 40 34 37 
sp|Q45539|CSBB_BACSU 38 7 7 7 10 9 9 
sp|O07558|YHJD_BACSU 14 8 10 9 13 12 11 
sp|P46918|GGAB_BACSU 107 93 93 81 131 103 119 
sp|O31506|YEEF_BACSU 74 9 8 8 13 10 10 
sp|P39646|PTAS_BACSU 35 82 74 69 100 102 94 
sp|P52998|PANC_BACSU 32 26 26 27 40 31 33 
sp|P29072|CHEA_BACSU 75 70 68 57 89 77 90 
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sp|Q03523|MURE_BACSU 54 25 28 24 33 34 34 
sp|P52996|PANB_BACSU 30 27 29 31 42 33 39 
sp|O34932|COAE_BACSU 22 13 13 13 18 17 16 
sp|P37876|YTXK_BACSU 37 19 21 20 26 27 25 
sp|O07573|NSRR_BACSU 17 8 8 8 10 11 10 
sp|P70962|RAPB_BACSU 45 20 16 17 22 21 25 
sp|P54576|MCPC_BACSU 72 49 52 57 68 63 72 
sp|P50830|YPRA_BACSU 85 24 19 21 30 24 28 
sp|O32192|CSSR_BACSU 26 13 14 12 17 17 16 
sp|P39576|ILVE2_BACSU 40 93 102 92 128 119 119 
sp|P24277|RECR_BACSU 22 8 7 7 10 9 9 
sp|P54173|YPJQ_BACSU 20 14 15 16 18 18 21 
sp|P71037|YWNB_BACSU 23 13 13 12 15 16 17 
sp|P51785|ILVD_BACSU 60 126 122 108 150 156 142 
sp|O31632|METC_BACSU 42 61 61 52 73 72 73 
sp|P54170|YPHP_BACSU 16 50 48 41 59 57 58 
sp|O34623|DPO3A_BACSU 125 66 74 76 88 84 96 
sp|P37565|HSLO_BACSU 32 39 40 35 50 47 44 
sp|P06224|SIGA_BACSU 43 52 47 49 68 57 57 
sp|P25994|CARB_BACSU 118 412 358 419 497 492 455 
sp|P23477|ADDB_BACSU 135 47 52 49 64 54 61 
sp|P37465|SYM_BACSU 76 95 100 100 113 122 121 
sp|P32396|HEMH_BACSU 35 10 10 11 13 12 12 
sp|P54381|SYGB_BACSU 76 79 86 80 94 98 99 
sp|O05392|RUVA_BACSU 23 15 16 17 19 18 20 
sp|P94512|YSAA_BACSU 30 35 30 36 39 41 39 
sp|P40924|PGK_BACSU 42 153 151 179 193 189 186 
sp|P25995|PYRC_BACSU 47 99 102 92 113 110 121 
sp|Q9KWU4|PYC_BACSU 128 642 587 656 791 692 693 
sp|P40871|DHBE_BACSU 60 233 242 240 299 267 259 
sp|P19669|TAL_BACSU 23 221 192 220 250 248 228 
sp|O31501|SWRC_BACSU 114 249 242 257 290 272 295 
sp|O07516|YHAH_BACSU 13 43 43 45 54 50 46 
sp|O06714|SBCC_BACSU 129 114 107 115 140 126 118 
sp|P09124|G3P1_BACSU 36 431 416 432 504 478 476 
sp|P37472|HPRT_BACSU 20 49 49 49 58 56 53 
sp|P42318|YXJG_BACSU 43 182 166 192 206 199 207 
sp|P05652|GYRB_BACSU 72 78 74 79 89 86 85 
sp|P25993|CARA_BACSU 40 81 81 81 92 90 90 
sp|P54517|AROQ_BACSU 16 16 15 16 15 15 15 
sp|P54519|YQHY_BACSU 15 46 43 42 40 39 41 
sp|P42924|RL23_BACSU 11 171 158 173 159 157 138 
sp|P13800|DEGU_BACSU 26 104 99 112 100 91 91 
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sp|P37522|SOJ_BACSU 28 25 26 25 25 21 22 
sp|P42972|YCSN_BACSU 34 11 12 11 10 10 10 
sp|O31534|HMOA_BACSU 13 78 71 72 65 67 62 
sp|O34660|ALDH4_BACSU 54 37 39 37 35 31 30 
sp|Q07836|WAPI_BACSU 16 83 81 92 74 70 72 
sp|P70948|YITV_BACSU 29 25 25 24 19 23 19 
sp|P39120|CISY2_BACSU 42 53 53 51 44 40 45 
sp|O34328|KGUA_BACSU 23 17 19 17 15 14 14 
sp|P51831|FABG_BACSU 26 90 76 78 67 63 66 
sp|O31684|YKVS_BACSU 7 5 5 5 4 4 4 
sp|P42108|YXAI_BACSU 17 19 17 18 15 13 15 
sp|P28599|CH10_BACSU 10 95 81 92 79 76 58 
sp|P54530|PTB_BACSU 32 15 17 17 15 12 12 
sp|P71066|YVFG_BACSU 8 24 21 22 17 20 15 
sp|O06492|GATC_BACSU 11 44 49 45 32 39 36 
sp|P39651|YWFO_BACSU 51 16 16 20 14 14 12 
sp|O34759|YDJO_BACSU 8 25 23 20 18 17 16 
sp|P33911|CSRA_BACSU 8 17 15 14 11 12 11 
sp|O34725|YJHA_BACSU 24 18 21 17 16 13 12 
sp|O07598|YHAA_BACSU 43 44 53 44 31 39 32 
sp|O31818|YNZC_BACSU 9 17 16 21 12 14 10 
sp|P54484|YQGA_BACSU 15 42 40 41 24 24 32 
sp|P26380|PTFB_BACSU 18 20 21 29 17 13 15 
sp|P39839|YUXL_BACSU 74 11 11 8 7 7 5 
sp|O05501|YDHI_BACSU 18 4 4 5 2 3 3 
sp|O34588|YKUJ_BACSU 9 31 29 39 23 21 17 
sp|O31697|YKZF_BACSU 8 8 8 9 6 4 5 
sp|Q04747|SRFAB_BACSU 401 2687 2358 2041 1478 1329 1422 
sp|O31804|TATAC_BACSU 7 13 12 14 8 9 6 
sp|P96714|YWQB_BACSU 63 5 7 5 3 3 4 
sp|P12667|NUCA_BACSU 16 15 15 11 9 7 8 
sp|P54507|COTN_BACSU 28 75 62 60 45 37 32 
sp|O05522|TATAY_BACSU 6 10 9 11 7 6 4 
sp|P45693|SP5S_BACSU 9 14 14 20 9 10 8 
sp|O32242|SDPR_BACSU 10 22 16 16 12 10 7 
sp|Q08787|SRFAC_BACSU 144 508 455 398 262 213 253 
sp|O34344|SDPC_BACSU 22 18 17 16 7 7 13 
sp|P54506|LEPW_BACSU 21 6 7 6 4 4 2 
sp|P96720|YWQH_BACSU 16 10 10 13 3 7 7 
sp|P42113|ASNH_BACSU 86 17 20 13 10 7 9 
sp|O34538|YCDA_BACSU 39 20 23 16 11 9 10 
sp|P94576|YWOF_BACSU 51 5 7 6 3 2 4 
sp|P27206|SRFAA_BACSU 402 2032 1788 1563 891 874 878 
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sp|P71002|RAPF_BACSU 46 39 38 42 9 26 22 
sp|P26942|YSXB_BACSU 12 5 9 7 3 4 3 
sp|O34313|NTPES_BACSU 160 13 12 13 5 6 7 
sp|O34722|YFMG_BACSU 57 47 55 46 21 25 22 
sp|P46325|YXBA_BACSU 10 17 15 12 5 8 5 
sp|O31852|CWLS_BACSU 44 9 10 11 3 4 5 
sp|P02968|FLA_BACSU 33 78 71 73 35 24 30 
sp|P46327|YXBC_BACSU 37 21 23 24 8 8 9 
sp|O32201|LIAH_BACSU 26 29 24 22 12 5 10 
sp|C0SPB6|SSBB_BACSU 13 36 29 22 9 5 15 
sp|Q00828|RAPA_BACSU 45 12 15 14 3 3 6 
sp|O31430|SKFH_BACSU 16 8 9 7 3 0 4 
sp|O07567|NTDR_BACSU 38 7 6 5 0 3 2 
sp|P50733|YPBG_BACSU 29 4 2 3 2 0 0 
sp|P94415|RAPC_BACSU 46 12 13 22 0 4 6 
sp|O34433|YOBO_BACSU 88 3 3 5 2 0 0 
sp|Q795R8|YTFP_BACSU 46 9 8 7 0 0 4 
sp|O34704|YXNB_BACSU 19 8 4 7 0 3 0 
sp|P39800|XLYA_BACSU 32 6 7 6 0 3 0 
sp|P25953|COMGA_BACSU 40 6 5 3 2 0 0 
sp|O34700|YEBG_BACSU 8 6 4 5 0 2 0 
sp|O31427|SKFE_BACSU 27 2 3 2 0 0 0 
sp|O34470|YLBL_BACSU 38 2 3 2 0 0 0 
sp|P54395|YPMA_BACSU 7 2 2 2 0 0 0 
sp|P46326|YXBB_BACSU 28 11 8 10 0 0 0 
sp|O34666|CTPA_BACSU 51 19 22 15 0 0 0 
sp|Q7WY62|SDA_BACSU 6 3 3 2 0 0 0 
sp|C0H3Z9|XKZA_BACSU 10 2 2 3 0 0 0 
sp|Q45595|YYDG_BACSU 37 5 3 5 0 0 0 
sp|P96724|NFI_BACSU 27 4 2 3 0 0 0 
sp|O07008|GANR_BACSU 37 2 4 2 0 0 0 
sp|O31635|YJCM_BACSU 47 2 7 8 0 0 0 
 
 
NSAF 
27255 
NSAF 27256 NSAF 27257 NSAF 27258 NSAF 27259 NSAF 27260 
0.00E+00 0.00E+00 0.00E+00 2.02E-05 2.11E-05 2.12E-05 
0.00E+00 0.00E+00 0.00E+00 3.64E-05 2.53E-05 2.54E-05 
0.00E+00 0.00E+00 0.00E+00 4.49E-05 8.33E-05 7.84E-05 
0.00E+00 0.00E+00 0.00E+00 2.28E-05 2.38E-05 2.39E-05 
0.00E+00 0.00E+00 0.00E+00 3.64E-05 3.80E-05 2.54E-05 
0.00E+00 0.00E+00 0.00E+00 3.03E-05 3.17E-05 4.77E-05 
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0.00E+00 0.00E+00 0.00E+00 1.52E-04 3.17E-04 2.23E-04 
0.00E+00 2.50E-05 0.00E+00 3.52E-05 8.59E-05 1.11E-04 
0.00E+00 0.00E+00 2.38E-05 4.55E-05 7.13E-05 7.16E-05 
0.00E+00 1.94E-05 0.00E+00 3.64E-05 3.80E-05 3.82E-05 
0.00E+00 0.00E+00 2.17E-05 4.16E-05 2.17E-05 4.36E-05 
3.51E-05 4.85E-05 2.38E-05 6.83E-05 1.31E-04 1.43E-04 
2.34E-05 2.91E-05 0.00E+00 4.55E-05 4.28E-05 6.20E-05 
4.53E-05 0.00E+00 4.61E-05 7.72E-05 6.91E-05 8.10E-05 
1.73E-04 8.95E-05 1.17E-04 2.80E-04 2.63E-04 3.82E-04 
3.40E-05 2.35E-05 2.31E-05 6.62E-05 4.61E-05 5.78E-05 
8.60E-06 1.78E-05 8.75E-06 2.09E-05 3.06E-05 2.19E-05 
4.82E-05 3.75E-05 3.68E-05 9.40E-05 6.13E-05 9.85E-05 
5.10E-05 3.52E-05 3.46E-05 6.62E-05 6.91E-05 1.04E-04 
1.95E-04 2.36E-04 2.65E-04 4.59E-04 3.80E-04 4.15E-04 
6.23E-05 5.17E-05 6.34E-05 1.09E-04 1.01E-04 1.02E-04 
1.64E-04 1.45E-04 1.19E-04 1.82E-04 2.85E-04 2.62E-04 
3.03E-05 5.24E-05 7.20E-05 8.86E-05 8.22E-05 9.28E-05 
6.89E-05 7.14E-05 9.01E-05 1.15E-04 1.20E-04 1.51E-04 
4.04E-05 5.24E-05 7.20E-05 7.87E-05 9.25E-05 1.03E-04 
9.69E-05 1.15E-04 1.13E-04 1.75E-04 1.55E-04 1.98E-04 
1.25E-04 1.45E-04 1.27E-04 2.43E-04 1.58E-04 2.39E-04 
1.09E-04 1.78E-04 1.59E-04 2.12E-04 2.38E-04 2.54E-04 
1.45E-04 1.25E-04 1.23E-04 2.00E-04 1.84E-04 2.22E-04 
1.15E-04 1.04E-04 1.02E-04 1.68E-04 1.46E-04 1.76E-04 
5.72E-04 5.02E-04 4.03E-04 7.92E-04 6.93E-04 7.63E-04 
2.88E-04 2.44E-04 3.04E-04 4.68E-04 3.69E-04 4.36E-04 
9.02E-05 6.68E-05 7.87E-05 1.00E-04 1.18E-04 1.32E-04 
1.87E-04 1.45E-04 2.38E-04 2.73E-04 2.85E-04 2.86E-04 
1.38E-04 1.43E-04 1.20E-04 2.11E-04 1.60E-04 2.21E-04 
2.49E-04 2.03E-04 2.17E-04 3.47E-04 2.72E-04 3.64E-04 
2.28E-04 2.15E-04 2.11E-04 3.24E-04 3.59E-04 2.76E-04 
2.96E-04 3.80E-04 3.95E-04 5.50E-04 5.60E-04 4.47E-04 
1.64E-04 1.13E-04 1.39E-04 1.86E-04 2.23E-04 1.96E-04 
6.68E-05 5.54E-05 5.43E-05 9.10E-05 8.15E-05 8.18E-05 
2.32E-04 1.74E-04 2.36E-04 3.01E-04 2.88E-04 3.29E-04 
3.74E-04 2.95E-04 2.90E-04 4.68E-04 4.35E-04 4.54E-04 
4.15E-04 3.88E-04 3.59E-04 5.46E-04 5.49E-04 5.30E-04 
1.60E-04 1.71E-04 1.93E-04 2.27E-04 2.62E-04 2.43E-04 
2.39E-04 2.35E-04 2.12E-04 3.28E-04 3.13E-04 3.16E-04 
2.43E-04 1.74E-04 2.28E-04 3.09E-04 3.04E-04 2.86E-04 
4.10E-04 3.93E-04 3.70E-04 5.16E-04 4.86E-04 6.26E-04 
1.92E-04 2.69E-04 2.27E-04 3.08E-04 3.01E-04 3.39E-04 
4.67E-04 4.85E-04 5.39E-04 6.68E-04 6.34E-04 7.32E-04 
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1.07E-03 7.92E-04 8.44E-04 1.28E-03 1.26E-03 1.11E-03 
3.48E-04 4.54E-04 3.54E-04 4.96E-04 4.92E-04 5.66E-04 
1.56E-04 2.05E-04 1.69E-04 2.12E-04 2.43E-04 2.54E-04 
1.78E-04 1.48E-04 1.81E-04 2.25E-04 1.99E-04 2.54E-04 
1.66E-04 1.72E-04 1.55E-04 2.29E-04 2.39E-04 1.84E-04 
2.78E-04 3.10E-04 2.83E-04 3.85E-04 3.59E-04 4.04E-04 
1.77E-04 1.63E-04 2.00E-04 2.11E-04 2.60E-04 2.41E-04 
1.06E-03 7.91E-04 8.56E-04 1.21E-03 1.17E-03 1.18E-03 
2.92E-04 3.51E-04 3.45E-04 4.55E-04 4.04E-04 4.41E-04 
6.89E-05 7.14E-05 7.01E-05 9.58E-05 9.01E-05 9.04E-05 
2.14E-04 2.77E-04 2.45E-04 3.38E-04 3.26E-04 3.00E-04 
3.25E-04 3.37E-04 2.88E-04 4.46E-04 3.66E-04 4.25E-04 
4.55E-05 4.19E-05 4.11E-05 6.40E-05 5.14E-05 5.16E-05 
8.76E-04 8.20E-04 7.50E-04 1.04E-03 1.11E-03 1.03E-03 
3.04E-04 3.15E-04 3.21E-04 4.55E-04 3.68E-04 3.94E-04 
3.49E-04 3.51E-04 2.89E-04 4.32E-04 3.90E-04 4.58E-04 
1.73E-04 2.01E-04 1.69E-04 2.23E-04 2.39E-04 2.40E-04 
3.37E-04 3.75E-04 3.93E-04 5.10E-04 4.18E-04 4.96E-04 
2.21E-04 2.29E-04 2.25E-04 2.98E-04 2.94E-04 2.78E-04 
1.92E-04 2.20E-04 2.06E-04 2.56E-04 2.77E-04 2.58E-04 
1.76E-04 1.82E-04 1.79E-04 2.14E-04 2.46E-04 2.25E-04 
1.66E-04 1.38E-04 1.44E-04 1.78E-04 1.77E-04 2.12E-04 
2.54E-04 2.80E-04 3.01E-04 3.44E-04 3.33E-04 3.82E-04 
1.06E-04 8.67E-05 9.40E-05 1.29E-04 1.07E-04 1.26E-04 
1.87E-04 2.09E-04 1.76E-04 2.38E-04 2.49E-04 2.35E-04 
8.69E-04 9.88E-04 8.75E-04 1.17E-03 1.13E-03 1.14E-03 
1.36E-04 1.23E-04 1.21E-04 1.66E-04 1.56E-04 1.56E-04 
2.62E-04 2.91E-04 3.04E-04 3.28E-04 3.42E-04 4.01E-04 
2.11E-04 2.19E-04 1.98E-04 2.37E-04 2.65E-04 2.82E-04 
7.85E-04 7.88E-04 6.85E-04 9.10E-04 9.89E-04 9.03E-04 
5.43E-04 5.63E-04 4.71E-04 6.33E-04 6.52E-04 6.63E-04 
1.17E-03 1.16E-03 9.75E-04 1.34E-03 1.35E-03 1.38E-03 
1.97E-04 2.29E-04 2.31E-04 2.56E-04 2.56E-04 2.93E-04 
4.56E-04 4.85E-04 4.16E-04 5.69E-04 5.58E-04 5.25E-04 
4.52E-04 4.24E-04 4.33E-04 5.76E-04 5.04E-04 5.06E-04 
1.31E-03 1.18E-03 1.35E-03 1.53E-03 1.59E-03 1.47E-03 
1.30E-04 1.49E-04 1.38E-04 1.73E-04 1.52E-04 1.72E-04 
4.67E-04 5.10E-04 5.01E-04 5.41E-04 6.10E-04 6.08E-04 
1.07E-04 1.11E-04 1.20E-04 1.35E-04 1.30E-04 1.31E-04 
3.89E-04 4.39E-04 4.00E-04 4.50E-04 4.90E-04 4.97E-04 
2.44E-04 2.70E-04 2.81E-04 3.01E-04 2.98E-04 3.32E-04 
4.36E-04 3.88E-04 4.57E-04 4.73E-04 5.20E-04 4.96E-04 
1.36E-03 1.39E-03 1.62E-03 1.67E-03 1.71E-03 1.69E-03 
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7.88E-04 8.41E-04 7.45E-04 8.75E-04 8.90E-04 9.83E-04 
1.88E-03 1.78E-03 1.95E-03 2.25E-03 2.06E-03 2.07E-03 
1.45E-03 1.56E-03 1.52E-03 1.81E-03 1.69E-03 1.65E-03 
3.59E-03 3.24E-03 3.64E-03 3.96E-03 4.10E-03 3.78E-03 
8.17E-04 8.23E-04 8.58E-04 9.26E-04 9.07E-04 9.88E-04 
1.24E-03 1.28E-03 1.32E-03 1.51E-03 1.46E-03 1.35E-03 
3.30E-04 3.22E-04 3.39E-04 3.95E-04 3.71E-04 3.49E-04 
4.48E-03 4.48E-03 4.57E-03 5.10E-03 5.05E-03 5.05E-03 
9.16E-04 9.50E-04 9.32E-04 1.06E-03 1.06E-03 1.01E-03 
1.58E-03 1.50E-03 1.70E-03 1.74E-03 1.76E-03 1.84E-03 
4.05E-04 3.98E-04 4.17E-04 4.50E-04 4.54E-04 4.51E-04 
7.57E-04 7.85E-04 7.70E-04 8.37E-04 8.56E-04 8.59E-04 
3.74E-04 3.63E-04 3.80E-04 3.41E-04 3.56E-04 3.58E-04 
1.15E-03 1.11E-03 1.07E-03 9.71E-04 9.89E-04 1.04E-03 
5.81E-03 5.57E-03 5.98E-03 5.26E-03 5.43E-03 4.79E-03 
1.50E-03 1.48E-03 1.64E-03 1.40E-03 1.33E-03 1.34E-03 
3.34E-04 3.60E-04 3.40E-04 3.25E-04 2.85E-04 3.00E-04 
1.21E-04 1.37E-04 1.23E-04 1.07E-04 1.12E-04 1.12E-04 
2.24E-03 2.12E-03 2.11E-03 1.82E-03 1.96E-03 1.82E-03 
2.56E-04 2.80E-04 2.61E-04 2.36E-04 2.18E-04 2.12E-04 
1.94E-03 1.96E-03 2.19E-03 1.68E-03 1.66E-03 1.72E-03 
3.22E-04 3.34E-04 3.15E-04 2.39E-04 3.02E-04 2.50E-04 
4.72E-04 4.89E-04 4.62E-04 3.81E-04 3.62E-04 4.09E-04 
2.76E-04 3.20E-04 2.81E-04 2.37E-04 2.31E-04 2.32E-04 
1.29E-03 1.13E-03 1.14E-03 9.38E-04 9.21E-04 9.69E-04 
2.67E-04 2.77E-04 2.72E-04 2.08E-04 2.17E-04 2.18E-04 
4.18E-04 3.88E-04 4.03E-04 3.21E-04 2.91E-04 3.37E-04 
3.55E-03 3.14E-03 3.50E-03 2.88E-03 2.89E-03 2.21E-03 
1.75E-04 2.06E-04 2.02E-04 1.71E-04 1.43E-04 1.43E-04 
1.12E-03 1.02E-03 1.05E-03 7.74E-04 9.51E-04 7.16E-04 
1.50E-03 1.73E-03 1.56E-03 1.06E-03 1.35E-03 1.25E-03 
1.17E-04 1.22E-04 1.49E-04 1.00E-04 1.04E-04 8.98E-05 
1.17E-03 1.11E-03 9.51E-04 8.19E-04 8.08E-04 7.63E-04 
7.95E-04 7.27E-04 6.66E-04 5.01E-04 5.70E-04 5.25E-04 
2.80E-04 3.39E-04 2.69E-04 2.43E-04 2.06E-04 1.91E-04 
3.83E-04 4.78E-04 3.89E-04 2.63E-04 3.45E-04 2.84E-04 
7.06E-04 6.89E-04 8.88E-04 4.85E-04 5.91E-04 4.24E-04 
1.05E-03 1.03E-03 1.04E-03 5.83E-04 6.08E-04 8.14E-04 
4.15E-04 4.52E-04 6.13E-04 3.44E-04 2.75E-04 3.18E-04 
5.56E-05 5.76E-05 4.11E-05 3.44E-05 3.60E-05 2.58E-05 
8.31E-05 8.61E-05 1.06E-04 4.05E-05 6.34E-05 6.36E-05 
1.29E-03 1.25E-03 1.65E-03 9.31E-04 8.87E-04 7.21E-04 
3.74E-04 3.88E-04 4.28E-04 2.73E-04 1.90E-04 2.39E-04 
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2.51E-03 2.28E-03 1.94E-03 1.34E-03 1.26E-03 1.35E-03 
6.94E-04 6.65E-04 7.61E-04 4.16E-04 4.89E-04 3.27E-04 
2.97E-05 4.31E-05 3.02E-05 1.73E-05 1.81E-05 2.42E-05 
3.51E-04 3.63E-04 2.62E-04 2.05E-04 1.66E-04 1.91E-04 
1.00E-03 8.58E-04 8.15E-04 5.85E-04 5.02E-04 4.36E-04 
6.23E-04 5.81E-04 6.97E-04 4.25E-04 3.80E-04 2.54E-04 
5.82E-04 6.03E-04 8.45E-04 3.64E-04 4.22E-04 3.39E-04 
8.23E-04 6.20E-04 6.09E-04 4.37E-04 3.80E-04 2.67E-04 
1.32E-03 1.22E-03 1.05E-03 6.62E-04 5.62E-04 6.71E-04 
3.06E-04 3.00E-04 2.77E-04 1.16E-04 1.21E-04 2.26E-04 
1.07E-04 1.29E-04 1.09E-04 6.94E-05 7.24E-05 3.64E-05 
2.34E-04 2.42E-04 3.09E-04 6.83E-05 1.66E-04 1.67E-04 
7.39E-05 9.02E-05 5.75E-05 4.23E-05 3.09E-05 3.99E-05 
1.92E-04 2.29E-04 1.56E-04 1.03E-04 8.77E-05 9.79E-05 
3.67E-05 5.32E-05 4.48E-05 2.14E-05 1.49E-05 2.99E-05 
1.89E-03 1.72E-03 1.48E-03 8.07E-04 8.27E-04 8.34E-04 
3.17E-04 3.20E-04 3.47E-04 7.12E-05 2.15E-04 1.83E-04 
1.56E-04 2.91E-04 2.22E-04 9.10E-05 1.27E-04 9.54E-05 
3.04E-05 2.91E-05 3.09E-05 1.14E-05 1.43E-05 1.67E-05 
3.08E-04 3.74E-04 3.07E-04 1.34E-04 1.67E-04 1.47E-04 
6.36E-04 5.81E-04 4.57E-04 1.82E-04 3.04E-04 1.91E-04 
7.65E-05 8.81E-05 9.51E-05 2.48E-05 3.46E-05 4.34E-05 
8.84E-04 8.34E-04 8.42E-04 3.86E-04 2.77E-04 3.47E-04 
2.12E-04 2.41E-04 2.47E-04 7.87E-05 8.22E-05 9.28E-05 
4.17E-04 3.58E-04 3.22E-04 1.68E-04 7.31E-05 1.47E-04 
1.04E-03 8.65E-04 6.44E-04 2.52E-04 1.46E-04 4.40E-04 
9.97E-05 1.29E-04 1.18E-04 2.43E-05 2.53E-05 5.09E-05 
1.87E-04 2.18E-04 1.66E-04 6.83E-05 0.00E+00 9.54E-05 
6.89E-05 6.12E-05 5.01E-05 0.00E+00 3.00E-05 2.01E-05 
5.16E-05 2.67E-05 3.94E-05 2.51E-05 0.00E+00 0.00E+00 
9.75E-05 1.10E-04 1.82E-04 0.00E+00 3.31E-05 4.98E-05 
1.27E-05 1.32E-05 2.16E-05 8.28E-06 0.00E+00 0.00E+00 
7.32E-05 6.74E-05 5.79E-05 0.00E+00 0.00E+00 3.32E-05 
1.57E-04 8.16E-05 1.40E-04 0.00E+00 6.00E-05 0.00E+00 
7.01E-05 8.48E-05 7.13E-05 0.00E+00 3.56E-05 0.00E+00 
5.61E-05 4.85E-05 2.85E-05 1.82E-05 0.00E+00 0.00E+00 
2.80E-04 1.94E-04 2.38E-04 0.00E+00 9.51E-05 0.00E+00 
2.77E-05 4.31E-05 2.82E-05 0.00E+00 0.00E+00 0.00E+00 
1.97E-05 3.06E-05 2.00E-05 0.00E+00 0.00E+00 0.00E+00 
1.07E-04 1.11E-04 1.09E-04 0.00E+00 0.00E+00 0.00E+00 
1.47E-04 1.11E-04 1.36E-04 0.00E+00 0.00E+00 0.00E+00 
1.39E-04 1.67E-04 1.12E-04 0.00E+00 0.00E+00 0.00E+00 
1.87E-04 1.94E-04 1.27E-04 0.00E+00 0.00E+00 0.00E+00 
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7.48E-05 7.75E-05 1.14E-04 0.00E+00 0.00E+00 0.00E+00 
5.05E-05 3.14E-05 5.14E-05 0.00E+00 0.00E+00 0.00E+00 
5.54E-05 2.87E-05 4.23E-05 0.00E+00 0.00E+00 0.00E+00 
2.02E-05 4.19E-05 2.06E-05 0.00E+00 0.00E+00 0.00E+00 
1.59E-05 5.77E-05 6.48E-05 0.00E+00 0.00E+00 0.00E+00 
 
Average 
NSAF WT 
Average 
NSAF 
Mutant 
Fold Change 
Average NSAF WT 
/ Average NSAF 
Mutant 
T-Test Estimated 
Fold change 
(Mut/WT) 
0.00E+00 2.09E-05 #DIV/0! 3.0E-07 6.02 
0.00E+00 2.91E-05 #DIV/0! 1.4E-03 7.00 
0.00E+00 6.89E-05 #DIV/0! 4.7E-03 40.35 
0.00E+00 2.35E-05 #DIV/0! 3.0E-07 6.02 
0.00E+00 3.33E-05 #DIV/0! 1.1E-03 8.01 
0.00E+00 3.66E-05 #DIV/0! 2.8E-03 7.04 
0.00E+00 2.30E-04 #DIV/0! 8.5E-03 22.19 
8.34E-06 7.73E-05 9.27 4.4E-02  
7.93E-06 6.28E-05 7.92 9.4E-03  
6.46E-06 3.75E-05 5.81 8.7E-03  
7.25E-06 3.57E-05 4.92 4.8E-02  
3.58E-05 1.14E-04 3.19 3.2E-02  
1.75E-05 5.01E-05 2.87 3.8E-02  
3.05E-05 7.58E-05 2.49 4.4E-02  
1.26E-04 3.08E-04 2.44 1.5E-02  
2.68E-05 5.67E-05 2.11 1.2E-02  
1.17E-05 2.45E-05 2.09 4.2E-02  
4.09E-05 8.46E-05 2.07 2.4E-02  
4.03E-05 7.98E-05 1.98 4.1E-02  
2.32E-04 4.18E-04 1.80 3.6E-03  
5.91E-05 1.04E-04 1.76 5.7E-04  
1.43E-04 2.43E-04 1.71 4.1E-02  
5.16E-05 8.79E-05 1.70 4.3E-02  
7.68E-05 1.29E-04 1.67 1.6E-02  
5.49E-05 9.15E-05 1.67 3.5E-02  
1.08E-04 1.76E-04 1.63 7.6E-03  
1.32E-04 2.13E-04 1.61 4.5E-02  
1.48E-04 2.35E-04 1.58 2.2E-02  
1.31E-04 2.02E-04 1.54 5.4E-03  
1.07E-04 1.63E-04 1.52 4.5E-03  
4.92E-04 7.50E-04 1.52 1.1E-02  
2.79E-04 4.25E-04 1.52 1.3E-02  
7.86E-05 1.17E-04 1.48 2.8E-02  
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1.90E-04 2.82E-04 1.48 2.8E-02  
1.34E-04 1.97E-04 1.48 3.4E-02  
2.23E-04 3.27E-04 1.47 3.0E-02  
2.18E-04 3.19E-04 1.46 1.5E-02  
3.57E-04 5.19E-04 1.45 2.7E-02  
1.39E-04 2.02E-04 1.45 2.6E-02  
5.88E-05 8.48E-05 1.44 6.9E-03  
2.14E-04 3.06E-04 1.43 1.7E-02  
3.20E-04 4.52E-04 1.42 1.0E-02  
3.87E-04 5.42E-04 1.40 8.6E-04  
1.75E-04 2.44E-04 1.40 7.5E-03  
2.29E-04 3.19E-04 1.39 7.0E-04  
2.15E-04 3.00E-04 1.39 1.8E-02  
3.91E-04 5.42E-04 1.39 2.6E-02  
2.30E-04 3.16E-04 1.38 2.6E-02  
4.97E-04 6.78E-04 1.36 7.3E-03  
9.03E-04 1.22E-03 1.35 3.6E-02  
3.86E-04 5.18E-04 1.34 3.5E-02  
1.76E-04 2.37E-04 1.34 3.5E-02  
1.69E-04 2.26E-04 1.34 4.0E-02  
1.64E-04 2.17E-04 1.32 4.1E-02  
2.90E-04 3.82E-04 1.32 5.0E-03  
1.80E-04 2.37E-04 1.32 3.3E-02  
9.02E-04 1.19E-03 1.32 2.5E-02  
3.29E-04 4.33E-04 1.32 1.3E-02  
7.01E-05 9.21E-05 1.31 3.9E-04  
2.45E-04 3.21E-04 1.31 2.4E-02  
3.17E-04 4.12E-04 1.30 2.7E-02  
4.28E-05 5.56E-05 1.30 4.3E-02  
8.15E-04 1.06E-03 1.30 5.5E-03  
3.13E-04 4.06E-04 1.30 2.4E-02  
3.30E-04 4.27E-04 1.29 2.7E-02  
1.81E-04 2.34E-04 1.29 1.0E-02  
3.68E-04 4.75E-04 1.29 3.2E-02  
2.25E-04 2.90E-04 1.29 6.1E-04  
2.06E-04 2.64E-04 1.28 5.5E-03  
1.79E-04 2.28E-04 1.27 6.8E-03  
1.49E-04 1.89E-04 1.27 5.0E-02  
2.79E-04 3.53E-04 1.27 2.1E-02  
9.54E-05 1.21E-04 1.26 4.3E-02  
1.90E-04 2.41E-04 1.26 9.0E-03  
9.11E-04 1.14E-03 1.26 4.4E-03  
1.27E-04 1.59E-04 1.25 4.6E-03  
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2.86E-04 3.57E-04 1.25 5.0E-02  
2.10E-04 2.61E-04 1.25 2.2E-02  
7.53E-04 9.34E-04 1.24 1.4E-02  
5.26E-04 6.49E-04 1.24 1.4E-02  
1.10E-03 1.36E-03 1.23 1.6E-02  
2.19E-04 2.68E-04 1.22 4.2E-02  
4.52E-04 5.51E-04 1.22 1.5E-02  
4.36E-04 5.29E-04 1.21 2.1E-02  
1.28E-03 1.53E-03 1.20 1.5E-02  
1.39E-04 1.66E-04 1.19 3.9E-02  
4.93E-04 5.86E-04 1.19 2.3E-02  
1.12E-04 1.32E-04 1.18 8.3E-03  
4.09E-04 4.79E-04 1.17 2.9E-02  
2.65E-04 3.10E-04 1.17 4.4E-02  
4.27E-04 4.96E-04 1.16 4.6E-02  
1.46E-03 1.69E-03 1.16 4.8E-02  
7.91E-04 9.16E-04 1.16 4.6E-02  
1.87E-03 2.12E-03 1.14 3.3E-02  
1.51E-03 1.72E-03 1.14 2.6E-02  
3.49E-03 3.95E-03 1.13 4.3E-02  
8.32E-04 9.40E-04 1.13 1.7E-02  
1.28E-03 1.44E-03 1.13 3.7E-02  
3.30E-04 3.72E-04 1.13 4.3E-02  
4.51E-03 5.06E-03 1.12 7.6E-05  
9.33E-04 1.04E-03 1.12 4.3E-03  
1.59E-03 1.78E-03 1.12 4.5E-02  
4.07E-04 4.52E-04 1.11 1.4E-03  
7.71E-04 8.51E-04 1.10 1.6E-03  
3.73E-04 3.52E-04 0.94 4.6E-02  
1.11E-03 1.00E-03 0.90 2.9E-02  
5.79E-03 5.16E-03 0.89 5.0E-02  
1.54E-03 1.36E-03 0.88 3.2E-02  
3.44E-04 3.03E-04 0.88 4.3E-02  
1.27E-04 1.10E-04 0.87 3.4E-02  
2.16E-03 1.87E-03 0.87 1.1E-02  
2.66E-04 2.22E-04 0.84 1.3E-02  
2.03E-03 1.69E-03 0.83 1.3E-02  
3.24E-04 2.63E-04 0.81 4.0E-02  
4.74E-04 3.84E-04 0.81 4.6E-03  
2.93E-04 2.34E-04 0.80 1.4E-02  
1.19E-03 9.43E-04 0.79 1.0E-02  
2.72E-04 2.14E-04 0.79 1.8E-04  
4.03E-04 3.16E-04 0.79 5.8E-03  
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3.40E-03 2.66E-03 0.78 4.6E-02  
1.94E-04 1.52E-04 0.78 3.4E-02  
1.06E-03 8.13E-04 0.77 3.2E-02  
1.59E-03 1.22E-03 0.77 2.7E-02  
1.29E-04 9.80E-05 0.76 4.5E-02  
1.08E-03 7.97E-04 0.74 1.4E-02  
7.29E-04 5.32E-04 0.73 9.7E-03  
2.96E-04 2.13E-04 0.72 3.5E-02  
4.17E-04 2.97E-04 0.71 3.9E-02  
7.61E-04 5.00E-04 0.66 3.1E-02  
1.04E-03 6.68E-04 0.64 7.2E-03  
4.94E-04 3.12E-04 0.63 4.7E-02  
5.14E-05 3.21E-05 0.62 3.3E-02  
9.16E-05 5.58E-05 0.61 2.7E-02  
1.40E-03 8.46E-04 0.61 1.8E-02  
3.97E-04 2.34E-04 0.59 5.0E-03  
2.24E-03 1.32E-03 0.59 5.4E-03  
7.07E-04 4.11E-04 0.58 5.7E-03  
3.43E-05 1.99E-05 0.58 4.2E-02  
3.25E-04 1.87E-04 0.58 1.5E-02  
8.92E-04 5.08E-04 0.57 5.6E-03  
6.34E-04 3.53E-04 0.56 1.0E-02  
6.77E-04 3.75E-04 0.55 2.7E-02  
6.84E-04 3.61E-04 0.53 2.0E-02  
1.20E-03 6.32E-04 0.53 2.7E-03  
2.94E-04 1.54E-04 0.52 1.9E-02  
1.15E-04 5.94E-05 0.52 1.5E-02  
2.62E-04 1.34E-04 0.51 3.4E-02  
7.39E-05 3.77E-05 0.51 2.3E-02  
1.92E-04 9.61E-05 0.50 1.1E-02  
4.49E-05 2.21E-05 0.49 2.4E-02  
1.70E-03 8.22E-04 0.48 1.9E-03  
3.28E-04 1.56E-04 0.48 1.8E-02  
2.23E-04 1.04E-04 0.47 4.3E-02  
3.01E-05 1.41E-05 0.47 6.1E-04  
3.30E-04 1.49E-04 0.45 1.7E-03  
5.58E-04 2.26E-04 0.40 7.3E-03  
8.66E-05 3.43E-05 0.40 2.4E-03  
8.53E-04 3.37E-04 0.39 1.3E-04  
2.33E-04 8.46E-05 0.36 2.1E-04  
3.66E-04 1.29E-04 0.35 4.1E-03  
8.48E-04 2.80E-04 0.33 1.6E-02  
1.16E-04 3.35E-05 0.29 2.6E-03  
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1.90E-04 5.46E-05 0.29 1.3E-02  
6.00E-05 1.67E-05 0.28 1.4E-02  
3.92E-05 8.37E-06 0.21 4.9E-02  
1.30E-04 2.76E-05 0.21 2.8E-02  
1.59E-05 2.76E-06 0.17 3.0E-02  
6.62E-05 1.11E-05 0.17 9.9E-03  
1.26E-04 2.00E-05 0.16 2.5E-02  
7.54E-05 1.19E-05 0.16 7.6E-03  
4.44E-05 6.07E-06 0.14 2.0E-02  
2.37E-04 3.17E-05 0.13 7.0E-03  
3.30E-05 0.00E+00 0.00 2.8E-03  
2.34E-05 0.00E+00 0.00 2.8E-03  
1.09E-04 0.00E+00 0.00 7.1E-08  
1.31E-04 0.00E+00 0.00 2.5E-04  
1.39E-04 0.00E+00 0.00 9.5E-04  
1.69E-04 0.00E+00 0.00 1.4E-03  
8.88E-05 0.00E+00 0.00 2.2E-03  
4.45E-05 0.00E+00 0.00 2.4E-03  
4.21E-05 0.00E+00 0.00 5.4E-03  
2.76E-05 0.00E+00 0.00 1.8E-02  
4.61E-05 0.00E+00 0.00 3.9E-02  
 
Table 2.5 Proteomics data set. The proteomics data for the 183 proteins identified as having 
significantly different levels (p-value < 0.05) in the protease double mutant relative to the control 
are presented. 
 
 
Strain Genotype Reference/Source 
PY79 B. subtilis PY79 Youngman et al., 1984 
BTH101 E. coli BTH101 Euromedex (EUB001) 
PEB66 E. coli Top10 ThermoFisher (C404010) 
PEB67 E. coli BL21 DE3 Lab stock 
PEB69 E. coli NiCo21 DE3 New England Biolabs 
(C2529H) 
PEB75 B. subtilis 168 ΔrecN::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE24240) 
PEB85 B. subtilis ΔrecN This study 
PEB111 E. coli BL21 DE3 pLysY/lacIq New England Biolabs (C3013) 
PEB233 E. coli XL1-Blue pCJ41 Bacillus Genetic Stock Center 
(ECE310) 
PEB234 E. coli (TB1) pMalC9 Bacillus Genetic Stock Center 
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(ECE309) 
PEB235 B. subtilis ΔrecR This study 
PEB278 B. subtilis ΔrnhC JWS224 
PEB307 B. subtilis ΔuvrA This study 
PEB308 B. subtilis ΔuvrB This study 
PEB310 B. subtilis ΔuvrC This study 
PEB316 B. subtilis ΔyprA This study 
PEB318 B. subtilis ΔyprB This study 
PEB322 B. subtilis ΔylbK This study 
PEB324 B. subtilis ΔylbL This study 
PEB334 B. subtilis ΔsodA This study 
PEB336 E. coli MC1061 Lab stock 
PEB346 B. subtilis amyE::Pxyl-ylbL-S234A (used to generate 
other strains only) 
This study 
PEB349 B. subtilis ΔylbL, amyE::Pxyl-ylbL (used to generate 
other strains only) 
This study 
PEB350 B.subtilis amyE::Pxyl-ylbK (used to generate other 
strains only) 
This study 
PEB353 B. subtilis ΔqueA This study 
PEB355 B. subtilis ΔctpA This study 
PEB357 B. subtilis ΔysoA This study 
PEB373 B. subtilis ΔylbK, amyE::Pxyl-ylbK This study 
PEB375 B. subtilis ΔylbL, amyE::Pxyl-ylbL This study 
PEB377 B. subtilis ΔylbL, amyE::Pxyl-ylbL-S243A This study 
PEB382 B. subtilis ΔylmE This study 
PEB384 B. subtilis ΔsepF This study 
PEB386 B. subtilis ΔylmG This study 
PEB390 B. subtilis ΔylbK, amyE::Pxyl-ylbL This study 
PEB392 B. subtilis ΔylbK, amyE::Pxyl-ylbL-S243A This study 
PEB418 B. subtilis ΔytmP This study 
PEB420 B. subtilis ΔbcrC This study 
PEB422 B. subtilis ΔecsA This study 
PEB424 B. subtilis ΔecsB This study 
PEB427 B. subtilis ΔylbK-2 This study 
PEB432 B. subtilis 168 ΔyneA::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE17860) 
PEB433 B. subtilis ΔyneA::erm This study 
PEB436 B. subtilis ΔylbL, ΔyneA::erm This study 
PEB439 B. subtilis ΔyneA::loxp This study 
PEB441 B. subtilis ΔylbL, ΔyneA::loxp This study 
PEB449 B. subtilis 168 Δcrh::erm (used to generate other strains 
only) 
Bacillus Genetic Stock Center 
(BKE34740) 
PEB450 B. subtilis 168 Δlgt::erm (used to generate other strains 
only) 
Bacillus Genetic Stock Center 
(BKE34990) 
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PEB452 B. subtilis 168 ΔsdaAB::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE15850) 
PEB453 B. subtilis 168 ΔydzU::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE06048) 
PEB454 B. subtilis 168 ΔradA::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE00870) 
PEB455 B. subtilis 168 ΔcymR::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE27520) 
PEB456 B. subtilis 168 ΔywrC::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE36110) 
PEB461 B. subtilis Δcrh::erm This study 
PEB463 B. subtilis Δlgt::erm This study 
PEB467 B. subtilis ΔsdaAB::erm This study 
PEB469 B. subtilis ΔydzU::erm This study 
PEB471 B. subtilis ΔradA::erm This study 
PEB473 B. subtilis ΔcymR::erm This study 
PEB475 B. subtilis ΔywrC::erm This study 
PEB477 B. subtilis 168 ΔrecG::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE15870) 
PEB478 B. subtilis ΔrecG::erm This study 
PEB482 B. subtilis ΔwalH This study 
PEB485 B. subtilis ΔyycI This study 
PEB488 B. subtilis ΔwalJ This study 
PEB491 B. subtilis ΔruvB This study 
PEB493 B. subtilis ΔripX This study 
PEB533 B. subtilis ΔylbL, amyE::Pxyl-ylbL-K279A This study 
PEB535 B. subtilis 168 ΔponA::erm (used to generate other 
strains only) 
Bacillus Genetic Stock Center 
(BKE22320) 
PEB551 B. subtilis ΔponA::erm This study 
PEB555 B. subtilis ΔylbL, ΔctpA This study 
PEB557 B. subtilis ΔylbL, amyE::Pxyl-ylbL, ΔctpA This study 
PEB559 B. subtilis ΔyneA::loxp, ΔctpA This study 
PEB561 B. subtilis ΔylbL, ΔyneA::loxp, ΔctpA This study 
PEB585 B. subtilis ΔuvrA, ΔyneA::loxp This study 
PEB595 B. subtilis ΔylbL, amyE::Pxyl-ctpA This study 
PEB597 B. subtilis ΔylbL, amyE::Pxyl-ctpA-S297A This study 
PEB599 B. subtilis ΔctpA, amyE::Pxyl-ctpA This study 
PEB601 B. subtilis ΔctpA, amyE::Pxyl-ctpA-S297A This study 
PEB603 B. subtilis ΔctpA, amyE::Pxyl-ctpA-K322A This study 
PEB605 B. subtilis ΔctpA, amyE::Pxyl-ylbL This study 
PEB607 B. subtilis ΔctpA, amyE::Pxyl-ylbL-S234A This study 
PEB619 B. subtilis ΔylbL, ΔctpA, amyE::Pxyl-ctpA This study 
PEB621 B. subtilis ΔylbL, ΔctpA, amyE::Pxyl-ctpA-S297A This study 
PEB623 B. subtilis ΔylbL, ΔctpA, amyE::Pxyl-ylbL-S234A This study 
PEB677 B. subtilis amyE::Phyp-yneA This study 
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PEB681 B. subtilis ΔylbL, amyE::Phyp-yneA This study 
PEB685 B. subtilis ΔctpA, amyE::Phyp-yneA This study 
PEB689 B. subtilis ΔylbL, ΔctpA, amyE::Phyp-yneA This study 
PEB778 B. subtilis ΔfhuG This study 
PEB780 B. subtilis ΔylbL, ΔctpA, ΔfhuG This study 
PEB782 B. subtilis ΔyfkH This study 
PEB784 B. subtilis ΔylbL, ΔctpA, ΔyfkH This study 
PEB786 B. subtilis ΔltaSA This study 
PEB788 B. subtilis ΔylbL, ΔctpA, ΔltaSA This study 
PEB790 B. subtilis ΔykgA This study 
PEB792 B. subtilis ΔylbL, ΔctpA, ΔykgA This study 
PEB794 B. subtilis ΔcgeE This study 
PEB796 B. subtilis ΔylbL, ΔctpA, ΔcgeE This study 
PEB798 B. subtilis ΔysnF This study 
PEB800 B. subtilis ΔylbL, ΔctpA, ΔysnF This study 
PEB802 B. subtilis ΔlytG This study 
PEB804 B. subtilis ΔylbL, ΔctpA, ΔlytG This study 
PEB806 B. subtilis ΔyxaB This study 
PEB808 B. subtilis ΔylbL, ΔctpA, ΔyxaB This study 
PEB810 B. subtilis ΔylbL, ΔctpA, ΔytmP This study 
 
Table 2.6 Strains used in this study. 
 
Plasmid 
number 
Plasmid name Reference/Source 
pDR244 pDR244 Bacillus Genetic Stock Center 
(ECE274) 
pDR110 pDR110 A gift from David Rudner 
pBR322 pBR322 New England Biolabs (N3033S) 
pKT25 pKT25 Euromedex (EUP-25C) 
pUT18C pUT18C Euromedex (EUP-18C) 
pPB12 pET28b-10xHis-Smt3 A gift from Jayakrishnan 
Nandakumar 
pPB13 pET28b-6xHis-Ulp1-403-621 A gift from Jayakrishnan 
Nandakumar 
pPB41 pPB41 Burby and Simmons, 2017a, b 
pPB44 pPB41-CRISPR::recR This study 
pPB46 pPB44-recR recombination template This study 
pPB47 pPB47 This study 
pPB72 pPB41-CRISPR::uvrA This study 
pPB73 pPB41-CRISPR::uvrB This study 
pPB74 pPB41-CRISPR::uvrC This study 
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pPB75 pPB41-CRISPR::yprA This study 
pPB76 pPB41-CRISPR::yprB This study 
pPB77 pPB41-CRISPR::ylbK This study 
pPB78 pPB41-CRISPR::ylbL This study 
pPB81 pPB41-CRISPR::sodA This study 
pPB82 pPB72-ΔuvrA recombination template This study 
pPB83 pPB73-ΔuvrB recombination template This study 
pPB85 pPB74-ΔuvrC recombination template This study 
pPB86 pPB75-ΔyprA recombination template This study 
pPB87 pPB76-ΔyprB recombination template This study 
pPB98 pPB77-ΔylbK recombination template This study 
pPB99 pPB78-ΔylbL recombination template This study 
pPB103 pPB81-ΔsodA recombination template This study 
pPB107 pPB47-amyE::Pxyl-ylbK-camR This study 
pPB108 pPB47-amyE::Pxyl-ylbL-camR This study 
pPB111 pPB47-amyE::Pxyl-ylbL-S234A-camR This study 
pPB113 pPB41-CRISPR::queA This study 
pPB114 pPB41-CRISPR::ctpA This study 
pPB115 pPB41-CRISPR::ysoA This study 
pPB116 pPB41-CRISPR::ylmE This study 
pPB117 pPB41-CRISPR::sepF This study 
pPB118 pPB41-CRISPR::ylmG This study 
pPB120 pPB113-ΔqueA recombination template This study 
pPB121 pPB114-ΔctpA recombination template This study 
pPB122 pPB115-ΔysoA recombination template This study 
pPB123 pPB116-ΔylmE recombination template This study 
pPB124 pPB117-ΔsepF recombination template This study 
pPB125 pPB118-ΔylmG recombination template This study 
pPB130 pPB41-CRISPR::ytmP This study 
pPB131 pPB41-CRISPR::bcrC This study 
pPB132 pPB41-CRISPR::ecsA This study 
pPB133 pPB41-CRISPR::ecsB This study 
pPB140 pPB130-ΔytmP recombination template This study 
pPB141 pPB131-ΔbcrC recombination template This study 
pPB142 pPB132-ΔecsA recombination template This study 
pPB143 pPB133-ΔecsB recombination template This study 
pPB149 pPB77-ΔylbK recombination template-2 This study 
pPB154 pPB41-CRISPR::walH This study 
pPB155 pPB41-CRISPR::yycI This study 
pPB156 pPB41-CRISPR::yycJ This study 
pPB157 pPB12-ylbL-36-341 This study 
pPB173 pPB47-amyE::Pxyl-ylbL-K279A-camR This study 
pPB174 pPB154-ΔwalH recombination template This study 
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pPB175 pPB155-ΔyycI recombination template This study 
pPB176 pPB156-ΔyycJ recombination template This study 
pPB177 pPB41-CRISPR::ruvB This study 
pPB178 pPB41-CRISPR::ripX This study 
pPB179 pPB177-ΔruvB recombination template This study 
pPB180 pPB178-ΔripX recombination template This study 
pPB181 pPB12-ylbL-36-341-S234A This study 
pPB184 pPB47-amyE::Pxyl-ctpA-camR This study 
pPB185 pPB47-amyE::Pxyl-ctpA-S297A-camR This study 
pPB186 pPB47-amyE::Pxyl-ctpA-K322A-camR This study 
pPB194 pDR110-Phyp-yneA This study 
pPB200 pET28b-MBP-6xHis-Ulp1-403-621 This study 
pPB203 pET28b-MBP-Smt3-ctpA-38-466 This study 
pPB204 pPB12-yneA-28-103 This study 
pPB214 pET28b-MBP-Smt3-ctpA-38-466-S297A This study 
pPB227 pPB41-CRISPR::fhuG This study 
pPB228 pPB41-CRISPR::yfkH This study 
pPB229 pPB41-CRISPR::ltaSA This study 
pPB230 pPB41-CRISPR::ykgA This study 
pPB231 pPB41-CRISPR::cgeE This study 
pPB232 pPB41-CRISPR::ysnF This study 
pPB233 pPB41-CRISPR::lytG This study 
pPB234 pPB41-CRISPR::yxaB This study 
pPB237 pPB227-fhuG This study 
pPB238 pPB228-yfkH This study 
pPB239 pPB229-ltaSA This study 
pPB240 pPB230-ykgA This study 
pPB241 pPB231-cgeE This study 
pPB242 pPB232-ysnF This study 
pPB243 pPB233-lytG This study 
pPB244 pPB234-yxaB This study 
pPB267 pU-T18-YneA This study 
pPB268 pU-T18-YneAΔN This study 
pPB270 pK-T25-YlbL-S234A This study 
pPB271 pK-T25-CtpA-S297A This study 
 
Table 2.7 Plasmids used in this study. 
 
Primer  Sequence 
oPEB3F GCTAGCCGCATGCAAGCTAATTCG 
oPEB54 ggcattgatggacgcatttgtg 
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oPEB55 gtttcaatcgcttgtgtttgggtttc 
oPEB56 ACCTCCAATCTGTTCGCGGTG 
oPEB57 taaTCGAGCACCACCACCACCAC 
oPEB58 GCTAGTTATTGCTCAGCGG 
oPEB116 ctctcgtttcatcggtatcattac 
oPEB117 cgcttcgttaatacagatgtaggt 
oPEB217 GAACCTCATTACGAATTCAGCATGC 
oPEB218 GAATGGCGATTTTCGTTCGTGAATAC 
oPEB227 CCGTCAATTGTCTGATTCGTTA 
oPEB232 GCTGTAGGCATAGGCTTGGTTATG 
oPEB234 GTATTCACGAACGAAAATCGCCATTCCTAGCAGCACGCCATAGTGACTG 
oPEB241 aaacGCGCTATTTCTCCAATGGACGGCATCGGACg 
oPEB242 aaaacGTCCGATGCCGTCCATTGGAGAAATAGCGC 
oPEB243 GCATGCTGAATTCGTAATGAGGTTCcttttaattacgggtgctgtttct 
oPEB244 cccatggatcgctttttcctccgttcttttatccccctagaataaacctggcatg 
oPEB245 tattctagggggataaaagaacggaggaaaaagcgatccatgggt 
oPEB246 GCATAACCAAGCCTATGCCTACAGCactctcctcttctgcactcaagtt 
oPEB253 GAAGGGTAGTCCAGAAGATAACGA 
oPEB259 ATGTATACCTCCTTAGTCGACTAAGCTTAATTGTTATCCGCTCACAATTACACACATTAT
GCCACACCTTGTAGATA 
oPEB267 TACGTTATTAGTTATAGTTActaacggattcaccactccaag 
oPEB268 AACCCTTGCATAGGGGGATCgcctcgtgatacgcctatttttat 
oPEB269 TAACTATAACTAATAACGTAACGTGACTGGCAAG 
oPEB270 GATCCCCCTATGCAAGGGTTTATTGT 
oPEB286 GCATGCTGAATTCGTAATGAGGTTCaagcacaatggggtaaaataagag 
oPEB287 GCATAACCAAGCCTATGCCTACAGCggtattcctaaaattccgctgata 
oPEB312 ACTCTTTCCCTACACGACGCTCTTCCGATCTNN 
oPEB313 AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGAT 
oPEB314 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTC 
oPEB315 CAAGCAGAAGACGGCATACGAGATATCACGGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB316 CAAGCAGAAGACGGCATACGAGATCGATGTGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB317 CAAGCAGAAGACGGCATACGAGATTTAGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB318 CAAGCAGAAGACGGCATACGAGATTGACCAGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB319 CAAGCAGAAGACGGCATACGAGATACAGTGGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB320 CAAGCAGAAGACGGCATACGAGATGCCAATGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB321 CAAGCAGAAGACGGCATACGAGATCAGATCGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
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oPEB322 CAAGCAGAAGACGGCATACGAGATACTTGAGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB323 CAAGCAGAAGACGGCATACGAGATGATCAGGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB324 CAAGCAGAAGACGGCATACGAGATTAGCTTGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB325 CAAGCAGAAGACGGCATACGAGATGGCTAGGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB326 CAAGCAGAAGACGGCATACGAGATCTTGTAGTGACTGGAGTTCAGACGTGTGCTCTTCCG
ATCAGACCGGGGACTTATCATCCAACCTGT 
oPEB345 actcctttgtttatccaccgaac 
oPEB348 TTATTTTTGACACCAGACCAACTG 
oPEB368 CGACGGCCAGTGAATTGTAATACG 
oPEB369 CAGGAAACAGCTATGACCATG 
oPEB370 cacctacatctgtattaacgaagcgTCAATGGGGAAGAGAACCGCTTAAG 
oPEB377 ggtaatgataccgatgaaacgagagAACAAAATTCTCCAGTCTTCACATCG 
oPEB383 atgtatacctccttaggatcccatttcc 
oPEB417 aaacGCTATGGATCGGATAGAGGTGAAGGGAGCCg 
oPEB418 aaaacGGCTCCCTTCACCTCTATCCGATCCATAGC 
oPEB419 GCATGCTGAATTCGTAATGAGGTTCCTTCTTGATTATTTCCCAGACGAT 
oPEB420 taacagagggttttgttcaTCATCCTTCCGCTTTTAG 
oPEB421 CTAAAAGCGGAAGGATGAtgaacaaaaccctctgttaagaggggacagcttgtcggcaag
tccatccttgggcttagcaggcaagctttttctttac 
oPEB422 GCATAACCAAGCCTATGCCTACAGCgaagactttgtaattgcggaaaac 
oPEB423 ATATGATCTTGAAATGATGCGTGA 
oPEB424 agaatgaatcgtgaaatgatcacc 
oPEB425 CGCCGATAAAATAACGAAGTCTAT 
oPEB426 aaacGCTTTGAGTTAGTCTCGAAATATCAGCCCCg 
oPEB427 aaaacGGGGCTGATATTTCGAGACTAACTCAAAGC 
oPEB428 GCATGCTGAATTCGTAATGAGGTTCtagtctcttgaagctggttgtcct 
oPEB429 ATCCGATCCATAGCCATttgttcaaaaaataagcctccgtttctttaacg 
oPEB430 ttaaagaaacggaggcttattttttgaacaaATGGCTATGGATCGGAT 
oPEB431 GCATAACCAAGCCTATGCCTACAGCGCATTCTCCTTCAATGACAAATCT 
oPEB432 acggatcgatatgattctctaagc 
oPEB433 TACAGCACTTTATCCAGTTGATGC 
oPEB434 ctgaggagggtttttgttgattac 
oPEB437 aaacAGAAAAACTCGCCCTCCTTCCTGATCAACCg 
oPEB438 aaaacGGTTGATCAGGAAGGAGGGCGAGTTTTTCT 
oPEB439 GCATGCTGAATTCGTAATGAGGTTCcaatgtcagtcgtcttacttacgc 
oPEB440 cagatcttatttaaaaggacaacaatgttacccttccttatgtttaatcct 
oPEB441 attaaacataaggaagggtaacattgttgtccttttaaataagatctgataaaatg 
oPEB442 GCATAACCAAGCCTATGCCTACAGCtgtcgtaatttcacaatcctctgt 
oPEB443 aaaccggaatccttcagacaatac 
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oPEB444 cttctaacggcacttggtaatttt 
oPEB445 gtaaaatgattgcacctgttcttg 
oPEB446 aaacATCACTGACTGAACTCATTTCTGATTTAAAg 
oPEB447 aaaacTTTAAATCAGAAATGAGTTCAGTCAGTGAT 
oPEB448 GCATGCTGAATTCGTAATGAGGTTCcgagttgattaggttctgaaatcc 
oPEB449 TAATGACATatccggcctccctcctctttacacctctttgtcaagtac 
oPEB450 gtacttgacaaagaggtgtaaagaggagggaggccggatATGTCATTA 
oPEB451 GCATAACCAAGCCTATGCCTACAGCCATTATGATGCAGGACACCTTTTA 
oPEB452 tcttgtcatgcttgtaaaggtagc 
oPEB453 CTGGTCCTCAAACGATTTTTCTAT 
oPEB454 agaaaatgatgggagaaggaatag 
oPEB455 aaacAAGGGAAACTCCAACGGATGAAAAAGCACAg 
oPEB456 aaaacTGTGCTTTTTCATCCGTTGGAGTTTCCCTT 
oPEB457 GCATGCTGAATTCGTAATGAGGTTCTCCCAGGAAAATGTCGTTATAGTT 
oPEB458 gggaatatatccggcctccctccTTACGACA 
oPEB459 AATGTCGTAAggagggaggccggatatattccccgggaaagcgcaaaagacgacttgttt
cgccatgaatttt 
oPEB460 GCATAACCAAGCCTATGCCTACAGCatggtgtgatgacagctaccttta 
oPEB461 AGCCATGGAAGTCAGTGATATTCT 
oPEB462 tctttattcggttctttccagttc 
oPEB463 GTACGTCATTGCACTACGGAGAC 
oPEB466 aaacCGGGTTAGCGTTAGGATCGGGAGGGGCCAGg 
oPEB467 aaaacCTGGCCCCTCCCGATCCTAACGCTAACCCG 
oPEB468 GCATGCTGAATTCGTAATGAGGTTCcataagaagcgtttgaacagaaga 
oPEB469 CTAAAATGTTTTTTACGTAGCAAaagcgttaacctcctgcctgaatt 
oPEB470 gaattcaggcaggaggttaacgcttTTGCTACGTAAAAAACATTTTAGCTGGAT 
oPEB471 GCATAACCAAGCCTATGCCTACAGCAATATCGTAGCCTTTTGTTTCGTC 
oPEB472 aaaacagacaaaacatcagtcagc 
oPEB473 ACTGCGTTCTTATAATCGGAATTG 
oPEB474 gcataaaaggctcaagcaaaac 
oPEB475 aaacCATAAtTTGCTACGTAAAAAACATTTTAGCg 
oPEB476 aaaacGCTAAAATGTTTTTTACGTAGCAAaTTATG 
oPEB477 GCATGCTGAATTCGTAATGAGGTTCagcagtacctgtcctcttgattct 
oPEB478 aatgtatagaaaaagcacctgagaaaTTATGAGCCCTCCCAATTCTCTAT 
oPEB479 ATAGAGAATTGGGAGGGCTCATAAtttctcaggtgctttttctatacattt 
oPEB480 GCATAACCAAGCCTATGCCTACAGCccagtatgtgacctcgattctaac 
oPEB481 TACATAAGCACCAAATTGAAGTGG 
oPEB482 agaaacagcacagcttattgatga 
oPEB483 GAGAAAAGATTGTGTTCCGAAAAG 
oPEB492 tgatgttctttttcctcctattcg 
oPEB493 acgatattgccgtattcctcttat 
oPEB504 aaacCGTACGATGCTTTAGAACCGCATATCGACAg 
oPEB505 aaaacTGTCGATATGCGGTTCTAAAGCATCGTACG 
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oPEB506 GCATGCTGAATTCGTAATGAGGTTCaacaggacagagagcaaaaataca 
oPEB507 ataatgaggaccttgtttgtgccagataattcctccttagtatatatgtac 
oPEB508 catatatactaaggaggaattatctggcacaaacaaggtcctcattat 
oPEB509 GCATAACCAAGCCTATGCCTACAGCagctcgctgtttgtctcaataaat 
oPEB510 attgattttacggtccctgtactt 
oPEB511 gcaaagtagtaggcaaagaaggaa 
oPEB512 gtttattaatcgggccttttgtc 
oPEB527 TAAAAGACAGGGTAAGGAAATGGA 
oPEB557 taaCGGTTTCCATATGGGGATTGGTG 
oPEB558 aatgggatcctaaggaggtatacatTTGGCCAAACCTAAAATCGGGTTAG 
oPEB559 ACCAATCCCCATATGGAAACCGttaTTATGAGCCCTCCCAATTCTCTATT 
oPEB560 aatgggatcctaaggaggtatacatTTGCTACGTAAAAAACATTTTAGCTG 
oPEB561 ACCAATCCCCATATGGAAACCGttaTCAGGTGCTTTTCGCTTTCAGCTT 
oPEB566 AATCGAAAATATTGGCGGCCCGGCTGCAGGGTTAATGATGTCCCTTGA 
oPEB567 CAAGGGACATCATTAACCCTGCAGCCGGGCCGCCAATATTTTCGA 
oPEB574 cattcttccgacataaattgtgag 
oPEB575 attagtggtggctgttgctttatc 
oPEB577 aaacTACCAGAACGTTTAATTGCACAAGTACCGTg 
oPEB578 aaaacACGGTACTTGTGCAATTAAACGTTCTGGTA 
oPEB579 GCATGCTGAATTCGTAATGAGGTTCgattgttgctaatgaaatgggagt 
oPEB580 ttgatgaggcctcctgttctcaaagatgatttcacctttattctagtctt 
oPEB581 gactagaataaaggtgaaatcatctttgagaacaggaggcctcatc 
oPEB582 GCATAACCAAGCCTATGCCTACAGCgcatttttcatattgagtcgtcct 
oPEB583 gtatatcgggcagcataaggtaaa 
oPEB584 actcttctctgaaatcacccagac 
oPEB585 cccgatatgactgaatttcctaa 
oPEB586 aaacACGGAGCAATTAAAGGAATGATTCAATCACg 
oPEB587 aaaacGTGATTGAATCATTCCTTTAATTGCTCCGT 
oPEB588 GCATGCTGAATTCGTAATGAGGTTCcccctcctatcctgactttctatc 
oPEB589 cgcggcagccgcgtatggttttttttaaacaccacctttttcttcttac 
oPEB590 aagaagaaaaaggtggtgtttaaaaaaaaccatacgcggctgccgc 
oPEB591 GCATAACCAAGCCTATGCCTACAGCtatgggtcattatgctgtttatgg 
oPEB592 acgactttaccttgatggtttttg 
oPEB593 gttgctctttacacattcttcagc 
oPEB594 ggatacagcaaatgtcctaaataagc 
oPEB595 aaacATGATACTGAATCCGATCTTCACTTAGGGAg 
oPEB596 aaaacTCCCTAAGTGAAGATCGGATTCAGTATCAT 
oPEB597 GCATGCTGAATTCGTAATGAGGTTCacatgatcaaagggaagaaggtag 
oPEB598 gcgctttcaactatatggcgcgatacctatattcctttcaggcatttatt 
oPEB599 taaatgcctgaaaggaatataggtatcgcgccatatagttgaaagc 
oPEB600 GCATAACCAAGCCTATGCCTACAGCagttaattcagcaagtgtttccac 
oPEB601 cgtgcttatgaatatatgggattg 
oPEB602 aacaagctcttcacgcaatttag 
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oPEB603 cattcgctgatattttccatca 
oPEB604 aaacTCACAAAATATGTATCACCTGAAAGAGCACg 
oPEB605 aaaacGTGCTCTTTCAGGTGATACATATTTTGTGA 
oPEB606 GCATGCTGAATTCGTAATGAGGTTCtaagtgaaccacatgcataaacct 
oPEB607 TTTCAGTTTATTTTTCATACTCATgatcttttatgcctccttcattcc 
oPEB608 ggaatgaaggaggcataaaagatcATGAGTATGAAAAATAAACTGAAAAACTTT 
oPEB609 GCATAACCAAGCCTATGCCTACAGCccacctccatttttacatttcagt 
oPEB610 aggtaaaggatgtcgtcaatgtct 
oPEB611 cgtaatcttttctgacttgggcta 
oPEB612 cctcagatatttacgctgttattgg 
oPEB613 aaacAATATATTGAGACAGAGCGGGAATCTCATGg 
oPEB614 aaaacCATGAGATTCCCGCTCTGTCTCAATATATT 
oPEB615 CGAAAAAACTTGATAAAGGATCATTGCTGTACACCCCCTGTTTCAT 
oPEB616 AAATGAAACAGGGGGTGTACAGCAATGATCCTTTATCAAGTTTTTTCGGT 
oPEB617 GAAGTCATTCCATTCATACAGGAG 
oPEB618 aaacTTTGCCCTGATCATATATATTTTTATGTCAg 
oPEB619 aaaacTGACATAAAAATATATATGATCAGGGCAAA 
oPEB620 ccaagcccctatcaaactgtcacactcgctTTACCACCTCTGATGTTC 
oPEB621 GAACATCAGAGGTGGTAAagcgagtgtgacagtttgataggggcttg 
oPEB622 TCCTCTAAAGTGGTGTTGAGTGAG 
oPEB623 tctaaaaagtcggtcagcttcatc 
oPEB624 GCATAACCAAGCCTATGCCTACAGCccaaaacctctgatagacagca 
oPEB638 aaacTTGGGAGATCTTCCCCGCCGGAGGAGCTACg 
oPEB639 aaaacGTAGCTCCTCCGGCGGGGAAGATCTCCCAA 
oPEB640 GCATGCTGAATTCGTAATGAGGTTCcaagccagtccatcaattatgtc 
oPEB641 aaggctaatcgtttctagtctatccagcgaatg 
oPEB642 aaaggcattcgctggatagactagaaacgattagccttaattctaaaatattttaagaaa
tgatgggtcaggaatacgaatccatttgct 
oPEB643 GCATAACCAAGCCTATGCCTACAGCaaaagttcaagtagacccgtttca 
oPEB644 gatatgtttcgtgacgctgtaaaa 
oPEB645 tactcaaataaacctcggttgtcc 
oPEB646 agacccaacagaaatcaagaaaac 
oPEB647 aaacCTCATCACAATTCAGTTCTCGATTCCATTAg 
oPEB648 aaaacTAATGGAATCGAGAACTGAATTGTGATGAG 
oPEB649 GCATGCTGAATTCGTAATGAGGTTCctcgcttaaaaagaaattcggatac 
oPEB650 ttcagacgccggcttttgtctttcataatcaccttttacatttttatatttagtag 
oPEB651 tataaaaatgtaaaaggtgattatgaaagacaaaagccggcgtctgaa 
oPEB652 GCATAACCAAGCCTATGCCTACAGCcgtagagcaaggtgacaaagtaaa 
oPEB653 cttccattattatcggcatcatc 
oPEB654 tcgactgtgtatcaatctctttcc 
oPEB655 aaatagaaattgtggtcagcaagg 
oPEB656 aaacTCGGTAAAAGACTTGACCGGCGGATATACAg 
oPEB657 aaaacTGTATATCCGCCGGTCAAGTCTTTTACCGA 
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oPEB658 GCATGCTGAATTCGTAATGAGGTTCgttttgcgatagaggaagagatgt 
oPEB659 CAAATATCAAGCATATTATTCATaagtttctccccttatagtgtttttc 
oPEB660 aaaaacactataaggggagaaacttATGAATAATATGCTTGATATTTGGCAG 
oPEB661 GCATAACCAAGCCTATGCCTACAGCCTGACAAGAATGCCCAAATAATC 
oPEB662 attatgatctctccctgttttcca 
oPEB663 GTAATGAAAATGGCAAACACAGTC 
oPEB664 acttgtttaatgcctaacgattcc 
oPEB665 aaacATATGCTTGATATTTGGCAGTCGCGGCTGCg 
oPEB666 aaaacGCAGCCGCGACTGCCAAATATCAAGCATAT 
oPEB667 GCATGCTGAATTCGTAATGAGGTTCggccttgtttttggtactatgaag 
oPEB668 gtcatttgattacctcttttcagtaTTATTCATGGCCAGCGTCTTCCTT 
oPEB669 AGGAAGACGCTGGCCATGAATAAtactgaaaagaggtaatcaaatgacag 
oPEB670 GCATAACCAAGCCTATGCCTACAGCgaacagccagagcgagtctatt 
oPEB671 atgtccagaaccctgtctctttat 
oPEB672 ggcgaggattttgcttattactta 
oPEB673 TGAAGCAGAAGGTTATGATTATGTG 
oPEB677 TGGTGGTGGTGGTGGTGCTCGAttaTCAGGTGCTTTTCGCTTTCAGCT 
oPEB709 TATTTCTTTTCTTATCTTGCTGATTTTGGCCAAagcgttaacctcct 
oPEB710 caggaggttaacgctTTGGCCAAAATCAGCAAGATAAGAAAAGAAATAGAGAA 
oPEB738 aaacACCCAAAAGCTGTCTGAAACGGTAAGGCCAg 
oPEB739 aaaacTGGCCTTACCGTTTCAGACAGCTTTTGGGT 
oPEB740 GCATGCTGAATTCGTAATGAGGTTCttagtggaacagcaggattctatg 
oPEB741 CTTCCTCAATAAATCCTTTGTAATTTCACGCTTCATcccaatcatcct 
oPEB742 gaggatgattgggATGAAGCGTGAAATTACAAAGGATTTATTGAGGAAGGAGG 
oPEB743 GCATAACCAAGCCTATGCCTACAGCtactcgaccgtaattctccatacc 
oPEB744 cttagaaatgccgattacgagttt 
oPEB745 tctaaaatcgtactctccaaagca 
oPEB746 tctatatcagcgtgaaggatgaag 
oPEB747 aaacGTATGAAGGCTTGAATAAGGAAGCAACAGAg 
oPEB748 aaaacTCTGTTGCTTCCTTATTCAAGCCTTCATAC 
oPEB749 GCATGCTGAATTCGTAATGAGGTTCaatcagcaaactaccggaacatta 
oPEB750 tcatgtttgtctcactccattatttTCACTTATTCCACTCCACtgttagc 
oPEB751 ggggctaacaGTGGAGTGGAATAAGTGAaaataatggagtgagacaaacatga 
oPEB752 GCATAACCAAGCCTATGCCTACAGCggatcggtgtcgtataagtcaaat 
oPEB753 agtcgtttgaatacagttcgtttg 
oPEB754 taatccaccatattccatcctttc 
oPEB755 ccgattaaaacaagtgaaacagag 
oPEB756 aaacGGACGCCGGTTTGAGCGGAAAAGCCATGGAg 
oPEB757 aaaacTCCATGGCTTTTCCGCTCAAACCGGCGTCC 
oPEB758 GCATGCTGAATTCGTAATGAGGTTCtcgttgccttcctcattttagata 
oPEB759 aatagtcatgatttacatagaaaaagtttgtctcactccattattttcattg 
oPEB760 atgaaaataatggagtgagacaaactttttctatgtaaatcatgactattctagg 
oPEB761 GCATAACCAAGCCTATGCCTACAGCcaatgaccttcccatccatattta 
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oPEB762 ccgattacaaaggatttattgagg 
oPEB763 cctttccgtatctctctaaatcctc 
oPEB764 aattacggtcgagtacgagaaaaa 
oPEB771 CCCGATCGGCGGCATTGATCAAGCTGTCGTCGCCGCAGACAAAGCC 
oPEB772 CGGCTTTGTCTGCGGCGACGACAGCTTGATCAATGCCGCCGATCGG 
oPEB773 GGCTCACCGCGAACAGATTGGAGGTACAGAGCTTGCTTCATTGATAAAAG 
oPEB780 gaaagagctaggggaaatggtag 
oPEB781 gccatagctcttcttttgtgatct 
oPEB782 aaatcttgcagtcatcatcgaagt 
oPEB783 gattcagcatatttcccagtacaa 
oPEB786 gtattccatgtgatgaggttatcg 
oPEB787 cttcatctgtaataaagggggttg 
oPEB788 gtacgaggagattgaggttgagat 
oPEB789 tcgaatataggcctgcaatttaac 
oPEB790 taaaggacaacaacactggtgaaa 
oPEB791 ttccttctcaactagcccattatc 
oPEB792 aggacagcatattgttcttgatgt 
oPEB793 cgtccaccacttcttttactttatc 
oPEB794 aatggcttcatctatcatctctcc 
oPEB795 tctctgccaaatgaatgaatactg 
oPEB796 ggagcctgatttttcacatctact 
oPEB797 atttctccgaattcatcatcgt 
oPEB798 aaacTAGATGCGGCGAAAATGAGACAGGAGACGCg 
oPEB799 aaaacGCGTCTCCTGTCTCATTTTCGCCGCATCTA 
oPEB800 GCATGCTGAATTCGTAATGAGGTTCattgatttagaaaggctggaaagc 
oPEB801 taatgatcttaggaaatTCAGTCATgaacatcaccTTACTTTAATAGTTTTTG 
oPEB802 AAACTATTAAAGTAAggtgatgttcATGACTGAatttcctaagatcattatg 
oPEB803 GCATAACCAAGCCTATGCCTACAGCatattatgctcttccacttcatcg 
oPEB804 aggtcaacgggtatatcggtgtat 
oPEB805 ccgccattttctcttactttgtt 
oPEB806 AGAAAGGCTTGAAAAGCAAACA 
oPEB807 aaacTACATATTATCCAATACTTAAAGCATTTGAg 
oPEB808 aaaacTCAAATGCTTTAAGTATTGGATAATATGTA 
oPEB809 GCATGCTGAATTCGTAATGAGGTTCaactgcactcatccagctataaac 
oPEB810 ttggaaataatgagaaacttcaatattttctgtcgctctaaacaaaaaagccgcagccac
ctgcggtcttgatctactccccgttttggt 
oPEB811 gagcgacagaaaatattgaagtttc 
oPEB812 GCATAACCAAGCCTATGCCTACAGCccttctccgtcgtaaatatcagag 
oPEB813 ttagcgctgatttcatctctcttt 
oPEB814 aagctcagacccgtaaaatcttct 
oPEB815 tataactggaaccatagggaaagg 
oPEB817 aatgggatcctaaggaggtatacatTTGAAACGGCAATTAAAACTGTTTTTTATTG 
oPEB818 ACCAATCCCCATATGGAAACCGttaTTACATTTCTTTTTTCAGTGTTTCAATTGC 
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oPEB819 AATGACGGTACAGCAGCTGCAGCCGAAATTATGGCCGCTGCCCTTCATGAATCGTCAAAC 
oPEB820 CAGCGGCCATAATTTCGGCTGCAGCTGCTGTACCGTCATTTACTAAAACG 
oPEB821 GTTAATCGGCGAGACGACATTCGGCGCTGGTACAGTACAAACGGCAAAAGAATATG 
oPEB822 ATATTCTTTTGCCGTTTGTACTGTACCAGCGCCGAATGTCGTCTCGCCGATTAA 
oPEB831 AGGCTCACCGCGAACAGATTGGAGGTAGCACAGGAGACAGCAAGTTCGAC 
oPEB832 GTGGTGGTGGTGGTGGTGCTCGAttaTTACATTTCTTTTTTCAGTGTTTCAATTGC 
oPEB833 GGTAAATGGAAAAAGCGTAAAAGG 
oPEB835 ACCCATGGTATATCTCCTTCTTAAA 
oPEB836 AAGAAGGAGATATACCATGGGTgaagaaggtaaactggtaatctggattaacggcgataa
aggctataacggtctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagt
caccgttgagcatccggataaactggaagagaaattcccacaggttgcggcaactggcga
tggccctgacattatcttctgggcacacgaccgctttggtggctacgctcaatctggcct
gttggctgaaatcaccccggacaaagcgttccaggacaagctgtatccgtttacctggga
tgccgtacgttacaacggcaagctgattgcttacccgatcgctgttgaagcgttatcgct
gatttataacaaagatctgctgccgaacccgccaaaaacctgggaagagatcccggcgct
ggataaagaactgaaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgta
cttcacctggccgctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaa
gtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcct
ggttgacctgattaaaaacaaacacatgaatgcagacaccgattactccatcgcagaagc
tgcctttaataaaggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacat
cgacaccagcaaagtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatc
caaaccgttcgttggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagct
ggcaaaagagttcctcgaaaactatctgctgactgatgaaggtctggaagcggttaataa
agacaaaccgctgggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatcc
acgtattgccgccactatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgca
gatgtccgctttctggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtca
gactgtcgatgaagccctgaaagacgcgcagactaattcgagctcgGGTGGTGGTGGTTC
TGGTGGTGGTGGTTCTGGGTCCCTGCAGGACTCAGAAGTCAATCAAGAAGCTAAGCCAGA
GGTCAAGCCAGAAGTCAAGCCTGAGACTCACATCAATTTAAAGGTGTCCGATGGATCTTC
AGAGATCTTCTTCAAGATCAAAAAGACCACTCCTTTAAGAAGGCTGATGGAAGCGTTCGC
TAAAAGACAGGGTAAGGAAATGGACTCCTTAAGATTCTTGTACGACGGTATTAGAATTCA
AGCTGATCAGGCCCCTGAAGATTTGGACATGGAGGATAACGATATTATTGAGGCTCACCG
CGAACAGATTGGAGGT 
oPEB837 aagtatgaaaacggcaagtacga 
oPEB838 TTTAAGAAGGAGATATACCATGGGTgaagaaggtaaactggtaatctgga 
oPEB839 cgagctcgaattagtctgcgcgtc 
oPEB840 gaaagacgcgcagactaattcgagctcgGGTGGTGGTGGTTCTGGTGGTGGTGGTTCTat
gcggggttctcatcatcatc 
oPEB841 TGGTGGTGGTGGTGGTGCTCGAttattattttaaagcgtcggttaaaatcaaatg 
oPEB842 AGGCTCACCGCGAACAGATTGGAGGTAGCGGCCAAGAGCTTAATCAGTAT 
oPEB843 TGGTGGTGGTGGTGGTGCTCGAttaCTATCTTACAGTTGCTAATTCATATG 
oPEB856 CTTAGTCGACTAAGGAGGTATACATATGAGTAAAGAATCTATTATTTTTGTCGGT 
oPEB857 GAATTAGCTTGCATGCGGCTAGCttaCTATCTTACAGTTGCTAATTCATATG 
oPEB866 TTTATGCAGCAATGGCAAGAAC 
oPEB867 GCCGACTCAAACATCAAATCTTAC 
oPEB912 aaacAAGCGTGTCTCAAAATGAACTTGCCGAGCCg 
oPEB913 aaaacGGCTCGGCAAGTTCATTTTGAGACACGCTT 
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oPEB914 GCATGCTGAATTCGTAATGAGGTTCcaaattatacatgatcttcggcttc 
oPEB915 aatgaattcatattcggccccctccttacagccctctcctttcacgacgt 
oPEB916 gcacgtcgtgaaaggagagggctgtaaggagggggccgaatatgaattca 
oPEB917 GCATAACCAAGCCTATGCCTACAGCcaagtcatatgtcaagcatacagg 
oPEB918 atatacggactgcatcagaagaaa 
oPEB919 tttcttcttggacacaacgatct 
oPEB920 actggttggcatgcttattgtagt 
oPEB921 aaacTCTGCGTCTAATGGAATGAATGCGATCGTCg 
oPEB922 aaaacGACGATCGCATTCATTCCATTAGACGCAGA 
oPEB923 GCATGCTGAATTCGTAATGAGGTTCagagaaataggggcaaagaatagg 
oPEB924 tgaaccgaagttcgtttatagggtgcggtcgtctcacctcgcatgtttga 
oPEB925 tgatcaaacatgcgaggtgagacgaccgcaccctataaacgaacttcggt 
oPEB926 GCATAACCAAGCCTATGCCTACAGCcgtggctttttgttttctttctac 
oPEB927 tccatcctttctatgcgcaatata 
oPEB928 acctgtctatttatgggctttcct 
oPEB929 tcactgtacaaaagcaacccagag 
oPEB930 aaacCATTCTCAAGCGCCGTCTTCTTTTTAGGACg 
oPEB931 aaaacGTCCTAAAAAGAAGACGGCGCTTGAGAATG 
oPEB932 GCATGCTGAATTCGTAATGAGGTTCgtgatgatgtcgtgatgtttatcc 
oPEB933 atgcgcccgctcaaggctctttttcatcatttacctgctctttatatcctg 
oPEB934 aggcaggatataaagagcaggtaaatgatgaaaaagagccttgagcgg 
oPEB935 GCATAACCAAGCCTATGCCTACAGCcatacttgttgtccttgattccac 
oPEB936 tactattcgatttcaagctctcca 
oPEB937 caccaaatagcttcctaaaagacc 
oPEB938 aaggcacacatgacaaaagaaatc 
oPEB939 aaacCGTTGAGGTCGTCCTTTTGCCCGTTCGCGAg 
oPEB940 aaaacTCGCGAACGGGCAAAAGGACGACCTCAACG 
oPEB941 GCATGCTGAATTCGTAATGAGGTTCcaatacgggtacagtgcttttaat 
oPEB942 aaaacatgaaaaaggggaagattctttgtttttcctcctaaagtgtgaag 
oPEB943 cttcacactttaggaggaaaaacaaagaatcttcccctttttcatgttttg 
oPEB944 GCATAACCAAGCCTATGCCTACAGCcctggctgttatctgtaaaatcatc 
oPEB945 gtttcctaattggtcaatgtttgc 
oPEB946 ttccttctgtcgacactctttctac 
oPEB947 gtattatggttgttcgtgtcaagc 
oPEB948 aaacGTTCAGCTCCATGATACGTTTCCATTGGAGg 
oPEB949 aaaacCTCCAATGGAAACGTATCATGGAGCTGAAC 
oPEB950 GCATGCTGAATTCGTAATGAGGTTCgccgttcgttacttaatctcattc 
oPEB951 ccaaatggtttgtgcaaacgcctattgaacgtctcctttttatgacctat 
oPEB952 gtataggtcataaaaaggagacgttcaataggcgtttgcacaaaccatttg 
oPEB953 GCATAACCAAGCCTATGCCTACAGCtttaatcatggtgtccagttcatc 
oPEB954 caagagttttcacataagcctgaa 
oPEB955 cacttcatctgcaataaaaagcac 
oPEB956 gattacgtggaaacgatctgaa 
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oPEB957 aaacCAGAAGTCAATCAAGCTATCGATGCACATCg 
oPEB958 aaaacGATGTGCATCGATAGCTTGATTGACTTCTG 
oPEB959 GCATGCTGAATTCGTAATGAGGTTCactccctctggaatgtactcctc 
oPEB960 aggttttttgttgtcggtctatgatttatcaatctcctcctttatgaatttgca 
oPEB961 tgcaaattcataaaggaggagattgataaatcatagaccgacaacaaaaaacct 
oPEB962 GCATAACCAAGCCTATGCCTACAGCtgttgaagggtatattgctgaaga 
oPEB963 caactttccgcagcagtactatc 
oPEB964 gagctgaaaggtatcgaaaaagaa 
oPEB965 gaagaaattgtgagacggctttat 
oPEB966 aaacGCATCACAATTGCTCAGGCCATTCTCGAATg 
oPEB967 aaaacATTCGAGAATGGCCTGAGCAATTGTGATGC 
oPEB968 GCATGCTGAATTCGTAATGAGGTTCgtttgctcattggtctattgattg 
oPEB969 gaattaaaaataccagtaaaaagggcgaaaaccttccttcgaattaaaagat 
oPEB970 atcttttaattcgaaggaaggttttcgccctttttactggtatttttaattc 
oPEB971 GCATAACCAAGCCTATGCCTACAGCctagattttggaagcatgagagaa 
oPEB972 atttctcaggagcatctcattctt 
oPEB973 cgctatgcttacggtctttatttt 
oPEB974 cgaaggcaactgtcaaatcata 
oPEB975 aaacATGAATACATTGAGATTATGGATTATGCGAg 
oPEB976 aaaacTCGCATAATCCATAATCTCAATGTATTCAT 
oPEB977 GCATGCTGAATTCGTAATGAGGTTCctcatcactacaacaaggggaac 
oPEB978 ccccgggggagggcagtctttttcgtatctgcgtcctccttctgggat 
oPEB979 aattcatcccagaaggaggacgcagatacgaaaaagactgccctcccccg 
oPEB980 GCATAACCAAGCCTATGCCTACAGCgcagggtttttattatccttcctt 
oPEB981 gatcatagagcaagttgtcacagg 
oPEB982 ccattcagcatctgtttcatttac 
oPEB983 ggatcaatttcccgagacagta 
oPEB101
4 
TTGGCCTTGTCCTTGACCTTCACCGGGATCCTCTAGAGTCGACCCTG 
oPEB101
5 
TAActaagaattcggccgtcgttt 
oPEB101
7 
TTGGCCTTGTCCTTGACCTTCACCCTCTAGAGTCGACCTGCAGTGG 
oPEB101
8 
TAActaagtaatatggtgcactctcagt 
oPEB102
1 
ATTATGCCGCATCTGTCCAACT 
oPEB102
2 
gcaaggcgattaagttgggtaa 
oPEB102
4 
TTCTCGCCGGATGTACTGGAAAC 
oPEB102
5 
tggcttaactatgcggcatcaga 
oPEB103
4 
CTAGAGGGTGAAGGTCAAGGACAAGGCCAAATGAGTAAAGAATCTATTATTTTTGTCGGT 
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oPEB103
5 
gtactgagagtgcaccatattacttagTTACTATCTTACAGTTGCTAATTCATATGCA 
oPEB103
6 
TAGAGGGTGAAGGTCAAGGACAAGGCCAAATGAGTAGCGGCCAAGAGCTTAATCAGT 
oPEB103
9 
GGATCCCGGTGAAGGTCAAGGACAAGGCCAATTGCTACGTAAAAAACATTTTAGCTGGA 
oPEB104
0 
acgttgtaaaacgacggccgaattcttagTTATCAGGTGCTTTTCGCTTTCAGCTT 
oPEB104
1 
ATCCCGGTGAAGGTCAAGGACAAGGCCAATTGAAACGGCAATTAAAACTGTTTTTTATTG 
oPEB104
2 
gttgtaaaacgacggccgaattcttagTTATTACATTTCTTTTTTCAGTGTTTCAATTGC 
 
Table 2.8 Oligonucleotides used in this study. 
 
 
Supplemental text 
Supplemental Results 
ylbK disruption results in a polar effect on ylbL 
We noticed that ylbK, the gene upstream of ylbL, had a phenotype similar to ylbL in the 
Tn-seq experiments (Tables 2.2, 2.3, & 2.4). Therefore, we tested whether ylbKL functioned 
together in the DNA damage response. Deletion of ylbK resulted in sensitivity to MMC (Fig 
2.14A). Ectopic expression of ylbK failed to complement the ΔylbK phenotype (Fig 2.14A). 
Given that ylbK is upstream of ylbL we attempted to complement the ΔylbK phenotype using 
ylbL and found that sensitivity to MMC was rescued (Fig 2.14A). Closer examination of the 
ylbKL locus revealed that a putative ribosome binding site (RBS) for ylbL translation was present 
within the 3′ end of ylbK (Fig 2.14B). Thus, a second deletion of ylbK was made (ΔylbK-2) 
which included deletion of the codons for all but the first 3 and the last 14 amino acids, leaving 
the RBS for ylbL intact (Fig 2.14B). This deletion was not sensitive to MMC (Fig 2.14A). 
Western blotting revealed that the initial ΔylbK strain did not express YlbL, whereas ΔylbK-2 did 
(Fig 2.14C). We conclude that disruption of ylbK results in a polar effect on ylbL, indicating that 
YlbL functions independently of YlbK. 
In order to better understand the prevalence of false positives in Tn-seq experiments we 
attempted to validate the MMC phenotypes of the forty genes with the lowest relative fitness 
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values in the second growth period of the experiment. Intriguingly, we found that seven 
additional genes, queA, ylmG, lgt, ylmE, sdaAB, cymR, and ywrC, resulted in no sensitivity to 
MMC when deleted (Table 2.3). We also found that the genomic loci of queA, cymR, ylmG, 
ylmE, and sdaAB, were proximal to genes with validated phenotypes (Table 2.3). The other two 
genes, ywrC and lgt have less obvious explanations. For lgt it is possible that the polar effect is 
on the upstream gene hprK, which codes for the kinase HprK that phosphorylates Crh (71). 
Deletion of crh resulted in sensitivity to MMC (Table 2.3), but we did not detect hprK in our Tn-
seq experiments. Finally, ywrC does not have a clear explanation. We could not identify 
validated mutant phenotypes or essential genes proximal to ywrC. It is possible that the 
transposon resulted in increased expression of neighboring genes that resulted in sensitivity to 
MMC, and that increased expression is not duplicated in the deletion mutant, though other 
explanations exist. Taken together, our results underscore the importance of validating results 
from forward genetic screens. 
Cell wall metabolism genes are sensitive to DNA damage 
Our forward genetic screens identified several cell wall metabolism genes as being 
sensitive to DNA damaging agents, including walH, yycI, walJ, ponA, and brcC (Tables 2.2 & 
2.3). We validated that deletion mutants were indeed sensitive to MMC (Table 2.3). These genes 
have not previously been implicated in the DNA damage response, though it is possible that they 
function in regulating cell division. Specifically, the genes walH and yycI are negative regulators 
of the essential two-component system WalRK (72-75). A recent publication provided evidence 
that the WalRK system interacts with components of the divisome (76). Further, a study of walJ 
found that WalJ likely coordinates cell division with DNA replication (77). As a result, it is 
tempting to speculate that WalRK and the associated WalHIJ represent one of the connections 
between DNA replication,  the DNA damage response, cell wall metabolism, and cell division.  
 
Supplemental Materials and Methods 
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Transposon insertion mutant library construction 
Extraction of PY79 chromosomal DNA 
Cell pellets (10 mL OD600 = 1 equivalent) from stationary phase cultures were re-
suspended in lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, pH 8.0, 1% (v/v) Triton X-100, 
0.5 mg/mL RNase A, 1 mg/mL lysozyme) and incubated at 37°C for 30 minutes. Proteins were 
digested by addition of 40 μL 10 mg/mL proteinase K (dissolved in TE buffer plus 10% 
glycerol) and 30 μL of 10% SDS and incubated at 55°C for 30 minutes. 600 μL of PB buffer (5 
M guanidine-HCl, and 30% (v/v) isopropanol) were added, mixed well by pipetting and added 
directly to a silica spin column (Epoch life sciences) and centrifuged at 12,000 g for 1 minute at 
room temperature. The column was washed with 500 μL PB buffer, then 750 μL PE buffer (10 
mM Tris, pH 7.5, and 80% (v/v) ethanol), centrifuging as above to remove buffer. The column 
was dried by centrifugation as above. Chromosomal DNA was eluted by adding 100 μL ultra-
pure water and centrifugation as above. 
Purification of Himar1-C9 transposase  
Himar1-C9 was purified as described previously (78). E. coli TB1 cells with plasmid 
pMalC9 (Strain PEB234) were struck out on LB + 100 μg/mL ampicillin and incubated at 37°C 
overnight. An overnight starter culture was grown in LB + 100 μg/mL ampicillin at 37°C. The 
starter culture was diluted 1:100 and incubated at 37°C until OD600 = 0.5 and Himar1-C9 was 
induced by addition of IPTG to a final concentration of 0.3 mM. The culture was incubated for 2 
hours at 37°C. Cells were collected via centrifugation: 5,000 g for 20 minutes at 4°C. Cell pellets 
were re-suspended in 20 mL ice-cold column buffer (CB; 20 mM Tris, pH 7.5, 200 mM NaCl, 1 
mM EDTA, and 1x Roche protease inhibitors). Cells were lysed via French press, and the lysate 
was clarified via centrifugation: 18,000 rpm (Sorvall SS-34 rotor) for 30 minutes at 4°C. The 
lysate was loaded onto 1 mL amylose resin (NEB) pre-equilibrated with CB, and placed on a 
rotator at 4°C for 1 hour. Resin was collected via centrifugation: 3,000 g for 10 minutes at 4°C. 
The supernatant was removed and the resin was washed with 4 volumes wash buffer (20 mM 
Tris, pH 7.5, 200 mM NaCl, 1 mM EDTA, 2 mM DTT, and 10% (v/v) glycerol) five times by re-
suspending the resin, then collecting via centrifugation and aspirating the wash buffer. The 
column was eluted by adding 0.8 volume of elution buffer (20 mM Tris-HCl, pH 7.5, 200 mM 
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NaCl, 1 mM EDTA, 2 mM DTT, 10% (v/v) glycerol, and 10 mM maltose) and incubating on ice 
for 5 minutes and agitating frequently. The protein was analyzed via SDS-PAGE and 
concentration was determined using a Bradford assay. The protein was aliquoted, frozen in liquid 
nitrogen and stored at -80°C. 
Transposition reaction 
A transposon insertion library was constructed in vitro as described with minor 
modifications (61). A 50 μL transposition was prepared: 3 μg chromosomal DNA, 1 μg PCR 
product mariner transposon (The mariner transposon was PCR amplified from pCJ41 using 
primers oPEB368/369 and Q5 DNA polymerase (NEB)), 10 μL 5x Buffer A (102.5 mM HEPES 
pH 7.9, 47.5% glycerol, 467.5 mM NaCl, 47.5 mM MgCl2, 1.19 mg/mL BSA, 9.5 mM DTT), 
100 nM Himar1-C9. Reactions were incubated at 30 °C for 16 hours. DNA was precipitated via 
addition of 0.1 volume sodium acetate, pH 5.2 and 2.5 volume 100% ice-cold ethanol. DNA was 
collected via centrifugation: 16,000g for 20 minutes at 4°C. DNA pellet was washed with 5 
volumes (relative to reaction volume) ice-cold 70% ethanol and pelleted again via centrifugation: 
16,000g for 10 minutes at 4°C. The ethanol wash was aspirated and the DNA pellet was dried at 
room temperature. The transposon junctions were repaired by re-suspending the DNA pellet in 
the following 50 μL reaction: 1x T4 DNA ligase buffer (Lucigen), 1 mg/mL BSA (NEB), 0.5 
mM dNTPs, 1 mM ATP, 50 mM NaCl, 6 units T4 DNA polymerase exo- (Lucigen), and 480 
units T4 DNA ligase (Lucigen), and incubating at room temperature for 2 hours. The reactions 
were mixed by pipetting every 30 minutes over the 2 hour incubation. The reactions were moved 
to 16°C for 16 hours, and then stored at 4°C until used to transform PY79. 
Transformation of PY79 
PY79 was struck out on LB agar and incubated at 37°C overnight. A single colony was 
used to inoculate a 2 mL LM culture (LB + 3 mM MgSO4) in a 14 mL round bottom culture 
tube. The culture was incubated at 37°C on a rolling rack until OD600 of about 1.5. Then, 40 μL 
of the LM culture was transferred to 1.2 mL pre-warmed MD media (1x PC buffer (107 g/L 
K2HPO4, 60 g/L KH2PO4, 11.8 g/L trisodium citrate dihydrate), 2% glucose, 50 μg/mL 
phenylalanine, 50 μg/mL tryptophan, 11 μg/mL ferric ammonium citrate, 2.5 mg/mL potassium 
aspartate, 3 mM MgSO4) and incubated on a rolling rack at 37°C for 6 hours. To each 1.2 mL 
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competent cell culture, 15 μL of the transposase reaction were added, and the cultures were 
incubated on a rolling rack at 37°C for an additional 1.5 hours. Transformations were plated on 
LB agar + 100 μg/mL spectinomycin (200 μL per 100 cm plate, and 124 plates in total), and 
incubated at 37°C overnight. The Library consisted of approximately 900,000 transformants, 
which were pooled in 1x S750 salts + 15% glycerol with a resulting OD600 of approximately 37.0. 
The library was distributed into 1 mL aliquots, frozen in liquid nitrogen, and stored at -80°C. 
Tn-seq experimental details 
Tn-seq experiments were designed with multiple growth periods similar to a prior 
description (28). The experiment was performed using triplicate samples for each condition, 
which originated from three aliquots of the transposon insertion library. The experiment was 
initiated by thawing three aliquots of the transposon insertion library in a beaker of water at 
37°C. Each aliquot of the thawed library was used to inoculate 50 mL starter cultures in 500 mL 
beakers. For the MMC experiment 270 μL were used to inoculate, and 500 μL were used for the 
MMS and phleomycin experiment. The three starter cultures were incubated with shaking (200 
rpm) at 30°C until OD600 of about 0.8. Starter cultures were used to inoculate paired 25 mL 
cultures in 250 mL flasks at an OD600 = 0.05 for control or treatment. For the MMC experiment, 
MMC was added to a final concentration of 15 ng/mL and an equal volume of the vehicle in 
which MMC was dissolved (25% v/v DMSO) was added to the control flasks. For MMS, a final 
concentration of 50 μg/mL was used, and a final concentration of 25 ng/mL was used for 
phleomycin. An equal volume of water was used for the vehicle control in the MMS and 
phleomycin experiment. The paired cultures were incubated with shaking (200 rpm) at 30°C 
until OD600 of about 1.5 (growth period 1). Then the cultures were back diluted into fresh control 
or treatment media at an OD600 = 0.05, and incubated with shaking (200 rpm) at 30°C until 
OD600 of about 1.5 (growth period 2). The cultures were back diluted as above one more time 
and grown as above (growth period 3). At all steps of the experiment three samples of OD600 = 
10 were saved as cell pellets, and each sample was serially diluted and plated for viable cells in 
triplicate to estimate the number of cells at the start and end of the growth periods (Table 2.1), 
which were used in the fitness calculations. 
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Tn-seq sequencing library construction 
Sequencing libraries were prepared similar to previous reports (35, 61), with some 
modifications in adaptor sequences to increase compatibility with standard Hi-seq reagents. 
Genomic DNA was extracted from each sample as described in “Extraction of PY79 genomic 
DNA.” A 200 μL restriction digest using MmeI was assembled for each sample as follows: 6 μg 
gDNA, 1x Cutsmart buffer (NEB), 64 μM SAM (NEB), 12 units MmeI (NEB). Reactions were 
incubated at 37°C for 4 hours. CIP (20 units) was added and the reactions were incubated at 
37°C for 1 hour. MmeI was heat inactivated by incubating at 65°C for 30 minutes, and the 
digested genomic DNA was extracted by addition of 600 μL of PB buffer and binding to a silica 
spin-column. The column was washed with 500 μL PB, then 750 μL PE buffer, and then eluted 
with 65 μL ultra-pure water. Adaptors (oPEB312/313) were annealed in 1x annealing buffer (10 
mM Tris, pH 8.0, 100 mM NaCl, 10 μM EDTA) at a concentration of 25 mM each, by boiling at 
100°C for 5 minutes, followed by transferring to a beaker of 100°C water which was allowed to 
cool slowly to room temperature. The adaptors were ligated to the digested genomic DNA in two 
40 μL reactions, each containing 30 μL of the eluate from above, 1x T4 DNA ligase buffer 
(NEB), 2.5 μM annealed adaptors, and 800 units T4 DNA ligase (NEB). Reactions were left at 
room temperature for 30 minutes, and then transferred to 16°C for 16 hours. The resulting 
reactions were pooled for each sample, and the DNA was extracted via spin-column as above, 
but the PB wash was excluded, and the sample was eluted with 100 μL ultra-pure water. 
Transposon/genomic DNA junctions were PCR amplified in two 50 μL reactions each containing 
4 μL of eluate from the previous step, 1x Q5 DNA polymerase buffer (NEB), 200 μM dNTPs, 
400 nM forward primer (oPEB314), 400 nM reverse primer with multiplexing barcode (one of 
oPEB315-326), and 1 unit of Q5 DNA polymerase (NEB). The reactions were cycled as follows: 
1) 98°C for 3 minutes; 2) 98°C for 30 seconds; 3) 55°C for 30 seconds; 4) 72°C for 30 seconds; 
5) repeat steps 2-4 for 18 cycles; 6) 72°C for 2 minutes; 7) hold at 4°C. The reactions were 
separated on a 2.5% agarose gel and the reaction product at approximately 160 bp was excised. 
The DNA was extracted by dissolving the gel slice in 400 μL QG buffer (5.5 M guanidine 
thiocyanate and 20 mM Tris, pH 6.6) by heating at 65°C, and then 250 μL of isopropanol were 
added and the mixture was added to a silica spin-column. The column was washed with PB and 
PE buffer as above, and eluted with 120 μL ultra-pure water. The eluate was submitted for 
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sequencing using a Hi-seq 2500 instrument on high output mode with v3 (MMC experiment) or 
v4 reagents (MMS and phleomycin experiment). 
Tn-seq data analysis 
The 50 bp sequencing reads were trimmed to 43 bp using Fastx Trimmer, because the 
sequencing reaction went outside of the inverted repeat, and those seven base pairs could not be 
aligned to our reference database. The trimmed reads were aligned to a reference database in 
which every TA site found in the PY79 genome was placed adjacent to the transposon sequence 
(reference database fasta file and sequencing data accession number GSE109366) using bwa 
(79). The reads were imported into the R statistical software package RStudio (RStudio 80) for 
further analysis. Each transposon insertion site was provided a coverage value where each read 
was equal to a coverage of one. Each transposon insertion site was indexed to its position in the 
genome and the gene or intergenic region in which it resides. Fitness was calculated for each 
insertion for the control and the treatment using the equation:  
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ln ௙ܰሺ1 െ ܨ௙ሻ
଴ܰሺ1 െ ܨ଴ሻ
 
where N0 and Nf are the number of bacteria at the start and end of the growth period, 
respectively, and F0 and Ff are the transposon frequency in the population as measured by 
Illumina sequencing (insertion coverage divided by total reads in the sample), respectively (35) 
(also see Fig 2.1C). The ratio of treatment to control was calculated and defined as the relative 
fitness (see Fig 2.1C). For each gene (or intergenic region), the insertions containing less than 10 
reads were removed and any gene without at least 12 insertions from the combined triplicate data 
were also removed, thus requiring that each gene have at least 4 insertions in each replicate to be 
included in the analysis. Each gene’s average relative fitness was then calculated by determining 
the mean relative fitness of all insertion sites within each gene. We trimmed insertions in our 
fitness calculation that were in the upper or lower five percent of the data for that gene, reasoning 
that not all insertions will be a true representation of a null allele. A t-test was used to determine 
if the gene relative fitness differed significantly from one. P-values were adjusted for multiple 
comparisons using the method of Benjamini and Hochberg (37). 
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Proteomics experimental details 
Ms Bioworks processed samples as described below. Submitted samples were washed 
three times with PBS. The washed pellets were suspended in modified RIPA buffer (2% SDS, 
150 mM NaCl, 50 mM Tris HCl pH 8) and lysed using mechanical disruption in a Next Advance 
Bullet Blender using 1.0mm silica beads, setting 8 for 3 minutes. The lysate was centrifuged at 
10,000 g for 10 minutes. Protein concentrations were determined by Qubit fluorometry. 20 μg of 
each sample was processed by SDS-PAGE using a 10% Bis-Tris NuPAGE gel (Invitrogen) with 
the MES buffer system; the gel was electrophoresed approximately 5 cm. The mobility region 
was excised into 20 equal sized segments for further processing by in-gel digestion. In-gel 
digestion was performed on each submitted sample using a robot (ProGest, DigiLab) with the 
following protocol: 1) Washed with 25mM ammonium bicarbonate followed by acetonitrile. 2) 
Reduced with 10mM dithiothreitol at 60°C followed by alkylation with 50mM iodoacetamide at 
room temperature. 3) Digested with trypsin (Promega) at 37°C for 4h. 4) Quenched with formic 
acid and the supernatant was analyzed directly without further processing. 
Each gel digest was analyzed by nano LC-MS/MS with a Waters NanoAcquity HPLC 
system interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and 
eluted over a 75μm analytical column at 350 nL/min; both columns were packed with Luna C18 
resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with the 
Orbitrap operating at 60,000 FWHM and 17,500 FWHM for MS and MS/MS, respectively. The 
fifteen most abundant ions were selected for MS/MS. 
Proteomics data analysis 
Data were processed as described by MS Bioworks. Data were searched using a local 
copy of Mascot with the following parameters: Enzyme: Trypsin/P; Database: UniProt Bacillus 
subtilis (concatenated forward and reverse plus common potential contaminants); Fixed 
modification: Carbamidomethyl (C); Variable modifications: Oxidation (M), Acetyl (N-term), 
Pyro-Glu (N-term Q), Deamidation (N/Q); Mass values: Monoisotopic; Peptide Mass Tolerance: 
10 ppm; Fragment Mass Tolerance: 0.02Da; Max Missed Cleavages: 2. Mascot DAT files were 
parsed into Scaffold (Proteome Sciences) for validation, filtering and to create a non-redundant 
list per sample. Data were filtered using at 1% protein and peptide FDR and requiring at least 
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two unique peptides per protein. A student’s t-test was performed to determine if wild-type and 
the double mutant levels were significantly different (α = 0.05). 
Protein purification 
YlbL 
YlbL for antibody production was purified as follows. 10xHis-Smt3-YlbL (a.a 36-341) 
was expressed from plasmid pPB157 in E. coli NiCo21 cells (NEBC2529H). One liter LB + 50 
μg/mL kanamycin cultures were inoculated with an overnight culture (1:100) and grown at 37°C 
with shaking (200 rpm) until OD600 of about 0.5. Cultures were iced briefly and IPTG was added 
to 0.5 mM and incubated at 20°C with shaking overnight. Cells were harvested via 
centrifugation: 4,000 g for 20 minutes at 4°C. Cell pellets were re-suspended in lysis buffer (50 
mM potassium phosphate pH 8.0, 300 mM NaCl, 5% (v/v) glycerol, and 20 mM imidazole). 
Cells were lysed via sonication and lysates were cleared via centrifugation: 18,000 rpm (Sorvall 
SS-34 rotor) for 45 minutes at 4°C. The supernatant was removed and incubated with Ni2+-NTA-
agarose (Qiagen) for 1 hour at 4°C. The lysate/bead slurry was loaded onto a gravity flow 
column and the beads were allowed to settle for 5-10 minutes. The lysate was collected as the 
flow-through. The column was washed with 50 column volumes wash buffer (50 mM potassium 
phosphate pH 8.0, 300 mM NaCl, 5% (v/v) glycerol, and 30 mM imidazole). YlbL was eluted 
from the column via digestion with 6xHis-Ulp1 in digestion buffer (50 mM potassium phosphate 
pH 8.0, 150 mM NaCl, 5% (v/v) glycerol, 1 mM DTT, and 10 mM imidazole) on a rotator at 
room temperature for 2 hours, yielding untagged YlbL (a.a. 36-341). The digestion buffer was 
collected as the flow-through and concentrated to approximately 5 mL using a 10 kDa Amicon 
centrifugal filter. YlbL was then loaded onto a HiLoad superdex 200-PG 16/60 column pre-
equilibrated with SEC buffer (50 mM potassium phosphate pH 8.0, 150 mM NaCl, and 5% (v/v) 
glycerol) and the column was washed using SEC buffer at a flow rate of 1 mL/min. The peak 
fractions were pooled, glycerol was added to a final concentration of 20%, and concentrated 
using a 10 kDa Amicon centrifugal filter. Aliquots were frozen in liquid nitrogen, and stored at 
80°C. 
YlbL and YlbL-S234A were purified for in vitro assays as follows. 10xHis-Smt3-YlbL 
(a.a 36-341) and 10His-Smt3-YlbL-S234A (a.a. 36-341) were expressed from plasmids pPB157 
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and pPB181, respectively, as described above for antibody production. Cell pellets from a one 
liter culture were re-suspended in 30 mL lysis buffer (50 mM Tris pH 7.5, 250 mM NaCl, 10% 
sucrose, and 20 mM imidazole) and lysed via sonication. Cell lysates were clarified via 
centrifugation: 18,000 rpm (Sorvall SS-34 rotor) for 30 minutes at 4°C. Clarified lysates were 
applied to Ni2+-NTA-agarose pre-equilibrated with lysis buffer. The column was washed with 20 
column volumes wash buffer (25 mM Tris pH 8.0, 100 mM NaCl, 30 mM imidazole, and 5% 
glycerol). The Ni2+ column was eluted in four fractions of 1.2 column volumes using elution 
buffer (25 mM Tris pH 8.0, 100 mM NaCl, 10% glycerol, and 250 mM imidazole). Fractions 1-3 
were pooled, DTT was added to 2.5 mM and 0.3 mg of Ulp1 was added. The elution was 
digested at 4°C overnight yielding untagged YlbL (a.a. 36-341) or untagged YlbL-S234A (a.a 
36-341). The digest was desalted using a Zeba spin column into equilibration buffer (25 mM Tris 
pH 8.0, 50 mM NaCl, 5% glycerol, and 10 mM imidazole). The desalted digest was applied to a 
second column of Ni2+-NTA-agarose and the flow-through was collected. The column was 
washed with one column volume of equilibration buffer. The flow-through and wash fractions 
were pooled and concentrated using a 10 kDa Amicon centrifugal filter. The concentrated protein 
was loaded onto a Sephacryl S-200 size exclusion column pre-equilibrated with SEC buffer (25 
mM Tris pH 7.5, 5% glycerol, and 25 mM NaCl) and eluted over 1 column volume with SEC 
buffer at a flow rate of 1 ml/min. Peak fractions were pooled, glycerol was added to 20% and the 
final protein was concentrated using a 10 kDa Amicon centrifugal filter. The concentrated 
protein was aliquoted, frozen in liquid nitrogen, and stored at -80°C. 
YneA 
10xHis-Smt3-YneA (a.a. 28-103) was expressed from pPB204 and harvested as 
described for YlbL above. Cell pellets were re-suspended in lysis buffer (50 mM Tris pH 7.5, 
250 mM NaCl, 10% (w/v) sucrose, 20 mM imidazole). Cells were lysed via sonication and the 
lysate was clarified as described for YlbL above. The clarified lysate was incubated with Ni2+-
NTA-agarose beads, pre-equilibrated with lysis buffer, and incubated on rotator at 4°C for 1 
hour. The lysate/bead slurry was loaded into a gravity flow column and the beads were allowed 
to settle for 5-10 minutes. The lysate was collected as the flow-through. The column was washed 
with 30 column volumes wash buffer (25 mM Tris pH 7.5, 150 mM NaCl, 5% (v/v) glycerol, 
and 20 mM imidazole). The column was eluted in 6 fractions of 1 column volume each of elution 
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buffer (25 mM Tris pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 250 mM imidazole). The 
fractions with the highest protein concentration were pooled, DTT was added to 1 mM and 
digested with MBP-Ulp1 overnight at 4°C. The resulting digest, yielding untagged YneA (a.a. 
28-103), was loaded onto a sephacryl S200 26/60 column pre-equilibrated with SEC buffer (25 
mM Tris pH 8.0, 100 mM NaCl, and 5% (v/v) glycerol) and washed at a flow rate of 2 mL/min. 
The peak fractions were pooled, and glycerol was added to 20%. The protein was loaded onto a 
HiTrap Q column (GE life sciences), pre-equilibrated with 7.5% Q-finish buffer (25 mM Tris pH 
8.0, 5% (v/v) glycerol, and 1 M NaCl) and 92.5% Q-start buffer (25 mM Tris pH 8.0, and 5% 
(v/v) glycerol). The column was washed with 5 column volumes 7.5% Q-finish buffer. The 
column was eluted with 30 column volumes over a linear gradient from 7.5% to 50% Q-finish 
buffer at a flow rate of 2 mL/min. Peak fractions were pooled, glycerol was added to a final 
concentration of 20%, and the protein was concentrated using a 3 kDa Amicon centrifugal filter. 
Aliquots were frozen in liquid nitrogen and stored at -80°C. 
CtpA and CtpA-S297A 
Expression conditions for CtpA fusions were similar to previous reports for CtpB (81). 
MBP-Smt3-CtpA and MBP-Smt3-CtpA-S297A were expressed in BL21 pLysY/LacIq 
(NEBC3013) cells from pPB203 and pPB214, respectively. A starter culture of LB + 50 μg/mL 
kanamycin was inoculated using several colonies from a fresh transformation and incubated at 
37°C with shaking (200 rpm) until an OD600 = 0.5. One liter LB + 50 μg/mL kanamycin cultures 
were inoculated by diluting the starter culture 1:50 and incubated at 37°C until an OD600 of about 
0.7. Glucose was added to 0.2% and expression was induced by addition of IPTG to 1 mM and 
incubating at 37°C for 45 minutes. Cells were harvested via centrifugation: 4,000 g for 20 
minutes at 4°C. Cell pellets were re-suspended in 30 mL lysis buffer (50 mM Tris pH 7.5, 250 
mM NaCl, 10% (w/v) sucrose) per one liter of culture and lysed via sonication. Lysates were 
clarified via centrifugation: 12,500 rpm (Sorvall SS-34 rotor) for 45 minutes at 4°C. Clarified 
lysates were mixed with pre-equilibrated 2.5 mL amylose resin (NEB) on a rotator at 4°C. The 
lysate/resin mixture was loaded into a gravity flow column and the resin was allowed to settle for 
5-10 minutes. The lysate was allowed to flow over the packed resin. The column was washed 
with 20 column volumes of wash buffer (25 mM Tris pH 8.0, 100 mM NaCl, 10%(v/v) glycerol). 
The column was eluted with 4 fractions of 3 mL each in elution buffer (25 mM Tris pH 8.0, 100 
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mM NaCl, 10%(v/v) glycerol, and 50 mM maltose). Fractions 1-3 were pooled, DTT was added 
to 2 mM, and digested with MBP-Ulp1 overnight at 4°C. The resulting digest, yielding untagged 
CtpA (or CtpA-S297A), was diluted two-fold with Q-start buffer (25 mM Tris, pH 8.0, 5% 
glycerol) to bring the NaCl concentration to 50 mM, and loaded onto a HiTrap Q-column pre-
equilibrated with 5% Q-finish buffer (25 mM Tris, pH 8.0, 1 M NaCl, 5% glycerol). The column 
was washed with 5 column volumes 5% Q-finish buffer. The column was eluted with 25 column 
volumes over a linear gradient from 5 to 50% Q finish buffer. The peak fractions were pooled, 
concentrated using a 30 kDa Amicon centrifugal filter, and loaded onto a sephacryl 16/60 S-200 
column pre-equilibrated with SEC buffer (25 mM Tris pH 7.5, 25 mM NaCl, 5% glycerol). The 
column was washed with SEC buffer at a flow rate of 1 mL/min. Peak fractions were pooled, 
glycerol was added to 20%, and concentrated using a 30 kDa Amicon centrifugal filter. Aliquots 
were frozen in liquid nitrogen, and stored at -80°C. 
6xHis-Ulp1 
6xHis-Ulp1 was expressed from plasmid pPB13 in E. coli NiCo21 cells (NEBC2529H). 
One liter cultures of LB + 50 μg/mL kanamycin were inoculated with an overnight culture at 
1:100 and grown at 37°C until OD600 of about 0.7. Cultures were induced with 0.5 mM IPTG 
and incubated at 37°C for 3 hours. Cells were pelleted via centrifugation: 4,000 g for 20 minutes 
at 4°C. Cells were re-suspended in lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl, 5% (w/v) 
sucrose, and 20 mM imidazole) and lysed via sonication. Lysates were clarified via 
centrifugation: 18,000 rpm (Sorvall SS-34 rotor) for 45 minutes at 4°C. Clarified lysates were 
loaded onto Ni 2+-NTA-agarose beads pre-equilibrated with lysis buffer and incubated at 4°C for 
1 hour on a rotator. The lysate was collected as the flow through and the column was washed 
with 25 column volumes wash buffer (25 mM Tris pH 7.5, 300 mM NaCl, and 20 mM 
imidazole). The column was eluted in elution buffer (25 mM Tris pH 7.5, 300 mM NaCl, and 
250 mM imidazole). The most concentrated fractions were pooled; aliquots were frozen in liquid 
nitrogen, and stored at -80°C. 
MBP-Ulp1 
MBP-Ulp1 was expressed from pPB200 in E. coli BL21 DE3 cells. One liter LB + 50 
μg/mL kanamycin cultures were inoculated with an overnight culture at 1:100. Cultures were 
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grown at 37°C until OD600 of about 0.5, glucose was added to 0.2%, and then protein expression 
was induced by addition of 0.25 mM IPTG. Cultures were incubated at 20°C overnight. Cells 
were pelleted via centrifugation: 4,000 g for 20 minutes at 4°C. Cell pellets were re-suspended in 
lysis buffer (50 mM Tris pH 7.5, 250 mM NaCl, 10% (w/v) sucrose, and 1 mM DTT), and lysed 
via sonication. Lysates were cleared via centrifugation and MBP-Ulp1 was purified on an 
amylose column as described for CtpA above. Peak fractions from the amylose column were 
loaded onto a sephacryl S200 26/60 column, pre-equilibrated with SEC buffer (25 mM Tris pH 
7.5, 200 mM NaCl, 2% glycerol). The column was washed with SEC buffer at a flow rate of 2 
mL/min. Peak fractions were pooled, glycerol was added to 20%, and DTT was added to 1 mM. 
MBP-Ulp1 was concentrated to about 1.7 mg/mL, aliquots were frozen in liquid nitrogen and 
stored at -80°C. 
Strain construction 
General strain construction methods 
Generation of competent B. subtilis cultures for generating new genotypes was performed 
as described below in “Transposon insertion mutant library construction,” or as previously 
reported (62). 
Genome editing using CRISPR/Cas9 was performed as described previously (62, 82). B. 
subtilis strains were transformed with the indicated plasmid (prepared from E. coli MC1061), 
plated on LB agar + 100 μg/mL spectinomycin and incubated at 30°C overnight. Isolates were 
colony purified by restreaking on LB agar + 100 μg/mL spectinomycin and incubating at 30°C 
overnight. The editing plasmid was evicted by restreaking isolates on LB agar and incubating at 
45°C for 8-12 hours or overnight. Loss of the editing plasmid was verified by restreaking LB 
agar + 100 μg/mL spectinomycin and on LB agar. Isolates that were unable to grow in the 
presence of spectinomycin were used for PCR genotyping. 
Gene deletions using the B. subtilis knockout library were performed as described (83). 
Chromosomal DNA, extracted as described below (see extraction of PY79 chromosomal DNA), 
was used to transform PY79 or the indicated strain. Incorporation of the erm cassette at the 
appropriate locus was verified via PCR genotyping. Removal of the erm cassette was performed 
following transformation with pDR244, which contains cre recombinase. Eviction of pDR244 
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was performed as described for a CRISPR/Cas9 genome editing plasmid. Loss of the erm 
cassette was verified by sensitivity to erythromycin and PCR genotyping. 
Integration of inducible constructs at the amyE locus was achieved via double crossover 
recombination. For constructs containing a xylose inducible promoter (Pxyl), strains were 
transformed with plasmids that had been digested with two unique restriction enzymes (KpnI-HF 
and ScaI-HF) or with genomic DNA of a strain already generated (see detailed strain 
construction) and transformants were selected using LB agar + 5 μg/mL chloramphenicol. 
Isolates were colony purified by restreaking on LB agar + 5 μg/mL chloramphenicol. 
Incorporation via double cross-over at amyE was determined by screening for an inability to 
utilize starch and by testing for the absence of a spectinomycin resistance cassette that is present 
on part of the plasmid that is not integrated. For constructs containing an IPTG inducible 
promoter (Phyp), strains were transformed with plasmids that had been digested with two unique 
restriction enzymes (SpeI and SacI-HF) and transformants were selected using LB agar + 100 
μg/mL spectinomycin. Isolates were colony purified by restreaking on LB agar + 100 μg/mL 
spectinomycin. Incorporation via double cross-over at amyE was determined by screening for an 
inability to utilize starch. 
Individual strain construction 
PEB85 (ΔrecN∷erm): PY79 was transformed with genomic DNA isolated from PEB75. 
Replacement of recN with the erm cassette was verified via PCR genotyping using oPEB54/55. 
PEB235 (ΔrecR): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB46. 
Deletion of recR was verified via PCR genotyping using oPEB243/246. 
PEB278 (ΔrnhC): PEB278 is a clonal isolate of JWS224, which was generated by deletion of 
rnhC from PY79 using the pMiniMAD method as described previously (62). 
PEB307 (ΔuvrA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB82. 
Deletion of uvrA was verified via PCR genotyping using oPEB423/424. 
PEB308 (ΔuvrB): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB83. 
Deletion of uvrB was verified via PCR genotyping using oPEB432/433. 
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PEB310 (ΔuvrC): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB85. 
Deletion of uvrC was verified via PCR genotyping using oPEB443/444. 
PEB316 (ΔyprA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB86. 
Deletion of yprA was verified via PCR genotyping using oPEB452/453. 
PEB318 (ΔyprB): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB87. 
Deletion of yprB was verified via PCR genotyping using oPEB461/462. 
PEB322 (ΔylbK): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB98. 
Deletion of ylbK was verified via PCR genotyping using oPEB472/473. 
PEB324 (ΔylbL): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB99. 
Deletion of ylbL was verified via PCR genotyping using oPEB481/482. 
PEB334 (ΔsodA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB103. 
Deletion of sodA was verified via PCR genotyping using oPEB510/511. 
PEB346: PY79 was transformed with plasmid pPB111. This strain was only used to generate 
other strains using extracted genomic DNA. 
PEB349: PEB324 was transformed with plasmid pPB108. This strain was only used to generate 
other strains using extracted genomic DNA. 
PEB350: PY79 was transformed with plasmid pPB107. This strain was only used to generate 
other strains using extracted genomic DNA. 
PEB353 (ΔqueA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB120. 
Deletion of queA was verified via PCR genotyping using oPEB583/584. 
PEB355 (ΔctpA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB121. 
Deletion of ctpA was verified via PCR genotyping using oPEB592/593. 
PEB357 (ΔysoA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB122. 
Deletion of ysoA was verified via PCR genotyping using oPEB601/602. 
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PEB373 (ΔylbK, amyE::Pxyl-ylbK): PEB322 was transformed with genomic DNA from 
PEB350. Retention of the ΔylbK allele was verified via PCR genotyping oPEB472/473. 
PEB375 (ΔylbL, amyE::Pxyl-ylbL): PEB324 was transformed with genomic DNA from PEB349. 
PEB377 (ΔylbL, amyE::Pxyl-ylbL-S243A): PEB324 was transformed with genomic DNA from 
PEB346. Retention of the ΔylbL allele was verified via PCR genotyping using oPEB481/482. 
PEB382 (ΔylmE): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB123 
as a Gibson assembly reaction because the plasmid was not able to be isolated from E. coli. 
Deletion of ylmE was verified via PCR genotyping using oPEB610/611. 
PEB384 (ΔsepF): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB124 as 
a Gibson assembly reaction because the plasmid was not able to be isolated from E. coli. 
Deletion of sepF was verified via PCR genotyping using oPEB612/623. 
PEB386 (ΔylmG): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB125 
as a Gibson assembly reaction because the plasmid was not able to be isolated from E. coli. 
Deletion of ylmG was verified via PCR genotyping using oPEB612/623. 
PEB390 (ΔylbK, amyE::Pxyl-ylbL): PEB322 was transformed with genomic DNA from PEB349. 
Retention of the ΔylbK allele was verified via PCR genotyping using oPEB472/473. A wild-type 
ylbL locus was verified via PCR genotyping using oPEB481/482. 
PEB392 (ΔylbK, amyE::Pxyl-ylbL-S243A): PEB322 was transformed with genomic DNA from 
PEB346. Retention of the ΔylbK allele was verified via PCR genotyping using oPEB472/473. 
PEB418 (ΔytmP): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB140. 
Deletion of ytmP was verified via PCR genotyping using oPEB644/645. 
PEB420 (ΔbcrC): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB141. 
Deletion of bcrC was verified via PCR genotyping using oPEB653/654. 
PEB422 (ΔecsA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB142. 
Deletion of ecsA was verified via PCR genotyping using oPEB662/663. 
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PEB424 (ΔecsB): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB143. 
Deletion of ecsB was verified via PCR genotyping using oPEB671/672. 
PEB427 (ΔylbK-2): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB149. 
Deletion of ylbK-2 (deletion of amino acids 4-246; leaving amino acids 1-3 and 247-260) was 
verified via PCR genotyping using oPEB472/473. 
PEB433 (ΔyneA::erm): PY79 was transformed using genomic DNA from PEB 432. 
Replacement of yneA with the erm cassette was verified via PCR genotyping using 
oPEB492/493. 
PEB436 (ΔylbL, ΔyneA::erm): PEB433 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB99. Deletion of ylbL was verified via PCR genotyping using oPEB481/482. 
PEB439 (ΔyneA::loxP): PEB433 was transformed with pDR244, which was then evicted. 
PEB441 (ΔylbL, ΔyneA::loxP): PEB436 was transformed with pDR244, which was then evicted. 
PEB461 (Δcrh∷erm): PY79 was transformed using genomic DNA from PEB 449. Replacement 
of crh with the erm cassette was verified via PCR genotyping using oPEB780/781. 
PEB463 (Δlgt∷erm): PY79 was transformed using genomic DNA from PEB 450. Replacement 
of lgt with the erm cassette was verified via PCR genotyping using oPEB780/781. 
PEB465 (Δcrh∷erm): PY79 was transformed using genomic DNA from PEB 449. Replacement 
of crh with the erm cassette was verified via PCR genotyping using oPEB782/783. 
PEB467 (ΔsdaAB∷erm): PY79 was transformed using genomic DNA from PEB 452. 
Replacement of sdaAB with the erm cassette was verified via PCR genotyping using 
oPEB788/789. 
PEB469 (ΔydzU∷erm): PY79 was transformed using genomic DNA from PEB 453. 
Replacement of ydzU with the erm cassette was verified via PCR genotyping using 
oPEB790/791. 
136 
 
PEB471 (ΔradA∷erm): PY79 was transformed using genomic DNA from PEB 454. 
Replacement of radA with the erm cassette was verified via PCR genotyping using 
oPEB792/793. 
PEB473 (ΔcymR∷erm): PY79 was transformed using genomic DNA from PEB 455. 
Replacement of cymR with the erm cassette was verified via PCR genotyping using 
oPEB794/795. 
PEB475 (ΔywrC∷erm): PY79 was transformed using genomic DNA from PEB 456. 
Replacement of ywrC with the erm cassette was verified via PCR genotyping using 
oPEB796/797. 
PEB478 (ΔrecG∷erm): PY79 was transformed using genomic DNA from PEB 477. 
Replacement of recG with the erm cassette was verified via PCR genotyping using 
oPEB786/787. 
PEB482 (ΔwalH): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB174. 
Deletion of walH was verified via PCR genotyping using oPEB744/745. 
PEB485 (ΔyycI): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB175. 
Deletion of yycI was verified via PCR genotyping using oPEB753/754. 
PEB488 (ΔwalJ): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB176. 
Deletion of walJ was verified via PCR genotyping using oPEB762/763. 
PEB491 (ΔruvB): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB179. 
Deletion of ruvB was verified via PCR genotyping using oPEB804/805. 
PEB493 (ΔripX): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB180. 
Deletion of ripX was verified via PCR genotyping using oPEB813/814. 
PEB533 (ΔylbL, amyE::Pxyl-ylbL-K279A): PEB324 was transformed with plasmid pPB173. 
PEB551 (ΔponA): PY79 was transformed using genomic DNA from PEB 535. Replacement of 
ponA with the erm cassette was verified via PCR genotyping using oPEB574/575. 
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PEB555 (ΔylbL, ΔctpA): PEB324 was edited using CRISPR/Cas9 genome editing with plasmid 
pPB121. Deletion of ctpA was verified via PCR genotyping using oPEB592/593. 
PEB557 (ΔylbL, ΔctpA, amyE::Pxyl-ylbL): PEB375 was edited using CRISPR/Cas9 genome 
editing with plasmid pPB121. Deletion of ctpA was verified via PCR genotyping using 
oPEB592/593. 
PEB559 (ΔyneA::loxP, ΔctpA): PEB439 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB121. Deletion of ctpA was verified via PCR genotyping using oPEB592/593. 
PEB561 (ΔylbL, ΔctpA, ΔyneA::loxP): PEB441 was edited using CRISPR/Cas9 genome editing 
with plasmid pPB121. Deletion of ctpA was verified via PCR genotyping using oPEB592/593. 
PEB585 (ΔuvrA, ΔyneA::loxP): PEB439 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB82. Deletion of uvrA was verified via PCR genotyping using oPEB423/424. 
PEB595 (ΔylbL, amyE::Pxyl-ctpA): PEB324 was transformed with plasmid pPB184. 
PEB597 (ΔylbL, amyE::Pxyl-ctpA-S297A): PEB324 was transformed with plasmid pPB185. 
PEB599 (ΔctpA, amyE::Pxyl-ctpA): PEB355 was transformed with plasmid pPB184. 
PEB601 (ΔctpA, amyE::Pxyl-ctpA-S297A): PEB355 was transformed with plasmid pPB185. 
PEB603 (ΔctpA, amyE::Pxyl-ctpA-K322A): PEB355 was transformed with plasmid pPB186. 
PEB605 (ΔctpA, amyE::Pxyl-ylbL): PEB355 was transformed with plasmid pPB108. 
PEB607 (ΔctpA, amyE::Pxyl-ylbL-S234A): PEB355 was transformed with plasmid pPB111. 
PEB619 (ΔylbL, ΔctpA, amyE::Pxyl-ctpA): PEB555 was transformed with plasmid pPB184. 
PEB621 (ΔylbL, ΔctpA, amyE::Pxyl-ctpA-S297A): PEB555 was transformed with plasmid 
pPB185. 
PEB623 (ΔylbL, ΔctpA, amyE::Pxyl-ylbL-S234A): PEB555 was transformed with plasmid 
pPB111. 
PEB677 (amyE::Phyp-yneA): PY79 was transformed with plasmid pPB194. 
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PEB681 (ΔylbL, amyE::Phyp-yneA): PEB324 was transformed with plasmid pPB194. 
PEB685 (ΔctpA, amyE::Phyp-yneA): PEB355 was transformed with plasmid pPB194. 
PEB689 (ΔylbL, ΔctpA, amyE::Phyp-yneA): PEB555 was transformed with plasmid pPB194. 
PEB778 (ΔfhuG): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB237. 
Deletion of fhuG was verified via PCR genotyping using oPEB918/919. 
PEB780 (ΔylbL, ΔctpA, ΔfhuG): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB237. Deletion of fhuG was verified via PCR genotyping using oPEB918/919. 
PEB782 (ΔyfkH): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB238. 
Deletion of yfkH was verified via PCR genotyping using oPEB927/928. 
PEB784 (ΔylbL, ΔctpA, ΔyfkH): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB238. Deletion of yfkH was verified via PCR genotyping using oPEB927/928. 
PEB786 (ΔltaSA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB239. 
Deletion of ltaSA was verified via PCR genotyping using oPEB936/937. 
PEB788 (ΔylbL, ΔctpA, ΔltaSA): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB239. Deletion of ltaSA was verified via PCR genotyping using oPEB936/937. 
PEB790 (ΔykgA): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB240. 
Deletion of ykgA was verified via PCR genotyping using oPEB945/946. 
PEB792 (ΔylbL, ΔctpA, ΔykgA): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB240. Deletion of ykgA was verified via PCR genotyping using oPEB945/946. 
PEB794 (ΔcgeE): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB241. 
Deletion of cgeE was verified via PCR genotyping using oPEB954/955. 
PEB796 (ΔylbL, ΔctpA, ΔcgeE): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB241. Deletion of cgeE was verified via PCR genotyping using oPEB954/955. 
PEB798 (ΔysnF): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB242. 
Deletion of ysnF was verified via PCR genotyping using oPEB963/964. 
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PEB800 (ΔylbL, ΔctpA, ΔysnF): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB242. Deletion of ysnF was verified via PCR genotyping using oPEB963/964. 
PEB802 (ΔlytG): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB243. 
Deletion of lytG was verified via PCR genotyping using oPEB972/973. 
PEB804 (ΔylbL, ΔctpA, ΔlytG): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB243. Deletion of lytG was verified via PCR genotyping using oPEB972/973. 
PEB806 (ΔyxaB): PY79 was edited using CRISPR/Cas9 genome editing with plasmid pPB244. 
Deletion of yxaB was verified via PCR genotyping using oPEB981/982. 
PEB808 (ΔylbL, ΔctpA, ΔyxaB): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB244. Deletion of yxaB was verified via PCR genotyping using oPEB981/982. 
PEB810 (ΔylbL, ΔctpA, ΔytmP): PEB555 was edited using CRISPR/Cas9 genome editing with 
plasmid pPB140. Deletion of ytmP was verified via PCR genotyping using oPEB644/645. 
Plasmid construction 
General cloning techniques 
Plasmids were assembled using Gibson assembly (84). Gibson assembly reactions were 
10 or 12 μL consisting of 1x Gibson assembly master mix (0.1 M Tris pH 8.0, 5% PEG-8000, 10 
mM MgCl2, 10 mM DTT, 0.2 mM dNTPs, 1 mM NAD+, 4 units/mL T5 exonuclease, 25 
units/mL Phusion DNA polymerase, 4,000 units/mL Taq DNA ligase) and 40-100 ng of each 
PCR product and incubated at 50°C for 60 minutes or 90 minutes for CRISPR/Cas9 editing 
plasmids. All PCR products were isolated via gel extraction from an agarose gel. Gibson 
assembly reactions were used to transform Top10 or MC1061 E. coli. 
Plasmids that were intermediate products of editing plasmids containing only the 
targeting spacer were generated by ligation of the proto-spacer into pPB41 as described 
previously (62, 82). Briefly, pPB41 was digested with BsaI-HF (NEB), and then treated with CIP 
(NEB). The digestion product was purified by gel extraction from an agarose gel. Proto-spacers 
were annealed in 1x annealing buffer (10 mM Tris, pH 8.0, 100 mM NaCl, 10 μM EDTA) at a 
concentration of 10 μM each by incubation in a 100°C heat block for 5 minutes, followed by 
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transferring to a beaker of water pre-heated to 100°C. The annealing reactions were allowed to 
cool slowly to room temperature in the beaker of water. The annealed proto-spacers were 
phosphorylated using T4 PNK (NEB). The phosphorylated proto-spacers were ligated to digested 
pPB41 using T4 DNA ligase (NEB). The resulting ligations were used to transform Top10 or 
MC1061 E. coli. Plasmids sequences were verified by Sanger sequencing using oPEB253. 
Individual plasmid construction 
pPB44: A proto-spacer targeting recR (oPEB241/242) was ligated to pPB41. 
pPB46: The upstream and downstream portions of the ΔrecR editing template were PCR 
amplified using oPEB286/244 and oPEB245/287, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB46 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔrecR editing plasmid. Clones were verified by Sanger sequencing with oPEB227 and 
oPEB253. 
pPB47: pBR322 was PCR amplified using oPEB267/268, and the spectinomycin resistance 
cassette was PCR amplified from pDR110 using oPEB269/270. The resulting PCR products 
were used in a Gibson assembly reaction generating a plasmid in which the tetracycline 
resistance cassette of pBR322 had been replaced with the spectinomycin resistance cassette of 
pDR110. 
pPB72: A proto-spacer targeting uvrA (oPEB417/418) was ligated to pPB41.  
pPB73: A proto-spacer targeting uvrB (oPEB426/427) was ligated to pPB41. 
pPB74: A proto-spacer targeting uvrC (oPEB437/438) was ligated to pPB41. 
pPB75: A proto-spacer targeting yprA (oPEB446/447) was ligated to pPB41. 
pPB76: A proto-spacer targeting yprB (oPEB455/456) was ligated to pPB41. 
pPB77: A proto-spacer targeting ylbK (oPEB466/467) was ligated to pPB41. 
pPB78: A proto-spacer targeting ylbL (oPEB475/476) was ligated to pPB41. 
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pPB81: A proto-spacer targeting sodA (oPEB504/505) was ligated to pPB41. 
pPB82: The upstream and downstream portions of the ΔuvrA editing template were PCR 
amplified using oPEB419/420 and oPEB421/422, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB72 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔuvrA editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB425. 
pPB83: The upstream and downstream portions of the ΔuvrB editing template were PCR 
amplified using oPEB428/429 and oPEB430/431, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB73 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔuvrB editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB434. 
pPB85: The upstream and downstream portions of the ΔuvrC editing template were PCR 
amplified using oPEB439/440 and oPEB441/442, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB74 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔuvrC editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB445. 
pPB86: The upstream and downstream portions of the ΔyprA editing template were PCR 
amplified using oPEB448/449 and oPEB450/451, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB75 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔyprA editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB454. 
pPB87: The upstream and downstream portions of the ΔyprB editing template were PCR 
amplified using oPEB457/458 and oPEB459/460, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB76 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
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generate a ΔyprB editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB463. 
pPB98: The upstream and downstream portions of the ΔylbK editing template were PCR 
amplified using oPEB468/469 and oPEB470/471, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB77 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔylbK editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB474. 
pPB99: The upstream and downstream portions of the ΔylbL editing template were PCR 
amplified using oPEB477/478 and oPEB479/480, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB78 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔylbL editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB483. 
pPB103: The upstream and downstream portions of the ΔsodA editing template were PCR 
amplified using oPEB506/507 and oPEB508/509, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB81 as the template. The pPB41 vector was PCR amplified 
using oPEB217/218. These four PCR products were used in a Gibson assembly reaction to 
generate a ΔsodA editing plasmid. Clones were verified by Sanger sequencing with oPEB227, 
oPEB253, and oPEB512. 
pPB107: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The open 
reading frame (ORF) of ylbK was PCR amplified using oPEB558/559. These four PCR products 
were used in a Gibson assembly reaction to generate a plasmid to integrate ylbK under the 
control of Pxyl at the amyE locus. Clones were verified by Sanger sequencing with oPEB345 and 
oPEB348. 
pPB108: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
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were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The ORF 
of ylbL was PCR amplified using oPEB560/561. These four PCR products were used in a Gibson 
assembly reaction to generate a plasmid to integrate ylbL under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
pPB111: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. Plasmid pPB47 was PCR amplified using oPEB116/117. 
The upstream portion of the ylbL ORF containing the S234A mutation was PCR amplified using 
oPEB560/567. The downstream portion of the ylbL ORF containing the S234A mutation was 
PCR amplified using oPEB566/561. These five PCR products were used in a Gibson assembly 
reaction to generate a plasmid to integrate ylbL-S234A under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
pPB113: A proto-spacer targeting queA (oPEB577/578) was ligated to pPB41. 
pPB114: A proto-spacer targeting ctpA (oPEB586/587) was ligated to pPB41. 
pPB115: A proto-spacer targeting ysoA (oPEB595/596) was ligated to pPB41. 
pPB116: A proto-spacer targeting ylmE (oPEB604/605) was ligated to pPB41. 
pPB117: A proto-spacer targeting sepF (oPEB613/614) was ligated to pPB41. 
pPB118: A proto-spacer targeting ylmG (oPEB618/619) was ligated to pPB41. 
pPB120: The upstream and downstream portions of the ΔqueA editing template were PCR 
amplified using oPEB579/580 and oPEB581/582, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB113 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔqueA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB585. 
pPB121: The upstream and downstream portions of the ΔctpA editing template were PCR 
amplified using oPEB588/589 and oPEB590/591, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB114 as the template. The pPB41 vector was PCR 
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amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔctpA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB594. 
pPB122: The upstream and downstream portions of the ΔysoA editing template were PCR 
amplified using oPEB597/598 and oPEB599/600, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB115 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔysoA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB603. 
pPB123: The upstream and downstream portions of the ΔylmE editing template were PCR 
amplified using oPEB606/607 and oPEB608/609, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB116 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔylmE editing plasmid. The Gibson assembly reaction was used to 
transform PY79. 
pPB124: The upstream and downstream portions of the ΔsepF editing template were PCR 
amplified using oPEB606/615 and oPEB616/609, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB117 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔsepF editing plasmid. The Gibson assembly reaction was used to 
transform PY79. 
pPB125: The upstream and downstream portions of the ΔylmG editing template were PCR 
amplified using oPEB606/620 and oPEB621/609, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB118 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔylmG editing plasmid. The Gibson assembly reaction was used to 
transform PY79. 
pPB130: A proto-spacer targeting ytmP (oPEB638/639) was ligated to pPB41. 
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pPB131: A proto-spacer targeting bcrC (oPEB647/648) was ligated to pPB41. 
pPB132: A proto-spacer targeting ecsA (oPEB656/657) was ligated to pPB41. 
pPB133: A proto-spacer targeting ecsB (oPEB665/666) was ligated to pPB41. 
pPB140: The upstream and downstream portions of the ΔytmP editing template were PCR 
amplified using oPEB640/641 and oPEB642/643, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB130 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔytmP editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB646. 
pPB141: The upstream and downstream portions of the ΔbcrC editing template were PCR 
amplified using oPEB649/650 and oPEB651/652, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB131 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔbcrC editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB655. 
pPB142: The upstream and downstream portions of the ΔecsA editing template were PCR 
amplified using oPEB658/659 and oPEB660/661, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB132 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔecsA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB664. 
pPB143: The upstream and downstream portions of the ΔecsB editing template were PCR 
amplified using oPEB667/668 and oPEB669/670, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB133 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔecsB editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB673. 
146 
 
pPB149: The upstream and downstream portions of the ΔylbK-2 (deletion of all but the codons 
for the first 3 and the last 14 amino acids) editing template were PCR amplified using 
oPEB468/709 and oPEB710/471, respectively. CRISPR/Cas9 was PCR amplified using 
oPEB232/234 and pPB77 as the template. The pPB41 vector was PCR amplified using 
oPEB217/218. These four PCR products were used in a Gibson assembly reaction to generate a 
ΔylbK-2 editing plasmid. Clones were verified by Sanger sequencing with oPEB227, oPEB253, 
and oPEB474. 
pPB154: A proto-spacer targeting walH (oPEB738/739) was ligated to pPB41. 
pPB155: A proto-spacer targeting yycI (oPEB747/748) was ligated to pPB41. 
pPB156: A proto-spacer targeting walJ (oPEB756/757) was ligated to pPB41. 
pPB157: The ORF coding for a.a. 36-341 of YlbL was PCR amplified using oPEB773/677. The 
plasmid pPB12 was PCR amplified using oPEB56/57. These two PCR products were used in a 
Gibson assembly to generate a plasmid for overexpression of a 10xHis-Smt3-YlbL(36-341) 
fusion protein in E. coli. Clones were verified via Sanger sequencing using oPEB527 and 
oPEB58. 
pPB173: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The 
upstream portion of the ylbL ORF containing the K279A mutation was PCR amplified using 
oPEB560/772. The downstream portion of the ylbL ORF containing the K279A mutation was 
PCR amplified using oPEB771/561. These five PCR products were used in a Gibson assembly 
reaction to generate a plasmid to integrate ylbL-K279A under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
pPB174: The upstream and downstream portions of the ΔwalH editing template were PCR 
amplified using oPEB740/741 and oPEB742/743, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB154 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
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reaction to generate a ΔwalH editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB746. 
pPB175: The upstream and downstream portions of the ΔyycI editing template were PCR 
amplified using oPEB749/750 and oPEB751/752, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB155 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔyycI editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB755. 
pPB176: The upstream and downstream portions of the ΔwalJ editing template were PCR 
amplified using oPEB758/759 and oPEB760/761, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB156 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔwalJ editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB764. 
pPB177: A proto-spacer targeting ruvB (oPEB798/799) was ligated to pPB41. 
pPB178: A proto-spacer targeting ripX (oPEB807/808) was ligated to pPB41. 
pPB179: The upstream and downstream portions of the ΔruvB editing template were PCR 
amplified using oPEB800/801 and oPEB802/803, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB177 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔruvB editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB806. 
pPB180: The upstream and downstream portions of the ΔripX editing template were PCR 
amplified using oPEB809/810 and oPEB811/812, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB178 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔripX editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB815. 
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pPB181: The ORF coding for a.a. 36-341 of YlbL was PCR amplified with primers 
oPEB773/677 using pPB111 as a template to incorporate the S234A mutation. The plasmid 
pPB12 was PCR amplified using oPEB56/57. These two PCR products were used in a Gibson 
assembly to generate a plasmid for overexpression of a 10xHis-Smt3-YlbL-S234A-(36-341) 
fusion protein in E. coli. Clones were verified via Sanger sequencing using oPEB527 and 
oPEB58. 
pPB184: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The ORF 
of ctpA was PCR amplified using oPEB817/818. These four PCR products were used in a Gibson 
assembly reaction to generate a plasmid to integrate ctpA under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
pPB185: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The 
upstream portion of the ctpA ORF containing the S297A mutation was PCR amplified using 
oPEB817/820. The downstream portion of the ctpA ORF containing the S297A mutation was 
PCR amplified using oPEB819/818. These five PCR products were used in a Gibson assembly 
reaction to generate a plasmid to integrate ctpA-S297A under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
pPB186: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. pPB47 was PCR amplified using oPEB116/117. The 
upstream portion of the ctpA ORF containing the K322A mutation was PCR amplified using 
oPEB817/822. The downstream portion of the ctpA ORF containing the K322A mutation was 
PCR amplified using oPEB821/818. These five PCR products were used in a Gibson assembly 
reaction to generate a plasmid to integrate ctpA-K322A under the control of Pxyl at the amyE 
locus. Clones were verified by Sanger sequencing with oPEB345 and oPEB348. 
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pPB194: pDR110 was amplified using primers oPEB3F/259, resulting in the conversion of 
promoter Pspac to Phyp. The yneA ORF was amplified using oPEB856/857. These two PCR 
products were used in a Gibson assembly reaction to generate a plasmid to integrate yneA under 
the control of Phyp at the amyE locus. Clones were verified by Sanger sequencing using oPEB866 
and oPEB867. 
pPB200: The pET28b vector was PCR amplified using oPEB835/57. The ORF of MBP was PCR 
amplified using oPEB838/839 with the IDT gBlock oPEB836 as a template. The Ulp1 ORF (a.a. 
403-621) was PCR amplified using oPEB840/841 with plasmid pPB13 as a template. These three 
PCR products were used in a Gibson assembly reaction to generate a plasmid for overexpression 
of the fusion protein MBP-Ulp1(403-621) in E. coli. Clones were verified by Sanger sequencing 
using oPEB527, oPEB58, and oPEB837. 
pPB203: The pET28b vector was PCR amplified using oPEB835/57. The CtpA ORF (coding for 
a.a. 38-466) was PCR amplified using oPEB831/832. These two PCR products and the IDT 
gBlock oPEB836 were used in a Gibson assembly reaction to generate a plasmid for 
overexpression of the fusion protein MBP-Smt3-CtpA(38-466) in E. coli. Clones were verified 
by Sanger sequencing using oPEB527, oPEB58, oPEB833, and oPEB837. 
pPB204: The ORF coding for a.a. 28-103 of YneA was PCR amplified using oPEB842/843. The 
plasmid pPB12 was PCR amplified using oPEB56/57. These two PCR products were used in a 
Gibson assembly to generate a plasmid for overexpression of a 10xHis-Smt3-YneA(28-103) 
fusion protein in E. coli. Clones were verified via Sanger sequencing using oPEB527 and 
oPEB58. 
pPB214: The pET28b-MBP-Smt3 vector was PCR amplified using oPEB56/57 using pPB203 as 
a template. The ctpA-S297A ORF (coding for a.a. 38-466) was PCR amplified using 
oPEB831/832 using pPB185 as a template. These two PCR products were used in a Gibson 
assembly reaction to generate a plasmid for overexpression of the fusion protein MBP-Smt3-
CtpA-S297A (38-466) in E. coli. Clones were verified by Sanger sequencing using oPEB527, 
oPEB58, and oPEB833. 
pPB227: A proto-spacer targeting fhuG (oPEB912/913) was ligated to pPB41. 
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pPB228: A proto-spacer targeting yfkH (oPEB921/922) was ligated to pPB41. 
pPB229: A proto-spacer targeting ltaSA (oPEB930/931) was ligated to pPB41. 
pPB230: A proto-spacer targeting ykgA (oPEB939/940) was ligated to pPB41. 
pPB231: A proto-spacer targeting cgeE (oPEB948/949) was ligated to pPB41. 
pPB232: A proto-spacer targeting ysnF (oPEB957/958) was ligated to pPB41. 
pPB233: A proto-spacer targeting lytG (oPEB966/967) was ligated to pPB41. 
pPB234: A proto-spacer targeting yxaB (oPEB975/976) was ligated to pPB41. 
pPB237: The upstream and downstream portions of the ΔfhuG editing template were PCR 
amplified using oPEB914/915 and oPEB916/917, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB227 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔfhuG editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB920. 
pPB238: The upstream and downstream portions of the ΔyfkH editing template were PCR 
amplified using oPEB923/924 and oPEB925/926, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB228 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔyfkH editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB929. 
pPB239: The upstream and downstream portions of the ΔltaSA editing template were PCR 
amplified using oPEB932/933 and oPEB934/935, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB229 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔltaSA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB938. 
151 
 
pPB240: The upstream and downstream portions of the ΔykgA editing template were PCR 
amplified using oPEB941/942 and oPEB943/944, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB230 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔykgA editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB947. 
pPB241: The upstream and downstream portions of the ΔcgeE editing template were PCR 
amplified using oPEB950/951 and oPEB952/953, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB231 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔcgeE editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB956. 
pPB242: The upstream and downstream portions of the ΔysnF editing template were PCR 
amplified using oPEB959/960 and oPEB961/962, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB232 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔysnF editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB965. 
pPB243: The upstream and downstream portions of the ΔlytG editing template were PCR 
amplified using oPEB968/969 and oPEB970/972, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB233 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ΔlytG editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB974. 
pPB244: The upstream and downstream portions of the ΔyxaB editing template were PCR 
amplified using oPEB977/978 and oPEB979/980, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB234 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
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reaction to generate a ΔyxaB editing plasmid. Clones were verified by Sanger sequencing with 
oPEB227, oPEB253, and oPEB983. 
pPB267: YneA was amplified with primers oPEB1034/1035 and the plasmid pUT18C was 
amplified using primers oPEB1017/1018. These two PCR products were used in a Gibson 
assembly reaction to generate a T18-YneA fusion for expression in BTH101 cells in a bacterial 
two-hybrid assay. Clones were selected on LB agar containing 100 μg/mL ampicillin and 0.2% 
glucose. Clones were verified via Sanger sequencing using oPEB1024 and 1025. 
pPB268: YneAΔN (a.a 28-103) was amplified with primers oPEB1036/1035 and the plasmid 
pUT18C was amplified using primers oPEB1017/1018. These two PCR products were used in a 
Gibson assembly reaction to generate a T18-YneAΔN (a.a 28-103) fusion for expression in 
BTH101 cells in a bacterial two-hybrid assay. Clones were selected on LB agar containing 100 
μg/mL ampicillin and 0.2% glucose. Clones were verified via Sanger sequencing using 
oPEB1024 and 1025. 
pPB270: YlbL-S234A was amplified with primers oPEB1039/1040 and using pPB111 as a 
template. The plasmid pKT25 was amplified with primers oPEB1014/1015. These two PCR 
products were used in a Gibson assembly reaction to generate a T25-YlbL-S234A fusion for 
expression in BTH101 cells in a bacterial two-hybrid assay. Clones were selected on LB agar 
containing 50 μg/mL kanamycin and 0.2% glucose. Clones were verified via Sanger sequencing 
using oPEB1021 and 1022. 
pPB271: CtpA-S297A was amplified with primers oPEB1041/1042 and using pPB185 as a 
template. The plasmid pKT25 was amplified with primers oPEB1014/1015. These two PCR 
products were used in a Gibson assembly reaction to generate a T25-CtpA-S297A fusion for 
expression in BTH101 cells in a bacterial two-hybrid assay. Clones were selected on LB agar 
containing 50 μg/mL kanamycin and 0.2% glucose. Clones were verified via Sanger sequencing 
using oPEB833, 1021, and 1022. 
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CHAPTER III
DdcA antagonizes a bacterial DNA damage checkpoint 
 
Abstract 
Bacteria coordinate DNA replication and cell division, ensuring a complete set of genetic 
material is passed onto the next generation. When bacteria encounter DNA damage, a cell cycle 
checkpoint is activated by expressing a cell division inhibitor. The prevailing model is that 
activation of the DNA damage response and protease mediated degradation of the inhibitor is 
sufficient to regulate the checkpoint process. Our recent genome-wide screens identified the gene 
ddcA as critical for surviving exposure to DNA damage. Similar to the checkpoint recovery 
proteases, the DNA damage sensitivity resulting from ddcA deletion depends on the checkpoint 
enforcement protein YneA. Using several genetic approaches, we show that DdcA function is 
distinct from the checkpoint recovery process. Deletion of ddcA resulted in sensitivity to yneA 
overexpression independent of YneA protein levels and stability, further supporting the 
conclusion that DdcA regulates YneA independent of proteolysis. Using a functional GFP-YneA 
fusion we found that DdcA prevents YneA-dependent cell elongation independent of YneA 
localization. Together, our results suggest that DdcA acts by helping to set a threshold of YneA 
required to establish the cell cycle checkpoint, uncovering a new regulatory step controlling 
activation of the DNA damage checkpoint in Bacillus subtilis.  
 
Introduction 
The logistics of the cell cycle are of fundamental importance in biology. All organisms 
need to control cell growth, DNA replication, and the process of cell division. In bacteria the 
                                                 
The contents of this chapter were published in Molecular Microbiology by Peter E. Burby, Zackary W. Simmons, 
and Lyle A. Simmons. ZWS helped with spot titer assays in figures 3.1, 3.2, 3.3, 3.5. I designed experiments and 
collected data. LAS and I analyzed data and wrote the manuscript. 
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initiation of DNA replication is coupled to growth rate and the cell cycle (1-4). Bacteria also 
regulate cell division in response to DNA replication status through the use of DNA damage 
checkpoints (5, 6). The models for the DNA damage response (SOS) were developed based on 
studies of Escherichia coli and subsequently extended to other bacteria. In these models, DNA 
damage results in perturbations to DNA replication and the accumulation of ssDNA (7). RecA is 
loaded onto ssDNA (8-12), and the resulting RecA/ssDNA nucleoprotein filament induces the 
SOS response by activating auto-cleavage of the transcriptional repressor LexA (13). LexA 
inactivation results in increased transcription of genes involved in DNA repair and the DNA 
damage checkpoint (14-18). The DNA damage checkpoint is established by relieving the LexA-
dependent repression of a cell division inhibitor that enforces the checkpoint by blocking cell 
division (19-22). Once the checkpoint is established, the delay in cytokinesis provides the cell 
with enough time to repair and complete DNA replication, thereby ensuring a complete and 
accurate copy of the chromosome is segregated to both daughter cells. Over several decades of 
study, this overarching model has been consistently demonstrated among bacteria that contain a 
RecA and LexA-dependent DNA damage checkpoint mechanism (5, 23). 
Where the DNA damage response varies between bacteria is in the process that enforces 
and alleviates the checkpoint. In E. coli and closely related Gram-negative bacteria, the 
checkpoint is enforced by SulA, which is a cytoplasmic protein that acts by directly inhibiting 
formation of the FtsZ proto-filament blocking cell division (20, 24-27). In many other bacteria 
the checkpoint is enforced by a small membrane binding protein (21, 28-31). In Caulobacter 
crescentus, the small membrane proteins SidA and DidA inhibit cell division through direct 
interactions with components of the essential cell division complex known as the divisome (30, 
31). In other bacteria the exact mechanism of checkpoint enforcement remains unclear. In the 
Gram-positive bacterium Bacillus subtilis, the checkpoint enforcement protein YneA inhibits cell 
division in response to DNA damage (21). YneA is a small protein containing a transmembrane 
domain as well as a LysM domain (22). A previous study found that several amino acids on one 
side of the transmembrane alpha helix are important for function, which led the authors to 
speculate that YneA may also interact with a component of the divisome (22). The same study 
also suggested full length YneA is the active form, and that the transmembrane domain alone is 
not sufficient for activity (22). Although YneA is clearly involved in cell division inhibition, the 
role of this checkpoint in ensuring that daughter cells each receive an intact copy of the genome 
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has not yet been firmly established, and the mechanism by which YneA enforces the checkpoint 
is still unknown. 
The mechanism of relieving the DNA damage checkpoint has only been identified in two 
bacterial species, E. coli and B. subtilis. Despite the checkpoint mechanisms functioning in 
different cellular compartments, the strategy for checkpoint recovery is remarkably similar 
between these two organisms. In E. coli, Lon protease is the major protease responsible for 
degrading SulA (32-34), and the protease ClpYQ appears to play a secondary role (35-37). In B. 
subtilis, there are two proteases YlbL, which we rename here to DdcP (DNA damage checkpoint 
recovery protease) and CtpA that degrade YneA (38). In the case of DdcP and CtpA, the former 
seems to be the primary protease in minimal media; however, during chronic exposure to DNA 
damage in rich media both proteases are important and they can functionally replace each other 
when overexpressed (38). DdcP and CtpA are not regulated by DNA damage (38), suggesting 
that the proteases act as a buffer to YneA accumulation helping to set the threshold for 
checkpoint activation. Thus, in order for the checkpoint to be enforced both proteases must be 
saturated. Following repair of damaged DNA, LexA represses expression of YneA, and the 
remaining YneA is cleared by DdcP and CtpA, allowing cell division to proceed (38). 
Although the DNA damage checkpoint in bacteria is well understood, it is becoming 
increasingly clear that establishing the checkpoint is more complex than what earlier models 
suggest. Work from Goranov and co-workers demonstrated that the initiation protein and 
transcription factor DnaA regulates ftsL levels in response to DNA replication perturbations, 
which contributes to cell filamentation (39). Further, our recent report identified several genes 
not previously implicated in genome maintenance or cell cycle control that are critical for 
surviving chronic exposure to a broad spectrum of DNA damage (38). We identified genes 
involved in cell division and cell wall synthesis as well as genes of unknown function that 
rendered the deletion mutants sensitive to DNA damage (38). To understand how the DNA 
damage response in bacteria is regulated, we investigated the contribution of one of the 
unstudied genes ddcA (formerly ysoA, see below) in the DNA damage response. We report here 
that DdcA antagonizes YneA action, functioning to help set a threshold of DNA damage 
required for checkpoint activation. 
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Results 
Deletion of ddcA (ysoA) results in sensitivity to DNA damage 
We recently published a set of genome wide screens using three distinct classes of DNA 
damaging agents, uncovering many genes that have not been previously implicated in the DNA 
damage response or DNA repair (38). One gene that conferred a sensitive phenotype to all three 
types of DNA damage tested was ysoA, which we rename here to DNA damage checkpoint 
antagonist (ddcA). DdcA is a protein that is predicted to have three tetratrichopeptide repeats 
(Fig 3.1A), which are often involved in protein-protein interactions, protein complex formation, 
and virulence mechanisms in bacteria (40). In order to better understand the mechanism of the 
DNA damage response in B. subtilis, we investigated the contribution of DdcA. To begin, we 
tested the sensitivity of the ddcA deletion to DNA damage. Deletion of ddcA resulted in 
sensitivity to mitomycin C (MMC), an agent that causes DNA crosslinks and bulky adducts (41, 
42), and phleomycin a peptide that forms double and single strand DNA breaks (43, 44). We 
found that expression of Pxyl-ddcA from an ectopic locus (amyE) was sufficient to complement 
deletion of ddcA with or without inducing expression using xylose (Fig 3.1B). We conclude that 
deletion of ddcA results in a bona-fide sensitivity to DNA damage. 
DNA damage sensitivity of ddcA deletion is dependent on yneA.  
We asked how DdcA functions in the DNA damage response. Our observation that a 
ddcA deletion allele results in sensitivity to several DNA damaging agents is similar to the result 
of deleting the checkpoint recovery proteases (38). Our prior study (38) showed that DNA 
damage phenotypes in checkpoint recovery protease mutants depend on the checkpoint 
enforcement protein, YneA, which is likely the result of aberrant activation of the checkpoint in 
the absence of YneA degradation. We asked whether deletion of yneA could rescue DNA 
damage sensitivity resulting from ddcA deletion. Indeed, deletion of yneA in the ddcA deletion 
background rescued sensitivity to MMC (Fig 3.2).  
We also tested for a genetic interaction with nucleotide excision repair, reasoning that the 
absence of nucleotide excision repair would result in increased yneA expression and increased 
sensitivity in the ddcA deletion. Indeed, deletion of uvrAB, genes coding for components of 
nucleotide excision repair (45), resulted in hypersensitivity to MMC (Fig 3.2). These data, 
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together with the initial observation of general DNA damage sensitivity and suppression of the 
sensitivity with loss of yneA function suggests that DdcA participates in regulating the DNA 
damage checkpoint protein YneA.  
DdcA functions independent of DNA damage checkpoint recovery proteases 
Based on the observation that sensitivity to DNA damage in a ΔddcA mutant was rescued 
by deletion of yneA, similar to our observations with the checkpoint recovery proteases (38), we 
hypothesized that DdcA could function within the checkpoint recovery process. For example, 
DdcA could affect CtpA and/or DdcP activity. To test this idea, we generated double mutant 
strains of ΔddcA with ΔctpA or ΔddcP. If DdcA functions together with CtpA or DdcP we would 
expect that the double mutant would have the same phenotype as the single mutant. In contrast, 
we observed that deletion of ddcA in a ctpA or ddcP mutant resulted in increased sensitivity to 
MMC (Fig 3.3A). These results support the hypothesis that DdcA does not function with the 
proteases in checkpoint recovery. To test this idea further, we determined the effect of deletion 
of ddcA in a ΔddcP, ΔctpA double mutant on MMC sensitivity. We found that deletion of ddcA 
resulted in increased MMC sensitivity relative to the double protease mutants (Fig 3.3B), 
suggesting that DdcA functions independently of both DdcP and CtpA. We then asked if yneA 
was responsible for the phenotype of ΔddcA in the absence of the checkpoint recovery proteases. 
Strikingly, we found that the sensitivity of the triple mutant was mostly dependent on yneA, but 
at elevated concentrations of MMC, there was a slight but reproducible difference when ddcA 
was deleted in the ΔddcP, ΔctpA, ΔyneA∷loxP mutant background (Fig 3.3B). Taken together, 
these data suggest that DdcA regulation of the checkpoint is independent of the recovery 
proteases. Further, because the ddcA phenotype is dependent on yneA we suggest that DdcA 
negatively regulates the checkpoint enforcement protein YneA. 
In our previous study we found that the checkpoint recovery proteases could substitute 
for each other (38). Therefore to more firmly establish when DdcA regulates the checkpoint we 
asked if DdcA could replace the checkpoint recovery proteases or if the proteases could function 
in place of DdcA. To test this idea, we overexpressed ddcP and ctpA in a ΔddcA mutant and 
found that neither protease could rescue a ddcA deletion phenotype (Fig 3.4A). We also found 
that expression of ddcA in the double protease mutant could not rescue the MMC sensitive 
phenotype (Fig 3.4B). Further, expression of ddcP or ctpA were each able to partially 
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complement the phenotype of the triple mutant, but expression of ddcA had no effect at higher 
concentrations of MMC (Fig 3.4B). As a control, we verified that overexpression of ddcA using 
high levels of xylose (0.5% xylose) could complement a ΔddcA mutant (Fig 3.5). We also found 
that at lower concentrations of MMC, expression of ddcA could rescue the ddcA deficiency of 
the triple mutant resulting in a phenotype indistinguishable from the double protease mutant (Fig 
3.4C). Given that DdcA cannot substitute for DdcP and CtpA, we hypothesized that DdcA would 
not affect YneA protein levels following DNA damage. We tested this by monitoring YneA 
protein levels following MMC treatment and after recovering from MMC treatment for two 
hours. Deletion of ddcA alone did not result in a detectable difference in YneA protein levels 
compared to WT (Fig 3.6). Further, deletion of ddcA in the double protease mutant also did not 
result in an increase in YneA protein levels relative to the double protease mutant with ddcA 
intact (Fig 3.6). With these data we conclude that DdcA does not regulate YneA protein 
abundance. 
ddcA deletion results in sensitivity to yneA overexpression independent of YneA stability 
Prior work established that overexpression of yneA resulted in growth inhibition (21, 22). 
Previously, we demonstrated that the double checkpoint recovery protease mutant was 
considerably more sensitive than the WT strain or the single checkpoint protease mutants to yneA 
overexpression (38). Given that treatment with DNA damage has cellular consequences in 
addition to expression of yneA, we wanted to test whether overexpression of yneA was sufficient 
for enhanced growth inhibition in the absence of ddcA. Indeed, we found that the ΔddcA mutant 
was more sensitive to yneA overexpression than WT (Fig 3.7A), and that deletion of ddcA in the 
double protease mutant background resulted in even greater sensitivity to yneA overexpression 
than the double mutant or each single mutant (Fig 3.7A) (38). Therefore, we asked whether 
YneA protein levels changed under these conditions, and again there was no detectable 
difference when ddcA was deleted alone or in combination with the double protease mutant (Fig 
3.7B). We also considered the possibility that DdcA could affect the stability of YneA rather 
than the overall amount. To test this idea, we performed a translation shut-off experiment and 
monitored YneA stability over time. We induced expression of yneA in the double protease 
mutant with and without ddcA and blocked translation. We found that YneA protein abundance 
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decreased at a similar rate regardless of whether ddcA was present (Fig 3.7C). We conclude that 
DdcA negatively regulates YneA independent of protein stability.  
DdcA is an intracellular protein and DdcP and CtpA are membrane anchored with 
extracellular protease domains 
The observation that DdcA and the checkpoint recovery proteases have distinct functions 
led us to ask where these proteins are located within the cell to determine if there are spatial 
constraints on their regulation of the DNA damage checkpoint. YneA is a membrane protein 
with the majority of the protein located extracellularly (22). We hypothesized that proteases 
DdcP and CtpA should be similarly localized since YneA is a direct substrate (38). We used the 
transmembrane prediction software TMHMM (46) and found that both DdcP and CtpA were 
predicted to have an N-terminal transmembrane domain, as reported previously (47). We tested 
this prediction directly using a subcellular fractionation assay (48). We found that DdcP and 
CtpA were present predominantly in the membrane fraction (Fig 3.8A). DdcP is predicted to 
have a signal peptide cleavage site (47), however, we did not detect DdcP in the media (Fig 
3.8A), suggesting that DdcP is membrane anchored and not secreted. The membrane topology of 
DdcP and CtpA could put the protease domains inside or outside of the cell (Fig 3.8B). To 
determine their location we used a protease sensitivity assay (Fig 3.8B) (49). Cells were treated 
with lysozyme, followed by incubation with proteinase K. We found that DdcP and CtpA were 
digested by proteinase K, but that the intracellular protein DnaN was not (Fig 3.8C). In control 
reactions we added Triton X-100 to disrupt the plasma membrane, which rendered all three 
proteins susceptible to proteinase K (Fig 3.8C). To verify that the N-terminal transmembrane 
domain is required for DdcP and CtpA to be extracellular we created N-terminal truncations (Fig 
3.8D) and repeated the proteinase K sensitivity assay. With these variants, DdcP and CtpA 
should be locked inside the cell, and indeed, both N-terminal truncations were now resistant to 
proteinase K similar to DnaN (Fig 3.8E). We conclude that DdcP and CtpA are tethered to the 
plasma membrane through N-terminal transmembrane domains and their protease domains are 
extracellular (Fig 3.8B, left panel). 
YneA has a transmembrane domain and has previously been shown to be localized to the 
plasma membrane (22), and we now show that DdcP and CtpA are membrane anchored as well. 
To better understand how DdcA limits YneA activity, we asked where DdcA is located. We were 
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unable to find DdcA detected in any previous proteomic experiments that interrogated cytosolic 
or extracellular proteins (50-52). Also, the secretome of B. subtilis was analyzed using 
bioinformatics and did not report DdcA as a secreted protein (47). Therefore, we used several 
programs to predict the subcellular location of DdcA (46, 53-55), all of which suggested that 
DdcA is cytosolic.  
In order to experimentally determine the location of DdcA, we generated GFP fusions to 
the N- and C-termini of DdcA. We tested whether GFP-DdcA and DdcA-GFP were functional 
by assaying for the ability to complement a ddcA deletion. We found that GFP-DdcA was able to 
complement a ddcA deletion in the presence or absence of xylose for induced expression (Fig 
3.9A), similar to that observed with untagged DdcA (Fig 3.1). In contrast, DdcA-GFP was 
partially functional, because complete complementation was only observed when expression of 
ddcA-gfp was induced using xylose, but not in the absence of xylose (Fig 3.9A). As a control we 
asked if we could detect free GFP via Western blotting using GFP specific antiserum. We did not 
detect the fusion proteins in lysates if expression was not induced using xylose. We found that 
both DdcA fusions were detectable at their approximate molecular weight of 67.6 kDa when 
induced with 0.05% xylose (Fig 3.9B), though we did see that the C-terminal fusion had a slight 
increase in mobility (Figure 3.9B, arrowhead). Importantly, we did not detect a significant band 
near 25 kDa, the approximate size of GFP (Fig 3.9B), suggesting that GFP is not cleaved from 
DdcA. We did detect a very faint proteolytic fragment (Fig 3.9B, arrow) that seemed to occur 
during the lysis procedure. After establishing the functionality and integrity of the GFP-DdcA 
fusion we chose to visualize DdcA localization via fluorescence microscopy.  
To compare the background fluorescence of B. subtilis cells, we imaged WT (PY79) cells 
under the same conditions as the GFP-DdcA fusion strain. We found a low level of background 
fluorescence in WT cells, and when a line scan of fluorescence intensity through a cell was 
plotted there was a very slight increase in signal intensity in the span between the fluorescent 
membrane peaks (Fig 3.9C). The GFP-DdcA fusion was detectable throughout the cell at very 
low levels in the absence of xylose induction, with the intensity being slightly greater than WT 
cells (Fig 3.9C). We then imaged cells under conditions in which gfp-ddcA expression was 
induced with 0.05% xylose. This experiment shows that GFP-DdcA was found throughout the 
cytosol, and the scan of fluorescence intensity was significantly greater than WT (Fig 3.9C). We 
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observed that the partially functional DdcA-GFP fusion was also present diffusely throughout the 
cytosol (Fig 3.6A). Finally, we tested DdcA localization using subcellular fractionation. We 
found that GFP-DdcA was detectable in the membrane and cytosolic fractions (Fig 3.9D), and 
similar results were obtained with DdcA-GFP (Fig 3.10B). As controls, we found that DdcP was 
found in the membrane fraction and not the cytosolic fraction (Fig 3.9D), and a cross-reacting 
protein detected by our GFP antiserum was found in the cytosol and not the membrane fractions 
(Fig 3.9D). Taken together, DdcA appears to be an intracellular protein that is primarily located 
in the cytosol with some molecules localized to the membrane. Importantly we now show that 
DdcA and the checkpoint recovery proteases are separated in space by the plasma membrane, 
demonstrating that YneA regulators are present in the cytosol (DdcA) and in the extracellular 
space (DdcP and CtpA). Further, the demonstration of DdcA occupying a different subcellular 
location from DdcP and CtpA explains their distinct roles in regulating YneA.  
YneA-dependent cell elongation is enhanced in cells lacking DdcA and the recovery 
proteases.  
DdcA appears to regulate YneA activity independently of protein abundance and 
stability. We initially hypothesized that DdcA could interact directly with YneA to inhibit its 
activity. To test this hypothesis, we assayed for a protein-protein interaction using a bacterial 
two-hybrid, but did not detect an interaction (Fig 3.11). We then asked whether DdcA affected 
the localization of YneA, hypothesizing that DdcA could prevent YneA from reaching the 
plasma membrane. To address this question, we built a strain in which GFP was fused to the N-
terminus of YneA, and placed gfp-yneA under the control of the xylose-inducible promoter Pxyl. 
We expressed both YneA and GFP-YneA in strains lacking ddcA, the checkpoint recovery 
proteases, or the triple mutant and found that GFP-YneA is able to inhibit growth to a similar 
extent as YneA (Fig 3.12A), suggesting that the GFP fusion is functional. We visualized GFP-
YneA following induction with 0.1% xylose for 30 minutes. We found that GFP-YneA localized 
to the mid-cell, while also demonstrating diffuse intracellular fluorescence (Fig 3.12B), which 
we suggest is free GFP generated by the checkpoint recovery proteases after YneA cleavage. 
Deletion of ddcA alone did not affect GFP-YneA localization, with both WT and ΔddcA strains 
having similar mid-cell localization frequencies (Fig 3.12B). The absence of both checkpoint 
recovery proteases resulted in puncta throughout the plasma membrane (Fig 3.12B).  
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Intriguingly, deletion of ddcA in addition to the checkpoint recovery proteases resulted in 
severe cell elongation, however, GFP-YneA localization was not affected (Fig 3.12B). The 
difference in cell length was quantified by measuring the cell length of at least 600 cells 
following growth in the presence of 0.1% xylose for 30 minutes. The cell length distributions of 
strains lacking ddcA or ddcP and ctpA were similar to the WT control (Fig 3.12C). The 
distribution for the strain lacking ddcA, ddcP, and ctpA had a significant skew to the right 
indicating greater cell lengths (Fig 3.12C). The percentage of cells greater than 5 μm in length 
was approximately 22% for the triple mutant and significantly greater than the other three strains 
in which approximately 1% of cells were greater than 5 μm (Table 3.1). As a control, we 
determined the cell length distributions prior to xylose addition and found all four strains to have 
similar cell length distributions in the absence of xylose (Fig 3.12C). With these data, we 
conclude that DdcA prevents YneA from inhibiting cell division. 
 
Discussion 
A model for DNA damage checkpoint activation and recovery  
The DNA damage checkpoint in bacteria was discovered through seminal work using E. 
coli as a model organism (7). An underlying assumption in the models is that the input signal of 
RecA coated ssDNA and the affinity of LexA for its binding site is sufficient to control the rate 
of cell division in response to DNA damage. A finding that the initiator protein, DnaA, controls 
the transcription of ftsL, and as a result the rate of cell division, in response to replication stress, 
gave a hint that coordination of cell division and DNA replication may be more complex (39). 
Here, we elaborate on the complexity of regulating cell division in response to DNA damage by 
uncovering a DNA damage checkpoint antagonist, DdcA (Fig 3.13). In response to DNA 
damage, the repressor LexA is inactivated, which results in expression of yneA. Accumulation of 
YneA must saturate two proteases, DdcP and CtpA, and overcome DdcA-dependent inhibition in 
order to block cell division. We previously reported that DdcP and CtpA are not induced by 
DNA damage (38), and a previous study reported that transcripts of ddcA, ddcP, and ctpA are not 
induced by DNA damage or inhibition of DNA replication (18). Thus, we model all three 
proteins functioning to set a threshold of YneA required for checkpoint activation with DdcA 
located in the cytosol and DdcP and CtpA protease domains located extracellularly. These 
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regulators require that YneA expression overcomes a cytosolic regulator and then two 
extracellular regulators before the checkpoint can be activated. After the checkpoint is 
established, DNA repair occurs and the integrity of the DNA is restored, the SOS response is 
turned off, LexA represses yneA expression, and the checkpoint recovery proteases degrade the 
remaining YneA. The genetic experiments attempting to substitute the checkpoint proteases for 
DdcA and vice versa strongly suggest that DdcA does not function in the checkpoint recovery 
process (Fig 3.4). Together, our results uncover a unique strategy in regulating a bacterial DNA 
damage checkpoint by identifying a proteolysis independent mechanism of setting a threshold for 
DNA damage checkpoint activation. 
How does DdcA inhibit YneA? 
Our results are most supportive of DdcA acting as an antagonist to YneA, rather than 
functioning in checkpoint recovery. Two lines of evidence support this model. First, DdcA does 
not affect YneA protein levels, stability, or localization (Fig 3.6 & 3.7). Second, if DdcA was 
involved in checkpoint recovery, we would predict that expression of one of the checkpoint 
proteases would be able to compensate for deletion of ddcA. Instead, we found that the 
checkpoint recovery proteases and DdcA cannot replace each other (Fig 3.4). As a result, we 
hypothesized that DdcA acts by preventing YneA from accessing its target. We tested for an 
interaction between YneA and DdcA using a bacterial two-hybrid assay and we were unable to 
identify an interaction with full length or a cytoplasmic “locked” YneA mutant lacking its 
transmembrane domain (Fig 3.11). We also ruled out the hypothesis that DdcA affects the 
subcellular localization of YneA using a GFP-YneA fusion, which had similar localization 
patterns with and without ddcA (Fig 3.12B). Taken together, all these results support a model 
where DdcA prevents YneA from inhibiting cell division, which could occur through preventing 
access to the target of YneA or through an indirect mechanism. 
The YneA target that results in the inhibition of cell division is unknown. YneA is a 
membrane bound cell division inhibitor. This class of inhibitor in bacteria is typified as being a 
small protein that contains an N-terminal transmembrane domain, and they have been identified 
in several species (21, 28-31, 56). In Caulobacter crescentus, the cell division inhibitors SidA 
and DidA inhibit the activity of FtsW/N, which are components of the divisome. A recent study 
in Staphylococcus aureus identified a small membrane division inhibitor, SosA, and its target 
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appears to be PBP1 (56), which is involved in peptidoglycan synthesis at the septum (57, 58). It 
is tempting to speculate that YneA could target an essential component of the cell division 
machinery, in particular because previous work found a conserved face of the transmembrane 
domain that was required for activity (22). Prior studies of C. crescentus and S. aureus were able 
to detect interactions between the cell division inhibitors and their targets using the bacterial two-
hybrid assay (30, 31, 56). We reasoned that we might be able to identify an interacting partner of 
YneA or DdcA using this approach. We used DdcA and YneA in a bacterial two-hybrid assay 
using several proteins involved in cell division and cell wall synthesis, many of which had 
phenotypes in our previous Tn-seq genetic screens (38), but we were unable to identify a positive 
interaction (data not shown). Still, there are fundamental differences between YneA and other 
membrane bound cell division inhibitors. YneA has two major predicted features: an N-terminal 
transmembrane domain and a C-terminal LysM domain, and both have been found to be required 
for full activity (22). The other cell division inhibitors SidA, DidA, and SosA do not have a 
LysM domain (30, 31, 56). LysM domains bind to peptidoglycan (PG) and many proteins 
containing LysM domains have cell wall hydrolase activity (59). Thus, another possibility is that 
YneA acts directly on the cell wall to inhibit cell division instead of or in addition to targeting  a 
membrane protein. 
Intriguingly, the cell division inhibitor of Mycobacterium tuberculosis, Rv2719c, also 
contains a LysM domain and was shown to have cell wall hydrolase activity in vitro (28). The 
localization of GFP-YneA is also similar to previous reports of fluorescent vancomycin labeling 
of nascent peptidoglycan synthesis (Fig 3.12B) (60, 61). The difficulty with the model of 
targeting cell wall synthesis directly is that it is not clear how DdcA would prevent YneA 
activity given that these proteins are separated by the plasma membrane. One explanation is that 
DdcA directly or indirectly affects the folding of YneA as it is transported across the membrane, 
resulting in a form of YneA that is not competent for PG binding. DdcA contains a TPR domain 
and proteins containing TPR domains have been found to have chaperone activity and act as co-
chaperones (62). It is intriguing that ddcA is just upstream of the chaperone trigger factor (tig) in 
the B. subtilis genome, and this organization is conserved in some bacterial species.  
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Negative regulation of YneA occurs through three distinct mechanisms 
The checkpoint recovery proteases and DdcA utilize multiple strategies to inhibit YneA. 
Although both DdcP and CtpA degrade YneA, they are very different proteases. DdcP has a Lon 
peptidase domain and a PDZ domain, whereas CtpA has an S41 peptidase domain and a PDZ 
domain. The PDZ domains of DdcP and CtpA have different functions in vivo and show 
homology to different classes of PDZ domains found in proteases in E. coli (Fig 3.14, see 
supplemental results). Thus, it appears that the proteases utilize different strategies to degrade 
YneA. DdcA is unique, because it acts as an antagonist without affecting protein abundance, 
stability, or localization. Also, DdcA appears to function prior to checkpoint establishment and 
not in recovery, whereas the proteases perform both functions. Together, DdcA, DdcP, and CtpA  
provide a buffer to expression of YneA, thereby setting a threshold of YneA for checkpoint 
enforcement. 
The discovery of a specific DNA damage checkpoint antagonist brings the total known 
proteins to negatively regulate YneA to three, which begs the question: why isn’t a single protein 
sufficient? One explanation is that the process can be fine-tuned. By utilizing several proteins, 
the process has more nodes for regulation, which is advantageous at least for B. subtilis. A 
second explanation is that this strategy evolved in response to more efficient DNA repair. The 
SOS-regulon is highly conserved in bacteria and yet the checkpoint strategies vary significantly 
(23). If an organism evolves a more efficient DNA repair system in which DNA repair could be 
completed faster, the same level of checkpoint protein will no longer be required, because the 
checkpoint would delay cell division longer than necessary to complete DNA repair. This could 
be the explanation for the highly divergent nature of cell division inhibitors in bacteria as well as 
the explanation for the complex control over YneA found in B. subtilis. 
 
Materials and Methods 
Bacteriological and molecular methods 
All B. subtilis strains are derivatives of PY79 (63), and are listed in Table 3.2. 
Construction of individual strains is detailed in the supporting methods using double cross-over 
recombination or CRISPR/Cas9 genome editing as previously described (38, 64). B. subtilis 
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strains were grown in LB (10 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract) or S750 media [1x 
S750 salts (diluted from 10x S750 salts: 104.7g/L MOPS, 13.2 g/L, ammonium sulfate, 6.8 g/L 
monobasic potassium phosphate, pH 7.0 adjusted with potassium hydroxide), 1x metals (diluted 
from 100x metals: 0.2 M MgCl2, 70 mM CaCl2, 5 mM MnCl2, 0.1 mM ZnCl2, 100 μg/mL 
thiamine-HCl, 2 mM HCl, 0.5 mM FeCl3), 0.1% potassium glutamate, 40 μg/mL phenylalanine, 
40 μg/mL tryptophan] containing either 2% glucose or 1% arabinose as indicated in each 
method. Plasmids used in this study are listed in Table 3.3. Individual plasmids were constructed 
using Gibson assembly as described previously (38, 65). The details of plasmid construction are 
described in the supporting methods. Oligonucleotides used in this study are listed in Table 3.4 
and were obtained from Integrated DNA technologies (IDT). Antibiotics for selection in B. 
subtilis were used at the following concentrations: 100 μg/mL spectinomycin, 5 μg/mL 
chloramphenicol, and 0.5 μg/mL erythromycin. Antibiotics used for selection in Escherichia coli 
were used at the following concentrations: 100 μg/mL spectinomycin, 100 μg/mL ampicillin, and 
50 μg/mL kanamycin. Mitomycin C (Fisher bioreagents) and phleomycin (Sigma) were used at 
the concentrations indicated in the figures and legends. 
Spot titer assays 
Spot titer assays were performed as previously described (38). Briefly, B. subtilis strains 
were grown on an LB agar plate at 30°C overnight and a single colony was used to inoculate a 
liquid LB culture. The cultures were grown at 37°C to an OD600 between 0.5 and 1. Cultures 
were normalized to an OD600 = 0.5, and serial dilutions were spotted on to LB agar media 
containing the drugs as indicated in the figures. Plates were grown at 30°C overnight (16-20 
hours). All spot titer assays were performed at least twice. 
Western blotting 
Western blotting experiments for YneA were performed essentially as described (38). 
Briefly, for the MMC recovery assay, samples of an OD600 = 10 were harvested via 
centrifugation and washed twice with 1x PBS pH 7.4 and re-suspended in 400 μL of sonication 
buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 20% glycerol, 2x Roche protease inhibitors, and 5 
mM PMSF) and lysed via sonication. SDS sample buffer was added to 2x and samples (10 μL) 
were incubated at 100°C and separated using 10% SDS-PAGE (DnaN) or 16.5% Tris-Tricine 
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SDS-PAGE (YneA). Proteins were transferred to a nitrocellulose membrane using the BioRad 
transblot-turbo following the manufacturer’s instructions. Membranes were blocked in 5% milk 
in TBST for 1 hour at room temperature. Membranes were incubated with YneA antiserum at a 
1:3000 dilution in 2% milk in TBST for two hours at room temperature or at 4°C overnight. 
Membranes were washed three times with TBST for five minutes each and secondary antibodies 
(LiCor goat anti-Rabbit-680LT; 1:15000) were added and incubated for one hour at room 
temperature. Membranes were washed three times with TBST for five minutes each. Images of 
membranes were captured using the LiCor Odyssey. 
For overexpression of YneA, cultures of LB were inoculated at an OD600 = 0.05 and 
incubated at 30°C until an OD600 of about 0.2 (about 90 minutes). Xylose was added to 0.1% and 
cultures were incubated at 30°C for 2 hours. Samples of an OD600 = 25 were harvested and re-
suspended in 500 μL sonication buffer as above. All subsequent steps were performed as 
described above. 
For GFP-DdcA and DdcA-GFP, samples of an OD600 = 1 were harvested from LB + 
0.05% xylose cultures via centrifugation and washed twice with 1x PBS pH 7.4. Samples were 
re-suspended in 100 μL 1x SMM buffer (0.5 M sucrose, 0.02 M maleic acid, 0.02 M MgCl2, 
adjusted to pH 6.5) containing 1 mg/mL lysozyme and 2x Roche protease inhibitors. Samples 
were incubated at room temperature for one hour and SDS sample buffer was added to 1x and 
incubated at 100°C for 7 minutes. Samples (10 μL) were separated via 10% or 4-20% SDS-
PAGE. All subsequent steps were as described above, except GFP antisera (lot 1360-ex) was 
used at a 1:5000 dilution at 4°C overnight. 
YneA stability assay 
Cultures of LB were inoculated at an OD600 = 0.05 and incubated at 30°C until an OD600 
of about 0.2 (about 90 minutes). Xylose was added to 0.1% and cultures were incubated at 30°C 
for 2 hours. To stop translation, erythromycin was added to 50 μg/mL and samples (OD600 = 10) 
were taken at 0, 60, 120, and 180 minutes (the strains for this experiment contain the 
chloramphenicol resistant gene, cat, which prevents chloramphenicol from being used). Western 
blotting was performed as described above. 
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Subcellular fractionation 
Fractionation experiments were performed as described previously (48). A cell pellet 
equivalent to 1 mL OD600 = 1 was harvested via centrifugation (10,000 g for 5 minutes at room 
temperature), and washed with 250 μL 1x PBS. Protoplasts were generated by resuspension in 
100 μL 1x SMM buffer (0.5 M sucrose, 0.02 M maleic acid, 0.02 M MgCl2, adjusted to pH 6.5) 
containing 1 mg/mL lysozyme and 1x Roche protease inhibitors at room temperature for 2 hours. 
Protoplasts were pelleted via centrifugation: 5,000 g for 6 minutes at room temperature. 
Protoplasts were re-suspended in 100 μL TM buffer (20 mM Tris, pH 8.0, 5 mM MgCl2, 40 
units/mL DNase I (NEB), 200 μg/mL RNase A (Sigma), 0.5 mM CaCl2, and 1x Roche protease 
inhibitors) and left at room temperature for 30 minutes. The membrane fraction was pelleted via 
centrifugation: 20,800 g for 30 minutes at 4°C. The cytosolic fraction (supernatant) was 
transferred to a new tube and placed on ice, and the pellet was washed with 100 μL of TM buffer 
and pelleted via centrifugation as above. The supernatant was discarded and the pellet was re-
suspended in 120 μL of 1x SDS dye. SDS loading dye was added to 1x to the cytosolic fraction 
and 12 μL of each fraction were used for Western blot analysis. 
Culture supernatant protein precipitation 
Culture supernatants were concentrated by TCA precipitation as described previously 
with minor modifications (66). A culture was grown at 30°C until OD600 about 1, and the cells 
were pelleted via centrifugation: 7,000 g for 10 minutes at room temperature. The culture 
supernatant (30 mL) was filtered using a 0.22 μm filter and placed on ice. Proteins were 
precipitated by addition of 6 mL ice-cold 100% TCA (6.1N), and left on ice for 30 minutes. 
Precipitated proteins were pelleted via centrifugation: 18,000 rpm (Sorvall SS-34 rotor) for 30 
minutes at 4°C. Pellets were washed with 1 mL ice-cold acetone and pelleted again via 
centrifugation: 20,000 g for 15 minutes at 4°C. The supernatant was discarded, and the residual 
acetone was evaporated by placing tubes in 100°C heat block for 1-2 minutes. Protein pellets 
were re-suspended in 120 μL 6x SDS-loading dye and 12 μL were used in Western blot analysis. 
Proteinase K sensitivity assay 
Proteinase K sensitivity assays were performed similar to previous reports (49, 67). A 
cell pellet from 0.5 mL OD600 = 1 equivalent was harvested and washed as in “subcellular 
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fractionation.” Protoplasts were generated by resuspension in 36 μL 1x SMM buffer (0.5 M 
sucrose, 0.02 M maleic acid, 0.02 M MgCl2, adjusted to pH 6.5) containing 1 mg/mL lysozyme 
at room temperature for 1 hour. Either 9 μL of 1x SMM buffer or 0.5 mg/mL proteinase K 
(dissolved in 1x SMM buffer) was added (final proteinase K concentration of 100 μg/mL) and 
incubated at 37°C for the time indicated in the figures. Reactions were stopped by the addition of 
5 μL 50 mM PMSF (final concentration of 5 mM) and 25 μL 6x SDS-dye (final concentration of 
2x). For Western blot analysis, 12 μL were used. 
Microscopy 
Strains were grown on LB agar plates containing 5 μg/mL chloramphenicol at 30°C 
overnight. For GFP-DdcA and DdcA-GFP, LB agar plates were washed with S750 media 
containing 1% arabinose and cultures of S750 media containing 1% arabinose and 0.05% xylose 
were inoculated at an OD600 = 0.1 and incubated at 30°C until an OD600 of about 0.4. Samples 
were taken and incubated with 2 μg/mL FM4-64 for 5 minutes and transferred to pads of 1x 
Spizizen salts and 1% agarose. Images were captured with an Olympus BX61 microscope using 
250 ms and 1000 ms exposure times for FM4-64 (membranes) and GFP, respectively. The 
brightness and contrast were adjusted for FM4-64 images with adjustments applied to the entire 
image. Strains with GFP-YneA were grown on LB agar plates containing 5 μg/mL 
chloramphenicol overnight at 30°C. Plates were washed with S750 minimal media containing 1% 
arabinose and cultures started at an OD600 = 0.1. Cultures were grown at 30°C until an OD600 of 
about 0.3 and xylose was added to 0.1%. Cultures were grown for 30 minutes at 30°C and 
imaged as for GFP-DdcA with exposure times of 300 ms for FM4-64 and 500 ms for GFP. 
 
175 
 
Figures and Tables 
 
Figure 3.1 Deletion of ddcA (ysoA) results in sensitivity to DNA damage. (A) A schematic of 
the DdcA protein. DdcA is predicted to have 334 amino acids and 3 tetratrichopeptide repeats at 
its N-terminus. (B) A spot titer assay in which exponentially growing cultures of B. subtilis 
strains WT (PY79), ΔddcA (PEB357), and ΔddcA, amyE∷Pxyl-ddcA (PEB503) were spotted on 
the indicated media and incubated at 30°C overnight. 
 
Figure 3.2 DNA damage sensitivity of ddcA deletion is dependent on DNA damage 
checkpoint protein YneA and independent of nucleotide excision repair. A spot titer assay 
using B. subtilis strains WT (PY79), ΔddcA (PEB357), ΔuvrAB (PEB309), ΔyneA∷erm 
(PEB433), ΔddcA ΔyneA∷erm (PEB495), and ΔddcA ΔuvrAB (PEB497) spotted on the indicated 
media. 
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Figure 3.3 DdcA functions independent of the checkpoint recovery proteases. (A) Spot titer 
assay using B. subtilis strains WT (PY79), ΔddcA (PEB357), ΔddcP (PEB324), ΔddcA ΔddcP 
(PEB499), ΔctpA (PEB355), and ΔddcA ΔctpA (PEB579) spotted on the indicated media. (B) 
Spot titer assay using B. subtilis strains WT (PY79), ΔddcA (PEB357), ΔddcP ΔctpA (PEB555), 
ΔddcA ΔddcP ΔctpA (PEB639), ΔyneA∷loxP (PEB439), ΔddcA ΔyneA∷loxP (PEB587), ΔddcP 
ΔctpA ΔyneA∷loxP (PEB561), and ΔddcA ΔddcP ΔctpA ΔyneA∷loxP (PEB643) spotted on the 
indicated media. 
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Figure 3.4 DdcA cannot complement loss of checkpoint recovery proteases. (A) Spot titer 
assay using B. subtilis strains WT (PY79), ΔddcA (PEB357), ΔddcA amyE∷Pxyl-ddcP (PEB836), 
and ΔddcA amyE∷Pxyl-ctpA (PEB837) spotted on the indicated media. (B) Spot titer assay using 
B. subtilis strains WT (PY79), ΔddcP ΔctpA (PEB555), ΔddcP, ΔctpA, amyE∷Pxyl-ddcA 
(PEB838), ΔddcP, ΔctpA, amyE∷Pxyl-ddcP (PEB557), ΔddcA ΔddcP ΔctpA (PEB639), ΔddcP, 
ΔctpA, ΔddcA, amyE∷Pxyl-ddcA (PEB840), ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ddcP (PEB839), 
and ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ctpA (PEB841) spotted on the indicated media. (C) Spot 
titer assay using B. subtilis strains WT (PY79), ΔddcP ΔctpA (PEB555), ΔddcP, ΔctpA, 
amyE∷Pxyl-ddcA (PEB838), ΔddcA ΔddcP ΔctpA (PEB639), ΔddcP, ΔctpA, and ΔddcA, 
amyE∷Pxyl-ddcA (PEB840) spotted on the indicated media. 
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Figure 3.5 Deletion of ddcA can be complemented by ectopic expression using high levels of 
xylose. A Spot titer assay using WT (PY79), ΔddcA (PEB357), and ΔddcA amyE∷Pxyl-ddcA 
(PEB503) spotted on the indicated media and incubated at 30°C overnight. 
 
Figure 3.6 Deletion of ddcA does not increase YneA protein levels following MMC 
treatment and recovery. Western blotting using antisera against YneA (top panel) or DnaN 
(bottom panel) using whole cell extracts from WT (PY79), ΔddcA (PEB357), ΔddcP ΔctpA 
(PEB555), ΔddcA ΔddcP ΔctpA (PEB639) after a two hour treatment with 100 ng/mL MMC 
(lanes labeled “MMC”) or after recovering for two hours from MMC treatment (lanes labeled 
“2h Rec”). 
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Figure 3.7 Deletion of ddcA results in sensitivity to yneA overexpression independent of 
YneA stability. (A) Spot titer testing the effect of yneA overexpression. B. subtilis strains WT 
(PY79), amyE∷Pxyl-yneA (PEB846), ΔddcA amyE∷Pxyl-yneA (PEB848), ΔddcP, ΔctpA, 
amyE∷Pxyl-yneA (PEB850), and ΔddcA ΔddcP ΔctpA, amyE∷Pxyl-yneA (PEB852) were spotted 
on LB agar media containing increasing concentrations of xylose to induce yneA expression. (B) 
A Western blot using antisera against YneA (Upper panels), or DnaN lower panel using B. 
subtilis strains WT (PY79), amyE∷Pxyl-yneA (PEB846), ΔddcA amyE∷Pxyl-yneA (PEB848), 
ΔddcP, ΔctpA, amyE∷Pxyl-yneA (PEB850), and ΔddcA ΔddcP ΔctpA, amyE∷Pxyl-yneA (PEB852) 
after growing in the presence of 0.1% xylose for two hours. The panel on the right is an 
increased exposure to show the faint bands of WT and ΔddcA. (C) A Western blot using antisera 
against YneA (upper panel) or DnaN (lower panel). Cultures of ΔddcP, ΔctpA, amyE∷Pxyl-yneA 
(PEB850) and ΔddcA ΔddcP ΔctpA, amyE∷Pxyl-yneA (PEB852) were grown as in panel B, 
except at 0 hours erythromycin was added and samples were harvest every hour for three hours. 
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Figure 3.8 DdcP and CtpA are membrane anchored with extracellular protease domains. 
(A) Subcellular fractionation followed by Western blot analysis of WT (PY79) lysates using 
DdcP and CtpA antisera (M, molecular weight standard, WCL, whole cell lysates; Media, 
precipitated media proteins; Cyt, cytosolic fraction; Mem, membrane fraction). (B) Competing 
models for membrane topology of DdcP and CtpA tested using a proteinase K sensitivity assay. 
(C) Proteinase K sensitivity assay followed by Western blot detection of DdcP, CtpA, and DnaN 
with antiserum. Samples were treated with lysozyme to generate protoplasts and incubated with 
proteinase K for the indicated time (lanes 1-6), or the samples were incubated with lysozyme and 
Triton X-100 to disrupt the plasma membrane and incubated with proteinase K for the indicated 
time (lanes 7-9). (D) Schematics depicting the DdcPΔTM (left) and CtpAΔTM (right) in which 
the transmembrane domain was deleted. (E) Proteinase K sensitivity assay followed by Western 
blot analysis of strains expressing DdcPΔTM (left, PEB719) or CtpAΔTM (right, PEB772) 
performed as in panel C using a 2 hour incubation with proteinase K. 
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Figure 3.9 GFP-DdcA is an intracellular protein and is present in the cytosolic and 
membrane fractions. (A) Spot titer assay using B. subtilis strains WT (PY79), ΔddcA 
(PEB357), ΔddcA amyE∷Pxyl-gfp-ddcA (PEB854), and ΔddcA amyE∷Pxyl-ddcA-gfp (PEB856) 
spotted on the indicated media. (B) Western blot of cell extracts from B. subtilis strains WT 
(PY79), ΔddcA amyE∷Pxyl-gfp-ddcA (PEB854), and ΔddcA amyE∷Pxyl-ddcA-gfp (PEB856) using 
antiserum against GFP. The arrowhead highlights the slightly increased mobility of DdcA-GFP, 
and the asterisk denotes a cross-reacting species detected by the GFP antiserum. The smaller 
arrow indicates the expected migration of free GFP. (C) Micrographs from WT (PY79) and 
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ΔddcA amyE∷Pxyl-gfp-ddcA (PEB854) cultures grown in S750 minimal media containing 1% 
arabinose with (far left and right  panels) or without (middle panels) 0.05% xylose. Images in red 
are the membrane stain FM4-64, green are GFP fluorescence and the bottom images are a merge 
of FM4-64 and GFP fluorescence. The white lines through cells in the images are a 
representation of the line scans of fluorescence intensity generated in ImageJ and plotted below 
the micrographs. Scale bar is 5 μm. (D) Western blot of whole cell lysate (WCL), cytosolic 
fraction (Cyt), and membrane fraction (Mem) from ΔddcA amyE∷Pxyl-gfp-ddcA (PEB854) cell 
extracts using antisera against GFP (upper panel) or DdcP (lower panel). The asterisk denotes a 
cross-reacting species detected by the GFP antiserum. 
 
Figure 3.10 DdcA-GFP is intracellular and found in the cytosolic and membrane fractions. 
(A) Micrographs from WT (PY79) and ΔddcA amyE∷Pxyl-ddcA-gfp (PEB856) cultures grown in 
S750 minimal media containing 1% arabinose and 0.05% xylose. Images in red are the membrane 
stain FM4-64, green are GFP fluorescence and the bottom images are a merge of FM4-64 and 
GFP fluorescence. The white lines through cells in the images are a representation of the line 
scans of fluorescence intensity generated in ImageJ and plotted below the micrographs. Scale bar 
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is 5 μm. (B) Western blot of the whole cell lysate (WCL), cytosolic fraction (Cyt), and 
membrane fraction (Mem) from ΔddcA amyE∷Pxyl-ddcA-gfp (PEB856) cell extracts using 
antisera against GFP (upper panel) or DdcP (lower panel). The asterisk denotes a cross-reacting 
species detected by the GFP antiserum. 
 
Figure 3.11 DdcA and YneA do not interact in bacterial two hybrid assay. Plasmids 
containing the indicated T18 (rows) and T25 (columns) fusions were used to co-transform E. coli 
BTH101 cells, which were spotted onto LB containing X-gal and IPTG. 
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Figure 3.12 DdcA inhibits YneA. (A) B. subtilis strains amyE∷Pxyl-yneA (PEB846), ΔddcA 
amyE∷Pxyl-yneA (PEB848), ΔddcP, ΔctpA, amyE∷Pxyl-yneA (PEB850), and ΔddcA ΔddcP 
ΔctpA, amyE∷Pxyl-yneA (PEB852), amyE∷Pxyl-gfp-yneA (PEB876), ΔddcA amyE∷Pxyl-gfp-yneA 
(PEB882), ΔddcP, ΔctpA, amyE∷Pxyl-gfp-yneA (PEB888), and ΔddcA ΔddcP ΔctpA, amyE∷Pxyl-
gfp-yneA (PEB894) were struck onto LB or LB + 0.1% xylose and incubated at 30°C overnight. 
(B) Micrographs from the indicated strains from Panel A, grown in minimal media and treated 
with 0.1% xylose for 30 minutes. Green images are GFP fluorescence and red images are FM4-
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64 membrane stain. The percentage of septal localization is shown for PEB876 (n=591) and 
PEB882 (n=542). The p-value of a two-tailed z-test was 0.516. Scale bar is 5 μm. (C) Cell length 
distributions of strains grown with (right) or without (left) 0.1% xylose. The number of cells 
measured (n) for each condition is indicated. The black vertical dashed line is at 2 μm and the 
blue vertical dashed line is at 5μm. 
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Figure 3.13 DdcA inhibits enforcement of the DNA damage checkpoint. A working model 
for how DdcA inhibits YneA. DdcA prevents access to the target of YneA, however, when the 
SOS response has been activated for a prolonged period of time, YneA is able to overcome 
DdcA dependent inhibition to prevent cell division. Following DNA repair and completion of 
DNA replication the SOS response is turned off and the checkpoint recovery proteases degrade 
YneA allowing cell division to resume. 
 
Figure 3.14 DdcP and CtpA PDZ domains have different functions in vivo. (A) Alignment of 
the PDZ domain of DdcP to the PDZ domains of DegP and DegS from E. coli. (B) Alignment of 
187 
 
the PDZ domain of CtpA to the PDZ domains of CtpB from B. subtilis and Prc from E. coli. (C) 
Schematics of ΔPDZ constructs used in panels B and C. (D) Spot titer assay using B. subtilis 
strains WT (PY79), ΔddcP (PEB324), ddcPΔPDZ (PEB774), ΔctpA (PEB355), and ctpAΔPDZ 
(PEB776) media. (E) Western blot analysis of WT (PY79), ddcPΔPDZ (PEB774), and 
ctpAΔPDZ (PEB776) cell lysates using DdcP, CtpA, and DnaN antiserum. 
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 No Xylose 0.1% Xylose 
Strain Genotype Cell length 
(mean ± sd)
Cell length 
(mean ± sd)
% ≥ 5 μm p-value 
PEB876 amyE∷Pxyl-gfp-yneA 1.98 ± 0.51 
(n = 685) 
2.91 ± 0.75 0.84%     
(6/717) 
N/A 
PEB882 ΔddcA, amyE∷Pxyl-gfp-
yneA 
2.48 ± 0.73 
(n = 672) 
2.86 ± 0.85 1.16%     
(7/601) 
0.55 
PEB888 ΔddcP, ΔctpA, 
amyE∷Pxyl-gfp-yneA 
2.18 ± 0.60 
(n = 690) 
2.49 ± 0.70 0.68%     
(5/734) 
0.73 
PEB894 ΔddcP, ΔctpA, ΔddcA, 
amyE∷Pxyl-gfp-yneA 
2.39 ± 1.10 
(n = 695) 
4.09 ± 2.09 22.4%   
(159/711) 
<0.00001 
Table 3.1 Over-expression of GFP-YneA results in a significant increase in cells greater 
than 5 μm in cells lacking ddcP, ctpA, and ddcA. Data are from expression of GFP-YneA using 
0.1% xylose for 30 minutes. The mean cell length ± the standard deviation is listed. The percent 
of cells greater than 5 μm (number/total cells scored) and the p-value from a two-tailed z-test are 
listed. 
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Strain Genotype Reference 
PY79 PY79 (63) 
PEB309 ΔuvrAB This study 
PEB324 ΔddcP (ylbL) (38) 
PEB355 ΔctpA (38) 
PEB357 ΔddcA (ysoA) (38) 
PEB433 ΔyneA∷erm (38) 
PEB439 ΔyneA∷loxP (38) 
PEB495 ΔddcA, ΔyneA::erm This study 
PEB497 ΔuvrAB, ΔddcA This study 
PEB499 ΔddcP, ΔddcA This study 
PEB503 ΔddcA, amyE∷Pxyl-ddcA This study 
PEB555 ΔddcP, ΔctpA (38) 
PEB557 ΔddcP, ΔctpA, amyE∷Pxyl-ddcP (38) 
PEB561 ΔddcP, ΔctpA, ΔyneA∷loxP (38) 
PEB579 ΔctpA, ΔddcA This study 
PEB587 ΔddcA, ΔyneA::loxP This study 
PEB619 ΔddcP, ΔctpA, amyE∷Pxyl-ctpA (38) 
PEB639 ΔddcP, ΔctpA, ΔddcA This study 
PEB643 ΔddcP, ΔctpA, ΔddcA, ΔyneA∷loxP This study 
PEB719 ΔddcP, amyE::Pxyl-ddcPΔTM This study 
PEB772 ΔctpA, amyE::Pxyl-ctpAΔTM This study 
PEB774 ddcPΔPDZ This study 
PEB776 ctpAΔPDZ This study 
PEB836 ΔddcA, amyE∷Pxyl-ddcP This study 
PEB837 ΔddcA, amyE∷Pxyl-ctpA This study 
PEB838 ΔddcP, ΔctpA, amyE∷Pxyl-ddcA This study 
PEB839 ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ddcP This study 
PEB840 ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ddcA This study 
PEB841 ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ctpA This study 
PEB846 amyE∷Pxyl-yneA This study 
PEB848 ΔddcA, amyE∷Pxyl-yneA This study 
PEB850 ΔddcP, ΔctpA, amyE∷Pxyl-yneA This study 
PEB852 ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-yneA This study 
PEB854 ΔddcA, amyE∷Pxyl-gfp-ddcA This study 
PEB856 ΔddcA, amyE∷Pxyl-ddcA-gfp This study 
PEB876 amyE∷Pxyl-gfp-yneA This study 
PEB882 ΔddcA, amyE∷Pxyl-gfp-yneA This study 
PEB888 ΔddcP, ΔctpA, amyE∷Pxyl-gfp-yneA This study 
PEB894 ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-gfp-yneA This study 
Table 3.2 Strains used in this study. 
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Plasmid number Plasmid name Reference/Source 
pKT25 pKT25 Euromedex (EUP-25C) 
pUT18C pUT18C Euromedex (EUP-18C) 
pDR244 pDR244 Bacillus Genetic Stock Center 
pPB41 pPB41 (64, 68) 
pPB47 pPB47 (38) 
pPB73 pPB41-CRISPR::uvrB (38) 
pPB84 pPB73-ΔuvrAB editing template This Study 
pPB108 pPB47-amyE::Pxyl-ddcP-camR (38) 
pPB122 pPB115-ΔddcA editing template (38) 
pPB147 pPB47-amyE::Pxyl-ddcA-camR This study 
pPB184 pPB47-amyE::Pxyl-ctpA-camR (38) 
pPB192 pPB47-amyE::Pxyl-yneA-camR This study 
pPB216 pPB47--amyE::Pxyl-ddcPΔTM-camR This study 
pPB235 pPB41-CRISPR∷ddcP-PDZ This study 
pPB236 pPB41-CRISPR∷ctpA-PDZ This study 
pPB245 pPB235-ddcPΔPDZ editing template This study 
pPB246 pPB236-ctpAΔPDZ editing template This study 
pPB254 pPB47-amyE::Pxyl-gfp-ddcA-camR This study 
pPB255 pPB47-amyE::Pxyl-ddcA-gfp-camR This study 
pPB257 pPB47-amyE::Pxyl-gfp-yneA-camR This study 
pPB267 pUT18-YneA (38) 
pPB268 pUT18-YneAΔN (38) 
pPB269 PKT25-DdcA This study 
pPB270 pKT25-DdcP-S234A (38) 
pPB271 pKT25-CtpA-S297A (38) 
Table 3.3 Plasmids used in this study. 
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Primer name Sequence 
oPEB116 Ctctcgtttcatcggtatcattac 
oPEB117 Cgcttcgttaatacagatgtaggt 
oPEB217 GAACCTCATTACGAATTCAGCATGC 
oPEB218 GAATGGCGATTTTCGTTCGTGAATAC 
oPEB227 CCGTCAATTGTCTGATTCGTTA 
oPEB232 GCTGTAGGCATAGGCTTGGTTATG 
oPEB234 GTATTCACGAACGAAAATCGCCATTCCTAGCAGCACGCCATAGTGACTG 
oPEB253 GAAGGGTAGTCCAGAAGATAACGA 
oPEB345 Actcctttgtttatccaccgaac 
oPEB348 TTATTTTTGACACCAGACCAACTG 
oPEB370 cacctacatctgtattaacgaagcgTCAATGGGGAAGAGAACCGCTTAAG 
oPEB377 ggtaatgataccgatgaaacgagagAACAAAATTCTCCAGTCTTCACATCG 
oPEB383 Atgtatacctccttaggatcccatttcc 
oPEB422 GCATAACCAAGCCTATGCCTACAGCgaagactttgtaattgcggaaaac 
oPEB424 Agaatgaatcgtgaaatgatcacc 
oPEB428 GCATGCTGAATTCGTAATGAGGTTCtagtctcttgaagctggttgtcct 
oPEB432 Acggatcgatatgattctctaagc 
oPEB434 Ctgaggagggtttttgttgattac 
oPEB435 Taacagagggttaaaaataagcctccgtttctttaacg 
oPEB436 Ttcgttaaagaaacggaggcttatttttaaccctctgttaagaggggacagcttgt
cggcaagtccatccttgggcttagcaggcaagctttttctttac 
oPEB477 GCATGCTGAATTCGTAATGAGGTTCagcagtacctgtcctcttgattct 
oPEB480 GCATAACCAAGCCTATGCCTACAGCccagtatgtgacctcgattctaac 
oPEB481 TACATAAGCACCAAATTGAAGTGG 
oPEB482 Agaaacagcacagcttattgatga 
oPEB483 GAGAAAAGATTGTGTTCCGAAAAG 
oPEB492 Tgatgttctttttcctcctattcg 
oPEB493 Acgatattgccgtattcctcttat 
oPEB557 taaCGGTTTCCATATGGGGATTGGTG 
oPEB561 ACCAATCCCCATATGGAAACCGttaTCAGGTGCTTTTCGCTTTCAGCTT 
oPEB588 GCATGCTGAATTCGTAATGAGGTTCcccctcctatcctgactttctatc 
oPEB591 GCATAACCAAGCCTATGCCTACAGCtatgggtcattatgctgtttatgg 
oPEB592 Acgactttaccttgatggtttttg 
oPEB593 Gttgctctttacacattcttcagc 
oPEB594 Ggatacagcaaatgtcctaaataagc 
oPEB601 Cgtgcttatgaatatatgggattg 
oPEB602 Aacaagctcttcacgcaatttag 
oPEB706 aaatgggatcctaaggaggtatacatATGACGCATGACAAGAAAAACGCA 
oPEB707 CACCAATCCCCATATGGAAACCGttaTTACAAATAAGAAATTTCTTCAATATCTTT
TAAC 
oPEB708 AGAAGTCAAAAGCACCATTGAAG 
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oPEB818 ACCAATCCCCATATGGAAACCGttaTTACATTTCTTTTTTCAGTGTTTCAATTGC 
oPEB854 aatgggatcctaaggaggtatacatATGAGTAAAGAATCTATTATTTTTGTCGGT 
oPEB855 CACCAATCCCCATATGGAAACCGttaCTATCTTACAGTTGCTAATTCATATG 
oPEB887 aatgggatcctaaggaggtatacatTTGACAGAGCTTGCTTCATTGATAA 
oPEB911 gaaatgggatcctaaggaggtatacatTTGAGCACAGGAGACAGCAAGTTCGAC 
oPEB984 aaacAGAAGTCGGTGATAAAATCATCAGCGCAGAg 
oPEB985 aaaacTCTGCGCTGATGATTTTATCACCGACTTCT 
oPEB986 TTCCTGCCCGATCCGGCTCATCAGGGCTGACTTTTTTTCCTGCCTTTTGA 
oPEB987 ATCAAAAGGCAGGAAAAAAAGTCAGCCCTGATGAGCCGGATCGGGCAG 
oPEB988 aaacGAATGTAAATGAAGCCGTCGCTTTAATCCGg 
oPEB989 aaaacCGGATTAAAGCGACGGCTTCATTTACATTC 
oPEB990 CATCTCTGAATAGACAGTCTCTACAGGTGCTGAAATCGTCTCGTCGAATG 
oPEB991 AATCATTCGACGAGACGATTTCAGCACCTGTAGAGACTGTCTATTCAGAG 
oPEB998 aaatgggatcctaaggaggtatacatATGAGTAAAGGAGAAGAACTTTTCAC 
oPEB999 TTTTGCGTTTTTCTTGTCATGCGTCATGAGCTCAGAGCGGTAAGCGTAA 
oPEB1000 GTGGTTACGCTTACCGCTCTGAGCTCATGACGCATGACAAGAAAAACGCA 
oPEB1001 AAAGATATTGAAGAAATTTCTTATTTGGGTGAAGGTCAAGGACAAGGCCA 
oPEB1002 CCACCAATCCCCATATGGAAACCGttaTTATTTGTATAGTTCATCCATGCCATGTG 
oPEB1003 TCCTTGGCCTTGTCCTTGACCTTCACCCAAATAAGAAATTTCTTCAATATCTTTTA
AC 
oPEB1005 GAGCTCAGAGCGGTAAGCGTAAC 
oPEB1006 GGACGTGGTTACGCTTACCGCTCTGAGCTCATGAGTAAAGAATCTATTATTTTTGT
CGGT 
oPEB1014 TTGGCCTTGTCCTTGACCTTCACCGGGATCCTCTAGAGTCGACCCTG 
oPEB1015 TAActaagaattcggccgtcgttt 
oPEB1021 ATTATGCCGCATCTGTCCAACT 
oPEB1022 Gcaaggcgattaagttgggtaa 
oPEB1037 AGGATCCCGGTGAAGGTCAAGGACAAGGCCAAATGACGCATGACAAGAAAAACGCA 
oPEB1038 taaaacgacggccgaattcttagTTATTACAAATAAGAAATTTCTTCAATATCTTT
TAAC 
Table 3.4 Oligonucleotides used in this study. 
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Supplemental text 
Supplemental Results 
The PDZ domains of DdcP and CtpA have different functions in vivo 
The influence of a PDZ domain on protease activity has been found to be both positive 
and negative (69). Both DdcP and CtpA have PDZ domains, but the function of the PDZ 
domains in YneA degradation is unknown. We performed a PSI-BLAST search using the PDZ 
domain of DdcP against the E. coli protein database. We found that the PDZ domain of DdcP 
was most similar to the PDZ domain of DegS and PDZ1 from DegP (Fig 3.14A), both of which 
have been reported to inhibit protease activity (70-73). We asked if CtpA would yield the same 
PSI-BLAST result, so we repeated our search using the PDZ domain of CtpA. CtpA was most 
similar to the PDZ domain of the C-terminal processing protease Prc (also known as Tsp; Fig 
3.14B), which was expected because CtpA and its homolog CtpB return Prc in a standard 
BLAST search (data not shown).  Intriguingly, the PDZ domains of CtpB and Prc have been 
reported to function in substrate recognition (74, 75). Together, our homology searches predict 
that the PDZ domains of DdcP and CtpA may have different functions. 
To test our hypothesis that DdcP and CtpA have PDZ domains with different functions, 
we constructed ΔPDZ constructs for both DdcP and CtpA (Fig 3.14C) at the native locus of each 
gene. We tested for MMC sensitivity using a spot titer assay. Deletion of the PDZ domain of 
DdcP had no effect on MMC sensitivity (Fig 3.14D), suggesting that this PDZ domain is 
inhibitory similar to the PDZ domain of DegS. Deletion of the PDZ domain of CtpA resulted in a 
mutant that was sensitive to MMC, but not to the same extent as deletion of ctpA (Fig 3.14D), 
suggesting that the PDZ domain of CtpA functions in substrate recognition similar to Prc and 
CtpB. As a control, we verified that the ΔPDZ variants were stably expressed in vivo (Fig 
3.14E). Taken together, our results support the bioinformatics predictions, and we conclude that 
the PDZ domains of DdcP and CtpA have different functions in regulating protease activity. 
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Supporting Materials and Methods 
Bacterial two-hybrid assays 
Bacterial two-hybrid assays were performed as previously described (38, 76, 77). 
Strain construction 
Individual strains were generated using CRISPR/Cas9 genome editing or double cross-
over recombination as previously described (38). Strains using Pxyl at the  amyE locus have a 
chloramphenicol resistance cassette and were selected for using LB agar + 5 μg/mL 
chloramphenicol. 
PEB309 (ΔuvrAB): PY79 was transformed with editing plasmid pPB84 to delete uvrAB. Deletion 
of uvrAB was verified via PCR genotyping using oPEB424/432. 
PEB495 (ΔddcA, ΔyneA::erm): PEB357 (ΔddcA) was transformed with chromosomal DNA 
purified from PEB432 (ΔyneA∷erm, BKE17860 from Bacillus Genetic Stock Center). 
Replacement of yneA with the erm cassette was verified via PCR genotyping using 
oPEB492/493. 
PEB497 (ΔuvrAB, ΔddcA): PEB309 was transformed with editing plasmid pPB122 to delete 
ddcA. Deletion of ddcA was verified via PCR genotyping using oPEB601/602. 
PEB499 (ΔddcP, ΔddcA): PEB324 was transformed with editing plasmid pPB122 to delete 
ddcA. Deletion of ddcA was verified via PCR genotyping using oPEB601/602. 
PEB503 (ΔddcA, amyE∷Pxyl-ddcA): PEB357 was transformed with pPB147 digested with two 
restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB579 (ΔctpA, ΔddcA): PEB355 was transformed with editing plasmid pPB122 to delete ddcA. 
Deletion of ddcA was verified via PCR genotyping using oPEB601/602. 
PEB587 (ΔddcA, ΔyneA::loxP): The erm cassette at the yneA locus was removed via Cre 
recombinase by transforming PEB495 with pDR244, which was subsequently evicted. The 
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absence of the erm cassette was verified by testing for sensitivity to erythromycin and by PCR 
genotyping using oPEB492/493. 
PEB639 (ΔddcP, ΔctpA, ΔddcA): PEB555 was transformed with editing plasmid pPB122 to 
delete ddcA. Deletion of ddcA was verified via PCR genotyping using oPEB601/602. 
PEB643 (ΔddcP, ΔctpA, ΔddcA, ΔyneA∷loxP): PEB561 was transformed with editing plasmid 
pPB122 to delete ddcA. Deletion of ddcA was verified via PCR genotyping using oPEB601/602. 
PEB719 (ΔddcP, amyE::Pxyl-ddcPΔTM): PEB324 was transformed with plasmid pPB216. 
PEB772 (ΔctpA, amyE::Pxyl-ctpAΔTM): PEB355 was transformed with a PCR product 
containing the portion of amyE∷Pxyl-ctpAΔTM using oPEB370/377, as the plasmid could not be 
isolated from E. coli. Briefly, ctpAΔTM was amplified using oPEB911/818, the upstream portion 
of amyE and the Pxyl promoter were amplified using oPEB370/383, and the chloramphenicol 
resistance cassette and the downstream portion of amyE were amplified using oPEB557/377. The 
final PCR product used for transformation of PEB355 was generated using the three preceding 
PCR products as a template and oPEB370/377. 
PEB774 (ddcPΔPDZ): PY79 was edited using CRISPR/Cas9 genome editing with plasmid 
pPB245. Deletion of the sequence encoding the PDZ domain of DdcP was verified via PCR 
genotyping using oPEB481/482. 
PEB776 (ctpAΔPDZ): PY79 was edited using CRISPR/Cas9 genome editing with plasmid 
pPB246. Deletion of the sequence encoding the PDZ domain of CtpA was verified via PCR 
genotyping using oPEB592/593. 
PEB836 (ΔddcA, amyE∷Pxyl-ddcP): PEB357 was transformed with pPB108 digested with two 
restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB837 (ΔddcA, amyE∷Pxyl-ctpA): PEB357 was transformed with pPB184 digested with two 
restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
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recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB838 (ΔddcP, ΔctpA, amyE∷Pxyl-ddcA): PEB555 was transformed with pPB147 digested with 
two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB839 (ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ddcP): PEB639 was transformed with pPB108 
digested with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
PEB840 (ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ddcA): PEB639 was transformed with pPB147 
digested with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
PEB841 (ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-ctpA): PEB639 was transformed with pPB184 
digested with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
PEB846 (amyE∷Pxyl-yneA): PY79 was transformed with pPB192 digested with two restriction 
enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover recombination 
was verified by testing for an inability to utilize starch and for the absence of a spectinomycin 
resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB848 (ΔddcA, amyE∷Pxyl-yneA): PEB357 was transformed with pPB192 digested with two 
restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
197 
 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB850 (ΔddcP, ΔctpA, amyE∷Pxyl-yneA): PEB555 was transformed with pPB192 digested with 
two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB852 (ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-yneA): PEB639 was transformed with pPB192 
digested with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
PEB854 (ΔddcA, amyE∷Pxyl-gfp-ddcA): PEB357 was transformed with pPB254 digested with 
two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB856 (ΔddcA, amyE∷Pxyl-ddcA-gfp): PEB357 was transformed with pPB255 digested with 
two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB876 (amyE∷Pxyl-gfp-yneA): PY79 was transformed with pPB257 digested with two 
restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
PEB882 (ΔddcA, amyE∷Pxyl-gfp-yneA): PEB357 was transformed with pPB257 digested with 
two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double crossover 
recombination was verified by testing for an inability to utilize starch and for the absence of a 
spectinomycin resistance cassette present on the portion of the plasmid that is not incorporated. 
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PEB888 (ΔddcP, ΔctpA, amyE∷Pxyl-gfp-yneA): PEB555 was transformed with pPB257 digested 
with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
PEB894 (ΔddcP, ΔctpA, ΔddcA, amyE∷Pxyl-gfp-yneA): PEB639 was transformed with pPB257 
digested with two restriction enzymes (KpnI-HF and ScaI-HF). Replacement of amyE via double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance cassette present on the portion of the plasmid that is not 
incorporated. 
Plasmid construction 
Plasmids were constructed via Gibson assembly (65) using the PCR amplicons listed 
below as previously described (38). 
pPB84: Plasmid pPB84 was constructed via Gibson assembly using four PCR products: 1) the 
vector pPB41 was amplified using oPEB217/218; 2) Cas9/CRISPR∷uvrB was amplified using 
pPB73 as a template with oPEB232/234; 3) the sequence upstream of uvrAB for the editing 
template was amplified using oPEB428/435; and 4) the sequence downstream of uvrAB for the 
editing template was amplified using oPEB436/422. Clones were verified via Sanger sequencing 
using oPEB227, oPEB253, and oPEB434. 
pPB147: Plasmid pPB147 was constructed via Gibson assembly using four PCR products: 1) 
pPB47 was amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl 
promoter was amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the 
downstream portion of amyE were amplified using oPEB557/377; 4) the ddcA ORF was 
amplified using oPEB706/707. Clones were verified via Sanger sequencing using oPEB345, 
oPEB348, and oPEB708. 
pPB192: Plasmid pPB192 was constructed via Gibson assembly using four PCR products: 1) 
pPB47 was amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl 
promoter was amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the 
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downstream portion of amyE were amplified using oPEB557/377; 4) the yneA ORF was 
amplified using oPEB854/855. Clones were verified via Sanger sequencing using oPEB345 and 
oPEB348. 
pPB216: The upstream portion of amyE and the Pxyl promoter were PCR amplified using 
oPEB370/383. The chloramphenicol resistance cassette and the downstream portion of amyE 
were amplified using oPEB557/377. Plasmid pPB47 was PCR amplified using oPEB116/117. 
The ORF of ddcP (coding for a.a. 36-341) was PCR amplified using oPEB887/561. These four 
PCR products were used in a Gibson assembly reaction to generate a plasmid to integrate 
ddcPΔTM under the control of Pxyl at the amyE locus. Clones were verified by Sanger 
sequencing with oPEB345 and oPEB348. 
pPB235: A proto-spacer targeting ddcP in the sequence coding for the PDZ domain 
(oPEB984/985) was ligated to pPB41. 
pPB236: A proto-spacer targeting ctpA in the sequence coding for the PDZ domain 
(oPEB988/989) was ligated to pPB41. 
pPB245: The upstream and downstream portions of the ddcPΔPDZ editing template were PCR 
amplified using oPEB477/986 and oPEB987/480, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB235 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ddcPΔPDZ editing plasmid. Clones were verified by Sanger sequencing 
with oPEB227, oPEB253, and oPEB483. 
pPB246: The upstream and downstream portions of the ctpAΔPDZ editing template were PCR 
amplified using oPEB588/990 and oPEB991/591, respectively. CRISPR/Cas9 was PCR 
amplified using oPEB232/234 and pPB236 as the template. The pPB41 vector was PCR 
amplified using oPEB217/218. These four PCR products were used in a Gibson assembly 
reaction to generate a ctpAΔPDZ editing plasmid. Clones were verified by Sanger sequencing 
with oPEB227, oPEB253, and oPEB594. 
pPB254: Plasmid pPB254 was constructed via Gibson assembly using five PCR products: 1) 
pPB47 was amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl 
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promoter was amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the 
downstream portion of amyE were amplified using oPEB557/377; 4) gfp with a linker was 
amplified using oPEB998/999; 5) the ddcA ORF was amplified using oPEB1000/707. Clones 
were verified via Sanger sequencing using oPEB345, oPEB348, and oPEB708. 
pPB255: Plasmid pPB255 was constructed via Gibson assembly using five PCR products: 1) 
pPB47 was amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl 
promoter was amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the 
downstream portion of amyE were amplified using oPEB557/377; 4) the ddcA ORF was 
amplified using oPEB706/1003; 5) gfp with a linker was amplified using oPEB1001/1002. 
Clones were verified via Sanger sequencing using oPEB345, oPEB348, and oPEB708. 
pPB257: Plasmid pPB257 was constructed via Gibson assembly using five PCR products: 1) 
pPB47 was amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl 
promoter was amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the 
downstream portion of amyE were amplified using oPEB557/377; 4) gfp with a linker was 
amplified using oPEB998/1005; 5) the yneA ORF was amplified using oPEB1006/855. Clones 
were verified via Sanger sequencing using oPEB345 and oPEB348. 
pPB269: DdcA was amplified with primers oPEB1037/1038. The plasmid pKT25 was amplified 
with primers oPEB1014/1015. These two PCR products were used in a Gibson assembly reaction 
to generate a T25-DdcA fusion for expression in BTH101 cells in a bacterial two-hybrid assay. 
Clones were selected on LB agar containing 50 μg/mL kanamycin and 0.2% glucose. Clones 
were verified via Sanger sequencing using oPEB708, 1021 and 1022. 
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CHAPTER IV
A bacterial DNA repair pathway specific to a natural antibiotic 
 
Abstract 
All organisms possess DNA repair pathways that are used to maintain the integrity of 
their genetic material. Although many DNA repair pathways are well understood, new pathways 
continue to be discovered. Here, we report an antibiotic specific DNA repair pathway in Bacillus 
subtilis that is composed of a previously uncharacterized helicase (mrfA) and exonuclease 
(mrfB). Deletion of mrfA and mrfB results in sensitivity to the DNA damaging agent mitomycin 
C, but not to any other type of DNA damage tested. We show that MrfAB function independent 
of canonical nucleotide excision repair, forming a novel excision repair pathway. We 
demonstrate that MrfB is a metal-dependent exonuclease and that the N-terminus of MrfB is 
required for interaction with MrfA. We determined that MrfAB failed to unhook inter-strand 
crosslinks in vivo, suggesting that MrfAB are specific to the monoadduct or the intra-strand 
crosslink. A phylogenetic analysis uncovered MrfAB homologs in diverse bacterial phyla, and 
cross-complementation indicates that MrfAB function is conserved in closely related species. B. 
subtilis is a soil dwelling organism and mitomycin C is a natural antibiotic produced by the soil 
bacterium Streptomyces lavendulae. The specificity of MrfAB suggests that these proteins are an 
adaptation to environments with mitomycin producing bacteria. 
 
Introduction 
A defining feature of biology is the ability to reproduce, which requires replication of the 
genetic material. High fidelity DNA replication depends on the integrity of the template DNA 
which can be damaged by UV light, ionizing radiation, and numerous chemicals (1). Many DNA 
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damaging agents have been used as chemotherapeutics and are also produced from natural 
sources such as bacteria, fungi, or plants (2). One such naturally produced antibiotic is 
mitomycin C (MMC), originally isolated from Streptomyces lavendulae (3). MMC is produced 
as an inactive metabolite that must be activated by enzymatic or chemical reduction to react with 
DNA (4). MMC reacts specifically with guanine residues in DNA and results in three principle 
modifications (5). MMC forms a mono-adduct by reacting with a single guanine, however, 
MMC has two reactive centers, which can result in intra-strand crosslinks on adjacent guanines 
on the same strand, or in inter-strand crosslinks wherein the two guanines on opposite strands of 
CpG sequences are covalently linked (6-12). The toxicity of these different adducts is a result of 
preventing DNA synthesis (5). 
In bacteria, MMC adducts and intra-strand crosslinks are repaired by nucleotide excision 
repair and inter-strand crosslinks are repaired by a combination of nucleotide excision repair and 
homologous recombination (13-15). Both mono-adducts and crosslinks are recognized in 
genomic DNA by UvrA to initiate repair (16-19). In some nucleotide excision repair models 
UvrB functions in complex with UvrA (17, 20, 21), while in vitro studies and a recent in vivo 
study using single molecule microscopy suggests that UvrB is recruited by UvrA (19, 22). In any 
event, once UvrA and UvrB are present at the lesion, the subsequent step is the disassociation of 
UvrA and the recruitment of UvrC which incises the DNA on either side of the lesion (22). 
In E. coli there is a second UvrC-like protein called Cho that can also perform the 
incision function (23, 24). Mono-adducts and intra-strand crosslinks are removed from the DNA 
via UvrD helicase in E. coli after UvrC excision. The resulting single-stranded gap is 
resynthesized by DNA polymerase with DNA ligase sealing the remaining nick, completing the 
repair process (17, 25). For an inter-strand crosslink, the process requires another step because 
the lesion containing DNA remains covalently bonded to the opposite strand. Most current 
models propose that homologous recombination acts subsequently to pair the lesion containing 
strand with a second copy of the chromosome if present and then an additional round of 
nucleotide excision repair can remove the crosslink followed by DNA polymerase and DNA 
ligase to complete the repair process (13, 14). Importantly, homologous recombination and 
UvrABC-dependent nucleotide excision repair are general DNA repair pathways that participate 
in the repair of many different types of DNA lesions including MMC adducted DNA. 
 208
 Although the pathways discussed above are known to function in the repair of MMC 
damaged DNA, it is unclear if other pathways exist in bacteria that also repair MMC lesions. We 
recently reported a forward genetic screen in B. subtilis where we identified two genes, mrfA and 
mrfB (formerly yprA and yprB, respectively) that when deleted resulted in sensitivity to MMC 
(26). Here, we report that MrfAB are part of a MMC specific DNA repair pathway in B. subtilis. 
Deletion of the mrfAB (formerly yprAB) operon renders B. subtilis sensitive to MMC, but not to 
other DNA damaging agents known to be repaired by the canonical nucleotide excision repair 
pathway. MrfAB are a putative helicase and exonuclease, respectively, and we demonstrate that 
conserved residues required for their activities are important for function in vivo. We show that 
MrfAB operate independent of UvrABC. We monitored DNA repair status over time using 
RecA-GFP as a reporter, and we show that deletion of mrfAB and uvrABC results in a synergistic 
decrease in RecA-GFP foci, suggesting that MrfAB are part of a novel nucleotide excision repair 
pathway in bacteria. We also found that MrfAB do not contribute to inter-strand crosslink repair, 
suggesting that MrfAB are specific to MMC mono-adducts or intra-strand crosslinks. A 
phylogenetic analysis shows that MrfAB homologs are present in many bacterial species and that 
the function of MrfAB is conserved in closely related species. Together, our study identifies a 
novel strategy used by bacteria to counteract the natural antibiotic MMC. 
 
Results 
DNA damage sensitivity of ΔmrfAB is specific to mitomycin C 
Our recent study using a forward genetic screen identified genes important for surviving 
exposure to several DNA damaging agents, uncovering many genes that had not previously been 
implicated in DNA repair or regulation of the SOS-response (26). As part of this screen, we 
identified a gene pair, yprAB, in which disruption by a transposon resulted in sensitivity to MMC 
but not phleomycin or methyl methanesulfonate (Fig 4.1A) (26). Because the phenotypes 
appeared specific to MMC (see below), we rename yprAB to mitomycin repair factors A and B 
(mrfAB). To follow up on the phenotype of the transposon insertions we tested clean deletion 
strains of mrfA and mrfB and found that deletion of either gene resulted in sensitivity to MMC 
(Fig 4.1B). Further, we ectopically expressed each gene in its respective deletion background 
and were able to complement the MMC sensitive phenotype (Fig 4.1B).  
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The absence of phenotypes with phleomycin and methyl methanesulfonate, is similar to 
the phenotypic profile of nucleotide excision repair (NER) mutants (Fig 4.1A) (26). Therefore, 
we asked if deletion of mrfA would result in sensitivity to other agents known to be repaired by 
NER. We tested for sensitivity to three other agents that cause DNA lesions that are repaired by 
NER: UV light, 4-NQO, and the DNA crosslinking agent psoralen (trioxsalen) (25). 
Interestingly, we found that deletion of mrfA did not cause sensitivity to any of these agents (Fig 
4.1C). We also tested whether the presence of uvrAB was masking the effect, but no additional 
sensitivity was observed when mrfA was deleted in the ΔuvrAB background (Fig 4.1C). Given 
the absence of phenotypes to other DNA damaging agents, MrfAB do not function as a general 
nucleotide excision repair pathway. In addition, mrfAB deletion did not result in sensitivity to 
another crosslinking agent, psoralen, indicating that MrfAB are not part of a general crosslink 
repair mechanism. We conclude that MrfAB are important for mitigating the toxicity of MMC-
generated DNA lesions. 
MrfA and MrfB function in the same pathway 
The phenotypes of mrfA and mrfB mutants were identical (Fig 4.1A & B), and the two 
genes are predicted to be an operon. Therefore, we hypothesized that MrfA and MrfB function 
together. We tested this hypothesis by combining the deletion mutants. We found that deletion of 
both genes gave the same sensitivity to MMC as each single mutant (Fig 4.2A), indicating that 
they function in the same pathway. If MrfAB function in the same pathway, it is possible that 
each protein acts successively, MrfA and MrfB interact forming a complex, or one protein serves 
to recruit the other in a stepwise fashion. 
 To provide insight into these possible mechanisms we tested for a protein-protein 
interaction between MrfA and MrfB using a bacterial two-hybrid assay (27, 28). We found that 
MrfA and MrfB formed a robust interaction, indicated by the formation of blue colonies (Fig 
4.2B). Next, we wanted to understand how these proteins interacted and whether  we could 
localize the interaction to a particular domain. We performed a deletion analysis with MrfA and 
found that deletion of either the N-terminus or the C-terminus was sufficient to abolish the 
interaction with MrfB (Fig 4.2C), and the N-terminus of MrfA was not sufficient for MrfB 
interaction (Fig 4.2C). Thus, it appears that the portion of MrfA that is required for the 
interaction is not limited to a single domain. We tested whether the N-terminus or C-terminus of 
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MrfB was required for MrfA interaction. We found that the C-terminus of MrfB was not 
required, though the signal was reduced, whereas deletion of the N-terminus of MrfB abolished 
the interaction with MrfA (Fig 4.2D). Therefore, the N-terminus of MrfB is required for 
interaction with MrfA. We conclude that MrfAB interaction is specific and that these proteins 
function as a complex or one protein subsequently recruits the other. 
MrfA helicase motifs and C-terminus is required for function in vivo 
MrfA is a predicted DEXH box helicase containing a C-terminal domain of unknown 
function (Fig 4.3 & 4.4A). The C-terminal domain of unknown function contains four conserved 
cysteines that are thought to function in coordinating a metal ion (29, 30). We initially searched 
for a similar helicase in other well studied organisms. We were unable to identify a homolog of 
MrfA containing both the ATPase domain and the C-terminal domain in E. coli, however, Hrq1 
from Saccharomyces cerevisiae shares the same domain structure with 32% identity and 55% 
positives. Hrq1 has been shown to be a RecQ family helicase with 3́  5́  helicase activity and 
has been observed to exist as a heptamer (31, 32). We performed an alignment with Hrq1 and 
identified helicase motifs typical of super family 2 helicases (Fig 4.3). A homolog of MrfA from 
Mycobacterium smegmatis has also been shown to be a 3́  5́  helicase, however, unlike Hrq1, 
SftH exists as a monomer in solution (29).  
To address whether residues predicted to be important for MrfA helicase activity are 
required for function, we used a complementation assay using variants containing alanine 
substitutions in several conserved helicase motifs. Mutations in helicase motif I (K82A), motif II 
(DE185-186AA), and motif III (S222A) all failed to complement a mrfA deficiency (Fig 4.4B). 
Intriguingly, when motif Ib (T134V) was mutated mrfA MMC sensitivity could still be 
complemented, and this residue, although conserved in Hrq1, it is not conserved in SftH (Fig 
4.4B). We asked whether the C-terminal domain of unknown function and the conserved 
cysteines were required for function. Deletion of the entire C-terminal domain, mutation of the 
first two cysteines, or mutation of all four cysteines all resulted in a failure to complement MMC 
sensitivity in a ΔmrfA strain (Fig 4.4B). Together, we suggest that both the putative helicase 
domain and the C-terminal domain of unknown function are required for MrfA in vivo. 
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MrfB is a metal-dependent exonuclease 
MrfB is predicted to be a DnaQ-like exonuclease and to have three tetratrichopeptide 
repeats at the C-terminus (Fig 4.5A). To search for putative catalytic residues in MrfB, we 
aligned MrfB to ExoI, ExoX, and DnaQ from E. coli (Fig 4.6A). MrfB has the four acidic 
residues typical of DnaQ-like exonucleases (Fig 4.6A). This type of nuclease also has a histidine 
located proximal to the last aspartate (33), and we identified two histidine residues, one of which 
was conserved (Fig 4.6A, conserved histidine highlighted in red and the other in green). DnaQ 
exonucleases coordinate a metal ion that is used in catalysis (33). We hypothesized that MrfB 
catalytic residues would cluster together in the tertiary structure. We modelled MrfB using 
Phyre2.0 (34), which used DNA polymerase epsilon catalytic subunit A (DnaQ) [pdb structure 
c5okiA (35)], and show that the conserved aspartate and glutamate residues are indeed clustered 
together in the model (Fig 4.6B). 
Interestingly, we found that the histidine conserved in the E. coli exonucleases was facing 
the opposite direction, whereas the non-conserved histidine was facing the putative catalytic 
residues in the MrfB model (Fig 4.6C). An alignment of MrfB homologs demonstrates that the 
histidine (labeled in green) facing the other putative catalytic residues is conserved in MrfB 
homologs, whereas the other is not (see supplemental text). To test whether these residues were 
important for function, we used variants with alanine substitutions at each putative catalytic 
residue in a complementation assay. We found that all five mutants could not complement the 
ΔmrfB mutant phenotype (Fig 4.5B).  
With these results we wanted to test whether MrfB had exonuclease activity in vitro. We 
overexpressed and purified MrfB to homogeneity as determined by SDS-PAGE (Fig 4.5C). We 
tested for exonuclease activity using a plasmid linearized by restriction digest. We found that 
MrfB could degrade linear dsDNA in the presence of Mg2+, demonstrating that MrfB is a metal-
dependent exonuclease (Fig 4.5D). With exonuclease activity established we tested the substrate 
preference of MrfB using a covalently closed circular plasmid (CCC), a nicked plasmid or a 
linear plasmid using T5 and λ exonucleases as controls. T5 exonuclease is able to degrade both 
nicked and linear substrates but T5 cannot degrade a CCC plasmid (36, 37). In contrast, λ 
exonuclease can only degrade a linear substrate (38). The T5 and λ exonuclease controls 
performed as predicted, and MrfB demonstrated activity on a linear substrate and lower activity 
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using a nicked substrate (Fig 4.5E). We conclude that MrfB is a metal-dependent exonuclease 
with a preference for linear DNA. 
MrfAB function independent of UvrABC dependent nucleotide excision repair 
Given that DNA damage sensitivity in mrfAB mutants was restricted to MMC and that 
both proteins have nucleic acid processing activities, we hypothesized that MrfAB were part of a 
nucleotide excision repair pathway. We tested whether MrfAB were within the canonical, 
UvrABC-dependent nucleotide excision repair pathway using an epistasis analysis. We found 
that deletion of mrfA or mrfB rendered B. subtilis hypersensitive to MMC in the absence of 
uvrAB (Fig 4.7A), uvrC, or uvrABC (Fig 4.7B). We also show that uvrABC function as a single 
pathway showing that deletion of each gene resulted in the same phenotype as the triple deletion 
(Fig 4.8). It is important to note that B. subtilis uvrABC functioning as a single pathway differs 
from E. coli (23, 39).  
To test whether deletion of mrfAB have an effect on acute treatment with MMC, we 
performed an epistasis analysis using a MMC survival assay. We tested mutants in mrfAB, 
uvrABC, and the double pathway mutant. We found that deletion of mrfAB had a limited, yet 
statistically significant (Mann-Whitney U-test; p-value < 0.05) effect on acute sensitivity to 
MMC at the 150 and 200 ng/mL treatments. Deletion of uvrABC had a significant and more 
pronounced decrease in survival following MMC treatment (Fig 4.7C). Deletion of both 
pathways resulted in hypersensitivity to acute MMC exposure, suggesting that MrfAB are part of 
a second nucleotide excision repair pathway. The difference in phenotypes between the 
individual pathway mutants suggests that the roles of each pathway may be specific for different 
MMC induced lesions. Given that the inter-strand crosslink is the more toxic lesion, our data 
suggest that UvrABC could be more efficient for repair of crosslinks and MrfAB could be more 
specific to the mono-adducted lesions (see below). We conclude that MrfAB and UvrABC are 
part of two distinct pathways for MMC repair. 
MrfAB are not required for unhooking inter-strand DNA crosslinks 
As stated previously, MMC results in several DNA lesions, one of which is the inter-
strand crosslink. Our results from treating acutely with MMC suggested that MrfAB may not 
function in repair of the inter-strand crosslink. Therefore, we asked whether one or both 
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pathways contribute to unhooking DNA crosslinks in vivo. Crosslinked DNA can be detected by 
heat denaturing and snap cooling due to the fact that crosslinked DNA will renature during the 
rapid cooling process and DNA that is not crosslinked will remain denatured when cooled 
rapidly (7). Therefore, we hypothesized that if both pathways contributed to unhooking a 
crosslink, we would observe stable DNA crosslinks only in the double pathway mutant. If only a 
single pathway was required, we would observe stable DNA crosslinks in one mutant and the 
double pathway mutant background. To test these ideas, we treated B. subtilis strains with MMC 
to crosslink genomic DNA, and then allowed the cells to recover for 45 or 90 minutes. We 
monitored DNA crosslinks by denaturing and snap cooling the DNA followed by analysis on an 
agarose gel. We found that in WT and ΔmrfAB cells we could detect some crosslinked DNA that 
decreased slightly over time (Fig 4.9A). Additionally, at the 90 minute recovery time point we 
observed a smaller DNA fragment in WT and ΔmrfAB samples, which we suggest is a result of a 
repair intermediate generated by UvrABC-dependent incision because formation of the 
intermediate requires UvrABC (Fig 4.9A). In the absence of uvrABC there was a significant 
stabilization of crosslinked DNA that did not decrease over time and deleting mrfAB had no 
effect in the uvrABC mutant strain on crosslink stabilization (Fig 4.9A). We quantified the 
crosslinked species and found that the inter-strand crosslink was stabilized in the absence of 
uvrABC and in the double pathway mutant (Fig 4.9B). We conclude that UvrABC are the 
primary proteins responsible for repair of inter-strand crosslinks and MrfAB likely repair the 
more abundant mono-adducts (40) and potentially intra-strand crosslinks that form, though we 
cannot formerly exclude the possibility that MrfAB act on an intermediate of a crosslink repair 
pathway that is specific to MMC. 
MrfAB and UvrABC are required for efficient RecA-GFP focus formation 
The synergistic sensitivity to MMC observed in the double pathway mutant suggests that 
MrfAB are part of a novel nucleotide excision repair pathway that does not function in inter-
strand crosslink repair. Thus, we sought to determine if DNA repair is altered following MMC 
treatment in the absence of mrfAB. Previous studies have demonstrated that RecA-GFP forms 
foci in response to DNA damage such as treatment with MMC (41-43). Additionally, the 
activation of the SOS response following treatment with MMC in bacteria requires the 
generation of a RecA/ssDNA nucleoprotein filament (44), which was also found to depend on 
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nucleotide excision repair (45). Therefore, to test whether the response of RecA was affected by 
the absence of mrfAB, uvrABC, or both pathways, we used a RecA-GFP fusion as a reporter to 
monitor RecA status over time (Fig 4.10A & 4.11). We quantified the percentage of cells 
containing a focus or foci of RecA-GFP, and found an increase in RecA-GFP focus formation 
over time (Fig 4.10B). In all three mutant strains there was a significant increase in RecA-GFP 
foci prior to MMC addition (Fig 4.10B). We found that deletion of mrfAB did not have a 
significant impact on RecA-GFP focus formation (Fig 4.10B). Deletion of uvrABC led to a slight 
decrease in RecA-GFP focus formation (Fig 4.10B & 4.11). The double pathway mutant had a 
significant decrease in RecA-GFP foci relative to WT (Fig 4.10B). With these results we suggest 
that the RecA response is substantially decreased in cells that lack the excision activity of 
uvrABC and mrfAB. These results further support the conclusion that MrfAB participate in the 
repair of MMC damaged DNA. 
MrfAB are conserved in diverse bacterial phyla 
Given the specificity of MrfAB for MMC, we became interested in understanding how 
conserved mrfA and mrfB are across different bacterial phyla. We performed a PSI-BLAST 
search using MrfA or MrfB against the proteomes of bacterial organisms from several phyla (Fig 
4.12A). We found that MrfA and MrfB are both present in organisms from 5 different phyla, 
though MrfA is more broadly conserved in bacteria (Fig 4.12A). To test if MrfA and MrfB 
function is conserved, we attempted to complement the MMC sensitive phenotype using codon-
optimized versions of the homologs from three organisms, Bacillus cereus, Streptococcus 
pneumoniae, and Pseudomonas aeruginosa. We found that expression of Bc-mrfA and Bc-mrfB 
were capable of complementing their respective deletions (Fig 4.12B). Interestingly, Sp-mrfB 
complemented, but Sp-mrfA did not (Fig 4.12B). The more distantly related homologs from P. 
aeruginosa were not able to complement the corresponding deletion alleles (Fig 4.12B). We 
conclude that MrfA and MrfB function is conserved in closely related species, and that they 
likely have been adapted to other uses in more distantly related bacteria. 
 
Discussion 
MrfAB are founding members of a novel bacterial nucleotide excision repair pathway. 
The observation that RecA-GFP foci changes in a synergistic manner with deletion of both 
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uvrABC and mrfAB suggests that MrfAB are acting as a second excision repair pathway. Indeed, 
a study of SOS activation in E. coli found that deletion of uvrA results in decreased SOS 
response activation when treated with MMC (45). The activation of the SOS response requires 
the formation of the RecA/ssDNA nucleoprotein filament that can be observed in vivo using a 
RecA-GFP fusion (42, 43, 46-48). Thus, our data are supportive of the excision repair model. We 
cannot formerly exclude the possibility that MrfAB act on a DNA repair intermediate, however, 
given that the mrfAB deletion did not render cells sensitive to other DNA damaging agents, this 
intermediate would have to be specific to the repair of MMC generated lesions. 
 Our current model is that a MMC mono-adduct or intra-strand crosslink is recognized by 
MrfA or an unknown factor (Fig 4.13). After the lesion is recognized it is possible that incisions 
occur on either side of the lesion or a single incision is used. It is also possible that no incision is 
required and that MrfAB make use of transient nicks in the chromosome that would be present 
during synthesis of the lagging strand, though this model would limit the lesions that MrfAB 
could repair. Once a nick is present, we hypothesize that MrfA acts as helicase to separate the 
DNA, exposing the MMC lesion. If a nick is generated 3′ to the lesion, MrfA could access the 
DNA at the nick and use its putative 3′5′ helicase activity to separate the lesion containing 
strand for degradation by MrfB (Fig 4.13). If MrfA made use of transient nicks in the 
chromosome generated during lagging strand synthesis, then it is possible that MrfA could 
recognize or be recruited to the MMC lesion and use its 3′5′ helicase activity on the strand 
opposite the lesion thereby exposing the lesion containing strand which could be stabilized by 
SSB, and upon reaching the nick in the DNA strand containing the lesion, MrfB could access the 
3′ end to degrade the lesion containing strand. Our data cannot distinguish between these models, 
however, Hrq1 and SftH have been observed to require a 3′ tail for helicase activity (29, 31, 49, 
50). Therefore, we hypothesize that a 3′ tail is necessary after lesion recognition, to allow for 
MrfA to separate the lesion containing strand.  
The specificity of the ΔmrfAB phenotype suggests that lesion recognition depends on 
MMC adduct structure. Our reported screen did not identify other candidates for this pathway 
(26) , though it remains possible that an essential protein or a protein that functions in 
homologous recombination, which would have a more severe phenotype than mrfAB, also acts as 
a lesion recognition factor. Nonetheless, we hypothesize that lesion recognition is a function 
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accomplished by either MrfA, MrfB, or by both proteins in complex. MrfA is a putative helicase 
with a C-terminal domain of unknown function containing four well conserved cysteine residues. 
A high throughput X-ray absorption spectroscopy study of over 3000 proteins including MrfA 
reported finding that MrfA binds zinc (30). Intriguingly, UvrA, the recognition factor of 
canonical nucleotide excision repair, also contains a zinc finger which is required for regulating 
recognition of damaged DNA (51). Indeed, three of the four recognition factors in eukaryotic 
nucleotide excision repair, XPA, RPA, and TFIIH also each contain a zinc finger component 
(25). Therefore, it is tempting to speculate that MrfA functions as the lesion recognition factor 
through its putative C-terminal zinc finger domain. 
The initial finding that sensitivity to DNA damage in mrfAB mutants is specific to MMC 
suggested an antibiotic specific repair pathway. The major source of toxicity from MMC has 
long been thought to be the inter-strand crosslink (5). We found that MrfAB do not contribute to 
unhooking an inter-strand crosslink in vivo and yet deletion of mrfAB in the uvrABC mutant 
resulted in a significant decrease in survival following MMC treatment. These observations 
strongly suggest that the mono-adducts and/or the intra-strand crosslink make a significant 
contribution to the overall toxicity of MMC. Therefore, through identifying a new repair 
pathway in bacteria, we are able to provide new insight into the toxicity profile of a well-studied, 
natural antibiotic. 
MrfAB homologs have likely evolved to perform different functions depending on the 
environments of their respective bacterial species, despite significant sequence similarity. We 
speculate that MrfAB specificity for MMC is a reflection of habitat overlap between B. subtilis 
and mitomycin producing bacteria such as S. lavendulae. Thus, MrfAB are an adaptation that 
allows B. subtilis to effectively compete in habitats where MMC is produced. Given that only 
closely related species could substitute for MrfA and MrfB in B. subtilis, we hypothesize that the 
MMC specific repair activity is restricted to those species. In fact, the homologs present in P. 
aeruginosa have diverged significantly. The N-terminus of Pa-MrfA is quite different from that 
of Bs-MrfA, and the C-terminal TPR domain of MrfB is completely absent in Pa-MrfB (see 
supplemental alignments), consistent with the notion that MrfAB function has diverged in more 
distantly related bacteria. Additionally, our results with MrfAB from S. pneumoniae are 
supportive of our hypothesis that MrfAB function in MMC repair is restricted to closely related 
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organisms. We speculate the interaction between Sp-MrfA and Sp-MrfB is conserved such that 
Sp-MrfB can still be recruited by Bs-MrfA and MrfB retains exonuclease activity, while the 
function of Sp-MrfA has diverged and the lesion recognition or recruitment activity is no longer 
present.  
We recently investigated the mismatch repair homolog MutS2 and arrived at a similar 
conclusion—MutS2 has been adapted to the specific DNA repair needs of different organisms. 
MutS2 in B. subtilis promotes homologous recombination (52), whereas MutS2 in several other 
organisms inhibits homologous recombination (53-56). The reality that distantly related 
organisms have adapted their genetic repertoire inherited from the most recent common ancestor 
would seem obvious. Still, a major thrust of biological exploration is often to examine processes 
that are highly conserved. While well conserved processes are often critical for more organisms, 
it is the divergent functions that make each organism unique, which is a property of inherent 
value found throughout nature. 
 
Materials and Methods 
Bacteriological methods 
All B. subtilis strains used in this study are isogenic derivatives of PY79 (57), and listed 
in Table 4.1. Detailed construction of strains, plasmids and a description of oligonucleotides 
used in this study are provided in the supplemental text. Plasmids and oligonucleotides are listed 
in Tables 4.2 and 4.3, respectively. Media used to culture B. subtilis include LB (10 g/L NaCl, 
10 g/L tryptone, and 5 g/L yeast extract) and S750 minimal media with 2% glucose (1x S750 salts 
(diluted from 10x S750 salts: 104.7g/L MOPS, 13.2 g/L, ammonium sulfate, 6.8 g/L monobasic 
potassium phosphate, pH 7.0 adjusted with potassium hydroxide), 1x metals (diluted from 100x 
metals: 0.2 M MgCl2, 70 mM CaCl2, 5 mM MnCl2, 0.1 mM ZnCl2, 100 μg/mL thiamine-HCl, 2 
mM HCl, 0.5 mM FeCl3), 0.1% potassium glutamate, 2% glucose, 40 μg/mL phenylalanine, 40 
μg/mL tryptophan). Selection of B. subtilis strains was done using spectinomycin (100 μg/mL) or 
chloramphenicol (5 μg/mL). 
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Spot titer and survival assays 
Spot titer assays were performed as described previously (26). Survival assays were 
performed as previously described (26), except cells were treated at a density of OD600 = 1 
instead of 0.5. 
Microscopy 
Strains containing RecA-GFP were grown on LB agar with 100 μg/mL spectinomycin at 
30°C overnight. Plates were washed with S750 minimal media with 2% glucose. Cultures of S750 
minimal media with 2% glucose and 100 μg/mL spectinomycin were inoculated at an OD600 = 
0.1 and incubated at 30°C protected from light until an OD600 of about 0.3 (about 3.5 hours). 
Cultures were treated with 5 ng/mL MMC and samples were taken for imaging prior to MMC 
addition, 45 minutes, 90 minutes, and 180 minutes after MMC addition. The vital membrane 
stain FM4-64 was added to 2 μg/mL and left at room temperature for five minutes. Samples were 
transferred to 1% agarose pads containing 1x Spizizen salts as previously described (26). Images 
were captured using an Olympus BX61 microscope using 250 ms exposure times for both FM4-
64 (membranes) and GFP. RecA-GFP foci were determined by using the find maxima function 
in ImageJ with the threshold set to the background of the image by comparing a line trace of an 
area without cells. The number of cells with foci was determined by taking the total number of 
foci and subtracting the foci greater than one in cells having multiple foci (i.e., if a cell had two 
foci, one would be subtracted and if a cell had 3 foci two would be subtracted and so on). The 
percentage was determined by dividing the number of cells with a focus or foci by the total 
number of cells observed. 
DNA crosslinking assay 
Strains of B. subtilis were struck out on LB agar and incubated at 30°C overnight. Plates 
were washed with LB and samples of 0.5 mL OD600 = 3 were aliquoted. One sample was 
untreated and three samples were treated with 1 μg/mL MMC. Samples were incubated at 37°C 
for 1 hour. For the untreated and MMC treatment samples, one volume (0.5 mL) of methanol 
was added and samples were mixed by inversion. Samples were harvested via centrifugation 
(12,000 g for 5 minutes, washed twice with 0.5 mL 1x PBS pH 7.4 and stored at -20°C 
overnight). For recovery samples, cells from the remaining two treated samples were pelleted via 
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centrifugation (10,000 g for 5 minutes) washed twice with 1 mL LB media and then re-
suspended in 0.6 mL LB media. Samples were then transferred to 14 mL round bottom culture 
tubes and incubated at 37°C on a rolling rack for 45 or 90 minutes. An equal volume (0.6 mL) of 
methanol was added and samples were mixed by inversion. Samples were harvested as stated 
above and stored at -20°C overnight. Chromosomal DNA was extracted using a silica spin-
column as previously described (26). Samples were normalized by A260 to 15 ng/μL. Samples 
were heat denatured by incubating at 100°C for 6 minutes followed by placing directly into an 
ice-water bath for 5 minutes. For native samples and heat denatured samples, 300 ng and 600 ng, 
respectively, were loaded onto a 0.8% agarose gel with ethidium bromide and electrophoresed at 
90 volts for approximately one hour. The crosslinked species was quantified in gels from two 
independent experiments in ImageJ. The intensity of the crosslinked band was determined using 
the Gel Analyzer tool, and the background from the region above the crosslinked band was 
subtracted and the difference was normalized to the intensity of the native chromosomal DNA 
band (Fig 4.9A, lower panel). The average of two independent experiments is shown, with error 
bars representing the range of the two measurements. 
Bacterial two-hybrid assays 
Bacterial two-hybrid assays were performed as described (26, 27). 
MrfB protein purification 
MrfB was purified from E. coli cells as follows. 10xHis-Smt3-MrfB was expressed from 
plasmid pPB97 in E. coli NiCo21 cells (NEB) at 37°C. Cells were pelleted and resuspended in 
lysis buffer (50 mM Tris pH7.5, 300 mM NaCl, 5% sucrose, 25 mM imidazole, 1x Roche 
protease inhibitor cocktail). Cells were lysed via sonication and lysates were clarified via 
centrifugation: 18,000 rpm (Sorvall SS-34 rotor) for 45 minutes at 4°C. Clarified lysates were 
loaded onto Ni2+-NTA-agarose pre-equilibrated in lysis buffer in a gravity column. The column 
was washed with 25 column volumes wash buffer (50 mM Tris pH 7.5, 500 mM NaCl, 10% 
(v/v) glycerol, 40 mM imidazole). MrfB was eluted from the column by cleavage of the 10xHis-
Smt3 tag using 6xHis-Ulp1 in 10 column volumes of digestion buffer (50 mM Tris pH 7.5, 150 
mM NaCl, 10% glycerol, 10 mM imidazole, 1 mM DTT, and 20 μg/mL 6xHis-Ulp1) at room 
temperature for 150 minutes. The eluate containing untagged MrfB was collected as the flow 
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through. MrfB was concentrated using a 10 kDa Amicon centrifugal filter. MrfB was loaded onto 
a HiLoad superdex 200-PG 16/60 column pre-equilibrated with gel filtration buffer (50 mM Tris 
pH 7.5, 250 mM NaCl, and 5% (v/v) glycerol). The column was eluted with gel filtration buffer 
at a flow rate of 1 mL/min. Peak fractions were pooled, glycerol was added to a final 
concentration of 20%, and concentrated using a 10 kDa Amicon centrifugal filter. MrfB aliquots 
were frozen at a final concentration of 2.6 μM in liquid nitrogen, and stored at 80°C. 
Exonuclease assays 
Exonuclease reactions (20 μL) were performed in 25 mM Tris pH 7.5, 20 mM KCl, and 5 
mM MgCl2 as indicated in the figure legends. The plasmid pUC19 was used as a substrate at a 
concentration of 13.5 ng/μL. To generate linear or nicked substrate, pUC19 was first incubated 
with BamHI-HF (NEB) or Nt.BSPQ1 (NEB), respectively, for 30 minutes at 37°C. To test metal 
dependency of MrfB, the linearized pUC19 was purified using a silica spin-column. Reactions 
were initiated by adding MrfB to 130 nM, 10 units of T5 exonuclease (NEB), or 5 units of λ 
exonuclease (NEB) and incubating at 37°C as indicated in the figure legends. Reactions were 
terminated by the addition of 8 μL of nuclease stop buffer (50% glycerol and 100 mM EDTA) 
followed by resolving reaction products by agarose gel electrophoresis. 
Phylogenetic analysis 
The protein sequences of MrfA (AHA78094.1) and MrfB (AHA78093.1) were used in a 
PSI-BLAST search in several organisms (Fig 4.12A). If a putative homolog was detected, the 
coverage and percent identity were both recorded. For MrfA, the protein was considered a 
homolog if the DEXH helicase domain, the C-terminal domain, and the four conserved cysteines 
were all present. For MrfB, the protein was considered a homolog if the putative catalytic 
residues were conserved. 
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Figures and Tables 
 
Figure 4.1 DNA damage sensitivity of ΔmrfAB is specific to mitomycin C. (A) Relative 
fitness plots for the indicated gene disruptions from Tn-seq experiments previously reported 
(26). The mean fitness is plotted as a bar graph and the error bars represent the 95% confidence 
interval. (B) Spot titer assay using strains with the indicated genotypes grown on LB with the 
indicated supplements. (C) Spot titer assay using strains with the indicated genotypes grown on 
LB media with the indicated treatments. For UV irradiation, cells were exposed to the indicated 
dose after serial dilutions were spotted on plates. For trioxsalen plates, 1 μg/mL was used and the 
UV wavelength for irradiation was 365 nm. 
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Figure 4.2 MrfA and MrfB function in the same pathway. (A) Spot titer assay using strains 
with the indicated genotypes grown on the indicated media. (B) Bacterial two-hybrid assay using 
the indicated T18 and T25 fusions. (C) MrfA constructs used in deletion analysis of MrfA-MrfB 
interaction (upper) and a bacterial two-hybrid assay using T25-MrfB and the indicated MrfA-
T18 fusions (lower). (D) MrfB constructs used in deletion analysis of MrfA-MrfB interaction 
(upper) and a bacterial two-hybrid assay using MrfA-T18 and the indicated T25-MrfB fusions 
(lower). 
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Figure 4.3 Helicase motifs of MrfA. An alignment of MrfA to Hrq1 from S. cerevisiae. 
Helicase motifs are highlighted as shown. The alignment was constructed using SIM (58). 
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Figure 4.4 MrfA helicase motifs and conserved cysteines are required for function. (A) A 
schematic of MrfA depicting putative helicase motifs, C-terminal (Ct) domain, and conserved 
cysteines. (B) Spot titer assay using strains with the indicated genotypes spotted on the indicated 
media.  
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Figure 4.5 MrfB is a metal-dependent exonuclease. (A) A schematic of MrfB depicting 
putative catalytic residues and C-terminal tetratrichopeptide repeat (TPR) domain. (B) Spot titer 
assay using strains with the indicated genotypes spotted on the indicated media. (C) 1 µg of 
purified MrfB stained with Coomassie brilliant blue. (D) Exonuclease assay using pUC19 
linearized with BamHI (lanes 3-7). Reactions were incubated at 37°C for 15 minutes with or 
without MrfB, MgCl2, or EDTA as indicated, and separated on an agarose gel stained with 
ethidium bromide. Lane 1 is a 1 kb plus molecular weight marker and lane 2 is undigested 
pUC19 plasmid. (E) Exonuclease assay testing substrate preference. The indicated exonucleases 
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were incubated with a covalently closed circular plasmid (CCC), a nicked plasmid (Nicked) or a 
linear plasmid (Linear) in the presence of Mg2+ at 37°C for 10 minutes. Reaction products were 
separated on an agarose gel stained with ethidium bromide. Lane 1 is a 1 kb plus molecular 
weight marker (M). 
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Figure 4.6 Putative catalytic residues of MrfB. (A) Alignment of the exonuclease domain of 
MrfB to ExoI (SbcD), DnaQ, and ExoX from E. coli using Clustal Omega (59). Putative 
catalytic residues are highlighted in red, and a putative non-conserved catalytic residue is 
highlighted in green. (B) A structural model of MrfB, modelled on DNA polymerase epsilon 
catalytic subunit A (pdb structure c5okiA (35)), was generated using Phyre2 (34). The model 
depicting amino acids 100-270 of MrfB is shown as a cartoon in blue, and the putative catalytic 
residues are colored as in A. (C) A close up view of the putative catalytic residues from the 
model shown in B. 
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Figure 4.7 MrfAB function independent of UvrABC dependent nucleotide excision repair. 
(A & B) Spot titer assays using strains with the indicated genotypes grown on the indicated 
media. (C) Survival assay using strains with the indicated genotypes. The y-axis is the percent 
survival relative to the untreated (0 ng/mL) condition. The x-axis indicates the concentration of 
MMC used for a 30 minute acute exposure. The data points represent the mean of three 
independent experiments performed in triplicate (n=9) ± SEM.  
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Figure 4.8 UvrABC function in the same pathway. Spot titer assay using the indicated uvr 
deletion strains grown on the indicated media.  
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Figure 4.9 MrfAB are not required for unhooking inter-strand DNA crosslinks. (A) DNA 
crosslinking repair assay. Chromosomal DNA from untreated samples (U), 1 μg/mL MMC 
treated samples (T), and recovery samples (45’ and 90’) were heat denatured and snap cooled 
(upper) or native chromosomal DNA (lower) was separated on an agarose gel stained with 
ethidium bromide. A 1 kb plus molecular weight marker is shown in the first lane. (B) A bar 
graph showing the mean percent of crosslinked DNA (see methods) from two independent 
experiments, and error bars represent the range of the two measurements. 
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Figure 4.10 MrfAB and UvrABC are required for efficient RecA-GFP focus formation. (A) 
Representative micrographs of strains containing RecA-GFP expressed from the native locus in 
addition to the indicated genotypes. Images were captured at the indicated times following MMC 
addition (5 ng/mL). RecA-GFP is shown in green and the merged images show RecA-GFP 
(green) and membranes stained with FM4-64 (red). The white bar indicates 5 µm (B) Percentage 
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of cells with a RecA-GFP focus or foci over the indicated time course of MMC treatment (5 
ng/mL). The error bars represent the 95% confidence interval. 
 
Figure 4.11 MrfAB are not required for unhooking inter-strand DNA crosslinks. 
Representative micrographs of cells from the indicated genotypes that also contain RecA-GFP 
expressed from the native locus. Time of imaging post MMC treatment (5 ng/mL) is indicated 
(rows). Membranes, stained with FM4-64 are shown in red, RecA-GFP is shown in green, and 
both are shown in the merged images. The white scale bar indicates 5 μm. The images for WT 
and ΔmrfAB, ΔuvrABC are also in Figure 4.10 and are shown here for comparison. 
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Figure 4.12 MrfAB are conserved in diverse bacterial phyla. (A) A rooted phylogenetic tree 
constructed using 16s rRNA sequences (18s rRNA for S. cerevisiae), aligned with muscle (60), 
using the neighbor joining method (61), and the evolutionary distances were calculated using the 
p-distance method (62). The percentage of replicate trees that resulted in the associated species 
clustering together in a bootstrap test (500 replicates) is indicated next to the branches (63). 
Evolutionary analysis was performed in MEGA (64). *In this organism MrfA and MrfB 
homologs are fused into a single protein. (B) Spot titer assay using codon optimized versions of 
MrfA and MrfB from the indicated species to complement ΔmrfA (upper) or ΔmrfB (lower). 
 
Figure 4.13 A model for MrfAB mediated nucleotide excision repair. We propose that either 
an unknown factor or MrfA recognizes an MMC adduct. MrfB is then recruited, and MrfA uses 
its helicase activity to separate the strand containing the MMC adduct, facilitating MrfB-
dependent degradation of the adduct containing DNA. The source of the nick used to direct 
excision is unknown.  
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Strain Genotype Reference
PY79 PY79 (57) 
LAS40 recA∷recA-gfp (43) 
PEB125 ΔrecU∷erm (52) 
PEB307 ΔuvrA (26) 
PEB308 ΔuvrB (26) 
PEB309 ΔuvrAB (65) 
PEB310 ΔuvrC (26) 
PEB316 ΔmrfA (yprA) (26) 
PEB318 ΔmrfB (yprB) (26) 
PEB320 ΔmrfAB This study 
PEB337 ΔmrfA, ΔuvrAB This study 
PEB339 ΔmrfB, ΔuvrAB This study 
PEB369 ΔmrfA, amyE::Pxyl-mrfA This study 
PEB371 ΔmrfB, amyE::Pxyl-mrfB This study 
PEB505 ΔmrfA, amyE::Pxyl-mrfA-K82A This study 
PEB507 ΔmrfA, amyE::Pxyl-mrfA-DE185-186AA This study 
PEB509 ΔmrfA, amyE::Pxyl-mrfA-T134V This study 
PEB511 ΔmrfA, amyE::Pxyl-mrfA-S222A This study 
PEB513 ΔmrfA, amyE::Pxyl-mrfA-ΔC This study 
PEB515 ΔmrfA, amyE::Pxyl-mrfA-C718A & C720A This study 
PEB517 ΔmrfA, amyE::Pxyl-mrfA-C718A, C720A, C724C, & C727A This study 
PEB519 ΔmrfB, amyE::Pxyl-mrfB-D107A This study 
PEB521 ΔmrfB, amyE::Pxyl-mrfB-E109A This study 
PEB523 ΔmrfB, amyE::Pxyl-mrfB-D172A This study 
PEB525 ΔmrfB, amyE::Pxyl-mrfB-D262A This study 
PEB527 ΔmrfB, amyE::Pxyl-mrfB-H258A This study 
PEB529 ΔmrfB, amyE::Pxyl-mrfB-ΔC This study 
PEB812 ΔmrfAB, ΔuvrAB This study 
PEB822 ΔuvrABC This study 
PEB824 ΔmrfAB, ΔuvrC This study 
PEB826 ΔmrfAB, ΔuvrABC This study 
PEB828 recA∷recA-gfp This study 
PEB830 ΔmrfAB, recA∷recA-gfp This study 
PEB832 ΔuvrABC, recA∷recA-gfp This study 
PEB834 ΔmrfAB, ΔuvrABC, recA∷recA-gfp This study 
PEB866 ΔmrfA, amyE::Pxyl-Bc-mrfA This study 
PEB870 ΔmrfB, amyE::Pxyl-Bc-mrfB This study 
PEB872 ΔmrfB, amyE::Pxyl-Pa-mrfB This study 
PEB898 ΔmrfA, amyE::Pxyl-Sp-mrfA This study 
PEB900 ΔmrfB, amyE::Pxyl-Sp-mrfB This study 
PEB902 ΔmrfA, amyE::Pxyl-Pa-mrfA This study 
Table 4.1 Strains used in this study. 
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Plasmid 
number 
Plasmid name Reference/Source 
pUC19 pUC19 NEB (3041S) 
pKT25 pKT25 Euromedex (EUP-25C) 
pKNT25 pKNT25 Euromedex (EUP-25N) 
pUT18 pUT18 Euromedex (EUP-18N) 
pUT18C pUT18C Euromedex (EUP-18C 
pPB41 pPB41 (52, 66) 
pPB47 pPB47 (26) 
pPB73 pPB41-CRISPR::uvrB (26) 
pPB74 pPB41-CRISPR∷uvrC (26) 
pPB75 pPB41-CRISPR::mrfA (26) 
pPB84 pPB73-ΔuvrAB editing template (65) 
pPB85 pPB74-ΔuvrC editing template (26) 
pPB88 pPB75-ΔmrfAB editing template This study 
pPB97 pET-28b-10xHis-Smt3-MrfB This study 
pPB109 pPB47-amyE::Pxyl-mrfA-camR This study 
pPB110 pPB47-amyE::Pxyl-mrfB-camR This study 
pPB159 pPB47-amyE::Pxyl-mrfA-K82A-camR This study 
pPB160 pPB47-amyE::Pxyl-mrfA-DE185-186AA-camR This study 
pPB161 pPB47-amyE::Pxyl-mrfA-T134V-camR This study 
pPB162 pPB47-amyE::Pxyl-mrfA-S222A-camR This study 
pPB163 pPB47-amyE::Pxyl-mrfA-ΔC-camR This study 
pPB164 pPB47-amyE::Pxyl-mrfA-C718A & C720A-camR This study 
pPB165 pPB47-amyE::Pxyl-mrfA-C718A, C720A, C724A, & 
C727A-camR 
This study 
pPB166 pPB47-amyE::Pxyl-mrfB-D107A-camR This study 
pPB167 pPB47-amyE::Pxyl-mrfB-E109A-camR This study 
pPB168 pPB47-amyE::Pxyl-mrfB-D172A-camR This study 
pPB169 pPB47-amyE::Pxyl-mrfB-D262A-camR This study 
pPB170 pPB47-amyE::Pxyl-mrfB-H258A-camR This study 
pPB171 pPB47-amyE::Pxyl-mrfB-ΔC-camR This study 
pPB263 pU-T18-MrfA This study 
pPB264 pU-MrfA-T18 This study 
pPB265 pK-T25-MrfB This study 
pPB266 pK-MrfB-T25 This study 
pPB273 pK-T25-MrfBΔC This study 
pPB274 pK-T25-MrfBΔN This study 
pPB283 pU-MrfAΔN-T18 This study 
pPB284 pU-MrfAΔC-T18 This study 
pPB285 pU-MrfA-N-T18 This study 
Table 4.2 Plasmids used in this study.  
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Primer name Sequence 
oPEB56 ACCTCCAATCTGTTCGCGGTG 
oPEB57 taaTCGAGCACCACCACCACCAC 
oPEB58 GCTAGTTATTGCTCAGCGG 
oPEB116 ctctcgtttcatcggtatcattac 
oPEB117 cgcttcgttaatacagatgtaggt 
oPEB217 GAACCTCATTACGAATTCAGCATGC 
oPEB218 GAATGGCGATTTTCGTTCGTGAATAC 
oPEB227 CCGTCAATTGTCTGATTCGTTA 
oPEB232 GCTGTAGGCATAGGCTTGGTTATG 
oPEB234 GTATTCACGAACGAAAATCGCCATTCCTAGCAGCACGCCATAGTGACTG 
oPEB253 GAAGGGTAGTCCAGAAGATAACGA 
oPEB345 actcctttgtttatccaccgaac 
oPEB348 TTATTTTTGACACCAGACCAACTG 
oPEB370 cacctacatctgtattaacgaagcgTCAATGGGGAAGAGAACCGCTTAAG 
oPEB377 ggtaatgataccgatgaaacgagagAACAAAATTCTCCAGTCTTCACATCG 
oPEB383 atgtatacctccttaggatcccatttcc 
oPEB424 agaatgaatcgtgaaatgatcacc 
oPEB432 acggatcgatatgattctctaagc 
oPEB443 aaaccggaatccttcagacaatac 
oPEB444 cttctaacggcacttggtaatttt 
oPEB448 GCATGCTGAATTCGTAATGAGGTTCcgagttgattaggttctgaaatcc 
oPEB452 tcttgtcatgcttgtaaaggtagc 
oPEB454 agaaaatgatgggagaaggaatag 
oPEB460 GCATAACCAAGCCTATGCCTACAGCatggtgtgatgacagctaccttta 
oPEB461 AGCCATGGAAGTCAGTGATATTCT 
oPEB462 tctttattcggttctttccagttc 
oPEB464 gggaatattctttacacctctttgtcaagtac 
oPEB465 tgtacttgacaaagaggtgtaaagaatattccccgggaaagcgcaaaagacgacttgtttcg
ccatgaatttt 
oPEB527 TAAAAGACAGGGTAAGGAAATGGA 
oPEB543 CAATCAGACAAAAGGTGAGAAAAG 
oPEB544 AGAAATCGAAAGAGGACTGAGAGA 
oPEB545 GCTCACCGCGAACAGATTGGAGGTATGTCATTAAAAGGGAAACTCCAAC 
oPEB546 CTCAGTGGTGGTGGTGGTGGTGCTCGAttaTTAAGAGGAATATTTCCTCTTTAGCCGGGCAA
TTCTCACATGCAGTT 
oPEB547 TAAGCGAGGTTGACATTACATCAC 
oPEB557 taaCGGTTTCCATATGGGGATTGGTG 
oPEB562 aatgggatcctaaggaggtatacatATGAAAAAGAAATCACTGACTGAACT 
oPEB563 ACCAATCCCCATATGGAAACCGttaTTACGACATTTGATCCAACAGCTG 
oPEB564 aatgggatcctaaggaggtatacatATGTCATTAAAAGGGAAACTCCAAC 
oPEB565 ACCAATCCCCATATGGAAACCGttaTTAAGAGGAATATTTCCTCTTTAGCCGGGCAATTCTC
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ACATGCAGTT 
oPEB720 GTAACGCCAACAGCATCAGGAGCTACGTTATGCTACAACCTCCCAGTC 
oPEB721 TGGGAGGTTGTAGCATAACGTAGCTCCTGATGCTGTTGGCGTTACGGT 
oPEB722 ACCTTAAGTATATCGTCATCGCTGCACTTCATACGTATCGAGGTGTGTTC 
oPEB723 ACACCTCGATACGTATGAAGTGCAGCGATGACGATATACTTAAGGTTTTCAAAC 
oPEB724 GGGCATTGATATTAAAAGCTTTGTATATGACGGGGATACGTCTCCGGCA 
oPEB725 CCGGAGACGTATCCCCGTCATATACAAAGCTTTTAATATCAATGCCCATTTCATC 
oPEB726 GTGATCCAGTTTTTATTTGTACTGCTGCAACGATTGCCAACCCAAAGGAA 
oPEB727 CCTTTGGGTTGGCAATCGTTGCAGCAGTACAAATAAAAACTGGATCACTTCCA 
oPEB728 CAATCCCCATATGGAAACCGttaTTAAGGGACAATATGCTGCAGCACA 
oPEB729 TCGCCACCAATCCCCATATGGAAACCGttaTTACGACATTTGATCCAACAGCTGCAAAATTC
TTTCCTTTGCTTTTATCCCTTCTATTTCCGTACCTATACAAGACGGACAGCCGTCATGAGCA
GGAGCATGTGTAATCAGTTGTTTCGCCGCTT 
oPEB730 TCGCCACCAATCCCCATATGGAAACCGttaTTACGACATTTGATCCAACAGCTGCAAAATTC
TTTCCTTTGCTTTTATCCCTTCTATTTCCGTACCTATAGCAGACGGAGCGCCGTCATGAGCA
GGAGCATGTGTAATCAGTTGTTTCGCCGCTT 
oPEB731 ACAAAAACAACCTCTTTTTCTTTGCTACAGAAACAACCGGTCTTGGGGGT 
oPEB732 CCCCAAGACCGGTTGTTTCTGTAGCAAAGAAAAAGAGGTTGTTTTTGTTATACCCT 
oPEB733 CAACCTCTTTTTCTTTGATACAGCTACAACCGGTCTTGGGGGTGGA 
oPEB734 CTCCACCCCCAAGACCGGTTGTAGCTGTATCAAAGAAAAAGAGGTTGTTTTTGTT 
oPEB735 GACCTACAACGGCAAAGCCTTTGCTTGGCCGCAGGTGAAAACAAGGCA 
oPEB736 GCCTTGTTTTCACCTGCGGCCAAGCAAAGGCTTTGCCGTTGTAGGTCAC 
oPEB737 CAATCCCCATATGGAAACCGttaTTATGGCGCATGTGATTCTGAAAGGAT 
oPEB765 TGTCCTGCATCATAATGAAATGGCTGTGTTATCACTCATTTCATTGTACATC 
oPEB766 ACAATGAAATGAGTGATAACACAGCCATTTCATTATGATGCAGGACACCT 
oPEB767 TCTTTTAAAAGGTGTCCTGCATGCTAATGAAATGGATGTGTTATCACTCATTTC 
oPEB768 GTGATAACACATCCATTTCATTAGCATGCAGGACACCTTTTAAAAGATCC 
oPEB1012 CATagctgtttcctgtgtgaaattg 
oPEB1013 GGTGAAGGTCAAGGACAAGGCCAAGCCTGCAGGTCGACTCTAGAGGA 
oPEB1014 TTGGCCTTGTCCTTGACCTTCACCGGGATCCTCTAGAGTCGACCCTG 
oPEB1015 TAActaagaattcggccgtcgttt 
oPEB1016 GGTGAAGGTCAAGGACAAGGCCAACCGAGCTCGAATTCAGCCGCCA 
oPEB1017 TTGGCCTTGTCCTTGACCTTCACCCTCTAGAGTCGACCTGCAGTGG 
oPEB1018 TAActaagtaatatggtgcactctcagt 
oPEB1019 caggctttacactttatgcttcc 
oPEB1020 GTAACCAGCCTGATGCGATT 
oPEB1021 ATTATGCCGCATCTGTCCAACT 
oPEB1022 gcaaggcgattaagttgggtaa 
oPEB1023 GATTTTCCACAACAAGTCGATG 
oPEB1024 TTCTCGCCGGATGTACTGGAAAC 
oPEB1025 tggcttaactatgcggcatcaga 
oPEB1026 GGTGAAGGTCAAGGACAAGGCCAAATGAAAAAGAAATCACTGACTGAACT 
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oPEB1027 actgagagtgcaccatattacttagTTATTACGACATTTGATCCAACAGCTG 
oPEB1028 acaatttcacacaggaaacagctATGAAAAAGAAATCACTGACTGAACT 
oPEB1029 CTCGGTTGGCCTTGTCCTTGACCTTCACCCGACATTTGATCCAACAGCTGCA 
oPEB1030 CCCGGTGAAGGTCAAGGACAAGGCCAAATGTCATTAAAAGGGAAACTCCAAC 
oPEB1031 aaaacgacggccgaattcttagTTATTAAGAGGAATATTTCCTCTTTAGCCGGGCAATTC 
oPEB1032 gataacaatttcacacaggaaacagctATGTCATTAAAAGGGAAACTCCAAC 
oPEB1033 AGGCTTGGCCTTGTCCTTGACCTTCACCAGAGGAATATTTCCTCTTTAGCCGGGCAATTC 
oPEB1053 cggataacaatttcacacaggaaacagctATGAAAGGAGAGAGCATCGTTACCGTAA 
oPEB1054 GAGCTCGGTTGGCCTTGTCCTTGACCTTCACCAGGGACAATATGCTGCAGCACATTC 
oPEB1055 CGAGCTCGGTTGGCCTTGTCCTTGACCTTCACCTTTTTGCACATATTGAAAAGCGGAA 
oPEB1056 ttgtaaaacgacggccgaattcttagTTATGGCGCATGTGATTCTGAAAGGAT 
oPEB1057 GGATCCCGGTGAAGGTCAAGGACAAGGCCAAATGAAAGAACACAGTGAAGCCTATG 
Table 4.3 Oligonucleotides used in this study. 
 
Supplemental text 
Supplemental Methods 
Strain construction 
Strains were constructed using CRISPR/Cas9 genome editing (52, 66) or double crossover 
recombination(26). 
PEB320 (ΔmrfAB): PY79 was transformed with pPB88 to delete mrfAB using CRISPR/Cas9 
genome editing. Deletion of mrfAB was verified by PCR genotyping using oPEB452/462. 
PEB337 (ΔmrfA, ΔuvrAB): PEB316 was transformed with pPB84 to delete uvrAB using 
CRISPR/Cas9 genome editing. Deletion of uvrAB was verified by PCR genotyping using 
oPEB424/432. 
PEB339 (ΔmrfB, ΔuvrAB): PEB316 was transformed with pPB84 to delete uvrAB using 
CRISPR/Cas9 genome editing. Deletion of uvrAB was verified by PCR genotyping using 
oPEB424/432. 
PEB369 (ΔmrfA, amyE::Pxyl-mrfA): PEB316 was transformed with pPB109. Replacement of 
amyE with Pxyl-mrfA by double crossover recombination was verified by testing for an inability 
to utilize starch and for the absence of a spectinomycin resistance marker found on the plasmid, 
 241
but not on the integrated construct. Genomic DNA from the resulting strain, PEB347, was used 
to transform PEB316, and replacement of amyE was verified by an inability to utilize starch. 
PEB371 (ΔmrfB, amyE::Pxyl-mrfB): PY79 was transformed with pPB110. Replacement of amyE 
with Pxyl-mrfB by double crossover recombination was verified by testing for an inability to 
utilize starch and for the absence of a spectinomycin resistance marker found on the plasmid, but 
not on the integrated construct. Genomic DNA from the resulting strain, PEB345, was used to 
transform PEB318, and replacement of amyE was verified by an inability to utilize starch. 
Retention of the mrfB deletion allele was verified by PCR genotyping using oPEB461/462. 
PEB505 (ΔmrfA, amyE::Pxyl-mrfA-K82A): PEB316 was transformed with pPB159 digested with 
the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfA-K82A by double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB507 (ΔmrfA, amyE::Pxyl-mrfA-DE185-186AA): PEB316 was transformed with pPB160 
digested with the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfA-
DE185-186AA by double crossover recombination was verified by testing for an inability to 
utilize starch and for the absence of a spectinomycin resistance marker found on the plasmid, but 
not on the integrated construct. 
PEB509 (ΔmrfA, amyE::Pxyl-mrfA-T134V): PEB316 was transformed with pPB161 digested 
with the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfA-T134V by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB511 (ΔmrfA, amyE::Pxyl-mrfA-S222A): PEB316 was transformed with pPB162 digested 
with the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfA-S222A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
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PEB513 (ΔmrfA, amyE::Pxyl-mrfA-ΔC): PEB316 was transformed with pPB163 digested with 
the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfAΔC by double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB515 (ΔmrfA, amyE::Pxyl-mrfA-C718A & C720A): PEB316 was transformed with pPB164 
digested with the restriction enzymes ScaI and BsaI. Replacement of amyE with Pxyl-mrfA-
C718A & C720A by double crossover recombination was verified by testing for an inability to 
utilize starch and for the absence of a spectinomycin resistance marker found on the plasmid, but 
not on the integrated construct. 
PEB517 (ΔmrfA, amyE::Pxyl-mrfA-C718A, C720A, C724C, & C727A): ): PEB316 was 
transformed with pPB165 digested with the restriction enzymes ScaI and BsaI. Replacement of 
amyE with Pxyl- mrfA-C718A, C720A, C724C, & C727A by double crossover recombination was 
verified by testing for an inability to utilize starch and for the absence of a spectinomycin 
resistance marker found on the plasmid, but not on the integrated construct. 
PEB519 (ΔmrfB, amyE::Pxyl-mrfB-D107A): PEB318 was transformed with pPB166 digested 
with the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl-mrfB-D107A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB521 (ΔmrfB, amyE::Pxyl-mrfB-E109A): PEB318 was transformed with pPB167 digested 
with the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl-mrfB-E109A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB523 (ΔmrfB, amyE::Pxyl-mrfB-D172A): PEB318 was transformed with pPB168 digested 
with the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl-mrfB-D172A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
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the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB525 (ΔmrfB, amyE::Pxyl-mrfB-D262A): PEB318 was transformed with pPB169 digested 
with the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl-mrfB-D262A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB527 (ΔmrfB, amyE::Pxyl-mrfB-H258A): PEB318 was transformed with pPB170 digested 
with the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl-mrfB-H258A by 
double crossover recombination was verified by testing for an inability to utilize starch and for 
the absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB529 (ΔmrfB, amyE::Pxyl-mrfB-ΔC): PEB318 was transformed with pPB171 digested with 
the restriction enzymes ScaI and KpnI. Replacement of amyE with Pxyl- mrfB-ΔC by double 
crossover recombination was verified by testing for an inability to utilize starch and for the 
absence of a spectinomycin resistance marker found on the plasmid, but not on the integrated 
construct. 
PEB812 (ΔmrfAB, ΔuvrAB): PEB320 was transformed with pPB84 to delete uvrAB using 
CRISPR/Cas9 genome editing. Deletion of uvrAB was verified by PCR genotyping using 
oPEB424/432. 
PEB822 (ΔuvrABC): PEB309 was transformed with pPB85 to delete uvrC using CRISPR/Cas9 
genome editing. Deletion of uvrC was confirmed by PCR genotyping using oPEB443/444. 
PEB824 (ΔmrfAB, ΔuvrC): PEB320 was transformed with pPB85 to delete uvrC using 
CRISPR/Cas9 genome editing. Deletion of uvrC was confirmed by PCR genotyping using 
oPEB443/444. 
PEB826 (ΔmrfAB, ΔuvrABC): PEB812 was transformed with pPB85 to delete uvrC using 
CRISPR/Cas9 genome editing. Deletion of uvrC was confirmed by PCR genotyping using 
oPEB443/444. 
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PEB828 (recA∷recA-gfp): PY79 was transformed with chromosomal DNA from LAS40. 
PEB830 (ΔmrfAB, recA∷recA-gfp): PEB320 was transformed with chromosomal DNA from 
LAS40. Retention of the ΔmrfAB allele was verified by PCR genotyping using oPEB452/462. 
PEB832 (ΔuvrABC, recA∷recA-gfp): PEB822 was transformed with chromosomal DNA from 
LAS40. Retention of the ΔuvrAB allele was verified by PCR genotyping using oPEB424/432, 
and retention of the ΔuvrC allele was verified by PCR genotyping using oPEB443/444. 
PEB834 (ΔmrfAB, ΔuvrABC, recA∷recA-gfp): PEB826 was transformed with chromosomal 
DNA from LAS40. Retention of the ΔmrfAB allele was verified by PCR genotyping using 
oPEB452/462. Retention of the ΔuvrAB allele was verified by PCR genotyping using 
oPEB424/432, and retention of the ΔuvrC allele was verified by PCR genotyping using 
oPEB443/444. 
PEB866 (ΔmrfA, amyE::Pxyl-Bc-mrfA): The mrfA homolog from Bacillus cereus (CUB17870.1) 
was codon optimized and used to generate a gBlock (IDT). The gBlock oPEB1044 was used in 
an overlap PCR reaction with two other PCR amplicons (amyE upstream and Pxyl generated 
using oPEB370/383 and a chloramphenicol resistance cassette and amyE downstream generated 
with oPEB557/377) using oPEB370/377. The resulting PCR product containing amyE-up-Pxyl-
Bc-mrfA-camR-amyE-down was gel extracted and used to transform PEB316. Replacement of 
amyE with Pxyl-Bc-mrfA-camR was verified by testing for an inability to utilize starch. 
PEB870 (ΔmrfB, amyE::Pxyl-Bc-mrfB): The mrfB homolog from Bacillus cereus (CUB17873.1) 
was codon optimized and used to generate a gBlock (IDT). The gBlock oPEB1046 was used in 
an overlap PCR reaction with two other PCR amplicons (amyE upstream and Pxyl generated 
using oPEB370/383 and a chloramphenicol resistance cassette and amyE downstream generated 
with oPEB557/377) using oPEB370/377. The resulting PCR product containing amyE-up-Pxyl-
Bc-mrfB-camR-amyE-down was gel extracted and used to transform PEB318. Replacement of 
amyE with Pxyl-Bc-mrfB-camR was verified by testing for an inability to utilize starch. 
PEB872 (ΔmrfB, amyE::Pxyl-Pa-mrfB): The mrfB homolog from Pseudomonas aeruginosa 
(CRP88025.1) was codon optimized and used to generate a gBlock (IDT). The gBlock 
oPEB1045 was used in an overlap PCR reaction with two other PCR amplicons (amyE upstream 
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and Pxyl generated using oPEB370/383 and a chloramphenicol resistance cassette and amyE 
downstream generated with oPEB557/377) using oPEB370/377. The resulting PCR product 
containing amyE-up-Pxyl-Pa-mrfB-camR-amyE-down was gel extracted and used to transform 
PEB318. Replacement of amyE with Pxyl-Pa-mrfB-camR was verified by testing for an inability 
to utilize starch. 
PEB898 (ΔmrfA, amyE::Pxyl-Sp-mrfA): The mrfA homolog from Streptococcus pneumoniae 
(COD01438.1) was codon optimized and used to generate a gBlock (IDT). The gBlock 
oPEB1047 was used in an overlap PCR reaction with two other PCR amplicons (amyE upstream 
and Pxyl generated using oPEB370/383 and a chloramphenicol resistance cassette and amyE 
downstream generated with oPEB557/377) using oPEB370/377. The resulting PCR product 
containing amyE-up-Pxyl-Sp-mrfA-camR-amyE-down was gel extracted and used to transform 
PEB318. Replacement of amyE with Pxyl-Sp-mrfA-camR was verified by testing for an inability 
to utilize starch. 
PEB900 (ΔmrfB, amyE::Pxyl-Sp-mrfB): The mrfB homolog from Streptococcus pneumoniae 
(COD01468.1) was codon optimized and used to generate a gBlock (IDT). The gBlock 
oPEB1048 was used in an overlap PCR reaction with two other PCR amplicons (amyE upstream 
and Pxyl generated using oPEB370/383 and a chloramphenicol resistance cassette and amyE 
downstream generated with oPEB557/377) using oPEB370/377. The resulting PCR product 
containing amyE-up-Pxyl-Sp-mrfB-camR-amyE-down was gel extracted and used to transform 
PEB318. Replacement of amyE with Pxyl-Sp-mrfB-camR was verified by testing for an inability 
to utilize starch. 
PEB902 (ΔmrfA, amyE::Pxyl-Pa-mrfA): The mrfA homolog from Pseudomonas aeruginosa 
(CRP88044.1) was codon optimized and used to generate a gBlock (IDT). The gBlock 
oPEB1043 was used in an overlap PCR reaction with two other PCR amplicons (amyE upstream 
and Pxyl generated using oPEB370/383 and a chloramphenicol resistance cassette and amyE 
downstream generated with oPEB557/377) using oPEB370/377. The resulting PCR product 
containing amyE-up-Pxyl-Pa-mrfA-camR-amyE-down was gel extracted and used to transform 
PEB318. Replacement of amyE with Pxyl-Pa-mrfA-camR was verified by testing for an inability 
to utilize starch. 
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Plasmid construction 
Plasmids were constructed via Gibson assembly as described (26, 67). Plasmids for the bacterial 
two-hybrid assays were constructed using 0.2% glucose in the media for selection of clones and 
cultures grown for plasmid isolation. 
pPB88: Plasmid pPB88 was constructed using four PCR products: 1) the vector pPB41 was 
amplified using oPEB217/218; 2) Cas9/CRISPR∷mrfA was amplified using pPB75 as a template 
with oPEB232/234; 3) the sequence upstream of mrfA for the editing template was amplified 
using oPEB448/464; and 4) the sequence downstream of mrfB for the editing template was 
amplified using oPEB465/460. Clones were verified via Sanger sequencing using oPEB227, 
oPEB253, and oPEB454. 
pPB97: Plasmid pPB97 was constructed using two PCR products: 1) the vector pET28b-10xHis-
Smt3 was amplified using oPEB56/57; and 2) the MrfB ORF was amplified using oPEB545/546. 
Clones were verified via Sanger sequencing using oPEB58, oPEB527, and oPEB547. 
pPB109: Plasmid oPEB109 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; and 4) the mrfA ORF was amplified using 
oPEB562/563. Clones were verified via Sanger sequencing using oPEB345, oPEB348, 
oPEB543, and oPEB544. 
pPB110: Plasmid oPEB110 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; and 4) the mrfB ORF was amplified using 
oPEB564/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB159: Plasmid oPEB159 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
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amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfA-K82A ORF was 
amplified using oPEB562/721; and 5) the 3́ portion of the mrfA-K82A ORF was amplified using 
oPEB720/563. Clones were verified via Sanger sequencing using oPEB345, oPEB348, 
oPEB543, and oPEB544. 
pPB160: Plasmid oPEB160 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfA-DE185-186AA 
ORF was amplified using oPEB562/723; and 5) the 3 ́ portion of the mrfAK-DE185-186AA ORF 
was amplified using oPEB722/563. Clones were verified via Sanger sequencing using oPEB345, 
oPEB348, oPEB543, and oPEB544. 
pPB161: Plasmid oPEB161 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfA-T134V ORF 
was amplified using oPEB562/725; and 5) the 3́ portion of the mrfA-T134V ORF was amplified 
using oPEB724/563. Clones were verified via Sanger sequencing using oPEB345, oPEB348, 
oPEB543, and oPEB544. 
pPB162: Plasmid oPEB162 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfA-S222A ORF 
was amplified using oPEB562/727; and 5) the 3́ portion of the mrfA-S222A ORF was amplified 
using oPEB726/563. Clones were verified via Sanger sequencing using oPEB345, oPEB348, 
oPEB543, and oPEB544. 
pPB163: Plasmid oPEB163 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
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portion of amyE was amplified using oPEB557/377; and 4) the mrfAΔC ORF was amplified 
using oPEB562/728. Clones were verified via Sanger sequencing using oPEB345, oPEB348, 
oPEB543, and oPEB544. 
pPB164: Plasmid oPEB164 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; and 4) the mrfA-C718A & C720A ORF was 
amplified using oPEB562/729. Clones were verified via Sanger sequencing using oPEB345, 
oPEB348, oPEB543, and oPEB544. 
pPB165: Plasmid oPEB165 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; and 4) the mrfA-C718A, C720A, C724A, & 
C727A ORF was amplified using oPEB562/730. Clones were verified via Sanger sequencing 
using oPEB345, oPEB348, oPEB543, and oPEB544. 
pPB166: Plasmid oPEB166 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfB-D107A ORF 
was amplified using oPEB564/732; and 5) the 3́  portion of the mrfB-D107A ORF was amplified 
using oPEB731/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB167: Plasmid oPEB167 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfB-E109A ORF 
was amplified using oPEB564/734; and 5) the 3́  portion of the mrfB-E109A ORF was amplified 
using oPEB733/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
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pPB168: Plasmid oPEB168 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfB-D172A ORF 
was amplified using oPEB564/736; and 5) the 3́  portion of the mrfB-D172A ORF was amplified 
using oPEB735/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB169: Plasmid oPEB169 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfB-D262A ORF 
was amplified using oPEB564/766; and 5) the 3́  portion of the mrfB-D262A ORF was amplified 
using oPEB765/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB170: Plasmid oPEB170 was constructed using five PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; 4) the 5́ portion of the mrfB-H258A ORF 
was amplified using oPEB564/768; and 5) the 3́  portion of the mrfB-H258A ORF was amplified 
using oPEB767/565. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB171: Plasmid oPEB171 was constructed using four PCR products: 1) the vector pPB47 was 
amplified using oPEB116/117; 2) the upstream portion of amyE and the Pxyl promoter were 
amplified using oPEB370/383; 3) the chloramphenicol resistance cassette and the downstream 
portion of amyE was amplified using oPEB557/377; and 4) the mrfBΔC ORF was amplified 
using oPEB564/737. Clones were verified via Sanger sequencing using oPEB345, oPEB348, and 
oPEB547. 
pPB263: Plasmid pPB263 was constructed using two PCR products: 1) the vector pUT18C was 
amplified using oPEB1017/1018; and 2) the mrfA ORF was amplified using oPEB1026/1027. 
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Clones were verified via Sanger sequencing using oPEB543, oPEB544, oPEB1024, and 
oPEB1025. 
pPB264: Plasmid pPB264 was constructed using two PCR products: 1) the vector pUT18 was 
amplified using oPEB1016/1012; and 2) the mrfA ORF was amplified using oPEB1028/1029. 
Clones were verified by Sanger sequencing using oPEB543, oPEB544, oPEB1019, and 
oPEB1023. 
pPB265: Plasmid pPB265 was constructed using two PCR products: 1) the vector pKT25 was 
amplified using oPEB1014/1015; and 2) the mrfB ORF was amplified using oPEB1030/1031. 
Clones were verified by Sanger sequencing using oPEB547, oPEB1021, and oPEB1022. 
pPB266: Plasmid pPB266 was constructed using two PCR products: 1) the vector pKNT25 was 
amplified using oPEB1012/1013; and 2) the mrfB ORF was amplified using oPEB1032/1033. 
Clones were verified by Sanger sequencing using oPEB547, oPEB1019, and oPEB1020. 
pPB273: Plasmid pPB273 was constructed using two PCR products: 1) the vector pKT25 was 
amplified using oPEB1014/1015; and 2) the mrfBΔC ORF was amplified using oPEB1030/1056. 
Clones were verified by Sanger sequencing using oPEB1021 and oPEB1022. 
pPB274: Plasmid pPB274 was constructed using two PCR products: 1) the vector pKT25 was 
amplified using oPEB1014/1015; and 2) the mrfBΔN ORF was amplified using oPEB1057/1031. 
Clones were verified by Sanger sequencing using oPEB1021 and oPEB1022. 
pPB283: Plasmid pPB283 was constructed using two PCR products: 1) the vector pUT18 was 
amplified using oPEB1016/1012; and 2) the mrfAΔN ORF was amplified using oPEB1053/1029. 
Clones were verified by Sanger sequencing using oPEB543, oPEB544, oPEB1019, and 
oPEB1023. 
pPB284: Plasmid pPB284 was constructed using two PCR products: 1) the vector pUT18 was 
amplified using oPEB1016/1012; and 2) the mrfAΔC ORF was amplified using oPEB1028/1054. 
Clones were verified by Sanger sequencing using oPEB543, oPEB544, oPEB1019, and 
oPEB1023. 
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pPB285: Plasmid pPB285 was constructed using two PCR products: 1) the vector pUT18 was 
amplified using oPEB1016/1012; and 2) the mrfA-N ORF was amplified using oPEB1028/1055. 
Clones were verified by Sanger sequencing using oPEB1019 and oPEB1023. 
gBlocks used in this study 
oPEB1043: 
caaagggggaaatgggatcctaaggaggtatacatATGGCGTACGAACTGGCGAAACGGACTGCGGACGCTGAACAG
AAGCTCGCTACTCGCGACGGACTTCCTGCCCGGGACGGGGCCCTGTTATCTGCTCGCCTTCAGAGAAGATATCAAGA
CCGTATTACGGGAAGCTTTGCGATCCCTGGACGTGAGGGCCGTTACGCTCCAATACCTGACTCTGTTCCACCTGCCC
TGGCAGCAGCCTTAAAGGCGCGTGGTATTGAACAGCTTTACAGCCATCAAGCTGAGGCCTGGGAGGCCTCTCAACGC
GGAGAGCACGTCGCGATCGTAACGCCGACAGCATCCGGCAAGAGCCTGTGCTATACCTTGCCTGTTGTTTCTGCAGC
TATGCAGGATAAGGCGAAGGCGCTCTACCTCTTCCCTACTAAGGCACTGGCTCAAGACCAGGTCGCCGAGCTCCTGG
AGTTGAACAGAGCAGGAGATCTGGGTGTCAAAGCATTCACTTTCGATGGCGATACGCCGGGGGATGCACGTCAAGCT
ATTCGCTTACATGGCGATATTGTCGTGAGTAACCCAGATATGTTACATCAAGCGATACTCCCACATCATACCAAATG
GGCACAGTTTTTTGAGAATTTGCGTTATATAGTGATCGATGAAGTTCATACGTACCGCGGAGTATTCGGGTCCCATG
TGACTAACGTATTGAGACGGCTCAAAAGAATCTGCGCGTTTTACGGCGTACAACCTCAGTTCATTCTCTGTTCTGCA
ACCATTGGCAATCCTCAGGCGCATGCAGAAGCACTCATCGAGGCTCCTGTAACTGCTGTTACTGAATCTGGCGCACC
TACAGGGCCGAAGCAAGTACTTTTGTGGAACCCACCGGTGATAAACCCGGATTTAGGGCTCCGTGCTAGCGCGAGAA
GTCAAAGCAATCGCATAGCCAGAATAGCTATCAAGTCTGGCCTTAAAACTTTAGTATTCGCCCAAACTCGCCTCATG
GTAGAAGTTTTGACGAAGTACTTAAAAGACATTTTCGATCACGACCCGCGTAAACCGCCGCGTATCCGCGCGTACAG
AGGAGGTTATTTACCGACTGAACGGCGGGAAACTGAAAGAGCCATGCGGGCCGGTAATATCGACGGGATAGTATCTA
CTAGCGCTTTGGAACTGGGTGTAGATATCGGAAGCTTGGACGTCGTCATTCTGAATGGCTATCCGGGAAGCGTAGCG
GCCACATGGCAGCGCTTCGGAAGAGCGGGACGTCGCCAACAACCTGCGTTGGGAGTCATGGTCGCCTCAAGCCAACC
ATTAGACCAATACGTTGTGCGGCATCCGGACTTCTTCGCCGAGGCCTCTCCTGAGCACGCCCGGATTGCTCCGGATC
AGCCACTGATTCTCTTCGATCATATAAGATGTGCCGCTTTTGAATTACCGTTTCGGGTGGGCGACGGTTTCGGGCCT
ATTGATCCTGAGGTCTTTCTCGAAGCATTGGCTGAGACAGAGGTGATTCATCGGGAAGGTGAGCGTTGGGAATGGAT
AGCCGACTCATATCCGGCGAATGCTGTGTCCTTGCGGGCTGTGGCAGATGGCAATTTCGTCGTTGTTGACCGGTCTG
ACGGTAGACAACAGATAATCGCGGAGGTTGATTATAGTGCTGCAGCTTTGACACTGTACGAAGGCGCGATCCACATG
GTGCAATCAACTCCATACCAAGTAGAAACTCTTGATTGGGAGGGACGTAAGGCTTACGTGACACGTACTCACGTCGA
CTACTATACGGACTCAATCGACTTTACAAAACTGAAGGTCCTTGATAGATTTGATGGAGGAGTCGCAGGACGTGGCG
ACTCCCATCATGGGGAGGTCCATGTAGTACGTCGCGTCGCTGGTTACAAAAAGATTCGCTATTATACCCATGAGAAT
ATCGGATACGGACCTGTTAACTTGCCGGACCAAGAACTTCACACCACCGCTGTCTGGTGGCAATTGCCACAGGCATT
ACTGCTGAGAGCCTTTGCCAGCCGGCAAGATCCTTTAGATGGTTTCTTGGGAGCTGCATATGCGTTGCACATCGTGG
CAACTGTCGCAGTAATGGCCGATGCAAGAGACTTGCAAAAGTCTGTAGGAAACGGAGATGGCTCATGGTTCGCAATT
GCAGACCAGTCAGGACGCGGTCAACTCCGGGGGAGTGAAGGTGACCCGGGCGGTGTTGAACTCTTGCAGGAATTTGT
TCCGACGGTGTATCTCTATGACAACTTTCCGGGAGGCGTGGGACTGAGCGAACCTCTCTGGCAACGGCAGGCAGAGC
TTGTGCAAAGAGCGAGAGAGCTCGTCCAAAGATGTGACTGCAAGGCCGGTTGCCCTGCTTGCGTAGGGCCGGTGTTG
GCAGCGCAAGAGGAAGACGAAACATCCCCTCGGGCGCTGGCACTCAGAGTCCTTGACTTGTTTGACGCGGAGGCCTG
TAGACATGTACCGGACGTAGTGGTGACTACACGCGACCCTATGGAATTACTTGCCCCGTAAtaaCGGTTTCCATATG
GGGATTGGTGGCGACGACT 
oPEB1044: 
caaagggggaaatgggatcctaaggaggtatacatATGAAAAAAAAAAGTTTAACCGAGTTGATAAGTGAACTCAAA
GGTAACGAAAACATAGTTAACTGGCACGAAATAGAACCGAGAGAAGCTAGAACGCGGCCTATGCCTGAAAGTATCGA
TGAGAGAATAAAGGCCGCCTTGAGCAAAAGAGGTATCGACGAATTATATACGCACCAATTCTCAGCTTTCCAATACG
TGCAAAAAGGGGAAAGTATTGTTACTGTCACCCCGACTGCTTCAGGAAAGACACTCAGTTACAATTTGCCAGTTCTG
CAAAGTATAGCCCAAGATGAGACGAATCGCGCACTTTACCTTTTCCCGACTAAGGCCCTGGCTCAAGATCAAAAATC
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TGAGCTGAACGAAATAATAGACGAAATGGGAATCGATATTAAAAGCTTTACGTACGATGGTGATACCAGCCCTGCTA
TACGGCAGAAAGTACGGAAAGCCGGTCATATCGTCATTACCAATCCTGACATGCTTCACAGTGCCATATTGCCGCAC
CATACAAAGTGGGTCAGTTTATTTGAAAACCTGAAGTACATCGTAATTGATGAGCTCCATACATATCGGGGCGTCTT
CGGCTCCCACGTAGCAAATGTTATACGTCGCCTGAAAAGAATATGTCGTTTTTACGGATCAGACCCAGTATTCATCT
GTACTTCAGCCACTATTGCTAATCCTAAGGAGTTGGGCGAGCAGTTGACTGGCAAGCCGATGCGTCTGGTCGATGAC
AATGGTGCGCCTTCTGGTAGAAAGCATTTTGTATTTTACAATCCTCCGATAGTTAACAAGCCGCTCAATATTCGTAA
GAGCGCGACAGCGGAGGTAAATGAACTGGCCAAGGAATTTCTTAAGAACAAGGTACAGACTATCGTCTTTGCACGGT
CACGCGTCCGTGTTGAAATTATATTGAGCCACATCCAGGAACTTGTAAAAAAGGAGATTGGTACTAAGAGCATCCGC
GGTTACCGGGGCGGGTACCTCCCGAAGGAAAGACGCGAGATAGAGCGCGGACTCCGGGAAGGTGAAATCCTGGGGGT
GGTAAGTACGAATGCTCTGGAACTCGGAGTGGACATCGGACAGTTACAGGTGTGTGTGATGACAGGCTATCCGGGAA
GTGTCGCGTCCGCATGGCAGCAAGCGGGCCGGGCCGGACGGAGACATGGCGAAAGCTTAATAATCATGGTAGCCAAC
TCCACGCCGATCGACCAGTATATAGTACGTCACCCGGAATACTTTTTTAACCGCTCTCCTGAAAGTGCTCGCATTAA
CCCGGAGAATCTTATTATCTTGGTCGATCACCTTAAGTGCGCGGCCTATGAATTACCATTCAGAGCTGATGAGGAGT
TCGGCCCTATGGACGTGTCTGATATTCTTGAATATTTACAAGAAGAAGCCGTCTTACATCGGAATGGCGAGCGTTAC
CATTGGGCATCCGAGAGCTTCCCTGCTAGCAATATCAGCCTCCGTTCTGCGTCACAGGAAAACGTTGTGATAGTTGA
TCAGTCTGACATAGCCAACGTTAGAATTATAGGAGAAATGGACCGTTTCTCCGCCATGACCCTTTTACATGATGAGG
CAATATACCTGCATGAAGGAGTGCAATATCAAGTTGAGAAACTCGATTGGGACCACAAAAAAGCGTACGTCCGGAAA
GTGGACGTGGAGTATTATACAGATGCCAACTTAGCCGTCCAGCTGAAGGTTTTAGAAATAGACAAGACTAAAGAAAA
GTCTAGAACGTCCCTCCATTATGGTGATGTCACAGTCAACGCGCTCCCAACGATTTTCAAAAAAATTAAAATGACAA
CCTTTGAGAACATTGGGAGCGGGCCTATCCACTTGCCGGAGGAAGAGTTGCATACCTCTGCCGCTTGGCTCGAAATT
AAGACGGCCGATGAAGATATAGGAGAAAAGACGCTCGAACAGCTCTTACTTGGTATATCAAATGTTTTACAGCACAT
AGTGCCGGTCTATATCATGTGCGACCGGAACGATGTTCATGTAATATCCCAGATCAAAGCTGCCCATACCGGACTTC
CGACAATTTTCTTGTATGATCACTATCCTGGGGGCATTGGCCTTGCTGAAGAGGTTTTTAAACGCTTCAGCGATATA
AACGAAGCAGCCAAACAGCTGATAAAGCAATGCCCATGCCACGACGGTTGTCCTTCATGTATTGGAACTGAAATCGA
GGGTATAAAAGCTAAAGAGCGTATACTGCAGTTGTTAGTTCAAATGGCGTAAtaaCGGTTTCCATATGGGGATTGGT
GGCGACGACT 
oPEB1045: 
caaagggggaaatgggatcctaaggaggtatacatATGTCATTAAGTTTGGATAAGCTTCGCCTGCTTCGGCGGCAA
GCCGGAGACCCAAAAGCAAGCACTCCTGCAGTCCCAGATGTACCGCCGGCCCCACCTGCCCCAGTTGCTGCTAACGA
CGCCCGCCAGCCACCTGCAGAGCGTAGTGTATTCGCCTGGGTGGAGCAAGAGATCCGCCACAAGCCAACAGGCGCGG
CTGCGCCAACCCCTGCTTCAGCACCTCTGCGGCGGCCAGAGGTTGGGTCCCTGCATAGACTCTTGGGGCTGCGCACC
AGAAGCGGGGCCACTCCTGCTCGCGCCAGTGCACAGGATCGCCAGTTGCCTGGAGAGGAAATAGCACCGGGCCTGTT
CCTCATTGAATCCCTTCAGCCGCAGGCTATACCGGCTCAACCTCTTAGCTTAGATTTCGCTCGGCGGGATGGCGAAC
ACGTTGCCGCTAGAGATTTGTTGTTTTTTGACACAGAAACCACGGGTCTTGCTGGCGGAACTGGCACGCGCGCTTTT
ATGATCGGAGCAGCCGACTGGCATGTATGCCCTCAACGTGGGGAGGGCCTGAGAATCAGACAACTCCTTATGGCTAC
GATGGCTGCTGAAGACGCTATGTTAGCAACGTTTGCAGGTTGGTTGCAGCCAAGTACGGTATTTTGCAGTTACAATG
GCCGTAGCTATGACGCCCCTTTATTGAAAGCTCGGTATCGTTTGGCAAGACAGCGCGACCCAATCAGTGCGTTAGAT
CACGTGGACCTGCTCTACCCAACACGTAGACGTTATCGCGGAACCTGGGAGAATTGCAAGCTTAGCACCATAGAACG
TCAGCTCCTTCGTGTAGTACGTGAGGATGACCTCCCTGGTAGTGAAGCGCCAGGTGCTTGGCTTCGGTTTCTGCGGG
GAGGAGACGCCGTTAACTTGAGACGCGTTGCAGACCATAATCACCAGGATGTAGTAACCCTTGCCCTGCTCCTGCAA
AGACTTGTCCGCGAGGAGCAACGTGAACGCGAGACACTTGCCCTTGTCGGACAGTAAtaaCGGTTTCCATATGGGGA
TTGGTGGCGACGACT 
oPEB1046: 
caaagggggaaatgggatcctaaggaggtatacatATGTCTTTGAAGGGAAAGTTACAACGTATGAAGAAACACATG
GTCCTTGACGAAGGAGAGCACAAAATAGAGGCGGGTCAGCGCGAGAACAATTTTGCAGAAATCCCATTTTTAGAGGA
ATGGGAGGCTTTTGGCATGAAGCCTTTCTTTTTTGAAGACGAATATTGTTTGATCCGTGAGGTAGAATATCCATTAT
CCCACCGCCATGGACTTTATCGGTTCAGTGAGTTAGATGAGGTCATAACATTGTGGAACCAAAGCAGTCTCAGTCAT
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ACGCTCAGTGCTAAGGGTTACAACAAAAATAGCCTTTTTTTTTTTGATACTGAAACCACAGGATTGGGAGGGGGGGC
TGGGAATACGATTTTTTTATTAGGACACGCACGGGTCTATGAAGACCGCGTGACAGTCAAGCAACATCTTCTCCCTA
AACCTGGTAACGAGGTGGCCTTGTATCAGTCCTTCCTGAGTGAGGTGGACATTACAAGCCTTGTTACATATAATGGC
AAAGCGTTCGATTGGCCACAGGTAAAGACTCGGCACACATTAATACGTGATCGTCTGCCAAAACTTCCTGAATTTGG
CCATTTCGATCTTCTTCATGGTGCTCGTCGCTTGTGGAAACACAAGATGGATCGGGTAAGCCTGGGAACGGTGGAAA
AGGAAGAATTGGGTATTCACCGGCAGGAGGACACCCCTGGGTACCTCGCTCCAATGCTCTATTTTCATTTCATTAAA
GCGCAAGAACCAGACCTTCTTAAAGGTGTACTTCACCACAATGAGATGGACGTTCTGTCTTTGATTTCTTTATATAT
CCACATGTCAAAAAAAATCTTATCCGCTAGTTACGCTAGTAAGGAACATATTGAGCACTCCGAAGCATATGCCATGG
CGAAGTGGTTTATGGCTCACAAAGAAACCGACCAAGCGGTGAAGCAACTTGAGCGGTTAAAGGAAAAATCATTCGAG
GACCAGGACCGTGCTCGGCTTGATCTCTCCCTCCTTTATAAAAAACAAAACAGACTCGAAGAGGCAGTACCTTTGTG
GGAAAAACTGAGCCGCTCTCAGAATCAGAAGTGTCGTTACACTGCCGTTATAGAGTTAGCCAAGTACTTTGAGCATA
AAAAAAAGGAATTCGGCAAAGCCTTATACATAGCGGAGCAACTTTTGAGTGATGCGGCGTTTCTGTCAGAAAAGGAA
AGTGAGAAGTTACAAGTACGCATAGCAAGACTTAAAAGAAAGTATTCCAGCTAAtaaCGGTTTCCATATGGGGATTG
GTGGCGACGACT 
oPEB1047: 
caaagggggaaatgggatcctaaggaggtatacatATGAAAAAGAAGAGCCTCTCAGAGCTTATTCAAGAGTTAAAG
AATCATGAGAATATAGTGCATTGGCATGAGGAGGAGCCGCGGGAAGCCAAAACTATGCCAATGCCGGAACAAGTTGA
CCCTAATATACGTGCAGCGCTGGAAAAGCGTGGAATTGAGCGGTTATTTACTCACCAGTACTCCGCGTTCCAAACTG
TCCAGAACGGTGAGAGTATTGTTGCAGTCACGCCGACCGCCTCTGGAAAGACTTTATGTTATAATCTTCCTGTATTA
CAGAGCATCGCCGAAGACGCGAGTTCCCGGGCTTTGTACTTGTTCCCAACCAAGGCGCTCGCACAGGACCAAAAGAG
CGAGCTCAACGAAATTATTGACGAGACAGGCATGGATATTAAGAGTTTCACATATGACGGCGATACTTCTCCGGCGA
TAAGACAGAAAGTACGTAAAGCCGGGCACATCGTTATCACTAACCCGGATATGCTCCATTCTGCGATCCTGCCTCAC
CATACCAAGTGGGTTAGCCTTTTCGAAAACTTGAAATATATCGTGATTGATGAACTTCATACCTACAGAGGCGTGTT
TGGTAGCCATGTCGCTAACGTGATTCGTCGTCTTATGCGCATTTGTGCCTTTTACGGATCAAAACCTTCTTTTATTT
GCACTTCAGCGACGATTGCTAATCCACGGGAATTGGCAGAACAGTTGACAGGGAAGTCAGTGCGTCTGATCGACGAT
AACGGGGCTCCAGCAGGGCGGAAACATTTTGCGTTCTATAATCCTCCGATAGTCAACAAACCGCTGCATATCCGCAA
GTCTGCAACGGTAGAGGTGAACGAATTAGCCAAGACTTTCCTTAAGAATAAAATACAAACGATCGTGTTTGCGCGGT
CCCGGGTGAGAGTGGAAATCATCCTTAGCCACATACAAGAGATAGTTAAGAAGGAGATCGGTGCTAAAAGCGTTCGT
GGTTATCGGGGCGGGTACCTCAGTAAGGAGAGAAGAGAGATCGAACGCGGACTCAGAGATGGAAGCATCCTTGGTGT
AGTCAGTACAAATGCTCTTGAGCTCGGTGTTGACATTGGACAGCTCCAAGTGTGCGTTATGACTGGTTATCCTGGAT
CTGTTGCAAGCGCTTGGCAGCAGGCAGGACGGGCCGGTAGACGGCAAGGCGAGGCATTGATTGTCATGGTTGCAAAC
TCAGATCCAATAGACCAGTACATAGTTAGACACCCTGATTACTTCTTCAAACGTAGTCCTGAAAGCGCACGCATAAA
CCCGGACAATCTGATTATACTTGTAGACCACTTAAAATGCGCAGCCTACGAGCTCCCTTTCCGTGCTGACGAGACAT
TCGGCGAGAACGACGCCCGTGATATTTTGGAATACCTCGAAGAAGAAGGCGTATTACATGAAAATCGGGAAAGATAT
CATTGGGCATCAGAATCATTTCCGGCGTCTAACATCAGTTTGCGGTCAGCATCTCAGGAGAACGTAGTCATTGTGGA
CCGCTCTGAGACGGCGGATGTCAAAATCATAGGGGAAATGGATCGCTTCTCTGCGATGACCCTCTTGCATGATGAAG
CGATCTATCTTCACGAAGGGGTGCAGTACCAGGTTGAAAAATTAGATTGGGATCATAAAAAGGCATACGTCAGAAAA
GTTGACGTAGAGTACTACACTGATGCAAACCTGGCAGTACAACTCAAGGTGCTTGACATAGATCGCACAGATAGCCG
TAAGAAAACAGCACTCCACTTTGGAGATGTTACCGTGAATGCGCTTCCGACTATATTTAAAAAAATTAAAATGACGA
CGTTCGAAAACATAGGTTCTGGTCCAATACACCTCCCGGAGGAAGAGTTGCACACTTCAGCAGCATGGTTGGAACTT
AAAGAAACTGATTCCGAGATAGGTGAAAAGACATTAGAGCAGCTGCTCCTTGGTATCGCACACGTTTTGCAGCACAT
TGTCCCTGTCTATGTCATGTGTGATCGTAATGACGTCCATGTAGTTCCTCAAATCAAGGCAGCACATACTGGCCTCC
CAACAATTTTTCTCTACGATCACTATCCTGGTGGCATTGGTTTAGCCGATGAAGTTTATAAGCGCTTCGATGAAATA
AATGAGGGAGCAGAACGCCTTATTCGTCAATGTCCATGTCAAGATGGATGTCCGTCTTGCATTGGGAGCGAAATAGA
AGGGATAGATGCGAAGAAGGCCATTCTTCGCTTACTGAATTATGTTTAAtaaCGGTTTCCATATGGGGATTGGTGGC
GACGACT 
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oPEB1048: 
caaagggggaaatgggatcctaaggaggtatacatATGTCTCTTAAAAATAAATTAAAGCGTATGAAGAATCACTTA
AATGTGCCGGAGGCAGAGAAAAAGCCAGCAGCAAGTCAATTGTCTGTCCCGGATATTCAAGTACCGTTCCGGGAGGA
GTGGGAAGCTCTGGGAGTCAAGCCGTTTTTTTTTGAAGACGAATACTGTTTGATTAGAGAGACGGTATATCCGTTAT
CCCATCGCCATGGGAGATATAGTTTTAGTGAGCTCGACGACGTGATGGCCTTATGGAATAAGGGAGGGCTCACACAC
ACCTTGTCTGCGAAAGGGTATGAGAAGAGCCAACTCTTTTTTTTCGATACGGAAACCACAGGCTTAGGAGGAGGTGC
GGGCAATATGATCTTTTTGCTTGGACACGCTCGTGTTTACGAAGATCGGGTTGCGGTGAAGCAGCACTTATTGCCAA
AGCCGGGCAATGAAACGGCATTGTACAAGAGCTTTCTGAGCGAGGTGGATATAACATCCCTTGTGACCTACAATGGA
AAAGCCTTCGATTGGCCACAGGTGAAAACGCGCCACACGCTTTTACGCGATAGACTGCCAAAGCTGCCAGATTTCGG
GCATTTCGACCTGTTGCATGGCGCTAGACGCCTGTGGAAACACAAATTGGAGCGTGTCTCATTATCCGCGGTAGAAA
ATGAGGAGTTAGCATTCAAACGTGACGAAGATACTCCTGGTTACCTCGCTCCGATGCTTTACTTCCAATTCCTTAAA
GCGGAAGACCCTGCCTTACTCAAGGGAGTGTTAAGCCATAATGAGCAGGACGTCCTCTCCCTTATAGCGCTTTACAT
CCATATGTCCAAAAAAATATTTGCTTCCTCAGACCAAACGTCCGAACGGCAAGAAGCGTATGCCATGGCTAAATGGT
TCATAGCTCACAAAGAGACCGACCGCGCGGTCAGTCAACTTGAGGCATTACAGGGTAAGGATTTCGAAGACTCTGAC
AGAGCCCTTTTTGATCTCGCTATGCTTTATAAGAAGCAAAATCGCCGTCAAGATGCTGTACCGCTCTGGGAAAAACT
TACAGATAGTGATTTACACACGTGTCGTCACCATAGTGCGGTCGAACTCGCCATCTACTTCGAACATCACGCTAAGG
ATTATAAGAAGGCACTCCAAGCCGCCCAGCAGGCGGCGGAGGACGGAGAGATATCTGAAAAAGAGGCAGAGAAACTC
CATGTCCGTATAGCCCGTCTGAAAAGAAAGTACAGTAGCTAAtaaCGGTTTCCATATGGGGATTGGTGGCGACGACT 
Supplemental alignments 
MrfA alignment 
Pa-MrfA      MAYELAKRTADAEQKLATRDGLPARDGALLSARLQRRYQDRITGSFAIPGREGRYAPIPD 60 
Sp-MrfA      -----------------------MKKKSLSELIQELKNHENIVHWHEEEPREAKTMPMPE 37 
Bs-MrfA      -----------------------MKKKSLTELISDLKGNENVVNWHEIEPREAKTRPMPE 37 
Bc-MrfA      -----------------------MKKKSLTELISELKGNENIVNWHEIEPREARTRPMPE 37 
                                     :. :* .   : : ::.:.  .    **.:  *:*: 
 
Pa-MrfA      SVPPALAAALKARGIEQLYSHQAEAWEASQRGEHVAIVTPTASGKSLCYTLPVVSAAMQD 120 
Sp-MrfA      QVDPNIRAALEKRGIERLFTHQYSAFQTVQNGESIVAVTPTASGKTLCYNLPVLQSIAED 97 
Bs-MrfA      SIDERIKAALSKRGIDELYTHQYSAFQYVQKGESIVTVTPTASGKTLCYNLPVLQSIAQD 97 
Bc-MrfA      SIDERIKAALSKRGIDELYTHQFSAFQYVQKGESIVTVTPTASGKTLSYNLPVLQSIAQD 97 
             .:   : ***. ***:.*::** .*::  *.** :. ********:*.*.***:.:  :* 
 
Pa-MrfA      -KAKALYLFPTKALAQDQVAELLELNRAGDLGVKAFTFDGDTPGDARQAIRLHGDIVVSN 179 
Sp-MrfA      ASSRALYLFPTKALAQDQKSELNEIIDETGMDIKSFTYDGDTSPAIRQKVRKAGHIVITN 157 
Bs-MrfA      ETNRALYLFPTKALAQDQKSELNEIIDEMGIDIKSFTYDGDTSPAIRQKVRKAGHIVITN 157 
Bc-MrfA      ETNRALYLFPTKALAQDQKSELNEIIDEMGIDIKSFTYDGDTSPAIRQKVRKAGHIVITN 157 
              . :************** :** *:    .:.:*:**:****    ** :*  *.**::* 
 
Pa-MrfA      PDMLHQAILPHHTKWAQFFENLRYIVIDEVHTYRGVFGSHVTNVLRRLKRICAFYGVQPQ 239 
Sp-MrfA      PDMLHSAILPHHTKWVSLFENLKYIVIDELHTYRGVFGSHVANVIRRLMRICAFYGSKPS 217 
Bs-MrfA      PDMLHSAILPHHTKWVSLFENLKYIVIDELHTYRGVFGSHVANVIRRLKRICRFYGSDPV 217 
Bc-MrfA      PDMLHSAILPHHTKWVSLFENLKYIVIDELHTYRGVFGSHVANVIRRLKRICRFYGSDPV 217 
             *****.*********..:****:******:***********:**:*** *** *** .*  
 
Pa-MrfA      FILCSATIGNPQAHAEALIEAPVTAVTESGAPTGPKQVLLWNPPVINPDLGLRASARSQS 299 
Sp-MrfA      FICTSATIANPRELAEQLTGKSVRLIDDNGAPAGRKHFAFYNPPIVNKPLHIRKSATVEV 277 
Bs-MrfA      FICTSATIANPKELGEQLTGKPMRLVDDNGAPSGRKHFVFYNPPIVNKPLNIRRSATAEV 277 
Bc-MrfA      FICTSATIANPKELGEQLTGKPMRLVDDNGAPSGRKHFVFYNPPIVNKPLNIRKSATAEV 277 
             **  ****.**:  .* *    :  : :.***:* *:. ::***::*  * :* **  :  
 
Pa-MrfA      NRIARIAIKSGLKTLVFAQTRLMVEVLTKYLKDIFDHDPRKPPRIRAYRGGYLPTERRET 359 
Sp-MrfA      NELAKTFLKNKIQTIVFARSRVRVEIILSHIQEIVKKE-IGAKSVRGYRGGYLSKERREI 336 
Bs-MrfA      NELAKEFLKNKVQTIVFARSRVRVEIILSHIQELVKKE-IGTKSIRGYRGGYLPKERREI 336 
Bc-MrfA      NELAKEFLKNKVQTIVFARSRVRVEIILSHIQELVKKE-IGTKSIRGYRGGYLPKERREI 336 
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             *.:*:  :*. ::*:***::*: **:: .:::::..::      :*.****** .****  
 
Pa-MrfA      ERAMRAGNIDGIVSTSALELGVDIGSLDVVILNGYPGSVAATWQRFGRAGRRQQPALGVM 419 
Sp-MrfA      ERGLRDGSILGVVSTNALELGVDIGQLQVCVMTGYPGSVASAWQQAGRAGRRQGEALIVM 396 
Bs-MrfA      ERGLREGDILGVVSTNALELGVDIGQLQVCVMTGYPGSVASAWQQAGRAGRRHGESLIIM 396 
Bc-MrfA      ERGLREGEILGVVSTNALELGVDIGQLQVCVMTGYPGSVASAWQQAGRAGRRHGESLIIM 396 
             **.:* *.* *:***.*********.*:* ::.*******::**: ******:  :* :* 
 
Pa-MrfA      VASSQPLDQYVVRHPDFFAEASPEHARIAPDQPLILFDHIRCAAFELPFRVGDGFGPIDP 479 
Sp-MrfA      VANSDPIDQYIVRHPDYFFKRSPESARINPDNLIILVDHLKCAAYELPFRADETFGENDA 456 
Bs-MrfA      VANSTPIDQYIVRHPEYFFNRSPESARINPENLIILVDHLKCAAYELPFRADEEFGAMEV 456 
Bc-MrfA      VANSTPIDQYIVRHPEYFFNRSPESARINPENLIILVDHLKCAAYELPFRADEEFGPMDV 456 
             **.* *:***:****::* : *** *** *:: :**.**::***:*****..: **  :  
 
Pa-MrfA      EVFLEALAETEVIHREGERWEWIADSYPANAVSLRAVADGNFVVVDRSDGRQ-QIIAEVD 538 
Sp-MrfA      RDILEYLEEEGVLHENRERYHWASESFPASNISLRSASQENVVIVDRSETADVKIIGEMD 516 
Bs-MrfA      SDILEYLQEEAVLHRNGERYHWASESFPASNISLRSASQENVVIVDQSDIANVRIIGEMD 516 
Bc-MrfA      SDILEYLQEEAVLHRNGERYHWASESFPASNISLRSASQENVVIVDQSDIANVRIIGEMD 516 
               :** * *  *:*.: **:.* ::*:**. :***:.:: *.*:**:*:  : :**.*:* 
 
Pa-MrfA      YSAAALTLYEGAIHMVQSTPYQVETLDWEGRKAYVTRTHVDYYTDSIDFTKLKVLDRFDG 598 
Sp-MrfA      RFSAMTLLHDEAIYLHEGVQYQVEKLDWDHKKAYVRKVDVEYYTDANLAVQLKVLDIDRT 576 
Bs-MrfA      RFSAMTLLHDEAIYLHEGVQYQVEKLDWDHKKAYVRKVDVEYYTDANLAVQLKVLEIDKT 576 
Bc-MrfA      RFSAMTLLHDEAIYLHEGVQYQVEKLDWDHKKAYVRKVDVEYYTDANLAVQLKVLEIDKT 576 
               :*   *:: **:: :.. ****.***: :**** :..*:****:   .:****:     
 
Pa-MrfA      GVAGRGDSHHGEVHVVRRVAGYKKIRYYTHENIGYGPVNLPDQELHTTAVWWQLPQALLL 658 
Sp-MrfA      DSRKKTALHFGDVTVNALPTIFKKIKMTTFENIGSGPIHLPEEELHTSAAWLELKETDSE 636 
Bs-MrfA      KEKSRTSLHYGDVTVNALPTIFKKIKMTTFENIGSGPIHLPEEELHTSAAWLEIKTADED 636 
Bc-MrfA      KEKSRTSLHYGDVTVNALPTIFKKIKMTTFENIGSGPIHLPEEELHTSAAWLEIKTADED 636 
                 :   *.*:* *    : :***:  *.**** **::**::****:*.* ::  :    
 
Pa-MrfA      RAFASRQDPLDGFLGAAYALHIVATVAVMADARDLQKSVGNGDGSWFAIADQSGRGQLRG 718 
Sp-MrfA      IGEKT---LEQLLLGIAHVLQHIVPVYVMCDRNDVHVV---------------------- 671 
Bs-MrfA      IGEKT---LEQLLLGISNVLQHIVPVYIMCDRNDVHVV---------------------- 671 
Bc-MrfA      IGEKT---LEQLLLGISNVLQHIVPVYIMCDRNDVHVI---------------------- 671 
              .  :     : :** : .*: :. * :*.* .*::                         
 
Pa-MrfA      SEGDPGGVELLQEFVPTVYLYDNFPGGVGLSEPLWQRQAELVQRARELVQRCDCKAGCPA 778 
Sp-MrfA      -----PQIKAAHTGLPTIFLYDHYPGGIGLADEVYKRFDEINEGAERLIRQCPCQDGCPS 726 
Bs-MrfA      -----SQIKAAHTGLPTIFLYDHYPGGIGLAEEVFKRFSDINEAAKQLITHCPCHDGCPS 726 
Bc-MrfA      -----SQIKAAHTGLPTIFLYDHYPGGIGLAEEVFKRFSDINEAAKQLIKQCPCHDGCPS 726 
                    ::  :  :**::***::***:**:: :::*  :: : *..*: :* *: ***: 
 
Pa-MrfA      CVGPVLAAQEEDETSPRALALRVLDLFDAEACRHVPDVVVTTRDPMELLAP 829 
Sp-MrfA      CIGSEIEGIDAKKAI-----LRLLNYV------------------------ 748 
Bs-MrfA      CIGTEIEGIKAKERI-----LQLLDQMS----------------------- 749 
Bc-MrfA      CIGTEIEGIKAKERI-----LQLLVQMA----------------------- 749 
             *:*  : . . .:       *::*  .                         
 
MrfB alignment 
Pa-MrfB      MSLSLDKLRLLRRQAGDPKASTPAVPDVPPAPPAPVAANDARQPPAERSVFAWVEQEIRH 60 
Sp-MrfB      MSLKNKLKR-MKNHLN--------VP------------------------------EAEK 21 
Bs-MrfB      MSLKGKLQR-MKKHMA--------LD------------------------------EGEQ 21 
Bc-MrfB      MSLKGKLQR-MKKHMV--------LD------------------------------EGEH 21 
             ***. .  * ::.:          :                               * .: 
 
Pa-MrfB      KPTGAAAPTP-ASAPLRRPEVGSLHRLLGLRTRSGATPARASA-----QDRQLPGEEIAP 114 
Sp-MrfB      KPAASQLSVPDIQVPFREE-----WEALGV------KPFFFEDEYCLIRETVYPL-SHRH 69 
Bs-MrfB      KIEAGKQENHFDDIPFLEE-----WEAFGM------KPFIFEDEYCLIREVEYPL-SHRH 69 
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Bc-MrfB      KIEAGQRENNFAEIPFLEE-----WEAFGM------KPFFFEDEYCLIREVEYPL-SHRH 69 
             *  ..       . *: .       . :*:      .*   .      ::   *  .    
 
Pa-MrfB      GLFLIESLQPQAIPAQPLSLDFARRDGEHVAARDLLFFDTETTGLAGGTGTRAFMIGAAD 174 
Sp-MrfB      GRYSFSELDDVMALWNKGGLT-HTLSAKGYEKSQLFFFDTETTGLGGGAGNMIFLLGHAR 128 
Bs-MrfB      GLYSFSELEEVITLWNQSGLS-HTLSAKGYNKNNLFFFDTETTGLGGGAGNTIFLLGHAR 128 
Bc-MrfB      GLYRFSELDEVITLWNQSSLS-HTLSAKGYNKNSLFFFDTETTGLGGGAGNTIFLLGHAR 128 
             * : :..*:      :  .*     ..:     .*:*********.**:*.  *::* *  
 
Pa-MrfB      WHVCPQRGEGLRIRQLLMATMAAEDAMLATFAGWLQPSTVFCSYNGRSYDAPLLKARYRL 234 
Sp-MrfB      VYE-----DRVAVKQHLLPKPGNETALYKSFLSEV-DITSLVTYNGKAFDWPQVKTRHTL 182 
Bs-MrfB      VYE-----DRVTVKQHLLPKPGNEVALYQSFLSEV-DITSLVTYNGKAFDWPQVKTRHTL 182 
Bc-MrfB      VYE-----DRVTVKQHLLPKPGNEVALYQSFLSEV-DITSLVTYNGKAFDWPQVKTRHTL 182 
              :      : : ::* *: . . * *:  :* . :   * : :***:::* * :*:*: * 
 
Pa-MrfB      ARQRDP-ISALDHVDLLYPTRRRYRGTWENCKLSTIERQLLRVVREDDLPGSEAPGAWLR 293 
Sp-MrfB      LRDRLPKLPDFGHFDLLHGARRLWKHKLERVSLSAVENEELAFKRDEDTPGYLAPMLYFQ 242 
Bs-MrfB      IRDRLPKLPEFGHFDLLHGARRLWKHKMDRVSLGTVEKEELGIRRLEDTPGYLAPMLYFH 242 
Bc-MrfB      IRDRLPKLPEFGHFDLLHGARRLWKHKMDRVSLGTVEKEELGIHRQEDTPGYLAPMLYFH 242 
              *:* * :  :.*.***: :** :: . :. .*.::*.: * . * :* **  **  ::: 
 
Pa-MrfB      FLRGGDAVNLRRVADHNHQDVVTLALLLQRLVREEQR---------E-RETLALVGQ--- 340 
Sp-MrfB      FLKAEDPALLKGVLSHNEQDVLSLIALYIHMSKKIFASSDQT---SERQEAYAMAKWFIA 299 
Bs-MrfB      FIKAQEPDLLKGVLHHNEMDVLSLISLYIHMSKKILSESHAPK---EHSEAYAMAKWFMA 299 
Bc-MrfB      FIKAQEPDLLKGVLHHNEMDVLSLISLYIHMSKKILSASYASKEHIEHSEAYAMAKWFMA 302 
             *::. :   *: *  **. **::*  *  :: ::            *  *: *:.      
 
Pa-MrfB      ------------------------------------------------------------ 340 
Sp-MrfB      HKETDRAVSQLEALQGKDFEDSDRALFDLAMLYKKQNRRQDAVPLWEKLTDSDLHTCRHH 359 
Bs-MrfB      HKETDQAIKQLERLIEKSFEDQDSARLDLSLLYKKQNRLEEAVPLWEKLSRSQNQKCRYA 359 
Bc-MrfB      HKETDQAVKQLERLKEKSFEDQDRARLDLSLLYKKQNRLEEAVPLWEKLSRSQNQKCRYT 362 
                                                                          
 
Pa-MrfB      ------------------------------------------------------ 340 
Sp-MrfB      SAVELAIYFEHHAKDYKKALQAAQQAAED-GEISEKEAEKLHVRIARLKRKYSS 412 
Bs-MrfB      AVIELAKYFEHKKKEFGKALQVAEQSLSDAACLSEKETEKLHVRIARLKRKYSS 413 
Bc-MrfB      AVIELAKYFEHKKKEFGKALYIAEQLLSDAAFLSEKESEKLQVRIARLKRKYSS 416 
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CHAPTER V 
MutS2 promotes homologous recombination in Bacillus subtilis 
 
Abstract 
Bacterial MutS proteins are subdivided into two families, MutS1 and MutS2. MutS1 
family members recognize DNA replication errors during their participation in the well-
characterized mismatch repair pathway (MMR). In contrast, to the well-described function of 
MutS1, the function of MutS2 in bacteria has remained less clear. In Helicobacter pylori and 
Thermus thermophilus, MutS2 has been shown to suppress homologous recombination. The role 
of MutS2 is unknown in the Gram-positive bacterium Bacillus subtilis.  In this work, we 
investigated the contribution of MutS2 to maintaining genome integrity in B. subtilis. We found 
that deletion of mutS2 renders B. subtilis sensitive to the natural antibiotic mitomycin C (MMC), 
which requires homologous recombination for repair. We demonstrate that the C-terminal Smr 
domain is necessary but not sufficient for tolerance to MMC. Further, we developed a 
CRISPR/Cas9 genome editing system to test if the inducible prophage PBSX was the underlying 
cause of the observed MMC sensitivity. Genetic analysis revealed that MMC sensitivity was 
dependent on recombination and not on nucleotide excision repair or a symptom of prophage 
PBSX replication and cell lysis. We found that deletion of mutS2 resulted in decreased 
transformation efficiency using both plasmid and chromosomal DNA. Further, deletion of mutS2 
in a strain lacking the Holliday junction endonuclease recU resulted in increased MMC 
sensitivity and decreased transformation efficiency, suggesting that MutS2 could function 
redundantly with RecU. Together, our results support a model where B. subtilis MutS2 helps to 
promote homologous recombination, demonstrating a new function for bacterial MutS2.  
                                                 
The contents of this chapter were published in the Journal of Bacteriology by Peter E. Burby and Lyle A. Simmons. 
I designed and performed the experiments, analyzed the data. LAS and I wrote the manuscript. 
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Importance 
Cells contain pathways that promote or inhibit recombination. MutS2 homologs are Smr-
endonuclease domain containing proteins that have been shown to function in anti-recombination 
in some bacteria. We present evidence that B. subtilis MutS2 promotes recombination providing 
a new function for MutS2. We found that cells lacking mutS2 are sensitive to DNA damage that 
requires homologous recombination for repair, and have reduced transformation efficiency. 
Further analysis indicates that the C-terminal Smr domain requires the N-terminal portion of 
MutS2 for function in vivo. Moreover, we show that a mutS2 deletion is additive with a recU 
deletion suggesting that these proteins may have a redundant function in homologous 
recombination. Together, our study shows that MutS2 proteins have adapted different functions 
that impact recombination. 
 
Introduction 
Many processes contribute to maintaining genetic information and generating genetic 
variation in bacterial cells. One process, critical for the repair of DNA breaks and horizontal 
gene transfer, is homologous recombination. Homologous recombination has been well-defined 
in organisms ranging from bacteria to mammals [for review (1)]. The Gram-positive soil 
bacterium Bacillus subtilis is a naturally competent organism that can uptake DNA from its 
surroundings and, if sufficient homology exists, incorporate the exogenous DNA into its 
chromosome [for review (2)]. In B. subtilis a number of proteins have been shown to function in 
promoting homologous recombination either by assaying for DNA uptake and integration or 
through the study of DNA damaging agents called clastogens that require homologous 
recombination for repair [for review (3, 4)]. These approaches have helped define the RecA-
dependent homologous recombination and the RecA-independent non-homologous end joining 
(NHEJ) pathways in B. subtilis [(3, 5-7)].  
In addition to promoting recombination many bacteria and eukaryotes contain anti-
recombination pathways. In general terms, anti-recombination suppresses the formation of 
deleterious crossover species, which have the potential to decrease cell viability [for review (8-
10). In eukaryotes, RecQ family helicases can unwind recombination intermediates thereby 
suppressing aberrant crossover formation (11). In Escherichia coli, deletion of the helicase uvrD 
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and the helicase ruvA from the RuvABC Holliday junction endonuclease causes the formation of 
toxic recombination intermediates referred to as bimolecular recombination intermediates (12). 
In addition to UvrD and RuvA, the MMR pathway has been shown to suppresses recombination 
between non-identical DNA sequences often referred to as homeologous recombination (13). 
Such an activity has been shown to provide a barrier to horizontal gene transfer by conjugation 
between E. coli and Salmonella typhimurium (14). Biochemical evidence shows that MutS 
interferes with RecA-mediated strand exchange inhibiting recombination intermediates between 
non-identical or methylated substrates (15, 16), and can recruit UvrD to unwind recombination 
intermediates (17). Therefore, in bacteria a number of different proteins have been shown to limit 
hyper-recombination between identical sequences or homeologous recombination between non-
identical sequences. 
Interestingly, some bacteria contain a MutS paralog, MutS2, which has been shown to 
possess anti-recombination activity (18-20). MutS2 is composed of an N-terminal region 
involved in DNA binding, followed by a central ABC ATPase domain, which also participates in 
dimerization (21, 22). The MutS2 C-terminal domain contains the small MutS related (Smr) 
region, harboring a DNase I-like endonuclease domain (22). MutS2 in Helicobacter pylori and 
Thermus thermophilus contributes to anti-recombination (19, 21). H. pylori and T. thermophilus 
strains lacking mutS2 are more efficiently transformed with DNA and ΔmutS2 T. thermophilus is 
more resistant than wild type to mitomycin C (MMC), an antibiotic that damages DNA and 
requires homologous recombination for repair (19, 22). Biochemical studies have shown that 
HpMutS2 and TtMutS2 both have ATPase activity that is stimulated by recombination 
intermediates, and TtMutS2 has endonuclease activity toward recombination intermediates 
including Holliday junctions (19, 22). These data support the hypothesis that MutS2 proteins 
suppress homologous recombination in bacteria. Therefore, although homologous recombination 
is critical for DNA repair and horizontal gene transfer, bacteria also contain pathways that 
suppress recombination because hyper-recombination can lead to genome instability and cell 
death. It is not clear, however, if the anti-recombination activity shown for H. pylori and T. 
thermophilus MutS2 are representative of how MutS2 functions in other bacteria. 
The Gram-positive bacterium B. subtilis has a mutS2 gene. (23). The function of B. 
subtilis MutS2 in genome maintenance is unknown. We initially hypothesized that B. subtilis 
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MutS2 participated in anti-recombination as demonstrated for H. pylori and T. thermophilus 
MutS2 (19, 22). Instead, here we report that MutS2 promotes homologous recombination in B. 
subtilis. We show that B. subtilis cells with mutS2 deleted have a lower efficiency of plasmid and 
chromosomal DNA transformation. In addition, deletion of mutS2 results in sensitivity to the 
DNA damaging agent MMC and we provide genetic evidence that MutS2 functions redundantly 
with the Holliday junction endonuclease RecU. Therefore, our results support a new function for 
the MutS2 endonuclease in bacteria where it functions as a Holliday junction endonuclease. In 
addition to our study of MutS2, we also describe a new, efficient single plasmid-based 
CRISPR/Cas9 genome editing system for use in B. subtilis. Our method allows for efficient 
removal of the plasmid after genome editing providing a significant advancement in marker-less 
genetic manipulation of B. subtilis. 
 
Results 
Bacillus subtilis MutS2 is a MutS paralog. In B. subtilis MutS2 is encoded by the yshC 
(or mutSB) gene referred to herein as mutS2 (23). MutS2 is a MutS paralog of 785 amino acids 
(Fig 5.1A) (18, 22, 24). Domain predictions suggest that the N-terminal region of MutS2 
corresponds to DNA binding, followed by a central ABC ATPase domain. The MutS2 C-
terminal domain harbors the Smr region containing endonuclease activity (18, 22, 24). Based on 
sequence alignment, B. subtilis MutS2 lacks the domain involved in mismatch recognition and 
the C-terminal unstructured region involved in β-clamp (DnaN) binding, two functions well 
characterized in B. subtilis MutS that are important for mismatch repair (MMR) (Fig 5.1A) (25-
27).  
 Prior work initially characterizing B. subtilis mutS2 showed that mutS2 transcript 
abundance was constant during exponential phase and decreased towards stationary phase in rich 
medium, using a transcriptional fusion reporter (23). To begin, we monitored MutS2 protein 
abundance in vivo using antiserum raised against purified MutS2 (“Materials and Methods”). In 
rich media, MutS2 protein abundance was stable throughout exponential growth and to the onset 
of stationary phase (Fig 5.1B). As a control, we show that the immune-reactive species is absent 
from a mutS2 bearing strain.  Therefore, we find that MutS2 protein abundance remains 
constant throughout exponential phase and into stationary phase (Fig 5.1B). 
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 We mentioned above that MutS2 lacks a recognizable mismatch-binding domain and -
clamp interaction site (23) (Fig 5.1A). Prior work showed that MutS2 has no impact on 
spontaneous mutagenesis using rifampin resistance as an indicator for mutation rate in the 
presence or absence of the MMR genes mutS and mutL (23). Interestingly, however this study 
also reported a modest increase in transversion mutations in a strain lacking mutS2 after 
sequencing the reporter. Although it seems clear that MutS2 does not function in MMR, it could 
impact mutagenesis through a different pathway (23). Assessing spontaneous rifampin resistance 
only provides a limited sampling of mutations due to the restricted group of point mutations in 
the rpoB gene that are able to confer rifampin resistance (28-30). As a result, the number of 
measurable transversion mutations is limited. Additionally, MutS homologs in eukaryotes have 
been shown to have more specialized roles in recognizing insertions and deletions, two mutations 
that are not detected in rifampin resistance assays (31).  
We chose to empirically test whether the absence of MutS2 could impact mutagenesis 
using an assay that can detect a broader range of mutations. We thus used an assay for 
spontaneous trimethoprim resistance, which samples a much wider range of base pair 
substitutions while also sampling insertion and deletion mutations that occur in the thyA gene 
(32). We found that the mutation rate of a ΔmutS2 mutant strain was identical to wild type, and if 
we combined the ΔmutS2 allele with a ΔmutL mutation, we found no difference relative to the 
mutL strain alone (Fig 5.1C).  Similar results using a mutational reporter were observed in H. 
pylori (19). If loss of mutS2 impacted the number of transversions, we should have observed 
some difference in the mutation rate using trimethoprim resistance as an indicator. With these 
data, we conclude B. subtilis MutS2 does not function in suppressing mutagenesis.  
The C-terminal Smr domain is necessary but not sufficient for mitomycin C 
tolerance. Having excluded MutS2 from suppressing mutagenesis we screened mutS2 cells 
through several different DNA damaging agents to determine if MutS2 was important for 
survival or resistance to damage (data not shown). We found that ΔmutS2 cells were 
reproducibly more sensitive to mitomycin C (MMC), a DNA cross-linking/alkylating agent (33-
36), than the wild type control (Fig 5.2A). An MMC titration revealed that ΔmutS2 cells are 
approximately 10-fold more sensitive relative to wild type cells during a chronic exposure (Fig 
5.2A). To better understand whether the sensitivity is a result of growth inhibition or survival we 
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used quantitative plating efficiency and survival assays. We found that during chronic exposure 
to MMC the strain lacking mutS2 was 10-fold more sensitive than wild-type (Fig 5.2B), whereas 
there was no difference in survival following acute treatment (Fig 5.2C). From these data, we 
conclude that the absence of mutS2 results in a 10-fold sensitivity to MMC, which results from 
growth inhibition. To our knowledge, our observation of MMC sensitivity is the first phenotype 
shown for a ΔmutS2 deletion in B. subtilis. A previous study of Thermus thermophilus mutS2 
found that deletion of mutS2 resulted in resistance to MMC treatment relative to wild type, 
consistent with the inhibitory effect of TtMutS2 on recombination (22). Given that deletion of B. 
subtilis mutS2 has the opposite effect compared with TtΔmutS2, these results could suggest that 
B. subtilis MutS2 may promote homologous recombination, a novel result for a bacterial MutS2 
protein. 
We next asked whether sensitivity could be complemented via ectopic expression of 
mutS2 from the chromosome. Indeed, expression of full-length MutS2 results in 
complementation of the MMC sensitivity observed with the deletion (Fig 5.3B & C).   We took 
advantage of the mutS2 complementation assay to determine functional domains of MutS2 
important for MMC tolerance (Fig 5.3A). We found that ectopic expression of a MutS2 variant 
lacking the C-terminal Smr domain (mutS2ΔC) failed to complement the observed MMC 
sensitivity (Fig 5.3B & C). A Western blot confirmed that MutS2ΔC was stably expressed (Fig 
5.3D). Conversely, expression of an N-terminal truncation (mutS2ΔN) leaving the Smr domain 
intact was able to partially complement the mutS2 MMC phenotype (Fig 5.3B & C), and 
Western blot analysis confirmed stable expression of the MutS2ΔN variant (Fig 5.3D). From 
these data we conclude that the Smr domain is necessary but not sufficient to allow for wild type 
growth in the presence of MMC, indicating that the Smr domain requires the N-terminal portion 
of MutS2 for full function in vivo. 
Genetic analysis suggests MutS2 participates in homologous recombination. To 
begin to understand the contribution of MutS2 to tolerating MMC exposure we performed a 
genetic analysis of the ΔmutS2 phenotype. B. subtilis contains a prophage PBSX that is induced 
following DNA damage (37, 38), and has the ability to cause cell lysis (39, 40). One potential 
explanation for the MMC sensitivity of the ΔmutS2 strain is that in the absence of MutS2, SOS 
induction has increased and PBSX prophage induction results in cell lysis conferring the 
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observed sensitivity. To test this idea, we developed a CRISPR/Cas9 genome editing system to 
delete the PBSX lysis genes (xlyABxhlB) (41) or the entire 30.5 kb PBSX prophage in an 
otherwise wild type strain or in a strain combined with mutS2 (Fig 5.4-5.6). The spot plate 
analysis showed that in both the ΔPBSX and ΔxlyABxhlB deletion strains a ΔmutS2 still 
conferred an ~10 fold sensitivity to MMC (Fig 5.7). We conclude that the growth inhibition of 
ΔmutS2 cells to DNA damage is independent of the PBSX prophage. 
 We asked whether MutS2 functioned in the pathways responsible for repair of MMC 
induced DNA damage. MMC adducts are repaired by the combined action of nucleotide excision 
repair (NER) and homologous recombination [for review (42, 43)]. We combined mutS2 with 
an uvrA deletion to determine if MutS2 contributed to the NER pathway. Because uvrA deficient 
strains are very sensitive to MMC we used a lower dose as compared to the experiment shown in 
Figure 3. If MutS2 functions in NER we would expect the sensitivity of a strain lacking uvrA 
(ΔuvrA::spc) to have the same sensitivity as a strain carrying both the ΔuvrA::spc (44) and 
ΔmutS2 alleles. Instead, we found that strains with ΔmutS2 and ΔuvrA::spec are more sensitive 
to MMC than the ΔuvrA::spec allele alone (Fig 5.8A). These data support the hypothesis that the 
mutS2 sensitivity to MMC is independent of NER.  
We then tested if ΔmutS2 was epistatic or additive with a recA deletion (ΔrecA::loxP). 
We found that the ΔmutS2, ΔrecA::loxP double mutant was as sensitive to MMC as the 
ΔrecA::loxp single mutant (Fig 5.8B). In this experiment we used an even lower dose of MMC 
because recA deficient strains are exquisitely sensitive to MMC. Taken together, these results 
suggest that during repair of MMC adducts, MutS2 contributes to a step that is recA-dependent 
and that MutS2 does not participate in a step of MMC repair involving NER. Given that MutS2 
proteins in other organisms have been shown to bind Holliday junctions (19, 22, 45), we chose to 
test whether there was a genetic interaction with the primary Holliday junction endonuclease 
recU (46). To this end, we tested a strain either lacking recU (ΔrecU∷erm) or lacking both 
mutS2 and recU in the plating efficiency assay. In contrast to the experiment with recA we found 
that deletion of mutS2 in a strain lacking recU resulted in an increased sensitivity to MMC (Fig 
5.8C). Taken together, our data suggest that MutS2 functions in a pathway dependent on RecA 
yet independent of RecU.   
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MutS2 is important for DNA transformation with plasmid and chromosomal DNA. 
To further test if MutS2 promotes homologous recombination, we employed a transformation 
efficiency assay. Transformation of naturally competent B. subtilis cells with plasmid or 
chromosomal DNA is dependent on the function of several homologous recombination proteins, 
although the requirements for chromosomal DNA integration relative to plasmid assembly and 
maintenance are not identical (47, 48). Thus, if MutS2 functions by promoting homologous 
recombination, as the MMC phenotype suggests, we would expect to observe decreased 
transformation efficiency using plasmid and/or chromosomal DNA. Indeed, we found that a 
strain lacking mutS2 had decreased transformation efficiency with both plasmid (Fig 5.9A) and 
chromosomal DNA (Fig 5.9B). In order to determine whether the transformation efficiency 
phenotype was specific to mutS2 or both mutS1 and mutS2, we tested transformation efficiency 
in a strain lacking mutS1 (ΔmutS), and a strain lacking both mutS genes. We found that cells with 
ΔmutS1 had decreased plasmid transformation efficiency that is independent of mutS2 (Fig 
5.10). In contrast, we found that in the absence of mutS1 there is no change in chromosomal 
DNA transformation efficiency and deletion of mutS1 in a mutS2 deletion strain resulted in a 
transformation efficiency indistinguishable from a mutS2 single mutant. As a result, it appears 
that decreased chromosomal transformation efficiency is specific to mutS2. 
 To further examine the role of MutS2 in transformation, we tested chromosomal DNA 
transformation in a strain lacking the Holliday junction endonuclease recU and the recU, mutS2 
double mutant. Our hypothesis that MutS2 functions in a pathway independent of RecU predicts 
that these mutants should have an additive effect on transformation efficiency. Indeed, we found 
that deletion of mutS2 or recU resulted in a 4.9-fold and 11.6-fold decrease in transformation 
efficiency, respectively (Fig 5.9B). An additive effect predicts an approximate 57-fold decrease 
in transformation efficiency, and strikingly the double mutant had a 57-fold decrease in 
transformation efficiency (Fig 5.9B). These data further support the hypothesis that MutS2 
functions independently of recU, potentially as a Holliday junction endonuclease (see 
discussion). 
 As a control we examined whether the complementation analysis performed in Figure 3 
would yield similar results in the chromosomal DNA transformation efficiency assay. Indeed, 
expression of full-length MutS2 resulted in a transformation efficiency that was not significantly 
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different from WT (Fig 5.9C). We also found that expression of the variant lacking the C-
terminus was not significantly different from the mutS2 deletion strain (Fig 5.9C). Further, 
expression of the C-terminal Smr domain alone resulted in a partial complementation similar to 
the results obtained in Figure 3 (Fig 5.9C). Together, these results indicate that the C-terminal 
Smr domain requires the N-terminal ATPase domain to fully function in vivo. 
MutS2-GFP is diffusely distributed in vivo. Our previous research investigating MutS1 
has shown that B. subtilis MutS1-GFP forms foci that are recruited to the site of DNA synthesis 
(25-28, 49). Further, both homologous recombination proteins and nucleotide excision repair 
proteins have been shown to form foci or localize to the nucleoid, respectively, following MMC 
treatment (44, 50). We fused a monomeric version of GFP (gfpmut3) to mutS2 resulting in a gfp-
mutS2 allele, which is functional in the spot-titer assay for MMC sensitivity (Fig 5.11A), 
expressed from the native locus as the only source of MutS2 in vivo (Fig 5.11B). Fluorescence 
microscopy showed that MutS2-GFP was diffusely distributed in cells and did not show focus 
formation during normal growth or following growth in the presence of MMC (Fig 5.11C). We 
conclude that MutS2 is diffusely distributed in B. subtilis cells, and that MutS2 is not specifically 
recruited to sites of DNA damage in quantities detectable using bulk fluorescence. 
 
Discussion 
Our investigation of B. subtilis MutS2 function led to the observation that cells lacking 
MutS2 are growth inhibited to the natural antibiotic mitomycin C (MMC). Although the 
sensitivity is a modest 10-fold during chronic exposure, it is highly reproducible, and can be 
complemented via ectopic mutS2 expression, suggesting the sensitivity is indeed dependent on 
the absence of mutS2. This observation is a novel phenotype for a bacterial mutS2 mutant and is 
the opposite of the phenotype observed in T. thermophilus (22), suggesting that MutS2 promotes 
recombination in B. subtilis.  
Our finding that a ΔmutS2 mutant is sensitive to MMC provided an assay to further 
characterize the genetic interactions of mutS2.  Our initial genetic analysis resulted in the 
creation of a CRISPR/Cas9 genome editing system on a single, temperature sensitive plasmid 
that results in marker-less mutations that can be quickly introduced into many genetic 
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backgrounds. Although this is not the first report of CRISPR/Cas9 genome editing in Bacillus 
subtilis (51, 52), the system described here does not require an inducer for Cas9 expression and 
still allows for efficient removal of the plasmid editing system. We further demonstrated that the 
novel mutS2 phenotype depends on recA, and does not depend on uvrA or recU. These results 
suggested that MutS2 functions in homologous recombination in a pathway independent of 
RecU.  
To further test the hypothesis that MutS2 promotes homologous recombination, we 
assayed transformation efficiency with both plasmid and chromosomal DNA. Our hypothesis 
predicts a decrease in transformation, and indeed we observed decreased transformation 
efficiency with plasmid and chromosomal DNA. We further demonstrate that the Smr 
endonuclease domain is necessary, but not sufficient for chromosomal transformation and MMC 
tolerance. These results indicate that the C-terminal Smr domain requires the N-terminal portion 
of the protein for complete function in vivo. Additionally, we performed an epistasis analysis 
with recU using chromosomal DNA transformation. Similar to our results with MMC sensitivity, 
the double mutant had a more severe reduction in transformation efficiency than either single 
mutant. In fact, this assay revealed an additive effect of recU and mutS2 deletions. With these 
results we suggest that MutS2 may function as a back-up Holliday junction endonuclease, though 
other mechanisms could also explain our results. 
Previous studies of bacterial mutS2 have observed a role in inhibiting recombination. Our 
findings suggest that different lineages of bacteria are capable of adapting specific proteins to 
their repair requirements. Interestingly, although a BLAST search finds 99% and 83% coverage 
when comparing B. subtilis MutS2 to T. thermophilus and H. pylori, respectively, the percent 
identity is only 35 and 28, respectively (data not shown). 
Despite the sequence divergence, we speculate that MutS2 performs a similar function in 
these bacteria: a nuclease that is capable of processing recombination intermediates. HpMutS2 
has been shown to have ATPase activity that is stimulated by a four-way junction (Holliday 
junction) and by a fork or “Y” structure (19). A more recent study found that HpMutS2 has 
nuclease activity toward both ssDNA and Holliday junctions that is dependent on two nuclease 
sites in the protein: the Smr domain and an N-terminal LDLK motif (45). Interestingly, the 
LDLK motif is not conserved in B. subtilis or T. thermophilus. Studies using TtMutS2 have 
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found that MutS2 has an Smr domain dependent nuclease activity (53). Further analysis revealed 
that TtMutS2 recognizes Holliday junctions and D-loops (22). Unfortunately, we were unable to 
obtain active preparations of BsMutS2 to gain a more mechanistic understanding of its role in 
promoting recombination. Based on our genetic results we suggest that BsMutS2 has activity 
toward Holliday junctions or D-loops, and MutS2 may function as a secondary Holliday junction 
endonuclease in addition to RecU. 
 
Materials and methods 
Bacteriological methods and chemicals 
All B. subtilis strains used in this study are isogenic derivatives of PY79. All strains, 
plasmids, and primers used in this study are listed in the supplemental materials (Tables 5.1-5.3). 
Construction of all strains and plasmids is detailed in the supplemental methods. For all 
experiments with B. subtilis, strains were struck out from frozen stocks on LB agar plates or LB 
agar plates containing the appropriate antibiotics and incubated at 30°C overnight. Antibiotics 
were used at the following concentrations: spectinomycin, 100 μg/mL; chloramphenicol, 5 
μg/mL; erythromycin, 0.5 μg/mL. Mitomycin C was obtained from Fisher Scientific (Fisher 
BioReagents), and used at the final concentrations as indicated in the figures. 
Trimethoprim resistance assay 
Trimethoprim resistance assays were performed essentially as described (32). Briefly, an 
LB (10 g/L NaCl, 10 g/L Tryptone, 5 g/L yeast extract) culture for each strain was inoculated 
and grown at 37°C until an OD600 of about 1.0. Cultures were back diluted 1:500 into LB with 
200 μM thymidine and grown for 4 hours at 37°C. Cultures were then serially diluted and plated 
on LB with 200 μM thymidine for viable cells, and minimal media plates containing 
trimethoprim (1x S750 salts (54, 55), 1% glucose, 0.1% glutamate, 0.1 μM tryptophan, 0.1 μM 
phenylalanine, 200 μM thymidine, 1x metals (54, 55), 0.2% casamino acids, 1.8% agar, and 34 
μM trimethoprim) to select for thyA mutants. For viable cells, 100 μL of the 10-6 dilution were 
incubated on plates at 30°C overnight. For trimethoprim plates, 100 μL of the 100 (PY79 and 
PEB11) or 10-1 (PEB112 and PEB118) dilutions were plated and incubated at 45°C overnight. A 
total of 17 independent cultures were used for each strain. Mutation rate was calculated via 
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fluctuation analysis using the online tool FALCOR at 
http://www.mitochondria.org/protocols/FALCOR.html as described (56, 57). 
Western blotting 
For Western blot analysis cultures were grown in LB at 37°C to an OD600 ~1-3 or as 
indicated for Figure 1B. Then 1 mL of an OD600 = 1 from each strain was pelleted via 
centrifugation (10,000g for 5 min at room temperature (RT)). Cell pellets were re-suspended in 
50 μL RE buffer (50 mM Tris·Cl pH 7.5, 150 mM NaCl, 50 mM EDTA, 1x Roche Complete 
EDTA-free protease inhibitor cocktail (04693132001), and 10 mg/mL lysozyme) and incubated 
at 37°C for 20 minutes. The samples were then iced briefly (2-3 minutes) followed by the 
addition of SDS to a final concentration of 1% and SDS loading dye to 1x. Samples were 
incubated at 100°C for 10 minutes, followed by SDS-PAGE (8% for Figure 1B and S5B; 4-15% 
gradient gel for Figure 3C). Proteins were transferred to a nitrocellulose membrane using the 
Bio-Rad Trans-Blot Turbo apparatus using the manufacturer’s kit and manufacturer’s 
recommendations. Membranes were blocked using 5% milk in TBST overnight at 4°C or for 1 
hour at RT. Primary antibodies were used at a 1:5,000 dilution (both MutS2 and DnaN) in 2% 
milk in TBST for 1 hour at RT. Secondary antibodies (LI-COR Goat anti-rabbit conjugated to an 
IR dye) were used at a 1:15,000 dilution in 2% milk in TBST for 1 hour at RT. The membranes 
were then visualized using the LI-COR Odyssey infra-red imaging system. For Figure 3, cells 
were lysed via sonication in RE buffer without lysozyme on ice. All Western blots were 
performed from two independent replicates. 
Spot-titer assays 
A single colony was used to inoculate an LB culture and grown to an OD600 ≈ 3. Cultures 
were normalized via OD600, serially diluted, and 5 μL of the 10-1 through 10-6 were spotted onto 
LB agar plates or plates with the indicated concentration of MMC. LB agar with a vehicle 
control was performed as well and showed identical results to the untreated control (data not 
shown). Dilutions were spotted using a BioTek precision XS pipetting robotics system. Plates 
were incubated at 30°C overnight (16-20 hours). All spot-titer assays were performed at least 
twice. 
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Plating efficiency assays 
A single colony was used to inoculate an LB culture grown to an OD600 between 0.5 and 
1. Cultures were normalized via OD600 and a scorable dilution resulting in approximately 30-300 
colonies was plated on LB for viable cells, and on plates containing the concentration of MMC 
indicated in the figures. Plating efficiency was determined by dividing the number of colony 
forming units (CFUs) on MMC plates by the number of CFUs on LB plates and multiplying by 
100 to obtain a percentage. All experiments were performed in biological triplicate and each 
triplicate was performed at least twice. The data plotted are the mean of the pooled data and the 
error bars represent standard errors of the mean. 
Acute MMC survival assays 
A single colony was used to inoculate an LB culture and grown to an OD600 between 0.5 
and 1. An equivalent OD600 was taken and cells were washed in 0.85% NaCl. Cells were then 
resuspended in saline as a no treatment control or the concentration of MMC in figure 2C and 
treated at 37°C for 30 minutes. Cells were pelleted, the supernatant removed, and resuspended in 
saline. As above a scorable serial dilution was then plated on LB to determine the number of 
surviving CFUs. The percent survival is the number of CFUs from the indicated MMC treatment 
divided by the number of CFUs from the no treatment control multiplied by 100. Each 
experiment was performed in triplicate at least twice. The data plotted are the mean of the pooled 
data and the error bars represent the standard errors of the mean. 
Transformation efficiency assays 
Transformation efficiency assays were performed by transforming cultures grown to 
natural competence. Competent cell cultures were prepared by inoculating a 2 mL culture of LM 
media (LB with 3 mM MgSO4) with a single colony and grown at 37°C to an OD600 between 1 
and 1.5, then transferring 20 μL of the LM culture into 500 μL pre-warmed MD media (1x PC 
buffer (10x PC buffer is 107 g/L K2HPO4, 60 g/L KH2PO4, and 10 g/L trisodium citrate· (H2O)5), 
2% glucose, 50 μg/mL tryptophan, 50 μg/mL phenylalanine, 11 μg/mL ferric ammonium citrate, 
2.5 mg/mL potassium aspartate, 3 mM MgSO4) and incubated at 37°C for 4 hours. 10 ng of 
pPB153 plasmid DNA (purified from E. coli strain MC1061, which is recA+ resulting in 
oligomeric plasmid preparations, using the Qiagen plasmid hi-speed midi kit with DNA eluted in 
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ddH2O) or 25 ng of chromosomal DNA (purified using a spin column method; see 
supplementary methods) from PEB43 were added to cultures followed by incubation at 37°C for 
1.5 hours. The cultures were serially diluted and 100 μL of the 10-6 were plated for viable cells 
on LB agar, and for transformants 100 μL of a scorable serial dilution as described above were 
plated on LB with 100 μg/mL spectinomycin (plasmid transformations) or LB with 5 μg/mL 
chloramphenicol (chrDNA transformations) followed by incubation at 30°C overnight. 
Transformation experiments were performed in at least biological triplicate and each experiment 
was performed three times. 
CRISPR/Cas9 editing plasmid construction 
Construction of a CRISPR/Cas9 genome editing plasmid was done in two cloning steps 
(see Fig S1). First the spacer was incorporated into the CRISPR array via restriction digest and 
ligation cloning. The plasmid was digested with BsaI-HF (NEB) in CutSmart buffer at 37°C. 
Meanwhile, the spacer was prepared to ligate into the plasmid. First the oligonucleotides, ordered 
with the correct overhangs (58), were annealed by mixing the oligonucleotides at 10 μM each in 
1x annealing buffer (10 mM Tris·Cl, pH 7.5, 100 mM NaCl, and 0.1 mM EDTA). Annealed 
oligonucleotides were phosphorylated using T4 polynucleotide kinase (PNK; NEB): a 50 μL 
reaction was assembled with 1x T4 DNA ligase buffer, and 1 μM annealed oligonucleotides and 
incubated at 37°C for 30 minutes. T4 PNK was heat inactivated at 65°C for 20 minutes. A 20 μL 
ligation reaction was assembled using 1x T4 DNA ligase buffer, 40-100 ng plasmid DNA, 25 nM 
phosphorylated and annealed oligonucleotides, and 400 units T4 DNA ligase (NEB). The ligase 
reaction was performed at room temperature for 2-3 hours. The ligation was then used to 
transform chemically competent (CaCl2 method) E.  coli cells (Top10; Thermo Fisher 
Scientific): 10 μL of the ligation reaction was used to transform 60-100 μL competent cells. The 
plasmid was verified via Sanger Sequencing. The resulting plasmid (essentially a targeting 
plasmid) was then used to create the editing plasmid. 
 The editing plasmid was constructed using Gibson Assembly (59) of the following four 
(or more) PCR amplicons that were gel purified from an agarose gel: 1) the vector backbone of 
pPB41, amplified using oPEB217/oPEB218; 2) the Cas9/CRISPR array containing the spacer 
incorporated in the “targeting plasmid” was amplified using oPEB232/oPEB234; 3) the upstream 
portion of the editing template was amplified and contains overlaps for pPB41 at oPEB217 and 
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for the downstream portion of the editing template (see pPB50 and pPB51 for examples); 4) the 
downstream portion of the editing template was amplified and contains overlaps for the upstream 
portion of the editing template and for pPB41 at oPEB232 (see pPB50 and pPB51 for examples). 
A 10 μL Gibson Assembly reaction was assembled using 1x Gibson Assembly master mix, 40-
100 ng of the vector backbone of pPB41, 40-100 ng of the Cas9/CRISPR array containing the 
spacer, and about 20-40 ng of each portion of the editing template. The Gibson reaction was 
performed at 50°C for 90 minutes. The reaction was then used to transform chemically 
competent MC1061 E. coli cells. Clones were verified using Sanger sequencing at the University 
of Michigan Core Facility. The result of this second step yields a complete editing plasmid that 
can be used to efficiently manipulate the B. subtilis genome. 
CRISPR/Cas9 genome editing 
After construction of the editing plasmid, fresh B. subtilis competent cells (500 μL; see 
transformation efficiency assays) were transformed with 200-600 ng of the editing plasmid that 
had been purified from a strain of E. coli that yields multimers (e.g., MC1061). Transformations 
were plated on LB agar plates with spectinomycin and incubated at 30°C overnight. The next day 
6-24 isolates were colony purified by re-streaking on LB agar plates with spectinomycin. The 
editing plasmid contains a temperature sensitive origin of replication (derived from pDR244). To 
evict the plasmid, isolates were re-struck on LB and incubated at 42-45°C for 10-16 hours. 
Isolates were then screened for loss of the plasmid by re-streaking on LB agar plates with and 
without spectinomycin and incubating at 42-45°C overnight. The isolates that were found to be 
spectinomycin sensitive were further screened via PCR to determine if the isolate had the 
expected deletion. 
Live cell microscopy 
For live imaging experiments, a plate grown overnight at 30°C was washed using S750 
minimal media supplemented with 2% glucose essentially as described (60). The OD600 was 
measured and cells were diluted to an OD600 of 0.1. Cultures were incubated at 30°C for 2 hours 
(OD600 = 0.2). Cultures were treated with either a vehicle control or 100 μg/mL MMC, and 
incubated at 30°C for an additional 2 hours (OD600 ≈ 0.5). An aliquot of cells were removed 
followed by incubation with the membrane stain FM4-64 at 1 μg/mL. Cells were then placed on 
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1% agarose pads made of 1x Spizizen’s salts (26, 27, 54, 55). Cells were imaged using an 
Olympus BX61 microscope as described previously (26, 27, 60). 
 
Figures and Tables 
 
Figure 5.1 MutS2 is a MutS paralog expressed throughout exponential growth, and has no 
role in mutagenesis. (A) A predicted domain alignment of MutS and MutS2 proteins. (B) 
Western blot of MutS2 protein levels throughout exponential growth. Cultures were grown at 
37°C and samples of equivalent OD600 were taken at increasing optical densities (OD600 from 
0.8-5.9). Lane 1: molecular weight marker, 2: WT (OD600 = 5.9), 3: ΔmutS2 control (OD600 = 
5.6), 4-9: samples taken at increasing OD600 (from 0.8-3.8). An antibody for DnaN was used as a 
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loading control. The lower panel is a growth curve of B. subtilis at 37°C. Data are the mean of 
six independent replicates from two experiments and the error bars are the standard errors of the 
mean. (C) A trimethoprim resistance assay to measure mutagenesis. Data were plotted as the 
average of three independent experiments and error bars represent the standard error of the mean. 
 
 
Figure 5.2 ΔmutS2 cells are sensitive to mitomycin C chronic exposure. (A) Spot-titer assay 
of WT and ΔmutS2 cells. Cultures were normalized via OD600, serial diluted, and the indicated 
dilutions were spotted on an untreated control plate and the indicated concentrations of 
mitomycin C (MMC). (B) Plating efficiency assay. Cultures were normalized via OD600, serial 
diluted, and plated on either LB or LB with 30 ng/mL MMC to determine colony forming units 
(CFUs). Plating efficiency is the percent CFUs on MMC relative to the LB control. A Mann-
Whitney U-test was used to determine statistical significance. *: one-sided p-value < 0.05. (C) 
Survival assay. WT and ΔmutS2 cultures were normalized via OD600, and treated with the 
indicated concentration of MMC for 30 minutes in saline followed by plating for viable cells on 
LB. Percent survival is the percentage of CFUs from the treatment relative to the untreated 
control. 
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Figure 5.3 The C-terminal Smr domain is necessary but not sufficient for MMC tolerance. 
(A) MutS2 constructs used for complementation experiments in B, C, & D. (B) A spot-titer assay 
was done as in Figure 2. Complementation constructs were under the control of the IPTG 
inducible Pspac promoter. (C) Plating efficiency assay performed as in Figure 2 with 1 mM IPTG 
(red bars) or without IPTG (blue bars). The Mann-Whitney U-test was used to determine 
statistical significance. ns: not significant; *: one-sided p-value < 0.05. (D) Western blot using a 
MutS2 antibody and a DnaN antibody as a loading control. Cultures of the indicated genotypes 
were grown in the absence (lanes 1-5) or presence (lanes 6-8) of IPTG. The cultures were 
normalized via OD600 and analyzed via Western blotting. 
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Figure 5.4 Overview of constructing a CRISPR/Cas9 editing plasmid. (A) The editing 
plasmid is created using two cloning stages. First the spacer is incorporated using the method 
previously described (58), wherein the BsaI digested plasmid is ligated to the spacer with the 
appropriate overhangs (see B). In the second stage Gibson Assembly is used to combine the 
temperature sensitive plasmid containing Cas9/CRISPR and the spacer of interest with the 
editing template. (B) A close up of the overhangs required to ligate a spacer inside of the 
CRISPR array as described (58). See “Materials and Methods” for a detailed protocol. 
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Figure 5.5 Overview of CRISPR/Cas9 genome editing in Bacillus subtilis. (A) The desired 
strain of B. subtilis is transformed with the editing plasmid containing Cas9, the CRISPR array 
with spacer, and the editing template and grown at the permissive temperature (30°C). (B) Upon 
transformation, Cas9 generates a double strand break, which the cell repairs utilizing the editing 
template on the plasmid containing the genetic change of interest. The cells are then cured of the 
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plasmid by growing at the non-permissive temperature (42-45°C). (C) Finally isolates are 
screened for loss of the plasmid and the genetic change. 
 
 
Figure 5.6 Deletion of prophage PBSX using CRISPR/Cas9 genome editing. (A) 
Transformation efficiency assay using a plasmid with no spacer (pPB41), a plasmid with a 
spacer targeting the genome inside PBSX (pPB49), and a plasmid containing the spacer and the 
editing template that would remove the entire 30.5 kb prophage from the B. subtilis genome. 
Data are plotted as the mean of two independent experiments performed in triplicate and the 
error bars represent the standard deviation of the pooled data set. (B) PBSX genomic locus and 
PCR primers, located outside the editing template sequence, used to verify deletion of the 
prophage. Of 24 isolates, 13 lost the antibiotic resistance of the plasmid. Those 13 were used in 
colony PCR genotyping reactions. Lane 1: Molecular weight standard, lane 2: PCR performed 
using WT genomic DNA (yielding no band), lanes 3-15: colony PCR reactions of 13 isolates that 
lost the plasmid. Four isolates (lanes 3, 4, 9, and 13) of 24 with the deletion were obtained using 
this method. 
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Figure 5.7 ΔmutS2 MMC sensitivity is independent of the prophage PBSX. Spot-titer assay 
as done in Figure 2 using the indicated strains spotted on an untreated control plate and the 
indicated concentrations of MMC. 
 
Figure 5.8 ΔmutS2 sensitivity is independent of uvrA and recU, and shows no additive 
effects with recA. (A), (B), & (C) Plating efficiency assays performed as in Figure 2 with the 
indicated genotypes and the indicated concentrations of MMC. The Mann-Whitney U-test was 
used to determine statistical significance. ns: not significant; *: one-sided p-value < 0.05. Note 
that lower concentrations of MMC were used for this experiment and ΔmutS2 cells do not show 
a phenotype. 
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Figure 5.9 MutS2 is important for plasmid transformation, and mutS2 deletion is additive 
with a recU deletion in chromosomal DNA transformation. (A) Transformation efficiency 
assay using plasmid DNA. (B) Transformation efficiency using chromosomal DNA. (C) 
Transformation efficiency assay using chromosomal DNA in the presence of 1 mM IPTG. 
Transformation efficiency is the ratio of transformants (CFUs) to viable cells (CFUs). The 
Mann-Whitney U-test was used to determine statistical significance. ns: not significant; *: two-
sided p-value < 0.05. 
 
Figure 5.10 MutS and MutS2 have different roles in recombination. Transformation 
efficiency assays using chromosomal and plasmid DNA. Transformation efficiency is a ratio of 
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transformants (CFU) to viable cell (CFU). Transformation efficiencies for WT and ΔmutS2 are 
the same as shown in Figure 5. 
 
Figure 5.11 A functional GFP-MutS2 fusion has a diffuse cytosolic distribution. (A) A spot-
titer assay showing that GFP fused to the N-terminus of MutS2 expressed from the native locus 
is functional. (B) Western blot using a MutS2 antibody shows that GFP-MutS2 is expressed and 
we do not detect degradative products indicating MutS2 is intact. (C) Fluorescence microscopy 
to visualize GFP-MutS2 under vehicle control, and 100 ng/mL Mitomycin C (MMC) treatment 
conditions (red: membranes stained with FM4-64; green: GFP-MutS2; scale bar is 2 μm). 
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Strain Relevant genotype Reference 
PY79 WT (62) 
PEB11 ΔmutSB This Work 
PEB32 mutSB::gfp-mutSB This Work 
PEB43 amyE::cat This Work 
PEB112 ΔmutL This Work 
PEB118 ΔmutSB, ΔmutL This Work 
PEB125 ΔrecU::erm This Work 
PEB128 ΔmutSB, ΔrecU::erm This Work 
PEB204 ΔrecA::erm This Work 
PEB207 ΔmutSB, ΔrecA::erm This Work 
PEB214 ΔrecA::loxP This Work 
PEB215 ΔmutSB, ΔrecA::loxP This Work 
PEB218 ΔmutS (27) 
PEB247 ΔxhlAB-xlyA This Work 
PEB249 ΔmutSB, ΔxhlAB-xlyA This Work 
PEB251 ΔxlyB-xlyA This Work 
PEB254 ΔmutSB, ΔxlyB-xlyA This Work 
PEB295 ΔuvrA::spec This Work 
PEB298 ΔmutSB, ΔuvrA::spec This Work 
PEB410 ΔmutSB, amyE::Pspac-mutSB This Work 
PEB412 ΔmutSB, amyE::Pspac-mutSB-ΔC This Work 
PEB414 ΔmutSB, amyE::Pspac-mutSB-ΔN This Work 
PEB671 ΔmutSB, ΔmutS This Work 
 
Table 5.1 Strains used in this study. 
Plasmid Plasmid name Reference 
pDR244 pDR244 BGSC (ECE274) 
pCas9 pCas9 (58); Addgene plasmid # 42876 
pDR110 pDR110 A gift from David Rudner 
pDR154 pDR154 A gift from David Rudner 
pPB1 pMini-MAD-MutSB-up/down This work 
pPB3 pMini-MAD-GFP-MutS2 This work 
pPB14 pET28b-10xHis-Smt3-MutS2 This work 
pPB31 pMiniMad-mutL This work 
pPB41 pDR244-cas9 This work 
pPB49 pPB41-CRISPR::PBSX This work 
pPB50 pPB49-PBSX-lysis recombination template This work 
pPB51 pPB49-PBSX-cure recombination template This work 
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pPB105 pPB41-ΔspecR::camR This work 
pPB126 pDR110-MutS2 This work 
pPB127 pDR110-MutS2-ΔC This work 
pPB128 pDR110-MutS2-ΔN This work 
pPB153 pDR244-Δcre This work 
 
Table 5.2 Plasmids used in this study. 
Primer Sequence 
o3F GCTAGCCGCATGCAAGCTAATTCG 
o3R ATGTATACCTCCTTAGTCGACTAAGCTTAATTGTTATC 
oPEB5F cccaggctttacactttatgcttccagatggatatcctgcctgacggtac 
oPEB5R aaatcactcatggccatactcccttgattgtgtgagcctccttacttaatcgt
tg 
oPEB6F attaagtaaggaggctcacacaatcaagggagtatggccatgagtgatttttg 
oPEB6R cacagatgcgtaaggagaaaataccaacagatatataagaccaattaacaaaa
agattcccgctg 
oPEB7F GGCTCACCGCGAACAGATTGGAGGTATGCAGCAAAAAGTATTATCAGCTCTTG
AATTTC 
oPEB7R CAGTGGTGGTGGTGGTGGTGCTCGAttaTTATTTTAGTTCAACAACCGTAACG
CCTGATC 
oPEB16 TGAAAAGTTCTTCTCCTTTACTCATgattgtgtgagcctccttacttaatcgt
tg 
oPEB17 attaagtaaggaggctcacacaatcATGAGTAAAGGAGAAGAACTTTTCACTG
GAG 
oPEB18 CTTGGCCTTGTCCTTGACCTTCACCTTTGTATAGTTCATCCATGCCATGTGTA
ATC 
oPEB19 GGTGAAGGTCAAGGACAAGGCCAAGGACCAGGACGTGGTTACGCTTACCGCTC
TGAGCTC 
oPEB20 GAGCTCAGAGCGGTAAGCGTAACCACGTCCTGGTCCTTGGCCTTGTCCTTGAC
CTTCACC 
oPEB21 TGGTTACGCTTACCGCTCTGAGCTCGTGCAGCAAAAAGTATTATCAGCTCTTG 
oPEB22 cacagatgcgtaaggagaaaataccGGATCTGTACTCCTGTTTGACCGG 
oPEB56 ACCTCCAATCTGTTCGCGGTG 
oPEB57 taaTCGAGCACCACCACCACCAC 
oPEB65 CTGCATGTGTCAGAGGTTTTCAC 
oPEB78 aatggatcaatgcctaccacccccgattcatcaccccgttttaatgtaatttc
ttttg 
oPEB79 attacattaaaacggggtgatgaatcgggggtggtaggcattgatc 
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oPEB114 ggtattttctccttacgcatctgtgc 
oPEB115 ggaagcataaagtgtaaagcctggg 
oPEB151 gctttacactttatgcttccaagcggtgctcccgattttcgat 
oPEB152 atgcgtaaggagaaaatacctctccatacttggcatcacatacgcttc 
oPEB174 ttcttccgacataaattgtgagac 
oPEB175 atgtgaaagaagggagtttttgac 
oPEB189 gagggaggaaaggcaggatacc 
oPEB190 CGCCGTATCTGTGCTCTCTCTACC 
oPEB201 acacctacatctgtattaacgaagcgactgttcttcgctttttcggtatc 
oPEB202 GGTATCCTGCCTTTCCTCCCTCtctattttttcctcctttatgttaccactac
a 
oPEB203 TAGAGAGAGCACAGATACGGCGaaataaaataagtttcaaatgatacaaaagg
ctgag 
oPEB204 gtaatgataccgatgaaacgagagataaatatcacccgctccatacag 
oPEB205 cttgtgttaaatgatgaggcattc 
oPEB206 ggcgtaaacatcttttcatagctt 
oPEB217 GAACCTCATTACGAATTCAGCATGC 
oPEB218 GAATGGCGATTTTCGTTCGTGAATAC 
oPEB229 agccggtgagcgtggTtcCcgcggtatcattgcagcactggg 
oPEB230 tgcaatgataccgcgGgaAccacgctcaccggctccagattta 
oPEB231 GAACCTCATTACGAATTCAGCATGCGCTATCTAGAGGGAAACCGTTGTGGGAT
CCCTATAGTGAGTCGTATTAATTTCGCGGGATCG 
oPEB232 GCTGTAGGCATAGGCTTGGTTATG 
oPEB233 GCATGCTGAATTCGTAATGAGGTTCGCTGTAGGCATAGGCTTGGTTATG 
oPEB234 GTATTCACGAACGAAAATCGCCATTCCTAGCAGCACGCCATAGTGACTG 
oPEB283 CGTGAGCTATTAAGCCGACCATTC 
oPEB288 aaacATTGTTAGATACGTGGGATTCGTTCAAAGCg 
oPEB289 aaaacGCTTTGAACGAATCCCACGTATCTAACAAT 
oPEB290 GCATGCTGAATTCGTAATGAGGTTCcgacggactgggtatatctttcta 
oPEB291 gctccgggatttttatggtctttgactctcactcctccttcacatgcag 
oPEB292 ctgcatgtgaaggaggagtgagagtcaaagaccataaaaatcccggagc 
oPEB293 GCATAACCAAGCCTATGCCTACAGCtattcgacacaggctgataaagac 
oPEB294 agatcgtgaaggtacgctctttat 
oPEB295 ctgctgaaaacctatgctgataaa 
oPEB298 GCATGCTGAATTCGTAATGAGGTTCacacagaatcagtctcacacacct 
oPEB299 ctccgggatttttatggtctttgactatcatctctccttttcttttttcataa
ataggtg 
oPEB300 gaaaaaagaaaaggagagatgatagtcaaagaccataaaaatcccggagc 
oPEB301 caagtcggaaaagttcgataatct 
 288
oPEB625 CTTAGTCGACTAAGGAGGTATACATgtgcagcaaaaagtattatcagctcttg
aatttc 
oPEB626 CCGAATTAGCTTGCATGCGGCTAGCttaTTATTTTAGTTCAACAACCGTAACG
CCTGATC 
oPEB627 CCGAATTAGCTTGCATGCGGCTAGCttaTTATTGCGTTTTCGGCTTTTCCGGT 
oPEB628 CTTAGTCGACTAAGGAGGTATACATGTGAAACGCGACTTTAAGCCTGG 
oPEB775 GCATGCTGAATTCGTAATGAGGTTCGAATGGCGATTTTCGTTCGTGAATAC 
 
Table 5.3 Oligonucleotides used in this study. 
 
Supplemental text 
MutS2 purification and antibody production 
 10xHis-Smt3-MutS2 was expressed in NiCo 21 E. coli cells (NEB) from pPB14. Cultures 
(3, 1 L cultures) were grown shaking at 37°C to an OD600 ≈ 0.8, and induced using 0.5 mM 
IPTG. Cultures were incubated at 37°C for another 3h after induction. Cells were pelleted via 
centrifugation at 8,000g for 25 minutes at 4°C. Cell pellets were re-suspended in 20 mL lysis 
buffer (50 mM Tris·HCl, pH 7.5, 300 mM NaCl, 5% (w/v) sucrose, 20 mM imidazole) per liter 
of culture. Cells were lysed via sonication on ice and lysates were clarified via centrifugation 
(Sorvall SS-34 rotor, 18,000 rpm for 45 minutes at 4°C). Lysate was loaded onto Ni2+-NTA 
agarose (Qiagen), 1 mL bead volume per 1 L of culture after prewashing with 5 column volumes 
lysis buffer, and left on a rotator at 4°C for 1 hour. The column was then loaded and flow-
through was collected. The column was washed 3 times with 8 column volumes of wash buffer 
(25 mM Tris·HCl, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 30 mM imidazole). The column 
was then re-suspended in 15 mL digestion buffer (50 mM Tris·HCl, pH 7.5, 300 mM NaCl, 10% 
(v/v) glycerol, 1 mM DTT, 10 mM imidazole), and the 10xHis-Smt3 tag was removed using 
6xHis-Ulp1-403-621, resulting in elution of untagged, full-length MutS2 from the column, which 
was collected as a flow-through fraction. The 15 mL sample was concentrated to 5 mL using a 
50 kDa molecular weight cutoff concentrator (Millipore), and loaded onto a Hiload 16/60 
superdex 200 prep grade gel filtration column (GE Healthcare) pre-equilibrated with GF buffer 
(50 mM Tris·HCl, pH 7.5, 150 mM NaCl), with a flow rate of 1 mL/min for 120 minutes. Peak 
fractions were pooled and diluted in HA dilution buffer resulting in a solution at the final 
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concentrations of 16.7 mM Tris·HCl, pH 7.5, 50 mM NaCl, 5 mM KPO4, pH 7.4, 1 mM DTT, 
10% (v/v) glycerol. The diluted sample was loaded onto a	hydroxyapatite Bio-Scale Mini CHT 
Type 1 column (Bio-Rad) pre-equilibrated with HA start buffer (5 mM KPO4, pH 7.4, 50 mM 
KCl, 1 mM DTT, 10% (v/v) glycerol). The column was washed with 10 column volumes HA 
start buffer. The column was then eluted using a linear phosphate gradient from 100% HA start 
buffer to 100% HA finish buffer (500 mM KPO4, pH 7.4, 50 mM KCl, 1 mM DTT, 10 % (v/v) 
glycerol), over 20 column volumes. The peak fractions were pooled and desalted using a HiPrep 
26/10 desalting column (GE Healthcare) pre-equilibrated with protein storage buffer (25 mM 
Tris·HCl, pH 7.5, 50 mM KCl, 10% (v/v) glycerol). Peak fractions were pooled, concentrated 
using a 50 kDa molecular weight cutoff concentrator (Millipore), frozen in liquid nitrogen, and 
stored at -80°C. 
 Purified MutS2 was sent to Covance for antibody production using the 77 day protocol 
using two different rabbits. The MutS2 antibody used throughout this study was from antiserum 
lot MI-1444-2. 
Chromosomal DNA purification 
 Cell pellets (OD600 mL-1 ≈ 4-8) were re-suspended in 200 μL lysis buffer (50 mM 
Tris·HCl, pH 8.0, 10 mM EDTA, pH 8.0, 1% Triton X-100, 0.5 mg/mL RNase A, 20 mg/mL 
lysozyme) and incubated at 37 °C for 30 minutes. SDS and protease K were added to a final 
concentration of 1% and 1.3 mg/mL, respectively and samples were incubated at 55-65°C for 30 
minutes. Then, 600 μL of PB buffer were added and the sample was added to a silica spin-
column (Epoch Life Sciences) and centrifuged at 13,000g for 1 min. The column was washed 
with 500 μL PB buffer, then 750 μL PE buffer. Finally columns were eluted with 100 μL ddH2O. 
Plasmid construction 
All plasmids were constructed via Gibson Assembly (59). All primer sequences used for 
plasmid construction are listed in Supplementary Table 3 (Table S3). All plasmid clones were 
sequenced at the University of Michigan Sequencing core facility to verify the sequence of the 
DNA insert(s). 
pPB1 was constructed using Gibson Assembly of the following three DNA amplicons: 1) 
the pMini-MAD vector, amplified with primers oPEB114/oPEB115; 2) a 505 bp fragment 
upstream of mutS2, amplified using oPEB5F/oPEB5R; 3) a 505 bp fragment downstream of 
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mutS2 amplified using oPEB6F/oPEB6R. The resulting construct contained an in-frame deletion 
of the mutS2 open reading frame (ORF) in the pMini-MAD vector. 
pPB3 was constructed using Gibson Assembly of a 60 bp annealed dsDNA fragment, 
using oPEB19/oPEB20 and the following four PCR amplicons: 1) the pMini-MAD vector, 
amplified with primers oPEB114/oPEB115; 2) a 505 bp fragment upstream of mutS2, amplified 
with oPEB5F/oPEB16; 3) gfp-mut3-A206K ORF, amplified using oPEB17/oPEB18; 4) a 621 bp 
fragment of the mutS2 N-terminal coding region, amplified using oPEB21/oPEB22. The 
resulting construct contained an in-frame insertion of gfp-mut3-A206K with a 20 amino acid 
flexible linker fused to the coding region of mutS2 in the pMini-MAD vector (27). 
pPB14 was constructed using Gibson Assembly of the following two PCR amplicons: 1) 
The pET28b-10xHis-Smt3 vector, amplified using oPEB56/oPEB57; 2) the MutS2 open reading 
frame with the GTG start codon replaced with ATG was amplified using oPEB7F/oPEB7R. The 
resulting vector contained a 10xHis-Smt3-MutS2 fusion protein that was under IPTG inducible 
expression. 
pPB31 was constructed using Gibson Assembly of the following three PCR amplicons: 1) 
the pMini-MAD vector, amplified with primers oPEB114/oPEB115; 2) a 698 bp fragment 
upstream of mutL, amplified using oPEB151/oPEB78; 3) a 711 bp fragment downstream of 
mutL, amplified using oPEB79/oPEB152. The resulting construct contained an in-frame deletion 
of the mutL ORF in the pMini-MAD vector. 
pPB41 was constructed by amplifying portions of pDR244 (obtained from the BGSC) 
and pCas9 (58) (purchased from Addgene). pPB41 was constructed using Gibson Assembly of 
the following three PCR amplicons: 1) a part of the pDR244 vector was amplified using 
oPEB229/oPEB231;  2) a second part of the pDR244 vector was amplified using 
oPEB218/oPEB230; 3) the Cas9/CRISPR array was amplified using oPEB233/oPEB234. The 
resulting construct consisted of pDR244 with its two BsaI sites mutated and the cre recombinase 
deleted, and in its place Cas9/CRISPR was inserted. 
pPB49 was constructed via restriction digest and ligation. The vector pPB41 was digested 
with BsaI-HF (NEB) and CIP (NEB) treated with alkaline phosphatase. The proto-spacer was 
generated by annealing oligos oPEB288/oPEB289 in annealing buffer (see section on editing 
plasmid construction), and phosphorylated using T4 polynucleotide kinase (NEB). The vector 
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and proto-spacer ligated together using T4 DNA ligase. The resulting construct consisted of 
pPB41 with the BsaI sites removed and a spacer targeting PBSX inserted into the CRISPR array. 
pPB50 was constructed using Gibson Assembly of the following four PCR amplicons: 1) 
the pPB41 vector was amplified using oPEB217/oPEB218; 2) the Cas9/CRISPR array 
containing the PBSX spacer was amplified from pPB49 using oPEB232/oPEB234; 3) a 570 bp 
fragment upstream of xhlA (the upstream portion of the editing template) was amplified using 
oPEB290/oPEB291; 4) a 690 bp fragment downstream of xlyA (the downstream portion of the 
editing template) was amplified using oPEB292/oPEB293. The resulting construct consists of 
pPB49 with the ΔxhlABxlyA editing template added next to Cas9 (see Fig S1). 
pPB51 was constructed using Gibson Assembly of the following four PCR amplicons: 1) 
the pPB41 vector was amplified using oPEB217/oPEB218; 2) the Cas9/CRISPR array 
containing the PBSX spacer was amplified from pPB49 using oPEB232/oPEB234; 3) a 725 bp 
fragment upstream of xlyBA (the upstream portion of the editing template) was amplified using 
oPEB298/oPEB299; 4) a 690 bp fragment downstream of xlyA (the downstream portion of the 
editing template) was amplified using oPEB293/oPEB300. The resulting construct consists of 
pPB49 with the ΔPBSX (xlyB through xylA) editing template added next to Cas9 (see Fig S1). 
pPB105, although not utilized in this study, was constructed to allow for use of the 
CRISPR/Cas9 genome editing system using a chloramphenicol resistance marker instead of the 
spectinomycin resistance marker. pPB105 was constructed using Gibson Assembly of the 
following two PCR amplicons: 1) the pPB41 vector without the spectinomycin resistance 
cassette was amplified using oPEB549/oPEB550; 2) the chloramphenicol resistance marker was 
amplified from pBGSC6 (Bacillus Stock Center) using oPEB65/oPEB283. The resulting vector 
consists of pPB41 with the spectinomycin resistance cassette replaced with a chloramphenicol 
resistance cassette. 
pPB126 was constructed using Gibson Assembly of the following two PCR amplicons: 1) 
the pDR110 vector (61) was amplified using oPEB3F/oPEB3R; the mutS2 ORF was amplified 
using oPEB625/oPEB626. The resulting construct consists of mutS2 under the control of the Pspac 
promoter in pDR110. 
pPB127 was constructed using Gibson Assembly of the following two PCR amplicons: 1) 
the pDR110 vector was amplified using oPEB3F/oPEB3R; the mutS2ΔC ORF (amino acids 1-
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635) was amplified using oPEB625/oPEB627. The resulting construct consists of mutS2ΔC 
under the control of the Pspac promoter in pDR110. 
pPB128 was constructed using Gibson Assembly of the following two PCR amplicons: 1) 
the pDR110 vector was amplified using oPEB3F/oPEB3R; the mutS2ΔN ORF (the start codon 
and amino acids 636-785) was amplified using oPEB626/oPEB628. The resulting construct 
consists of mutS2ΔN under the control of the Pspac promoter in pDR110. 
pPB153 was constructed using Gibson Assembly of a single PCR amplicon: pDR244 was 
amplified using oPEB217/oPEB775. The resulting construct consists of pDR244 without cre 
recombinase. 
 
Strain construction 
 All B. subtilis strains are isogenic derivatives of PY79 (62) and were generated by 
transforming cells with a PCR product, plasmid DNA, or genomic DNA via natural competence 
(55). 
 PEB11 was generated by transforming PY79 with pPB1 plating on LB agar plates 
containing erythromycin and incubating at 37°C overnight, as the plasmid contains a temperature 
sensitive origin that is inactive at 37°C, which forces single crossover integration of the plasmid 
with the chromosome. Isolates were colony purified by re-streaking on LB agar plates with 
erythromycin and incubating at 37°C overnight. Isolates were then grown in 2 mL liquid LB at 
the permissive temperature (room temperature) for 10-14 hours. Cultures were back-diluted 100 
fold and grown at the permissive temperature for 10-14 hours four times. Cultures were then 
back-diluted 100 fold and grown at 37°C until an OD600 ≈ 1. Cultures were serially diluted and 
100 μL of the 10-5 dilution were plated on LB agar and incubated at 37°C overnight. Single 
colonies were then colony purified and tested for sensitivity to erythromycin to screen for 
plasmid loss by re-streaking on LB agar plates and LB agar plates containing erythromycin. 
Erythromycin sensitive clones were further screened for loss of the mutS2 ORF using PCR with 
primers oPEB5F/oPEB6R. 
 PEB32 was constructed as PEB11 with the exception of using pPB3 as the plasmid, and 
using PCR primers oPEB5F/oPEB22 to screen for GFP insertion at the mutS2 locus. 
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 PEB43 was constructed by transforming PY79 with pDR154 via double-crossover 
recombination at the amyE locus. Double crossover recombination was verified by screening for 
an inability to utilize starch (55). 
 PEB112 was constructed as PEB11 with the exception of using pPB31 as the plasmid, 
and using PCR primers oPEB151/oPEB152 were used to screen for the loss of the mutL ORF. 
 PEB118 was constructed as PEB112 using PEB11 as the parent strain instead of PY79. 
 PEB125 was constructed by transforming PY79 using genomic DNA from the B. subtilis 
knockout library strain BKE22310. Clones were verified via PCR genotyping at the recU locus 
using primers oPEB174/oPEB175. 
 PEB128 was constructed as described for PEB125 using PEB11 as the parent strain. 
 PEB204 was constructed by transforming PY79 with a PCR product containing 871 bp 
upstream of recA, a erythromycin resistance cassette from the Bacillus knockout library, and 
1052 bp downstream of recA via double-crossover recombination. This PCR product was 
generated via overlap PCR using oPEB201/oPEB204, and the following three PCR amplicons as 
templates: 1) 871 bp upstream of recA were amplified using oPEB201/oPEB202; 2) the 
erythromycin resistance cassette was amplified using oPEB189/oPEB190; 3) 1052 bp 
downstream of recA were amplified using oPEB203/oPEB204. Clones were genotyped for the 
allelic replacement at the recA locus using PCR primers oPEB205/206. 
 PEB207 was constructed as PEB204, except PEB11 was used as the parent strain. 
 PEB214 was constructed by transforming PEB204 with pDR244 and plating on LB agar 
plates containing spectinomycin and incubating at 30°C overnight (the permissive temperature 
for the temperature sensitive origin of replication). Transformants were then colony purified by 
re-streaking on LB agar containing spectinomycin and incubating at 30°C overnight. The 
plasmid was evicted by re-streaking on LB agar plates and incubating at 45°C overnight. Isolates 
were screened for loss of the plasmid and the erythromycin cassette by re-streaking on LB, LB 
containing spectinomycin, and LB containing erythromycin agar plates. Isolates were further 
genotyped at the recA locus using PCR primers oPEB205/oPEB206. 
 PEB215 was constructed as was PEB214, except PEB207 was used as the parent strain. 
 PEB218 was saved from JSL 281 (27). 
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 PEB247 & PEB249 were constructed via CRISPR/Cas9 genome editing described herein, 
by transforming PY79 and PEB11, respectively, with pPB50. Clones were genotyped at the 
xhlABxlyA loci using PCR primers oPEB294/oPEB295. 
 PEB251 & PEB254 were constructed via CRISPR/Cas9 genome editing described herein, 
by transforming PY79 and PEB11, respectively, with pPB51. Clones were genotyped at the 
PBSX locus using PCR primers oPEB295/oPEB301. 
 PEB295 was constructed by transforming PY79 with genomic DNA from LAS409 (32, 
44). Loss of uvrA was verified by testing for sensitivity to UV (265 nm) light. 
 PEB298 was constructed by transforming PEB11 with genomic DNA from LAS409. 
Loss of uvrA was verified by testing for sensitivity to UV (265 nm) light. 
 PEB410 was constructed by transforming PEB11 with pPB126 via double-crossover 
recombination at the amyE locus. Double crossover recombination was verified by screening for 
an inability to utilize starch. 
 PEB412 was constructed by transforming PEB11 with pPB127 via double-crossover 
recombination at the amyE locus. Double crossover recombination was verified by screening for 
an inability to utilize starch. 
 PEB414 was constructed by transforming PEB11 with pPB128 via double-crossover 
recombination at the amyE locus. Double crossover recombination was verified by screening for 
an inability to utilize starch. 
 PEB671 was constructed as described for PEB11 using PEB218 as the parent strain. 
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CHAPTER VI 
Future research and concluding remarks 
 
Introduction 
The DNA damage response is a cellular solution to a fundamental problem in biology—
reproduction requires DNA replication, which can be prevented by DNA modifications called 
DNA damage. A major facet of the DNA damage response is the coordination of DNA 
replication and cell division (1, 2). Regulation of cell division in response to DNA damage was 
initially identified in Escherichia coli, and subsequent studies described in molecular detail how 
the process occurs (2). The application of the models developed in E. coli, however, has proved 
difficult as studies in numerous bacterial species have demonstrated that the cell division 
checkpoint exists, yet the mechanisms are not conserved. Although cell division inhibitors have 
been identified in several bacteria (3-8), the rest of the pathway remains unclear in these 
organisms. In Chapter II, I used forward genetics to identify the proteases responsible for 
removing the cell division inhibitor in Bacillus subtilis. In Chapter III, I demonstrate that a gene 
of unknown function helps to establish a threshold of cell division inhibitor required for 
establishing the cell cycle checkpoint. In addition, in Chapters IV and V, I describe roles for 
three genes involved in DNA repair. Prior to my studies it was not clear how organisms that use 
membrane bound cell division inhibitors would control the cell cycle checkpoint. Further, by 
identifying multiple mechanisms for regulating establishment of the checkpoint, my work 
underscores the complexity of this process. As discussed in Chapter I, the DNA damage 
checkpoint will be a function of DNA damage and the rate of cell division. Given that these 
factors will be highly variable depending on the environment and the organism, it should be no 
surprise that the mechanisms of the DNA damage checkpoint would also vary considerably. 
Thus, my study of the DNA damage response in B. subtilis has provided important insight into 
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this complex process, while also providing the basis for several new areas of research that are 
discussed below. 
 
Checkpoint recovery proteases 
The identification of the B. subtilis DNA damage checkpoint recovery mechanism is an 
important step toward understanding the mechanisms by which cell division and DNA 
replication are coupled. My studies of the proteases DdcP (YlbL) and CtpA presented in Chapter 
II led to the discovery that these proteases relieve the DNA damage-dependent cell cycle 
checkpoint. Both proteases degrade the cell division inhibitor YneA, resulting in removal of the 
protein that enforces the checkpoint, and therefore allowing cell division to proceed. Still, 
exactly how DdcP and CtpA recognize their substrate, YneA, is still not clear and warrants 
further exploration. 
Substrate recognition is a critical aspect of protease function (9, 10). DdcP and CtpA are 
excellent model proteases for understanding how proteases with PDZ domains recognize their 
substrates. CtpA is similar to Tail-specific protease (Tsp) in E. coli which recognizes the C-
terminus of its substrate through the PDZ domain (11). Substrate binding through the PDZ 
domain is most likely how CtpA recognizes YneA. I showed in Chapter III that the PDZ domain 
of CtpA is important for function (Fig 3.14). In addition, a previous study found that a D97A 
mutation in the C-terminus of YneA resulted in a stabilized variant of YneA (12). Interestingly, 
CtpA from Staphylococcus aureus (Sa-CtpA) was found to negatively regulate the SOS-
dependent cell division inhibitor SosA (8). The authors found the connection between Sa-CtpA 
and SosA because deletion of ten amino acids at the C-terminus of SosA resulted in a 
hyperactive variant, leading to the suggestion that Sa-CtpA recognizes the C-terminus of SosA 
(8). The hypothesis that B. subtilis CtpA recognizes YneA at its C-terminus can be tested by 
assaying YneA stability using C-terminal truncations and the D97A variant in cells lacking ddcP 
and in the presence or absence of CtpA. The model could be tested in vitro as well by purifying 
YneA variants that were stabilized and testing for CtpA protease activity. The requirement of the 
PDZ domain of CtpA could also be tested in vitro by examining protease activity of CtpAΔPDZ. 
Together, these experiments would test the hypothesis that CtpA uses its PDZ domain to 
recognize the C-terminus of YneA. 
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Although there is a very clear direction for CtpA, there is no clear hypothesis for how 
DdcP recognizes YneA. The protease domain of DdcP is similar to that of Lon proteases. Lon 
proteases are energy-dependent proteases that utilize an ATPase domain to drive substrate 
unfolding and proteolysis (13). In Chapter III DdcP was shown to be membrane anchored with 
an extracellular protease domain. Given that ATP is exceedingly low or absent outside the cell, it 
is no surprise that DdcP does not have an ATPase domain, and instead has a PDZ domain. The 
PDZ domain of DdcP is not required for function in the DNA damage checkpoint, as deletion of 
the PDZ domain had no effect on DNA damage sensitivity (Fig 3.14). Intriguingly, a BLAST 
search revealed that the PDZ domain of DdcP is most similar to the one found in DegS (Fig 
3.14). The PDZ domain of DegS acts as an allosteric inhibitor of protease activity and was also 
found to be dispensable for function in vivo (14-16). For DdcP it is not clear what function, if 
any, the PDZ domain serves. To better understand how DdcP recognizes YneA two general 
strategies should be employed. First, a purification scheme yielding active DdcP should be 
devised. Optimizing purification of full length DdcP from B. subtilis should be the starting point. 
With active DdcP purified, detailed hypotheses about substrate recognition could be examined in 
vitro. Second, the stability of several YneA truncation variants should be measured in the 
presence and absence of DdcP to determine the critical parts of the substrate. Together, these 
experiments have the potential to elucidate how a Lon protease is able to function without an 
ATPase domain to degrade protein substrates. 
 
DNA damage checkpoint antagonist 
The discovery of a DNA damage checkpoint antagonist marks an exciting advance in the 
bacterial DNA damage response field that simultaneously opens new avenues of research. DdcA 
along with the checkpoint recovery proteases, DdcP and CtpA, set the threshold of YneA 
required for establishing the cell cycle checkpoint. It is still unclear whether DdcA acts on YneA 
or another cellular target. To address the gap in our understanding of DdcA function, parallel 
approaches should be employed to test each hypothesis. 
The observation that DdcA and the checkpoint recovery proteases have YneA-dependent 
phenotypes, yet they are not functionally interchangeable, may suggest that DdcA acts on a 
protein other than YneA. DdcA contains a tetratrichopeptide repeat (TPR) domain, which could 
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mediate protein-protein interactions (17). I attempted to find a binding partner of DdcA using a 
bacterial two-hybrid assay. I screened several candidate proteins that are known to be involved in 
cell division for interaction with DdcA without obtaining a positive result. To more rigorously 
test the hypothesis that DdcA interacts with another protein, two methods should be employed. 
First, a tandem-affinity purification tag should be fused to DdcA and a pull-down assay should 
be optimized. Second, full-length DdcA, DdcA containing only the TPR domain, and DdcA 
lacking the TPR domain should be used in a genome-wide bacterial two-hybrid assay. DdcA 
likely interacts with other cellular proteins, and dissecting the entire network of interactions 
could help elucidate the function of DdcA in the DNA damage checkpoint, but could also inform 
whether DdcA has other important cellular functions. 
DdcA could inhibit YneA function directly. DdcA does not affect YneA protein levels, 
stability, or localization. DdcA also did not interact with YneA in a bacterial two-hybrid assay 
(Fig 3.11), though this experiment had two confounding factors. DdcA and YneA were likely 
separated by the plasma membrane, and in order to keep YneA in the cytoplasm the N-terminus 
of YneA had to be deleted, which could be required for DdcA to interact with YneA. Thus, it 
remains possible that DdcA acts on YneA prior to or during secretion, resulting in a form of 
YneA that is incompetent for cell division inhibition. I observed that DdcA is primarily 
intracellular, however, a portion of DdcA localized to the membrane fraction (Fig 3.9). It is 
possible that DdcA interferes with YneA secretion in a way that does not alter GFP-YneA 
localization. One possibility is that the topology of YneA is somehow reversed when DdcA is 
present. The result would be that the extracellular portion of YneA would be inside the cell, 
preventing YneA from inhibiting cell division. This hypothesis could be tested by placing the N-
terminal secretion signal of YneA at its C-terminus. If YneA orientation is reversed when DdcA 
is present, then by moving the secretion signal to the other side of the LysM domain, the function 
of DdcA would also be reversed. Another possibility is that DdcA affects YneA prior to 
secretion. Proteins containing TPR domains have been found to act as chaperones (18). 
Therefore, DdcA could act as a chaperone promoting YneA to fold into an inactive form. If 
YneA has cell wall hydrolase activity similar to that of the Mycobacterium tuberculosis cell 
division inhibitor (7) (see next section), then the effect of DdcA on YneA activity could be tested 
in vitro. In addition, the secondary structure of YneA could be monitored via circular dichroism 
or sensitivity of YneA to trypsin digestion could be tested to discern whether DdcA could indeed 
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alter YneA structure. Together with the more comprehensive study of DdcA interacting partners 
described above, these experiments will provide a deeper understanding of how the threshold for 
DNA damage checkpoint activation is established in B. subtilis. 
 
Checkpoint enforcement 
Although not a focus of my research, the mechanism by which YneA inhibits cell 
division remains the major open question in the B. subtilis DNA damage response field. YneA 
was identified as the SOS-dependent cell division inhibitor in B. subtilis in the early 2000s (3). A 
subsequent study provided evidence that full length YneA was the active form, and that several 
amino acids in the transmembrane domain were important for function (12). There are two major 
questions about YneA function that remain: 1) how does YneA inhibit cell division? and 2) what 
is the biological function of the YneA-dependent checkpoint? 
The data that YneA can inhibit cell division are clear (3, 12), yet how this occurs remains 
obscure. There are two primary hypotheses that should be tested: 1) YneA inhibits activity of an 
essential component of the cell division or cell wall synthesis machinery; and 2) YneA acts on 
the cell wall to prevent cell division. Of course, these hypotheses are not mutually exclusive and 
both could be part of the mechanism of cell division inhibition.  
I attempted to identify potential interacting partners of YneA using a bacterial two hybrid 
assay by using a candidate approach to screen several cell division and cell wall synthesis 
proteins. The experiment did not generate a positive result. It remains possible that YneA 
interacts with a component of the cell division or cell wall synthesis machinery. It is possible that 
YneA interacts with a protein I did not test or that YneA forms a complex with multiple proteins. 
To circumvent these technical difficulties, a pull down assay followed by mass-spectrometry 
using full length YneA similar to a previous report should be adapted (19), and a genome wide 
bacterial two hybrid should be performed. A genetic approach using a suppressor screen could 
also be used. Suppressor screens performed thus far have failed to identify suppressor mutations 
in genes other than yneA, however, a more high throughput approach can be employed based on 
my findings in Chapter II and Chapter III. A strain lacking both checkpoint proteases and ddcA 
with yneA under the control of the Pxyl promoter integrated at the amyE locus in addition to the 
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native yneA locus (genotype: ΔddcA, ΔddcP, ΔctpA, amyE∷Pxyl-yneA)  should be grown for 
many generations using multiple parallel liquid cultures. The cultures should be plated on media 
containing xylose periodically to identify strains that are no longer sensitive to over-expression 
of YneA. Any suppressors that are identified should subsequently be screened for sensitivity to 
MMC. Suppressor strains that are resistant to both xylose and MMC could result from mutations 
at both loci expressing yneA (yneA and amyE∷Pxyl-yneA), which would be a low probability 
event because the same cell would require two mutations. Alternatively, if a mutation occurred in 
a gene that functions downstream of YneA, such as the target or binding partner of YneA, the 
resulting strain would also be resistant to xylose and MMC. These experiments utilizing multiple 
independent approaches could identify potential binding partners of YneA and genetic 
suppressors of YneA over-expression. 
It remains possible that YneA function does not depend on protein-protein interactions. 
YneA has a LysM domain, and LysM domains typically bind to the peptidoglycan cell wall (20). 
The cell division inhibitor of Mycobacterium tuberculosis contains a LysM domain and also has 
cell wall hydrolase activity (7, 21). It is possible that YneA has hydrolase activity and prevents 
cell division by interfering directly with cell wall synthesis. This hypothesis should be tested 
using three independent approaches. First, if YneA inhibits cell wall synthesis, we might predict 
that over-expression of YneA would lead to a cell morphology phenotype similar to that 
observed for mutants that cannot properly synthesize the cell wall (22, 23). Although I did not 
observe differences in cell morphology, I only imaged strains overexpressing lower levels of 
YneA after thirty minutes. Moreover, the original reports of YneA overexpression wherein cells 
were visualized following YneA over-expression were done in strain backgrounds containing 
DdcA, DdcP, and CtpA, which would allow for removal and inhibition of YneA. Thus, the 
experiment should be repeated using high levels of YneA expression in a strain lacking ddcA, 
ddcP, and ctpA, and cell morphology should be monitored over a longer period of time, such as 
four to eight hours following YneA induction. Second, YneA could be tested for cell wall 
hydrolase activity using purified YneA similar to previously described (7). If YneA has 
hydrolase activity, the amino acids required for activity should be identified. The residues should 
be mutated, and the resulting YneA variant should be tested for hydrolase activity in vitro and its 
ability to inhibit cell division in vivo. Finally, given that GFP-YneA localization resembles the 
localization pattern of nascent peptidoglycan synthesis (Fig 3.12) (24, 25), the effect of YneA 
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over-expression on peptidoglycan synthesis should be tested. If YneA interferes with cell wall 
synthesis, it is possible that staining of nascent peptidoglycan using fluorescent vancomycin is 
altered upon over-expression of YneA. The experiments outlined above will help elucidate how 
YneA inhibits cell division and further our understanding of the DNA damage checkpoint in 
bacteria. 
The rationale for having a cell division inhibitor is to slow cell division to allow DNA 
repair and replication to complete prior to division. If the cell cycle checkpoint is removed, one 
would imagine that cells would not survive treatment with drugs that damage DNA. 
Paradoxically, deletion of yneA results in resistance to MMC relative to the wild type strain (Fig 
2.11). Thus, the question arises, what is the purpose of the YneA checkpoint? In Caulobacter 
crescentus there are two cell division inhibitors and deletion of either one alone gives no 
phenotype; however, the double mutant is sensitive to DNA damage (6). Further, although YneA 
is required for a significant portion of cell division inhibition in response to DNA damage, cells 
still elongate when YneA is deleted. It follows that there must be other mechanisms of 
checkpoint enforcement. As mentioned previously in Chapters I, II, and III, regulation of ftsL 
transcripts is a second mechanism of controlling cell division in response to replication stress 
(26). Still, there are other candidates for additional DNA damage-dependent cell division 
inhibitors. First, there are proteins in the prophage PBSX that have LysM domains (20), which 
could be functional analogs of YneA. I showed in Chapter V that deletion of PBSX results in a 
slight resistance to MMC (Fig 5.7), similar to deletion of yneA. If there is an additional cell 
division inhibitor that is part of the PBSX prophage, we would predict that deletion of both 
PBSX and yneA would result in sensitivity to MMC if the checkpoint is completely ablated. A 
second possibility is that the FtsZ inhibitor EzrA contributes to establishing the DNA damage 
checkpoint. In my genetic screens presented in Chapter II, transposon insertions in ezrA resulted 
in decreased relative fitness measurements in all three experiments, consistent with the 
hypothesis that EzrA is an important checkpoint regulator. How this occurs is not clear as ezrA 
was not found to be DNA damage-inducible (27). A genetic investigation of ezrA in the DNA 
damage response would be informative. Overall, a methodical dissection of YneA function will 
be required to understand how the DNA damage checkpoint is controlled in B. subtilis. 
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Mitomycin specific nucleotide excision repair 
My discovery of a nucleotide excision repair pathway specific for MMC is a fascinating 
observation that illuminated several open questions for further study. As I demonstrated in 
Chapter IV, mrfAB are important for surviving treatment with MMC, but not other types of DNA 
damage. I also found that MrfAB were not important for repair of the interstrand cross-link. 
These data strongly suggest that MrfAB repair the intrastrand cross-link and/or the mono-adducts 
(hereafter, referred to collectively as adducts). It is not clear how MrfAB recognize DNA 
containing MMC adducts. Understanding how MrfAB recognize adducts will help explain the 
specificity of this DNA repair pathway. 
Although MrfAB are important for repair of DNA containing MMC adducts, it is not 
clear how those adducts are recognized. The observation that MrfAB are specific to MMC 
adducts suggests that some aspect of adduct structure can be recognized by this pathway. An 
attractive explanation is that the C-terminal domain of MrfA recognizes MMC adducts in DNA. 
The C-terminus of MrfA contains four highly conserved cysteines that likely coordinate a zinc 
ion (28, 29). Zinc binding domains are prevalent in DNA binding proteins (30), and the 
recognition factors in bacterial and eukaryotic nucleotide excision repair also have zinc binding 
domains (31, 32). Although MrfA functioning as the recognition factor is an intuitive hypothesis, 
it is possible that MrfB or both MrfA and MrfB are required for MMC adduct recognition. 
Therefore, each protein individually and the MrfAB combination should be tested for a direct 
interaction with DNA containing an MMC adduct in vitro, similar to experiments performed 
with UvrABC (33). These experiments are straightforward in theory, but in practice MMC reacts 
with DNA forming several different adducts, so generating a single substrate is challenging (34). 
If MrfA is found to be the recognition factor, testing the requirement of the C-terminal binding 
domain may not be possible in vitro. A study of the MrfA homolog in M. smegmatis found that 
deletion of the C-terminal domain or mutation of the cysteines rendered the protein insoluble 
when produced in E. coli (29). To overcome this obstacle, MrfA could be tagged with GFP, and 
localization of MrfA in the presence and absence of MMC could be tested. It was previously 
shown that UvrA-GFP localizes to the nucleoid region following treatment with UV and MMC 
(35). Thus, it is possible that MrfA would localize to the nucleoid region following MMC 
treatment and that effect would depend on the C-terminus. Together, these experiments will 
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clarify how MrfAB recognize DNA containing MMC adducts and further our understanding of 
the specificity of this pathway. 
 
Concluding remarks 
Throughout this dissertation I have shown that the DNA damage response has multiple 
ways to accomplish one task. I showed in Chapter II that two proteases degrade the cell division 
inhibitor, and I described in Chapter III the identification of a third protein, DdcA, that acts to 
antagonize the same cell division inhibitor. In Chapter IV, I demonstrated that there are two 
pathways for repair of MMC adducts. Finally, in Chapter V I provided evidence that MutS2, a 
paralog of MutS, functions as a secondary Holliday junction endonuclease.  
Why are there so many cases of genetic redundancy in the DNA damage response 
pathway? Genetic redundancy in eukaryotes has been studied in numerous important cellular and 
developmental processes (36). The use of genetic redundancy in development is important for 
two main reasons. First, it allows for proteins with similar function to be used in different cell 
types or at different times, thus allowing a greater versatility than a single protein would allow. 
Second, if two proteins are under selective pressure for the same function, but each has an 
additional function that is also under selective pressure, then genes coding for both proteins 
would be maintained. Another, perhaps not inconsequential, advantage is that having two 
proteins for a single function would increase the robustness of the overall process. If one protein 
fails in early development, having the second protein could allow development to progress, 
thereby increasing survival rates. Bacteria have considerably smaller genomes than those of 
eukaryotes, and therefore it has long been thought that selective pressure against redundancy 
must be great. Although this argument seems intuitive, the same logic for the existence of 
genetic redundancy in eukaryotes applies to prokaryotes. By using multiple proteins with 
overlapping functions, the robustness of the process increases (37). Thus, when stress is 
encountered and cellular processes begin to fail, organisms with multiple strategies of mitigating 
the stress will outcompete those reliant on a single strategy that can be overwhelmed. As a result, 
when considering genetic redundancy in bacteria, the underlying circumstances also need to be 
incorporated into the model. The DNA damage response pathway is a stress response system; 
therefore, in hindsight it should not be surprising that nature would select for a robust response. 
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As research into mechanisms of bacterial stress response pathways progresses, I expect that the 
principles of redundancy I have uncovered in B. subtilis will serve as a model, allowing 
researchers to elucidate complex regulatory strategies present in bacteria. 
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